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 Abstract 
 
Abstract 
A growing problem with drug resistance in Human African Trypanosomiasis has 
necessitated the implementation of screening programmes to monitor for its spread. This 
thesis describes the study of several factors that can influence the selection and 
propagation of drug resistance in T. brucei. 
Human African Trypanosomiasis (HAT) is caused by T. brucei gambiense and T. brucei 
rhodesiense. The few drugs used for the treatment of the disease are either toxic, cause 
severe side effects or suffer from parasite resistance. The T. brucei P2 transporter, which is 
encoded by the gene TbAT1, mediates uptake of melaminophenyl arsenicals and 
diamidines. Reduced P2 uptake is associated with drug resistance. A number of point 
mutations found in a laboratory derived melarsoprol resistant T. brucei stock (STIB 777R) 
allowed development of a PCR/RFLP based molecular method to identify resistance 
alleles. By 1999, 20-30% of patients treated in Omugo, NW Uganda were failing to 
respond to melarsoprol. PCR/RFLP analysis indicated that mutant alleles accounted for 
58.5% of those in circulation. Melarsoprol was withdrawn in 2001 and by 2003 mutant 
TbAT1 alleles accounted for only 14% of those in circulation in NW Uganda. The current 
study aimed to determine the incidence of the PCR/Sfa NI TbAT1 mutant alleles in 2006, 
some five years after melarsoprol had been withdrawn as first-line treatment. Successful 
molecular analysis of 91 of 132 (68.9%) T. b. gambiense field isolates from Omugo and 
Moyo in NW Uganda indicated the presence of only TbAT1 wild type alleles. Mutant 
alleles thus appear to have disappeared. This may be the result of parasite fitness cost 
following the withdrawal of melarsoprol as a stage II first-line drug from Omugo health 
centre, Arua, since 2001. This apparent instability of TbAT1 mutants in the field may be 
exploited for rational or alternating use of melarsoprol and eflornithine (DFMO) to ensure 
a longer life for eflornithine, delaying the onset of resistance.  
Insight into the overall population structure of the T. b. gambiense from Omugo, Arua 
(N=54) and Moyo (N=17) was obtained using mini/microsatellite marker analysis. Genetic 
diversity was observed to be more intra than inter regional. Multilocus genotype data 
analysis revealed the Omugo, Arua, population was genetically distinct from the Moyo 
population (Nei’s genetic distance=0.176). The evidence indicated surprisingly little 
genetic exchange with an excess in homozygosity (Fis >0) and alleles in linkage 
disequilibrium (P<0.05) within the Omugo, trypanosome population. This excess in 
homozygosity may be due to population sub-structuring, trypanosome inbreeding, or Abstract 
migration of patients. The latter is likely occurring from the neighbouring T. b. gambiense 
endemic disease focus in Southern Sudan. The findings suggested that the T. b. gambiense 
from Arua is not panmictic, clonal or epidemic but there is some level of genetic exchange. 
The possibility that T. b. gambiense can infect animals raises the prospect that wild or 
domestic animals may act as a reservoir and that a veterinary link to gambiense Human 
African Trypanosomiasis exists. Treatment of animals for babesiosis and trypanosomes 
with diminazene, uptake of which is mediated through TbAT1/P2 could select for P2-
defective drug resistant trypanosomes, thereby threatening control of the human disease as 
well. Species detection by PCR for animal and human trypanosomes in dog isolates 
(N=190) from the tsetse fly endemic Jos Plataeu, Nigeria did not reveal T. b. gambiense, 
but multiple infections with T. brucei (95%), T. vivax (89%), and subspecies T. congolense 
forest (54%) and savannah (50%) were detected. The dogs were also infected with other 
parasites, including Babesia canis (22%) and Hepatozoon canis (16%). Multiple infections 
can make correct diagnosis difficult and the infections are likely to be missed by the less 
sensitive microscopy method. 
The trypanocidal action of the diamidine group of trypanocides, diminazene, pentamidine 
and furamidine (DB75) are principally mediated through the TbAT1/P2. In addition, 
pentamidine is taken up by two additional T. brucei transporters called High Affinity 
Pentamidine Transporter (HAPT1) and the Low Affinity Pentamidine Transporter 
(LAPT1). DB75 also has a secondary unknown route. Loss of TbAT1/P2 leads to 
significant resistance to DB75 and diminazene but not pentamidine. Identification of other 
markers of resistance is necessary to determine if other routes of drug entry do exist apart 
from P2 and whether these can be exploited for the delivery of new trypanocides into the 
trypanosomes. Adaptation of the T. brucei tbat1 knock-out cell line to higher 
concentrations of diminazene by in vitro selection for resistance led to loss of HAPT1. The 
resultant phenotype was similar to the previously characterised pentamidine resistant clone 
B48, but more resistant to diminazene and DB75. The adapted line was still capable of 
accumulating 1 µM radiolabelled diminazene suggesting both HAPT1 and LAPT1 as 
possible routes for diminazene uptake. Adaptation of the T. brucei tbat1 knock-out cell line 
to a high concentration of DB75 over the same 6 months period did not lead to increased 
resistance.  
Overall the project has confirmed an important role for tbat1/P2 in development of 
resistance to melarsoprol in the field. Importantly, it appears that removal of the selection 
pressure of melarsoprol leads to a loss of tbat1 alleles associated with resistance in a Abstract 
population of trypanosomes capable of genetic exchange in NW Uganda. Although 
evidence for a dog reservoir for T. b. gambiense in Nigeria was lacking in this study, a risk 
of selecting resistance in animals must remain high on any list of consideration. I have 
further shown that the diamidine drug, diminazene, used in veterinary medicine also 
appears to enter T. brucei via the HAPT1 transporter, as well as the P2 transporter. Loss of 
HAPT1 through selection with diminazene leads to high level pentamidine resistance, 
which could indicate a further risk in selection of human infectious trypanosomes also 
resistant to drugs like pentamidine. 
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1  Introduction 
1.1 Human African Trypanosomiasis 
Human African trypanosomiasis (HAT) or sleeping sickness is a deadly disease that occurs 
in 36 countries in sub-Saharan Africa. It is one more public health problem alongside other 
diseases including malaria, human immune deficiency virus, filariasis and tuberculosis 
with a major impact on social and economic development. It is endemic in several 
countries, which include Uganda, Angola, the Democratic Republic of Congo (DRC), 
Sudan, the Central African Republic (CAR), and the Republic of Congo. HAT is caused by 
a group of parasitic haemato-protozoa called trypanosomes, most of which are solely 
transmitted by the tsetse flies of the genus Glossina. There are three subspecies of 
Trypanosoma brucei (T. b.) namely T. b. brucei, T. b. rhodesiense and T. b. gambiense. 
Only two of these infect humans: T. b. rhodesiense and T. b. gambiense. T. b. gambiense, 
which causes the chronic form of the disease, is seen in West and Central Africa and T. b. 
rhodesiense, which causes the acute form of the disease, is found in East and Southern 
Africa (Figure 1.1). The West and Central African form of the disease is transmitted by the 
riverine species (G. palpalis, G. fuscipes and G. tachinoides) tsetse flies, which prefer a 
humid and dense riverine habitat while the East and South African form is transmitted by 
the savannah species (G. morsitans, G. pallidipes, and G. swynnertoni), which prefer dry, 
open woodland, and savannah habitat. An exception is the East African T. b. rhodesiense 
form, which is transmitted by the riverine species G. fuscipes (Smith et al, 1998;Waiswa et 
al, 2006). The disease has an early stage which later progresses into a late stage and is fatal 
if left untreated. The chronic form of the disease due to T. b. gambiense is responsible for 
more than 90 % of all HAT patient cases (Barrett, 2006).  
An equivalent disease transmitted by tsetse flies in animals is referred to as nagana and is 
caused by T. b. brucei, T. congolense (sub-genus Nannomonas) and T. vivax (sub-genus 
Dutonella). While wild and domestic animals do act as reservoirs of infection for T. b. 
rhodesiense, the importance for humans of the T. b. gambiense infection in wild and 
domestic animals is still unclear although there is some evidence of animals acting as host 
reservoirs of this parasite (Gibson et al, 1978;Nkinin et al, 2002;Herder et al, 2002;Simo et 
al, 2008a).Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 1, 17 
 
 
Figure 1.1 Map showing the distribution of T. b. gambiense and T. b. rhodesiense in Sub-
Saharan Africa (World Health Organisation, 2001).  
Melarsoprol treatment failures are confined to a belt stretching from Angola, through 
Congo, NW Uganda and S.Sudan (Matovu et al, 2001). 
 
Chemotherapy has been widely used for many decades as one of the control strategies in 
addition to vector control. Treatment of the disease is still carried out using the few 
available old drugs, which can cause adverse side effects, suffer from parasite resistance 
and require a parenteral mode of administration hence making effectiveness of treatment 
and efforts to prevent the disease very difficult. Pentamidine and suramin are effective for 
treatment of early stage T. b. gambiense and T. b. rhodesiense respectively while 
melarsoprol is used for treatment of both T. b. gambiense and T. b. rhodesiense late stage 
disease. Melarsoprol is known to be toxic, causing a fatal reactive encephalopathy in 5-10 
% of the treated patients (Pepin et al, 1995;Barrett, 2000). Eflornithine (DFMO), the most 
recently introduced drug, is only effective against T. b. gambiense and used for late stage 
West African sleeping sickness. Nifurtimox, although not yet registered, is another 
promising drug when used in combination with eflornithine (Priotto et al, 2006;Checchi, 
2007). Melarsoprol with eflornithine and melarsoprol with nifurtimox are other Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 1, 18 
combinations for treatment of late stage disease although the latter combination is more 
promising following recent drug trials (Bisser et al, 2007). 
Since drug treatment is the major control strategy used, there is an urgent need to develop 
rapid laboratory tools for the diagnosis and detection of any early signs of developing drug 
resistance in the field. This is one of the highest priorities in HAT research. Until recently, 
there has been no molecular marker for the detection of melarsoprol resistance in HAT. 
However, mutations in the Trypanosoma brucei adenosine transporter 1 gene that encodes 
the P2 activity (TbAT1/P2) that are linked to melarsoprol treatment failure (Mäser et al, 
1999), have been identified in a limited number of relapsed patient isolates (Matovu et al, 
2001b;Nerima et al, 2007). Decreased drug uptake due to loss of the TbAT1/P2 
transporter, or mutations in TbAT1, is implicated in the development of arsenical and 
diamidine resistance (Carter & Fairlamb, 1993;Barrett et al, 1995;Ross & Barns, 
1996;Mäser et al, 1999;de Koning & Jarvis, 1999;de Koning et al, 2000;Matovu et al, 
2001b;Witola et al, 2004;Stewart et al, 2005;Delespaux et al, 2006). 
1.1.1 Clinical manifestation 
Both T. b. gambiense and T. b. rhodesiense are known to infect and cause clinical disease 
in humans. Both types of parasites cause early and late stage disease, which if not treated 
leads to death. Transmission to a human occurs from the bite of an infected tsetse fly 
(Cattand & de Raadt, 1991;Pentreath, 1995). T. b. rhodesiense causes the acute form of the 
disease that can lead to death with in a matter of weeks to 6-8 months (Odiit et al, 1997). 
The observed difference in the rate of progression of the disease has been attributed to 
geographic variation (MacLean et al, 2004). The disease due to T. b. gambiense, which 
causes the chronic form, manifests with few specific symptoms over a period of several 
months to years (≥ 2 years) (Taelman et al, 1987). During the early stage of the disease 
when the parasites multiply by binary fission in the bloodstream and the lymphatic system, 
the patient develops a primary chancre at the site of the tsetse fly bite (Moore et al, 2002). 
The parasites then invade all organs of the body including the heart. Swelling of the 
cervical nodes (Winterbottom’s sign), cyclical fever patterns and headaches are some of 
the symptoms of the early stage disease. The late stage or meningo-encephalitic stage 
occurs after the parasites cross the blood-brain barrier and get into the central nervous 
system. This invasion leads to inflammation of the brain tissues (and visceral organs) as 
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brain. The patient deteriorates rapidly as a result of alterations of the mental state, sensory 
disorders, coordination problems, changes in the sleep/wake cycle, organ and 
immunological malfunctions, loss of weight which eventually lead to irreversible coma and 
death (World Health Organisation, 2001;Barrett et al, 2003).  
1.1.2 Historical 
The parasite that causes sleeping sickness (the human form of the disease) or nagana (the 
animal form of the disease) is transmitted by the tsetse fly vector. Sleeping sickness was 
reported by the descriptions given by Arab merchants and slave traders. But little was 
known of the disease until the end of the 19th century (1896) and early 20th century (1906) 
when serious epidemics of nagana and sleeping sickness were reported in the Congo basin 
and Uganda. T. b. gambiense was discovered by Forde in 1902 and this was followed by 
the identification of its mode of transmission and its life cycle in the tsetse fly by Bruce in 
1903 (Cattand et al, 2001;Cox, 2004). T. b. rhodesiense was first identified by Stephens 
and Fantham (1910) in Zambia (Fevre et al, 2006a). It was at that time that the two 
parasites were confirmed as the cause of sleeping sickness. The second epidemics, which 
occurred between 1920 and 1945, were in Angola, Cameroon, Sudan, Liberia, Sierrra 
Leone and Guinea leaving millions of people dead (Duggan, 1970). By the early 1960s, the 
disease was successfully brought under control to a level of almost being eliminated in 
most foci; an example being Uganda (World Health Organisation, 2001). However, the 
disease resurged in the 1970s resulting again into serious epidemics in the 1990s (Figure 
1.2). This was blamed on the collapse of the health systems as result of national neglect, 
insufficient budgets, and unending armed conflicts in the most affected regions which 
made it impossible for screening and vector control activities to continue (Barrett, 1999). 
With the assistance of various organisations, the current situation is now different (section 
1.3).  
Recent reports have predicted an overlap between the geographical distributions of the two 
diseases in Uganda (Enyaru et al, 1999;Hutchinson et al, 2003) but there are no reports 
showing evidence that this has happened yet. Furthermore, the areas that were once 
endemic for T. b. gambiense are not affected by T. b. rhodesiense and vice versa indicating 
that the endemic foci of the two diseases have hardly changed (Fevre et al, 2005). Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 1, 20 
 
Figure 1.2 Annual trends in reported number of cases of African Trypanosomiasis in 
Uganda between 1939 and 1998. 
(WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases, 2001). 
 
 
1.1.3 Scale of the problem 
By the end of the twentieth century, the deadly disease was estimated to affect 
approximately 0.5 million people annually with 1.59 M disability adjusted life years 
(DALYs) leaving 60 million people at risk (Barrett, 1999;World Health Organisation, 
2001), although the number of afflicted people is considered an under-estimate as a result 
of low detection rates (Fevre et al, 2006a). Current reports indicate a decline in disease 
incidence with an estimate of about 70,000 people infected annually (World Health 
Organisation, 2006;Barrett, 2006). Most of the reported cases occurred in regions of high 
endemicity (> 500 cases per year) namely; Angola, the Democratic Republic of Congo, 
southern Sudan, Uganda and Central African Republic. The globally declining trend is 
considered a positive step towards the control of the disease. This is thought possibly to be 
a result of the renewed efforts put in by various international organisations, academic 
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together with the national control programmes and health authorities of the affected 
countries. For some regions of low-level endemicity (<50 cases/year) like Chad, Ivory 
Coast, Gabon and Cameroon it was noted that when the control activities are relaxed, a 
resurgence of the disease is observed (World Health Organisation, 2001;Cattand et al, 
2001). This is therefore an indication that increased surveillance has to continue in all foci 
to be able to successfully control the disease. 
The disease caused by T .congolense and T. vivax, which is also devastating in livestock, 
leads to massive reduction in production amounting to US $1-1.2 billion seriously 
affecting livestock keepers socially as well as having a huge impact on the rural economy 
as a whole (Shaw, 2004). 
In spite of all the continued efforts, which include screening, diagnosis, treatment and 
vector control, it is not yet possible to completely eliminate the disease both in humans and 
animals. This is thought to be due to several factors. The presence of an animal reservoir 
for example in West Africa has been thought to play an important role in the resurgence of 
the disease (Gibson et al, 1978;Zillman et al, 1984;Nkinin et al, 2002;Herder et al, 
2002;Fevre et al, 2005;Fevre et al, 2006c;Simo et al, 2006;Njiokou et al, 2006). Also 
human /animal movements to and from an endemic region possibly increases the chance of 
introducing the disease to a disease free region as in the case of Uganda (Fevre et al, 
2001;Fevre et al, 2006c;United Nations Report, 2004). Another factor of major importance 
to consider is the existing problem of emerging parasite strains that are resistant to the 
available drugs used for treating both humans and animals (Kalu, 1995;Mäser et al, 
1999;Matovu et al, 2001c;Geerts et al, 2001;Anene et al, 2001). 
1.2 Animal Trypanosomiasis as a reservoir 
T. b. rhodesiense is a zoonotic parasite, which infects both humans and domestic animals. 
Cattle are mostly affected but also pigs, goats and sheep are known to be infected and these 
serve as reservoirs of this parasite (Gibson & Gashumba, 1983;Welburn et al, 
2001a;Waiswa et al, 2003;Njiru et al, 2004;Fevre et al, 2005). Dogs are also reported to 
act as host reservoirs of this parasite (Gibson & Gashumba, 1983). Apart from causing 
acute disease ,T. b. rhodesiense can also cause mild disease in humans as reported for 
Malawi (MacLean et al, 2004). Therefore both humans and animals can act as host 
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gambiense is known to cause the chronic form of the disease in humans who are major 
reservoir  
Because of the endemic nature of the disease, it has been speculated that there could be an 
animal link to gambiense Human African Trypanosomiasis. The possibility that T. b. 
gambiense can infect animals suggests that wild or domestic animals may have a role to 
play. This has been hypothesized in an attempt to explain the continued endemic situation 
and recurrent epidemics in high and low-level endemic foci in most of sub-Saharan Africa 
in spite of animal-tsetse-human transmission generally being considered to be of low 
importance. The human infective T. b. gambiense parasite is transmitted to animals by the 
same tsetse fly vector, Glossina palpalis. With the previous and new advancements in 
molecular methods using molecular markers specific for each trypanosome species it is 
possible to differentiate between T. brucei species infecting humans, animals and tsetse 
flies (Moser et al, 1989;Masiga et al, 1992;MacLeod et al, 1999;Biteau et al, 
2000;Welburn et al, 2001a;Gibson et al, 2002;Radwanska et al, 2002a;Radwanska et al, 
2002b;Herder et al, 2002;Njiru et al, 2004). Studies done to identify the different 
trypanosome species that infect animals do implicate animals as a possible reservoir of T. 
b. gambiense (Gibson et al, 1978;Mehlitz et al, 1982;Zillman et al, 1984;Nkinin et al, 
2002;Herder et al, 2002;Simo et al, 2006;Njiokou et al, 2006). These studies have revealed 
that domestic animals, mostly pigs, dogs and wild animal species (rodents, ungulates, 
primates, carnivores, and reptiles), harbour T. b. gambiense. It was also revealed that 
animals belonging to different species were also infected with other animal trypanosome 
species which include T. b. brucei, T. congolense, T. vivax and T. simiae (Herder et al, 
2002;Simo et al, 2006). In a more recent study performed in Central Africa involving the 
use of Amplified Fragment Length Polymorphism (AFLP), which is a more sensitive 
molecular method, it was revealed that pigs were infected with a T. b. gambiense genotype 
similar to the one that affects man in the same and other different foci (Simo et al, 2008a). 
This finding further strengthens and supports the earlier hypothesis that domestic animals 
can act as host reservoirs of T. b. gambiense and therefore play a role in the maintenance 
and circulation of this parasite in the human population (Simo et al, 2008a). 
1.3 Control Programmes and their role 
The control and management of HAT has been made at least possible by the inputs of 
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Health Organisation (WHO) and international donors. This was initiated by the WHO 
which encouraged and supported endemic countries and those prone to epidemics (WHO 
report, 1998) to set up National Sleeping Sickness Control Programmes (NSSCP) to help 
in the surveillance and control of the disease (Cattand et al, 2001). Uganda, Kenya, 
Tanzania, Angola, the Democratic Republic of Congo, Ivory Coast, Chad, Cameroon, 
Central African Republic, Gabon, and Sudan are some of the countries, which have 
established control programmes. Other countries including Ghana, Liberia, Sierra Leone 
and Nigeria, although among the affected, still lack national surveillance programmes. 
However, Nigeria is currently seeking support from the WHO to ensure a surveillance 
programme is set up. The main aim of these programmes is to eliminate the disease. HAT 
is commonly referred to as a disease of the poor and the most marginalised communities in 
sub-Saharan Africa, which are ravaged with wars, insecurity, social instability, and weak 
health systems. The role of the control programmes is to ensure that the people at high risk, 
mostly those from rural areas not easily accessible and lacking adequate health services, 
are reached and treated. Well trained technical and health personnel, reagents, screening 
and diagnostic tools and drugs are some of the requirements. The control programmes also 
ensure reinforced monitoring, which involves mobile teams for active case detection, and 
established health centres or hospitals for passive case detection 
http://www.who.int/trypanosomiasis_african/resources/afro_tryps_strategy.pdf. Control of 
the disease is also ensured through networks that bring together affected countries annually 
for exchange of information hence leading to the setting of new strategies for the future. 
An example is the East African Network for Trypanosomiasis (EANETT), which was set 
up eight years ago http://www.eanett.org/whatis/ and includes Uganda, Kenya, Tanzania, 
Sudan, Ethiopia and Zambia. Malawi has just recently come on board. 
Control programmes require sufficient financial and human resources to be able to carry 
out such activities successfully. In most of the affected countries where the disease re-
emerged in the late 1970s this was next to impossible because of inadequate budgets and 
the lack of political will to recognise the disease as of public health importance (Barrett, 
1999). Various international organisations stepped in to try and alleviate the problem; The 
United Nations Children’s Fund, United Nations Development Programme, World Bank 
and World Health Organisation Tropical Diseases Research (UNICEF-UNDP-World 
Bank-WHO/TDR), research institutions (e.g. Bill & Mellinda Gates Foundation, Drugs for 
Neglected Diseases Initiative (DNDi), Foundation for Innovative New Diagnostics 
(FIND), Swiss Tropical Institute-Basel (STI), University of North Carolina, Institute of Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 1, 24 
Tropical Medicine- Antwerp (ITMA), University of Glasgow, University of Dundee), 
pharmaceutical companies (Sanofi-Aventis, Bayer (World Health Organisation, 
2006;Barrett, 2006). Non-governmental organisations like Médecins Sans Frontières 
(MSF), an international humanitarian aid organisation that provides emergency medical 
assistance to people at risk in affected countries, have also played an important role 
regarding control of the disease. 
1.4 Drugs (Human and Veterinary) 
Chemotherapy is one of the major strategies used for the control of the disease in both man 
and animals. The drugs used for the treatment of disease due to T. b. gambiense and T. b. 
rhodesiense differ because of the differences in their clinical manifestations. In the case of 
humans, treatment relies on a few drugs which have been in use for more than 50 years 
namely; pentamidine, suramin and melarsoprol (MelB). Eflornithine (DFMO), which is the 
most recently (1990) licensed drug, is used not only for the treatment of melarsoprol 
refractory late stage T. b. gambiense but it is also used increasingly as first-line therapy. 
Nifurtimox, which was developed in the 1960s for the treatment of Chagas’ disease, is 
another drug used on a compassionate basis in combination with eflornithine although it is 
not yet licensed for treatment of sleeping sickness (Priotto et al, 2006;Priotto et al, 
2007;Checchi, 2007). Its use still requires further investigations. Other combinations of 
melarsoprol and eflornithine or nifurtimox have also been used (Bisser et al, 2007). DB75 
(2,5-bis(4-amidinophenyl)furan) or furamidine a diamidine whose prodrug DB289 (the O-
methyl amidoxime) derivative (pafuramidine) is a promising oral drug currently 
undergoing phase III clinical trials for use against early stage sleeping sickness (Jannin & 
Cattand, 2004). 
Diminazene aceturate (Berenil), Isometamidium chloride (Trypamidium), and Homidium 
salt (Ethidium), cymelarsan and suramin are the drugs on which the treatment of African 
animal trypanosomiasis relies. 
1.4.1 Drug resistance 
It is of concern that the few available drugs relied on for the treatment of both human and 
animal African trypanosomiasis have been threatened by the emergence of parasite strains 
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sulphadoxine-pyrimethamine-resistant Plasmodium falciparum (P. falciparum) is reported 
to confer immunity with age and exposure (Djimde et al, 2001;Omar et al, 2001). 
However, infection with drug resistant trypanosomes can occur after treatment for T. b. 
gambiense resulting in clinical disease although an in vivo study among adults in Zaire 
indicates evidence for immunity following infection with T. b. gambiense (Khonde et al, 
1995). 
Drug resistance is defined by (Schnitzer & Grunberg, 1957) as ‘the heritable, temporary or 
permanent loss of the initial sensitivity of the population of micro organisms against the 
active substance’. Drug resistance in T. brucei therefore may not necessarily be indefinite 
(Matovu et al, 2001c). Resistance may arise as a result of the parasites surviving in high 
drug concentrations, not tolerable to the host, or the parasites may be naturally resistant to 
the drug not as a result of previous drug exposure but due to other factors; for example, 
drug pharmacokinetics, host, vector or parasite-related (Matovu et al, 2001c). An example 
is T. b. rhodesiense, which is naturally refractory to eflornithine and therefore cannot be 
treated with this drug. This was first observed by Iten and others (1995) using T. b. 
gambiense isolates from West Africa, which after 10 days of exposure were found to be 
susceptible in vitro at 16.3 ± 7.8 µg/ml (the level of eflornithine concentration in CSF 
during treatment), while T. b. rhodesiense isolates from S.E Uganda were found to be 
inhibited only at the higher eflornithine concentrations of 25-100 µg/ml. T. b. gambiense 
isolates from NW Uganda displayed minimum inhibitory concentrations (MIC) ranging 
between 1.13-6.3 µg/ml while the T. b. rhodesiense isolates from SE Uganda had higher 
MIC values between 25-50 µg/ml, further confirming their natural refractoriness to 
eflornithine (Matovu et al, 2001a). 
For reasons other than drug resistant parasite strains, treatment failure can also occur due 
to a complete lack of clinical response. These may include non-compliance with the 
duration of the dosing regimen, drug interactions, poor drug metabolism, misdiagnosis and 
re-infection (Burri et al, 1993;Geerts et al, 2001). In such cases exposure of parasites to 
sub-optimal drug levels may enhance the development of true drug resistance. Following 
the high incidence of melarsoprol treatment failures in NW Uganda (Legros et al, 1999) 
that are associated with melarsoprol resistance (Matovu et al, 2001b), in vitro and 
pharmacokinetic analyses were performed on T. b. gambiense isolates collected from the 
successfully treated and failed patients (Brun et al, 2001;Burri & Keiser, 2001). Results 
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such as host or parasite-related responsible for treatment failure since no differences were 
observed between the melarsoprol sensitivities, plasma and CSF drug concentrations of the 
two patient groups (Brun et al, 2001;Burri & Keiser, 2001). 
Melarsoprol 
Melarsoprol is an organic arsenical that was introduced by Friedham in 1949 is 
nonspecies-specific, cheap, and still widely used as first-line therapy for late stage human 
sleeping sickness. It is the drug of choice for both T. b .rhodesiense and T. b. gambiense 
late stage disease (Van Nieuwenhove, 1992). The drug is capable of crossing the blood 
brain barrier during a central nervous system infection. However; it is toxic and induces 
severe side effects. It is reported that 10% of patients treated with melarsoprol suffer an 
acute encephalopathy, which may result in paralysis, permanent brain damage or death in 
5% of the treated cases (Pepin et al, 1995;World Health Organisation, 1998;Barrett, 2000). 
The predominant active metabolite of melarsoprol in the body is melarsen oxide (MelOx) 
(Keiser & Burri, 2000). The mechanism of action is still not clear although it is reported 
that it inhibits enzymes of the glycolytic pathway (Flynn & Bowman, 1974;Schaftingen et 
al, 1987) 6-phosphogluconate dehydrogenase (Hanau et al, 1996), and also forms a stable 
complex with trypanothione (MelT), which inhibits trypanothione reductase (Fairlamb, 
1989;Cunningham et al, 1994). Laboratory induction of cymelarsen (an equivalent of 
melarsoprol) resistance in T. brucei was achieved by repeated selection in vivo in mice, 
suggesting another mechanism that was transport mediated. Cross resistance was also 
observed with the diamidine group compounds, which implicated involvement of the same 
adenosine transporter system (Fairlamb et al, 1992;Carter & Fairlamb, 1993). 
In endemic areas of Uganda, Southern Sudan, Angola and DR Congo, the effectiveness of 
treatment and efforts to prevent sleeping sickness have been threatened by the increasing 
incidence of melarsoprol treatment failures (between 15-30%) (Legros et al, 1999;Moore 
& Richer, 2001;Stanghellini & Josenando, 2001;Burri & Keiser, 2001;Brun et al, 2001) 
associated with the problem of developing drug resistance (Matovu et al, 2001b). The high 
number of melarsoprol refractory cases led to a change in treatment policy, which resulted 
in the complete withdrawal of the arsenical and its replacement with eflornithine as first-
line therapy for late stage T. b. gambiense in Southern Sudan, North Western Uganda 
(Omugo) in 2001, and recently in Angola (Chappuis et al, 2005;Priotto et al, 2006).  
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Pentamidine 
Pentamidine, an aromatic diamidine, was introduced in the 1940s and has remained one of 
the principal drugs used for treatment of early stage T. b. gambiense sleeping sickness 
(Pepin & Milord, 1994). Nephrotoxicity and diabetes mellitus are among the adverse 
effects caused by the use of pentamidine. Diamidines are thought to act directly against the 
parasites, independently of their physiological action against the host. At one time it was 
considered that hypo-glycaemia might influence activity but their mode of action is not 
clear. They are reported to interact with cellular anions by binding tightly to the highly 
intercalated network of circular DNA molecules that comprise the kinetoplast and nucleus 
hence inhibiting nucleic acid replication (Shapiro, 1993). A laboratory derived T. brucei 
pentamidine resistant line generated in vivo and in vitro with an intact adenosine transport 
system was found to be less virulent with no cross resistance to other diamidine group 
compounds in vivo but was 2-fold resistant to melarsoprol. This suggested another 
mechanism of transport other than P2 or possibly a non-transport related mechanism 
(Berger et al, 1995). Very few cases of pentamidine refractory T. b. gambiense have been 
reported indicating that pentamidine resistance in the field is a rare occurrence (Pepin & 
Khonde, 1996). The few isolated cases are thought to be due to improper diagnosis of what 
would supposedly have been late stage cases (Nok, 2003). A T. brucei line selected in vitro 
for high level pentamidine resistance but lacking the adenosine transport system was less 
virulent and 15-fold cross resistant to melarsoprol thereby implicating loss of another 
transporter system (HAPT1) as another mechanism in addition to loss of TbAT1/P2 for 
development of high level pentamidine and melarsoprol resistance (Bridges et al, 2007). 
Suramin 
Suramin is a polysulphonated, symmetrical naphthalene derivative that was introduced in 
1922. Since it cannot cross the blood brain barrier because of its large size and strong 
negative charge, it is only effective in the treatment of early stage T. b. rhodesiense and T. 
b. gambiense human disease (Hawking, 1940). However, it is considered the drug of 
choice for the treatment of early stage T. b. rhodesiense sleeping sickness in East Africa 
(World Health Organisation, 1995) because it is more effective than pentamidine (Fevre et 
al, 2006a). While pentamidine is the drug of choice for T. b. gambiense (Pepin & Milord, 
1994) since high treatment failure rates (30%) were reported in the 1950s, following 
therapy with suramin http://www.who.int/tdr/publications/publications/pdf/aftryp_swg.pdf. 
Adrenal failure is one of the adverse effects following prolonged treatment with suramin 
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suramin might interfere with trypanosome metabolism by inhibiting several enzymes 
(Misset & Opperdoes, 1987;Wierenga et al, 1987). Later studies have suggested its mode 
of action is linked to the binding of low density lipoproteins (Vansterkenburg et al, 1993). 
Reports on suramin resistance in HAT are very rare. Like pentamidine, treatment failures 
are attributed to misdiagnosis of late stage cases (Burri et al, 2004). However, expression 
of resistance to suramin in bloodstream form T. brucei incubated 24 hours in axenic in 
vitro cultures has been demonstrated in a laboratory derived suramin induced line (Scott et 
al, 1996). Resistance to suramin in animal trypanosomiasis has also been reported for T. 
evansi from China (Zhou et al, 2004). But the drug has been shown to successfully treat 
the first known T. evansi infection that occurred in a human in India (Joshi et al, 2006). 
Eflornithine or α-Diflouromethyl ornithine (DFMO)  
Eflornithine (DFMO) is an ornithine analogue that was developed as an anti-cancer agent 
(Wickware, 2002). It was introduced over a decade ago (Nightingale, 1991). Eflornithine 
was confirmed effective against human trypanosomes in animal models (mice) and humans 
as well as having an anti-neuroinflammatory role in animal models and humans (Burri & 
Brun, 2002). It is only effective in the treatment of both early and late stage T. b. 
gambiense human sleeping sickness (Burri & Brun, 2003). Eflornithine has the ability to 
cross the blood-brain barrier and is currently licensed for the treatment of melarsoprol 
refractory cases but it is also becoming widely used as a first line treatment. However, its 
mode of administration, which requires a hospital setting, and high cost limit its use 
although in the last few years it has been provided free to the World Health Organisation 
by Sanofi-Aventis (Barrett, 2006). Eflornithine is the only drug whose mode of action is 
well understood. It irreversibly inhibits ornithine decarboxylase (ODC) an essential 
enzyme in polyamine biosynthesis (i.e. formation of putrescine from ornithine), critical to 
cell division and which offers protection against oxidant stress in the parasites (Bacchi et 
al, 1980). Trypanocidal activity was shown to be abolished when eflornithine was 
administered together with putrescine confirming its inhibition of ODC (Bacchi et al, 
1980). 
Unlike T. b. gambiense, T. b. rhodesiense cannot be treated using eflornithine. In an in 
vitro study done using T. b. rhodesiense field isolates, it was demonstrated that these 
parasites are naturally refractory to the drug (Iten et al, 1995). In a follow-on study, the T. 
b. rhodesiense parasites were observed to have a higher ODC turnover with the enzyme 
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turnover (t1/2~19 hours). The fast rate at which the T. b. rhodesiense enzyme is replaced 
explains their natural refractoriness (Iten et al, 1997). There were no reports of eflornithine 
resistance or cross-resistance with other drugs (World Health Organisation, 2001), but 
some instances of eflornithine failure have appeared which suggest eflornithine resistance 
is a possibility (Dr. Simmaro, WHO, personal communication, Dr. Truc, OCEAC, personal 
communication, Dr. Matovu, MUK, personal communication). In vitro selection for 
resistance to eflornithine by passage in increased drug concentration has been 
demonstrated in T. brucei procyclics which were found to have a 7-fold decrease in drug 
uptake and increased levels of ornithine (Phillips & Wang, 1987;Bellofatto et al, 1987). In 
Leishmania, which also belong to the kinetoplastid group, this increased ODC activity was 
also suggested as another mechanism as observed in a Leishmania tarentolae line selected 
for resistance to arsenite as (Légaré et al, 1997). However, in vitro selection for resistance 
to eflornithine by passage in increased drug concentration has also been demonstrated in T. 
brucei blood stream forms (Barrett et al, unpublished). 
Nifurtimox 
Nifurtimox is mainly used for the treatment of Chagas’ disease which is caused by T. cruzi 
in South and Central America (Rodrigues & de Castro, 2002). Its mechanism if action is 
linked to the generation of free radicals following the bioreduction of the nitro group, 
which is considered identical in both T. cruzi and T. brucei (Delespaux & De Koning, 
2007). It has been successfully used in the treatment of melarsoprol-refractory late stage T. 
b. gambiense patients but it lacks the TbAT1/P2 transporter recognition motif suggesting 
its mode of uptake is not P2 related and neither is it transported by HAPT1 (Delespaux & 
De Koning, 2007). Although unlicensed, it is another potential drug with the hope of being 
used in combination with other drugs for the treatment of human African trypanosomiasis. 
This is part of the effort to improve on the efficacy and protection against resistance to the 
drugs used for late stage therapy. There are currently no new drugs in development with 
the exception of the novel diamidine DB75 whose orally active prodrug DB289 is still 
undergoing phase III clinical trials. However, its inability to cross the blood-brain barrier 
implies that, if successfully developed, it will be licensed for the treatment of early stage 
disease (Jannin & Cattand, 2004). Clinical trials which involved using nifurtimox in 
combination with eflornithine have indicated promising results (Priotto et al, 2006;Priotto 
et al, 2007;Checchi, 2007).  
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Diminazene aceturate (Berenil) 
Diminazene, an aromatic diamidine, is widely used for treatment of the three common 
animal trypanosome species (T. b. brucei, T. vivax and T. congolense) but the development 
of resistance  to this drug is now a serious problem in different regions of sub Saharan 
Africa for example Burkina Faso, Nigeria, and Ethiopia, (Clausen et al, 1992;Kalu, 
1995;Mulugeta et al, 1997;Afewerk et al, 2000;Anene et al, 2001;Geerts et al, 2001;Anene 
et al, 2006). This has complicated the control of the disease. Berenil has been used in 
experimental studies to successfully treat humans although it is not licensed (Delespaux & 
De Koning, 2007). The drug is taken up through the same P2 transporter system like for 
the arsenicals and other diamidine compounds whose loss leads to resistance. However, it 
is speculated that treatment of animals acting as reservoirs of the human infective T. b. 
gambiense with this less effective trypanocide could lead to selection of drug resistant 
human T. b. gambiense. This is likely to result in cross resistance to human P2 
trypanocides as reported for a T. brucei berenil resistant isolate from a dog that was cross 
resistant to pentamidine (Anene et al, 2006). The drug is also used for treatment of other 
animal parasites e.g. babesiosis, which might make this route a possible way of selecting 
P2 drug resistant parasites if the infected animals are treated for one disease instead of 
another. The idea of considering licensing of diminazene for human use is of great concern 
because of the loss of effectiveness. A variety of generic brands of diminazene aceturate 
are available which contain lower levels of the stated active component diminazene 
(Atsriku et al, 2002). This may also contribute to the drug being less effective although this 
was found not be responsible for resistance in a T. brucei berenil resistant isolate from a 
dog in Nigeria (Anene et al, 2006). 
Isometamidium Chloride (Trypamidium or Samorin) 
Introduced in 1961 (Berg et al, 1961), isometamidium chloride is a phenanthridine-
aromatic amidine (Leach & Roberts, 1981), a complex of part of the diminazene molecule 
and homidium. Isometamidium was first used in 1963 (Delespaux & De Koning, 2007). It 
is used widely both as a prophylactic and therapeutic treatment for all the three principal 
African animal trypanosomes, especially in cattle and small ruminants. However, it has 
also been threatened by resistance in Somalia, Nigeria, Kenya, Ethiopia and Burkina Faso 
(Schönefeld et al, 1987;Kaggwa et al, 1988;Clausen et al, 1992;Gray et al, 1993;Codjia et 
al, 1993;Kalu, 1995;Mulugeta et al, 1997;Afewerk et al, 2000). 
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Homidium bromide/ homidium chloride(Ethidium) 
Homidium, a phenanthridine, is another drug that has both chemophylactic and therapeutic 
effects like isometamidium chloride. Ethidium was first used in in vitro experiments as a 
dye (tryparsamide) which lost its trypanocidal activity when incubated with susceptible T. 
b. rhodesiense trypanosomes but this activity was not lost on incubation with resistant 
trypanosomes, which suggested that there was less affinity for the drug target or changes in 
the transport system (Yorke et al, 1931;Hawking, 1936). The drug is mostly used for T. 
vivax and T. congolense animal infections. Resistance is associated with diminazene 
aceturate and isometamidium and has been reported in animal isolates from West and East 
Africa tested either in vivo or in vitro (Codjia et al, 1993;Mulugeta et al, 1997;Olila et al, 
2002). 
1.4.2 Possible mechanisms of drug resistance in T. brucei 
The mechanism by which parasites can acquire resistance to drugs depends to a great 
extent on the drug’s mode of action. Paul Ehrlich, in 1907, was the first person to 
undertake experiments to understand the mechanism of drug resistance in T. brucei species 
(Maser et al, 2003). He formulated the ‘chemoreceptor’ hypothesis, which states that drugs 
act via specific receptors and that drug resistance is caused by a reduction of affinity of the 
respective target or reduction of net drug uptake due to loss of a transporter. This was 
demonstrated using tryparsamide (the first clinically effective arsenical for HAT) 
containing medium which lost its trypanocidal activity when incubated with susceptible T. 
b. rhodesiense trypanosomes but this activity was not lost on incubation with resistant 
trypanosomes, which suggested that there was less affinity for the drug target or changes in 
the transport system (Yorke et al, 1931;Hawking, 1936). Later on lower accumulation 
levels of diamidines 4',6-diamidino-2-phenyl-indole (DAPI) and Hoechst 33342, the 
phenanthridine ethidium bromide, and the acridine acriflavine were demonstrated in both 
the blood stream melarsoprol resistant T. b. brucei and T. b. rhodesiense clones that were 
cross resistant to pentamidine and berenil in vivo when compared to the sensitive T. brucei 
clones (Frommel & Balber, 1987). However, accumulation of DAPI was shown to be the 
same in both sensitive and the resistant clones following treatment with the detergent 
Triton-X which suggested alterations in the surface membrane were responsible for low 
drug accumulation observed in the drug resistant parasites (Frommel & Balber, 1987). The 
mechanism, which involves the T. brucei adenosine transporter 1 responsible for P2 
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pentamidine transporter (LAPT1), will be discussed in detail later in section 1.6. However, 
resistance in T. brucei procyclics selected for resistance to eflornithine in vitro has been 
associated with alterations in a biochemical target other than a membrane target. This was 
because of the accumulation of more of the polyamine ornithine than the drug as observed 
in the resistant parasites in comparison to the drug sensitive parasites (Phillips & Wang, 
1987). 
Increased drug export by the multidrug–resistance associated protein that belongs to the 
ATP-binding cassette (ABC) subfamily C transporters is another mechanism that may be 
linked to the development of drug resistance in T. brucei (Shahi et al, 2002;Luscher et al, 
2006). These proteins are able to pump out of the cytosol products formed between drugs 
and complexes of trypanothione, which is a glutathione-spermidine conjugate, and 
melarsen oxide (Maser et al, 2003). In T. brucei, Shahi and others (2002) characterised two 
of these proteins and were able to demonstrate that over expression of the protein 
TbMRPA resulted in reduced susceptibility to melarsoprol/ melarsen oxide by 10-fold in 
vitro. Over expression of two of the enzymes involved in synthesis of glutathione and 
hence trypanothione (ornithine decarboxylase and gamma-glutamyl-cysteine) resulted in a 
2-4 fold reduction in susceptibility to melarsoprol (Shahi et al, 2002). To assess the effect 
of reduction of the production of TbMRPA could have on melarsoprol susceptibility, RNA 
interference was used to reduce its over expression in patient isolates, which were then 
tested in vivo in mice (Alibu et al, 2006). The isolates were found to be hypersensitive to 
melarsoprol and attempting to increase the levels of trypanothione so that the 
trypanosomes could over express TbMRPA turned out to be ineffective in vivo which 
suggested that lack of a TbMRPA expression mechanism in vivo alone may not lead to 
melarsoprol resistance. 
Alterations in TbAT1 or loss of P2 activity and over-expression of TbMRPA were 
pinpointed as possible mechanisms leading to melarsoprol resistance. Based on those 
observations a study was undertaken to assess the melarsoprol sensitivities in T. brucei in 
vitro using T. b. brucei bloodstream form trypanosomes lacking TbAT1/P2 activity and at 
the same time over expressing TbMRPA. Such lines were found to be 6-fold less 
susceptible to melarsoprol when compared to the T. brucei line lacking only P2 activity 
(Luscher et al, 2006). This finding suggests that more than one mechanism can potentially 
play a role in the development of resistance to melarsoprol, which is in agreement with the 
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in the in trypanosomes shown to lack over expression of TbMRPA in vivo (Alibu et al, 
2006). 
Hypotheses are still being considered to further understand the mechanisms underlying the 
development of drug resistance in T. brucei. One hypothesis is of a veterinary link to 
human disease (see section 1.2) and the continuous treatment of animals with the 
trypanocide diminazene aceturate leading to resistance problems (Geerts et al, 2001), 
which may contribute to the selection of resistant trypanosomes that can infect man 
(Barrett, 2001). Diminazene resistance in the field is a problem in some regions of sub 
Saharan Africa for example Burkina Faso Nigeria, and Ethiopia, (Clausen et al, 1992;Kalu, 
1995;Anene et al, 2001;Afewerk et al, 2000). Diamidine resistance in T. brucei is 
associated with loss of P2 function in T. brucei (section 1.4.2). Uptake of diminazene has 
been shown to principally depend on the P2 transporters (Matovu et al, 2003;de Koning et 
al, 2004).  
A diminazene (berenil) resistant T. b. brucei isolate from a dog in Nigeria used to infect 
albino rats which were treated with berenil (7 mg/kg) and pentamidine (4 mg/kg) and was 
confirmed to be resistant to berenil (relapse rates 83-100%) and cross resistant to 
pentamidine (relapse rate 50%) (Anene et al, 2006). This possibly indicated that other 
transporters such as HAPT1, LAPT1 were also missing from these trypanosomes. The 
problem of animals acting as reservoirs of human-infective trypanosomes has led to 
speculation that this might enhance the selection of P2 resistant trypanosomes in the field 
hence worsening the drug resistance situation for the few drugs which are in use (Geerts et 
al, 2001). It is also speculated that through this mechanism faster development of 
resistance may occur for the promising new diamidine compound DB75 (pro drug DB289) 
whose uptake also occurs through P2 transport although an unknown secondary route is 
also involved in the uptake of this drug (Lanteri et al, 2006) and loss of P2 alone gives 
only low levels of resistance in vivo. 
1.5 Human African Trypanosomiasis in Uganda 
Uganda is the only country in East Africa affected by both the T. b. gambiense and T. b. 
rhodesiense forms of disease, although both species have also been seen in Angola, which 
is located in Southern Africa. North-west Uganda suffers epidemics due to T. b. gambiense 
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separated by a vast terrain, mostly plateau with a rim of mountains, where no documented 
evidence of sleeping sickness has emerged. The number of reported cases has been shown 
to be rising since the early 1980s (Figure 1.2). Human trypanosomiasis seems to be 
restricted to particular foci and occurs during epidemics but the animal form of the disease 
is endemic and spreads over wide areas. 
1.5.1 T. b. rhodesiense in S.E. Uganda 
T. b. rhodesiense which causes acute disease and serious epidemics in SE. Uganda 
constitutes a major public health problem, which affects both man and livestock hence 
having a huge impact on rural development and the general health of the rural poor. The 
disease was first reported from the Busoga region in 1898 (Picozzi et al, 2005). The 
disease, which is endemic in 12 districts, is fatal if not treated. It is a zoonotic disease with 
evidence showing that cattle are the primary reservoir following the recent out-break in 
Soroti (Welburn et al, 2001a;Fevre et al, 2001). The continuous movement of infected 
animals is another way that can lead to the spread of the disease in to new areas infested 
with tsetse flies. Alarming reports of a possible overlap (Figure 1.3) between the traditional 
SE Uganda focus and foci further North have appeared (Enyaru et al, 1999;Hutchinson et 
al, 2003;Picozzi et al, 2005). Moreover the serological test used for screening T. b. 
gambiense infections does not work for T. b. rhodesiense and parasitological diagnosis by 
microscopy cannot distinguish between T. b. rhodesiense and T. b. brucei. Clinical 
symptoms and the PCR technique, using the serum resistance associated (SRA) and the T. 
b. gambiense specific glycoprotein (TgsGP) as markers specific for T. b. rhodesiense and 
T. b. gambiense are used to define the two species (Welburn et al, 2001a;Gibson et al, 
2002;Radwanska et al, 2002b;Radwanska et al, 2002a). The Soroti outbreak was later on 
linked to the uncontrolled movement of animals (Fevre et al, 2005;Fevre et al, 2006c) as 
the hospitalised patients from the SE Uganda were confirmed as infected with T. b. 
rhodesiense and patients from NW Uganda were confirmed as infected with T. b. 
gambiense indicating no overlap (Welburn et al, 2006).  
1.5.2 T. b. gambiense in N.W. Uganda 
T. b. gambiense, which causes chronic disease that recently resurged in NW. Uganda, is a 
public health problem with a prevalence estimated at 1% (Matovu et al, 2001a). The 
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Humans are the major source of the T. b. gambiense parasite. The HAT outbreak in south 
Sudan (Moore & Richer, 2001) coupled with movements of displaced refugees as a result 
of civil unrest (Hovil & Bagenda, 2003;United Nations Report, 2004) is implicated in the 
spread of the disease to other districts in NW Uganda (Picozzi et al, 2005) (Figure 1.3). 
 
Figure 1.3 Maps showing the convergence of T. b. rhodesiense and T. b. gambiense in 
Uganda.  
Distribution of rhodesiense (red) and gambiense (orange) (Picozzi et al, 2005). 
 
1.5.3 Local policies 
One of the policies applied to the control of Trypanosomiasis in Uganda is the mass 
screening of people at risk followed by proper diagnosis of sleeping sickness patients, 
before monitored treatment with the appropriate drug, administered at specific health care 
facilities. As a result of surveillance, reports of high melarsoprol failure rates associated 
with drug resistance in Arua, NW Uganda (Legros et al, 1999;Matovu et al, 2001b) led to 
a change in treatment policy in 2001 for Omugo Health Centre with melarsoprol being 
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Livestock farmers, on the other hand, acquire drugs easily through decentralised and 
private veterinary services, for example agroveterinary suppliers, local pharmacists and the 
informal sector. This has affected the livestock management practices of many farmers 
who misuse the drugs without proper diagnosis and this can lead to development of drug 
resistance (Geerts et al, 2001). A central government funded programme is currently 
responsible for the treatment of cattle with Trypanosomiasis (DFID Animal Health 
Programme, 2003). As a result of the reports of the spread of the disease (Picozzi et al, 
2005) that was linked to the uncontrolled movement of animals in Soroti (Fevre et al, 
2005;Fevre et al, 2006c) a new policy was implemented to reduce the risk of spreading the 
parasites to disease free areas (Wendo, 2002). Cattle transported from one district to 
another as part of the restocking programme receive a single dose of trypanocide as 
prophylaxis at the point of sale. It is a rule that before an animal permit to leave the market 
is issued, traders and livestock farmers must purchase as part of the overall market fee the 
injectable drug, which is administered by the district veterinary officials.  
1.5.4 Drugs 
Treatment of both stages of human disease differs in the T. b. gambiense North west foci 
and T. b. rhodesiense South east foci in Uganda. Pentamidine, which is given 
intramuscularly at a dosage of 4 mg/kg body weight/day for 10 days, is used as the first-
line therapy for early stage T. b. gambiense. However, it is reportedly less effective against 
early stage T. b. rhodesiense which is treated using 5 injections of suramin at a dosage of 
20 mg/kg body weight (a maximum of 1g/ injection) at intervals of 5-7 days (World Health 
Organisation, 1998). Late stage disease, in Moyo, NW Uganda and SE Uganda, is treated 
with melarsoprol at a dosage of between 1.2 -3.6 mg/kg body weight with 4 daily 
injections in 3 series each separated by 7 days. Currently, the 10 day course at a dosage of 
2.2 mg/kg body weight/day for 10 days (Burri et al, 2000) is undergoing a trial in 
Kaberamaido (Dr. E. Matovu personal communication). Eflornithine which is administered 
intravenously at 100 mg/kg body weight every 6 hours with 4 daily infusions for 14 days is 
used for late stage T. b. gambiense disease at Omugo, NW Uganda. The Nifurtimox and 
eflornithine combination is undergoing a trial at Omugo and Moyo in NW Uganda for 
treatment of late stage disease (Dr. E. Matovu, personal communication).  
Treatment of animal disease in Uganda is carried out using diminazene aceturate and 
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which are other animal trypanocides, are not used. Diminazene aceturate, which is 
curative, is used at a single dosage of 3.5 mg/Kg body weight for T. b. rhodesiense 
infection and 7 mg/Kg body weight for T. b. brucei infections. The two parasites, which 
are indistinguishable by microscopy, are instead distinguished using clinical symptoms and 
the PCR technique using the SRA marker. Isometamidium, which is curative, offers more 
benefit to the farmers and is used at 0.5 to 1 mg/Kg body weight. Resistance to both 
diminazene and isometamidium in Uganda is not considered a problem and even then 
treatment using both drugs as a sanative pair is effective with the hope of prolonging the 
effective life of the drugs. This is considered because cross-resistance is thought to be a 
rare phenomenon (Nerima et al, 2007). Of concern were reports of PCR /Sfa NI TbAT1/P2 
mutant alleles associated with isometamidium resistance in T. brucei animal isolates from 
Somalia, which isolates were also resistant to diminazene (Afework et al, 2006). However 
there is sceptism that the observed TbAT1/P2 mutant alleles were due to isometamidium 
resistance rather than diminazene (Nerima et al, 2007), which is believed to be entirely 
depend on P2 transport although there are indications that diminazene may have a second 
route of entry into the parasite other than the P2 transporter (De Koning, 2008). 
1.5.5 Control situation 
The main strategy for the control of both human and animal trypanosomiasis in Uganda is 
by detection and treatment. This is currently achieved by surveillance, which is both active 
and passive. Active case detection and mass screening of people at risk is carried out by 
mobile teams, which involve personnel from various national programmes as explained 
later (see section1.5.6). Most of the human early stage cases are detected by active case 
finding while passive surveillance (patients reporting on their own at health units) is the 
commonest mode of detection for the late stage cases. Detection is by screening using 
serological and molecular methods while microscopy is used to confirm the parasitological 
status of the confirmed cases. However, the Card Agglutination Test for Trypanosomiasis 
(CATT) (Magnus et al, 1978) used for screening of T. b. gambiense is not applicable for T. 
b. rhodesiense and distinguishing between these parasites is carried as described earlier 
(section 1.5.1). Patients are staged as either early or late stage as will be described later in 
Chapter 3. Treatment is then carried out with the most appropriate drug (see section 1.5.4). 
This control strategy of screening has also targeted individuals who may be serologically 
positive but parasitological negative for T. b. gambiense as these may act as a reservoir of 
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In the case of animals, block treatment is commonly used because of the low sensitivities 
of diagnostic tests. Therefore, detection of parasites resulting from any single infection 
leads to the treatment of the entire herd. This may target animals that could act as 
reservoirs of the human infective T. b. rhodesiense.  
Vector control is another strategy and this needs sustainability to achieve its effect on 
trypanosomiasis control 
(http://www.afro.who.int/ddc/publications/rc55_trypanosomiasis_strategy.pdf). In the past 
this relied on clearing of tsetse breeding grounds and resting places like bushes. Aerial 
spraying of insecticides which, although successful in completely eliminating tsetse in the 
Delta region of Botswana (Kgori et al, 2006), is expensive and of environmental concern 
for Uganda. Cost-effective methods using insecticide treated or baited traps and 
community participation are the current approaches used in the control of trypanosomiasis. 
Mass trapping of tsetse flies using attractant or deltamethrin-treated baited pyramidal traps, 
and cattle derived odor baited traps have since contributed to a decline in the tsetse 
densities (Katunguka-Rwakishaya & Kabagambe, 1996;Magona et al, 2005).  
1.5.6 National programmes 
Activities involving the control of the disease (vector and sleeping sickness) are carried out 
in an integrated way between different bodies. The Ministry of Agriculture Animal 
Industry and Fisheries (MAAIF) embraces Livestock Health and Entomology and this 
body employs the Veterinary Officers, Central Government Officers, District 
Entomologists and Tsetse Catchers involved in Trypanosomiasis control. The National 
Sleeping Sickness Control Programme (NSSCP), which is under the Ministry of Health 
employs the District Sleeping Sickness Officers and Sleeping Sickness Assistants. Finally, 
the Livestock Health Research Institute (LIRI) now called the National Livestock Health 
Research Institute (NALIRI), which is under the National Agricultural Research 
Organisation (NARO) employs Research Officers and Laboratory Technicians. 
The NSSCP has the duty of carrying out control activities in the T. b. rhodesiense region of 
SE Uganda. Similar activities in the T. b. gambiense region of North and NW Uganda also 
involve NSSCP in collaboration with a French non governmental organisation, Medecins 
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disease report to the Coordinating Office for Control of Trypanosomiasis in Uganda 
(COCTU), which is responsible for advising on policy. 
Efforts by these national programmes to coordinate and control the disease are also 
supported by WHO and the international community. The Ugandan government pays 
counterpart funding, e.g. payment of salaries to control staff. 
1.5.7 Drug resistance problem 
The occurrence of drug resistance in human sleeping sickness in Uganda threatens the 
control of the disease, which depends on a few old drugs. Melarsoprol, the cheapest and 
most affordable drug used for treatment of human late stage disease, has been replaced by 
eflornithine at Omugo Health Centre in Arua as a result of high treatment failure rates 
(30%) associated with drug resistance (Legros et al, 1999;Matovu et al, 2001b;Matovu et 
al, 2001a). A current concern, based on findings from an earlier study, is that eflornithine 
may not be effective in treatment of immune suppressed patients since it is trypanostatic 
and not trypanocidal (Pepin et al, 1992). Moreover, HIV-AIDS is prevalent in North 
Uganda where the health system is struggling to recover after a long period of insurgency 
by the Lord’s Resistance Army http://www.avert.org/aidsuganda.htm. Another concern is 
that resistance may develop rapidly if eflornithine is overused as a monotherapy. 
Combination therapies have been suggested to preserve efficacy and the slow development 
of resistance to the few drugs in use. Drug trials to assess the efficacy of the different 
combination therapies in Uganda have been undertaken and the treatment outcome results 
of some have been assessed as effective while others may require further investigations. 
The combination of melarsoprol and nifurtimox showed high relapse rates (>10%) with 
increased toxicity in patients presenting at Omugo Health Centre (Priotto et al, 2006). The 
combination of melarsoprol and eflornithine also had adverse effects while the 
combination of eflornithine and nifurtimox gave good efficacy with no registered relapses 
in patients presenting at both Omugo Health Centre and Yumbe Hospital (Priotto et al, 
2006;Checchi, 2007). The use of these promising combinations will have to wait for 
licensing.  
Pentamidine resistance is not considered a serious problem. The few isolated cases are 
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Resistance to the two commonly used animal trypanocides diminazene aceturate and 
isometamidium chloride has not been considered as a problem in Uganda (Dr. E. Matovu 
,personal communication,). 
1.6 Overview of the TbAT1/P2 transporter and arsenical/ 
diamidine resistance 
Parasitic protozoa such as T. brucei and Leishmania cannot synthesize purines and 
pyrimidines de novo so they entirely rely on membrane transporters to obtain these 
nutrients from their hosts (Marr et al, 1978;Fish et al, 1982). One key purine transporter is 
the characterised T. brucei adenosine transporter 1 (TbAT1) responsible for P2 activity 
(Mäser et al, 1999). TbAT1 is a single copy gene encoding a protein of 463 amino acids 
with 11 transmembrane domains predicted. It is 30% identical at the amino acid level to 
Leishmania donovani nucleoside transporter LdNT1 (Vasudevan et al, 1998). The 
trypanosomatid transporters belong to the equilibrative nucleoside transporter (ENT) 
family (Mäser et al, 1999). Alterations in TbAT1, or loss of the P2 transporter which is 
known to mediate the cellular uptake of adenosine, adenine, melarsoprol or its analogues 
and diamidines across the plasma membrane, is associated with the development of 
arsenical and diamidine resistance (de Koning, 2001a;Maser et al, 2003;Delespaux & De 
Koning, 2007). Carter and Fairlamb (1993) were the first to perform a study that showed 
that a T. b. brucei melarsen-resistant clone derived from a wild-type parental clone lacked 
the P2 transporter and was 67-fold less sensitive to melarsoprol in vitro when compared to 
the parental clone. Further more, it was demonstrated, using melarsen resistant T. brucei 
bloodstream forms, that the P2 purine transport system was implicated in the reduced 
import of the diamidine, pentamidine, leading to the suggestion of its involvement in 
pentamidine resistance (Carter et al, 1995). The P2 adenosine transport system was also 
found to be present in T. equiperdum whereby the P2 transporter of a berenil resistant 
clone also cross resistant to melarsoprol, had reduced activity and possibly decreased 
affinity for adenosine (the main P2 substrate) in comparison to the drug sensitive clone 
(Barrett et al, 1995). Recent work has shown that TbAT1 is no longer transcribed in the 
resistant cells and the residual adenine sensitive adenosine transport is due to another 
transporter protein (Barrett et al, unpublished). Other in vitro studies also revealed that 
alterations in P2 transport activity are associated with diminished drug uptake giving rise 
to drug resistance in T. brucei group organisms (Ross & Barns, 1996;Scott et al, 
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Molecular characterisation of the gene encoding the T. brucei adenosine transporter 
(TbAT1), (Mäser et al, 1999) has played a major role in further understanding the 
mechanisms underlying drug resistance in T. brucei. Identification of the TbAT1/P2 gene 
was undertaken by expression in the yeast Saccharomyces cerevisiae. The gene was found 
to encode an adenine sensitive adenosine transporter P2, whose alteration due to mutations 
resulted in melaminophenyl arsenical resistance in vitro and in vivo (Mäser et al, 
1999;Matovu et al, 2001b). Mäser and others (1999) also demonstrated that the TbAT1 
gene cloned from a melarsen-resistant clone (STIB 777R) had ten nucleotide differences in 
its cloned TbAT1 Open Reading Frame (ORF) when compared to the TbAT1 of the 
melarsen-sensitive clone (STIB 777S). Trypanosomes are diploid in nature; therefore they 
possess a copy of this gene on each of the two chromosomes. Sequencing suggested the 
possibility of STIB 777S being homozygous for the sensitive allele. The TbAT1 gene 
cloned from the melarsen-resistant clone (STIB 777R) was reintroduced into yeast and was 
shown to be unable to stimulate the uptake of exogenous adenosine and did not confer 
susceptibility to melarsen-oxide, confirming its lack of P2 activity. In this same study a 
PCR/ RFLP (Restriction fragment based polymorphism) method using the Sfa NI enzyme 
was shown to differentiate between the T. brucei melarsen sensitive (STIB 777S) and 
melarsen resistant clone (STIB 777R) by displaying different allele patterns, 566 bp & 111 
bp for the wild type TbAT1 and 435 bp and 242 bp for the mutated TbAT1 (Figure 1.4). 
The method was also used to demonstrate the presence of a mixed banding pattern in 
patient samples which were either infected with trypanosomes homozygous for both the 
sensitive and resistant TbAT1 alleles or heterozygous for the sensitive or resistant TbAT1 
alleles (Matovu et al, 2001b). Of the 10 mutations identified in the melarsen resistant 
clone, one led to an amino acid change (Ala
178→Thr (A178T) as a result of a base change 
G to A at position 532 which eliminated the Sfa NI site present in the wild type TbAT1. 
Another mutation led to an amino acid change Asn
286→Ser (A286S), as a result of a base 
change A to G at position 857 leading to a new Sfa NI site 325 bp further downstream 
(Figure 1.5). The PCR/RFLP method can differentiate between a single infection due to a 
trypanosome that is TbAT1 homozygous or hemizygous for wild type allele (TbAT1
s/s or 
TbAT1
-/s) and a single infection due to a trypanosome that is TbAT1 homozygous or 
hemizygous for the mutant allele (TbAT1
r/r or TbAT1
-/r). However, the method cannot be 
used to differentiate between a mixed infection due to both (TbAT1
s/sand TbAT1
r/r) and a 
single infection due to a trypanosome that is TbAT1 heterozygous for the wild type or 
mutant alleles (TbAT1
s/r) in case such gene information is needed. This is one of the 
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report from a field study performed in NW Uganda, shows the use of an allele specific 
PCR approach based on primers targeting the TbAT1 PCR/Sfa NI 677 bp fragment and are 
specific only for the wild type TbAT1 and mutant TbAT1 (Nerima et al, 2007). This new 
method involves using a PCR universal reverse primer (Sfa-mut) in the same PCR assay 
with two forward primers one specific for the TbAT1 wild type allele (Sfa-s) and another 
specific for the TbAT1 mutant allele (Sfa-as) for detection of melarsoprol TbAT1 mutants. 
However, the results correlate with those of the PCR/Sfa NI approach although the new 
method is faster and cheaper in terms of cost (Nerima et al, 2007). Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 1, 43 
 
 
 
Figure 1.4 Schematic of the PCR/SfaNI of the wild type (Black) and mutant (red) TbAT1. 
The schematic of the agarose gel shows the different TbAT1 PCR/RFLP band size patterns. 
TbAT1, wild type T. brucei adenosine transporter  
TbAT1
R, mutant T. brucei adenosine transporter. 
 
 
Figure 1.5 Schematic of the TbAT1 ORF and the positions of the SfaNI sites 
The schematic shows the nucleotide positions of the Sfa NI sites and the targeted TbAT1 
RFLP fragment. It also depicts the deletion of Sfa NI site in the TbAT1 wild type T. brucei 
and creation of the new site 323 bp downstream in the TbAT1 of the drug resistant T. brucei. 
ORF, open reading frame. RFLP, Restriction fragment length polymorphism. 
 
Results from these and other studies linking the loss of P2 uptake or its loss to diamidine 
and arsenical resistance, led to the suggestion that loss of P2 activity may easily result in 
cross resistance to both classes of drugs (Barrett & Fairlamb, 1999;de Koning et al, 
2000;de Koning, 2001b;de Koning et al, 2004). This was supported to some extent in a 
study in which the TbAT1/P2 gene was deleted by gene knock-out leading to reduced 
susceptibility of T. brucei to melaminophenyl arsenicals and diamidines, although only a 2-Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 1, 44 
3 fold resistance was observed for melarsoprol and pentamidine suggesting other altered 
routes of drug uptake might lead to higher level of resistance to other diamidines (Matovu 
et al, 2003). This finding was later related to a kinetic study in which it was demonstrated 
that, unlike the transport of diminazene which is almost entirely accumulated through P2 
(de Koning et al, 2004), pentamidine uptake also involves at least two additional carriers 
termed HAPT1 and LAPT1 (de Koning & Jarvis, 2001;de Koning, 2001b). Neither 
HAPT1 nor LAPT1 have yet been characterised at the molecular level. Development of 
pentamidine resistance may therefore not occur easily because of the presence of multiple 
transporters. However, in a very recent study it was demonstrated using bloodstream 
TbAT1 null mutants selected for resistance to pentamidine in vitro that loss of HAPT1 had 
occurred and this resulted in high levels of resistance (130-fold) to pentamidine when 
compared to the wild type strain 427 (Bridges et al, 2007). Cross resistance in the selected 
line to melarsoprol was increased (15-fold) while no further increase was observed for 
diminazene aceturate leading to the conclusion that loss of HAPT1 can occur due to 
pentamidine selection provided T. brucei already lacks the TbAT1/P2 which may lead to 
high arsenical resistance (Bridges et al, 2007). The observed increase in resistance to 
melarsoprol in the pentamidine resistant line KO-B48 compared to 2 to 3-fold in the 
TbAT1 knock-out was an indication that HAPT1 may also be a second route of melarsoprol 
uptake and, for pentamidine resistance to occur; more than one transporter needs to be 
altered. 
The animal trypanocide isometamidium has also been proposed to accumulate to some 
extent through the P2 transporter since it inhibited uptake of adenosine, a P2 substrate in T. 
b. brucei (Mäser et al, 1999). There are recent reports linking P2 changes in 
isometamidium resistant T. congolense although it is likely that isometamidium enters 
through other routes associated with changes in the mitochondrial membrane potential 
(Wilkes et al, 1997).  
1.6.1 The North Western Uganda (Omugo) situation 
Arua district, Omugo is one of the regions in NW Uganda that has been affected by the T. 
b. gambiense strains thought to be resistant or less susceptible to melarsoprol. During the 
time when melarsoprol treatment failures were becoming common with a prevalence as 
high as 30% (Legros et al, 1999), a field study to analyse isolates collected from 22 newly 
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the PCR/RFLP based method (Mäser et al, 1999) to investigate whether an association 
between mutations in TbAT1/P2 and treatment failure as reported in the laboratory (Mäser 
et al, 1999) was evident. They demonstrated that 38 patient isolates (59%) possessed the 
mutated TbAT1 pattern and 30 of these isolates were from relapsed patients. The remaining 
13 isolates from relapsed patients possessed a wild type TbAT1. Sequencing of TbAT1 
from the isolates revealed the presence of nine mutations, which were similar to those 
found by Mäser and others (1999), in TbAT1 from the T. brucei melarsen resistant clone 
STIB 777R. Six of these mutations were expressed at the amino acid level although one 
mutation (∆F316) was only found in the field isolates, but not in the laboratory derived 
STIB 777R. The three remaining mutations (C21T, T144C and C471T) were silent. STIB 
777R was found to possess two additional mutations; L380P causing an amino acid change 
at position 1139 and a silent mutation (C501T), which were both absent in the field isolates 
K003 (a T. b. gambiense stock from a relapse patient from Angola) and STIB 871 (a 
multidrug resistant field isolate).  
It was concluded from this study that mutations in TbAT1/P2 may play a role in 
melarsoprol treatment failures and possibly not true resistance but the presence of wild 
type TbAT1 alleles in isolates from relapse patients suggested TbAT1 may not be the only 
gene responsible (Matovu et al, 2001b) or that multiple strains were present in individual 
patients. It is also a possibility that the wild type TbAT1 alleles picked in these patient 
isolates were simply picked up from treatment failure due to inadequate drug treatment. 
However, these isolates were not tested in vitro for arsenical sensitivity. Eflornithine is the 
only other drug registered for the treatment of T. b. gambiense late stage disease, its use is 
limited because it is expensive and difficult to administer. More research was undertaken 
to understand how the melarsoprol-resistant parasites would respond to treatment with 
eflornithine. Matovu and others (2001b) performed a study using isolates collected from 
this region during the same period. The T. b. gambiense field isolates propagated in 
Mastomys rats and later adapted to culture medium were analysed in comparison to 
reference T. b. gambiense isolates from Ivory Coast and T. b. rhodesiense isolates from SE 
Uganda for their sensitivities to melarsoprol and DFMO using the long term feeder layer 
viability assay (Kaminsky et al, 1989). The eflornithine minimum inhibitory concentration 
(MIC) values were between 1.13-6.3 µg/ml indicating the NW Uganda isolates were 
sensitive but the melarsoprol MIC values of several isolates were higher (0.036 µg/ml and 
0.072 µg/ml) than those of the isolates from Ivory Coast (0.001 µ/mg-0.018µ/mg). This 
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2001a). A combination of these findings led to a change in treatment policy at Omugo 
Health Centre with melarsoprol being replaced with eflornithine in 2001.  
In Moyo district, NW Uganda (another region affected by the disease) melarsoprol is still 
used as the treatment for late stage cases as the melarsoprol relapse situation is not as 
frequent as in Arua district. However, surveillance in this region is on-going and the most 
recently released report on a study using isolates collected from Moyo between 2003-2004 
which were analysed by the PCR/Sfa NI RFLP based method (Mäser et al, 1999;Matovu et 
al, 2001b) indicated that 10 of 73 isolates possessed both wild type and mutated TbAT1 
alleles. A more sensitive allele specific PCR method identified only mutated TbAT1 in 
their samples (Nerima et al, 2007).  
Recently in South Sudan, Ibba centre, were melarsoprol was withdrawn in 2001, because 
of high treatment failure rates (Moore & Richer, 2001), analysis of isolates from T. b. 
gambiense sleeping sickness patients (18) collected in 2003 was carried out using the same 
PCR/RFLP method and sequencing. The results indicated the presence of TbAT1 wild type 
alleles only and no evidence for the resistant mutations. The isolates were tested in vitro 
and they were found to be sensitive to melarsoprol leading to the suggestion that 
melarsoprol resistant alleles were never there or melarsoprol resistant mutations can not 
survive without drug pressure (Maina et al, 2007). 
1.6.2 Drug resistance in South Eastern Uganda 
Melarsoprol is still relied on as an effective trypanocide for the treatment of human late 
stage T. b. rhodesiense. There are increasing number of reports of resistance to veterinary 
trypanocides, including diminazene and isometamidium (Schönefeld et al, 1987;Kaggwa et 
al, 1988;Clausen et al, 1992;Kalu, 1995;Mulugeta et al, 1997;Afewerk et al, 2000;Geerts 
et al, 2001), in various sub-Saharan African countries and it is surprising that resistance to 
these drugs, which have been in use for 40 years, has not yet become a major problem in 
SE Uganda although reports indicate the potential exists (Matovu et al, 1997;Enyaru et al, 
1998;Waiswa et al, 2003). With animals acting as reservoirs of the human infective T. b. 
rhodesiense parasite (see section 1.2), it is of concern that parasites transmitted by tsetse 
flies to both animals and humans may be resistant to diminazene, isometamidium and 
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involves the loss of the P2 transporter would have clear implications on possible treatment 
failure in humans using drugs that also depend on P2 for uptake. 
Block treatment of animals following identification of a clinical case in a herd is 
commonly used in Uganda. Mass chemoprophylactic treatment of the animal reservoir 
with sub curative doses of drug may also result in selection of parasites with reduced 
susceptibility to these drugs. An in vitro study was performed by Matovu and others (1997) 
to investigate the susceptibility to melarsoprol, diminazene and isometamidium of T. b. 
rhodesiense isolates collected from sleeping sickness patients and animal reservoirs, which 
indicated all of the isolates were sensitive to melarsoprol but one isolate from man was 
found to be less sensitive to both diminazene (>100 ng/ml) and isometamidium (0.78 
ng/ml) when compared to 0.8-6.3 ng/ml for diminazene and 0.01-0.20 ng/ml for 
isometamidium used to clear the rest of isolates from man and animals. This difference 
could have been due to man being infected with different parasite strains having varying 
responses to the drugs. An in vivo study by Enyaru and others (1998) to treat mice and 
cattle infected with the diminazene and isometamidium resistant T. b. rhodesiense stock 
from man and a T. b. brucei isolate that was susceptible to both drugs, revealed that 7 
mg/kg of diminazene cleared both parasite infections in cattle and the T. b. brucei infection 
in mice but 14 mg/kg of diminazene could not clear the infection in all of the T. b. 
rhodesiense infected mice. This observed difference indicated possible pharmacokinetic 
differences between the mice and cattle or differences in the parasite strains. However, 2.0 
mg/kg of isometamidium were able to clear the T. b. brucei infection in mice as well as 
both parasite infections in cattle but the same dosage failed to cure 33% of infected mice 
which suggested that the reduced susceptibility of this T. b. rhodesiense isolate in vitro and 
in vivo in mice could be a signal that resistance to animal trypanocides may develop with 
time in this region (Enyaru et al, 1998). Alternatively, to investigate the usefulness of 
treating the animal reservoir with diminazene and isometamidium, Waiswa and others 
(2003) used pigs infected with parasites from the T. brucei group and the findings showed 
that treatment with a 7.0 mg/kg body weight of diminazene resulted in relapses which were 
not observed if a dosage of 14.0 mg/kg body weight was used but a 1.0 mg/kg body weight 
of isometamidium registered no relapses. A similar study was done by Olila and others 
(2002) using T. brucei or T. vivax stabilates originally isolated from cattle in Mukono, SE 
Uganda (1995-1996) to determine their susceptibility to the three trypanocides diminazene, 
isometamidium and homidium after inoculation in cattle, goats and mice. All of the 
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isometamidium (0.5 mg/kg body weight) when compared to reference stocks, but some 
isolates in goats were less susceptible to homidium (1.0 mg/kg body weight). The same 
trend was observed in the mice indicating that homidium susceptibility was reduced. 
However, homidium is not used in Uganda. 
Preserving the efficacy of these drugs and to avoid the development of resistance is of 
great importance. Stringent vector control activities to reduce transmission and a reduction 
in mass treatment of animals would reduce drug pressure and may be the best options to 
achieving this. This would reduce the risk of the selection of resistance in humans and 
animals as this could complicate successful treatment of humans.  
1.7 Human African Trypanosomiasis situation in other 
parts of Africa 
West and Central African countries, Angola, the Democratic Republic of Congo (DRC), 
and Central African Republic (CAR) are among the regions that have suffered serious 
trypanosomiasis epidemics like Uganda (World Health Organisation, 2001). All of these 
countries which face the problem of drug resistance tend to fall within the same belt as 
shown in Figure 1.1. Several common factors have been linked to the disease in these parts 
of Africa as will be highlighted later. It is of interest to see how the Uganda T. b. 
gambiense trypanosome population structure compares with that of the chosen countries 
listed below. The population structures have earlier been proposed for T. brucei as 
panmictic (Tait, 1980), clonal (Tibayrenc et al, 1990) or epidemic (Maynard-Smith et al, 
1993). Various methods e.g. isoenzyme analysis (Gibson et al, 1978;Tait et al, 1984), 
restriction fragment polymorphism (RFLP),(Hide et al, 1994) random amplification of 
polymorphic DNA (RAPD) (Stevens & Tibayrenc, 1995) and mini/ microsatellites 
(MacLeod et al, 1999;MacLeod et al, 2000;MacLean et al, 2007;Morrison et al, 2008) 
have been used for determining population structures in T. brucei. Availability of drug 
resistance candidate microsatellite markers (MacLeod et al, 2005b) even highlights the 
possibility of using such markers for identifying drug resistance which is a problem in 
these regions. 
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1.7.1 Cameroon 
Cameroon is one of the countries in West Africa highly endemic for the Gambian form of 
the disease. The disease was thought to have been eliminated in the sixties but resurged in 
the early 1990’s resulting in a persistent epidemic in the late 1990s. Campo, which borders 
Equatorial Guinea, is one of the human foci of the disease. Although the focus is still 
active, the disease is not as prevalent (0.2-0.5%) and the outbreak was linked to pigs in the 
area which were found to be carrying the parasite (Penchenier et al, 1999). Although an 
earlier study to screen domestic animals for T. b. gambiense in the Fontem region, another 
sleeping sickness focus, indicated an absence of T. b. gambiense (Asonganyi et al, 1990), 
recent reports show evidence of domestic and wild animals acting as reservoirs of the 
human infective parasite in this region (Herder et al, 2002;Simo et al, 2006;Njiokou et al, 
2006). This may possibly be a way of maintaining the parasite in the population leading to 
the persistent epidemics. 
1.7.2 Central African Republic 
The disease, due to T. b. gambiense, is highly endemic in Central African Republic. The 
most recent outbreak occurred in the late 1990s but with no established national control 
programme, the control of the disease was complicated (Simarro et al, 2001). Animals are 
implicated as possible reservoirs for the disease since the epidemiology shows that human 
to fly contact, in comparison to pig-fly contact, varies depending on the fly species which 
should be of importance in prevention of the disease (Gouteux et al, 1993;Simo et al, 
2008b). 
1.7.3 The Democratic Republic of Congo 
Located in West-Central Africa, the Democratic Republic of Congo experienced a 
resurgence of the disease due to T. b. gambiense in the mid 1980s, which resulted in 
epidemic levels by the mid 1990s. This was attributed to a breakdown of the surveillance 
and control activities (Ekwanzala et al, 1996;Smith et al, 1998). The situation has 
improved recently with control activities in place (Nieuwenhove et al, 2001) although 
treatment failures with melarsoprol, the first line drug, still poses a challenge. Melarsoprol 
relapses are treated with eflornithine as the alternative. Trials to assess the efficacy of 
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of melarsoprol and eflornithine showed high relapse rates (Mpia & Pépin, 2002) while 
melarsoprol and nifurtimox proved more efficacious with low or no relapses (World Health 
Organisation, 2002). However, melarsoprol is still used and a randomised trial to assess its 
efficacy as a monotherapy at the standard regimen and at an improved 10 day short course 
regimen (Burri et al, 2000) in comparison to eflornithine monotherapy indicated that 
melarsoprol was less efficacious than eflornithine (Balasegaram et al, 2006). In spite of 
these findings the treatment policy has not yet been changed and melarsoprol remains the 
first choice for treatment in this country. 
1.7.4 Congo/Brazaville 
Congo is another country highly endemic for the disease, which is due to T. b. gambiense. 
The disease resurged in this country in the early 1980s with the prevalence of the disease 
increasing up to the early 1990s. Melarsoprol relapses are common and a combination 
therapy involving nifurtimox-eflornithine has been shown to be better than eflornithine 
alone (Priotto et al, 2007). Results from a similar randomised trial using melarsoprol and 
nifurtimox as monotherapy and as combination therapy have revealed that the 10-day short 
course melarsoprol and nifurtimox combination as more effective than the standard 
melarsoprol regimen (Bisser et al, 2007). Therefore these combinations offer hope. 
1.7.5 Angola 
The disease due to T. b. gambiense is a serious endemic problem for Angola. Angola 
experienced serious epidemics in the late 1990s with the prevalence of the disease varying 
between zones (0.9-9.7%) and villages (16%) (Stanghellini & Josenando, 2001). The 
recurring outbreaks are blamed on wars that hamper surveillance and control activities in 
the affected regions (Smith et al, 1998). With established disease management and control 
programmes, the prevalence of the disease is reported to have greatly reduced (Ruiz et al, 
2002;Abel et al, 2004). Melarsoprol, which is widely used for the treatment of the late 
stage disease, is associated with toxicity. A randomised trial was conducted to compare the 
efficacy and toxicity levels of a 10 day short melarsoprol regimen to the 26 day regimen 
but the results indicated a similar outcome for both (Burri et al, 2000). The short regimen 
was therefore considered an alternative and is now widely used across Africa. However, 
the increase in the relapse rate (25%) has led to increased use of the expensive and rarely 
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of melarsoprol and nifurtimox was then thought to be a promising alternative as registered 
for other countries. Melarsoprol monotherapy has just recently been replaced. 
1.8 Diagnosis of Drug Resistance 
1.8.1 Treatment and follow-up 
Management of the disease, as highlighted earlier, relies on diagnosis and treatment (see 
section 1.5.5). Patients are treated with the intention to cure taken as the overall outcome. 
Therefore follow up of patients post-treatment is crucial. This is the current approach used 
to determine treatment failures. Cut offs are used to determine the effectiveness of the 
drugs. In T. b. gambiense infections a relapse rate of 5-9% is considered normal for 
melarsoprol as the drug is not always active in cerebral spinal fluid (Wang, 1995;Onyango 
et al, 2000). Relapse rates of 15-30%, as reported in several regions in sub Saharan Africa 
in the late twentieth century were an indication that the drug was losing efficacy (Legros et 
al, 1999;Burri & Keiser, 2001;Matovu et al, 2001a;Brun et al, 2001;Moore & Richer, 
2001;Balasegaram et al, 2006). Such high relapse rates have not been registered for T. b. 
rhodesiense. Patients are requested to return at intervals of 6 months for retesting to check 
for presence of parasites in any of their body fluids. Treatment is considered successful if 
no parasites are detected at the end of a 24 months follow up period. However, a draw back 
with this method, as clear from a number of surveillance studies, relates to the fact that 
patients are frequently lost at some point during the follow up process making the 
interpretation of the findings difficult (Burri et al, 2000;Robays et al, 2004;Lejon & 
Buscher, 2005). Reports on drug trials carried out in several African countries registered 
49.3% of patients at discharge not attending any of the 4 scheduled follow up visits while 
50.7% of the patients attended only 1 visit (Schmid et al, 2004;Schmid et al, 2005). Follow 
up numbers were reported to drop from 64% at 6 months to 46% at 12 months post 
treatment (Chappuis et al, 2005). This has resulted in restricting the treatment outcome 
analysis from 24 months to 12 months in particular studies since the numbers drop even 
lower beyond this period (Balasegaram et al, 2006). It is assumed that the loss to follow up 
patients are possibly cured otherwise they would be passively detected. However, patients 
could also have died in this period. Patients still showing clinical symptoms, or parasites, 
at any of the follow up points are assessed and a decision is made. Follow up may continue 
for some while those regarded as treatment failures are retreated appropriately for example 
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1.8.2 PCR genotyping for possible presence of gene mutations 
The use of parasitological detection during follow up post-treatment is clearly an 
unsatisfactorily means of assessing treatment success. Other methods are urgently needed. 
Point mutations in drug target genes or drug transporter genes have been linked with the 
development of drug resistance in trypanosomes (Balasegaram et al, 2006;Delespaux et al, 
2006) and other parasites e.g.. P. falciparum (Foote et al, 1989;Basco et al, 1995;Plowe et 
al, 1997;Djimde et al, 2001;Babiker et al, 2001;Dorsey et al, 2001). Genotyping for 
mutations by PCR is another method used to identify clinical treatment failures that are 
drug resistant related. The method has been used before for identifying clinical treatment 
failures with chloroquine (CQ) in malaria. Such studies revealed that clinical treatment 
failure with CQ was significantly associated with parasites with the mutated forms of both 
the P. falciparum chloroquine resistance transporter gene (Pfcrt) and P. falciparum 
multidrug resistance gene (Pfmdr1) (Babiker et al, 2001;Dorsey et al, 2001;Mockenhaupt 
et al, 2001). Similar molecular methods have also been used to detect mutations in the 
dihydrofolate reductase (DHFR) and Dihydropteroate synthetase (DHPS) genes (Peterson 
et al, 1990;Foote et al, 1990;Plowe et al, 1997;Wang et al, 1997), which are associated 
with sulphadoxine-pyrimethamine resistance using isolates collected in E. Uganda from 
malaria patients below 5 years infected with P. falciparum. The findings revealed that 
presence of the triple DHFR mutant (DHFR108Asn/51Ile/59Arg) resulted in earlier 
treatment failure than the double (DHFR108Asn/59Arg) or the single mutant 
(DHFR108Asn) (Nalunkuma-Kazibwe, MSc Thesis, 2003, University of Glasgow). 
A PCR/RFLP based method has recently been developed for the detection of specific 
mutations (Ala
178 →Thr and Asn
286 →Ser) in the T. brucei purine transporter gene 
(TbAT1/P2) of trypanosomes which are melarsoprol resistant and differentiating them from 
the melarsoprol sensitive trypanosomes (Mäser et al, 1999) as displayed in Figure 1.4 and 
Figure 1.5. This method has been used to identify similar mutations in T. b. gambiense 
relapse patient isolates from NW Uganda as referred to in section 1.6.1 (Matovu et al, 
2001b;Nerima et al, 2007). The results from PCR/Sfa NI RFLP analysis revealed that 30 of 
43 relapsed patient isolates possessed the mutated TbAT1 alleles whilst the remaining 13 
possessed wild type isolates which suggested the method may miss detecting some 
treatment failure cases (Matovu et al, 2001b). The method has also been used in S. Sudan 
(Maina et al, 2007). This PCR/Sfa NI method was developed to detect only two of 
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mutations to TbAT1/P2 such as deletions observed in the T. brucei resistant isolate derived 
by selection in vitro to the furamidine DB75 (Lanteri et al, 2006).  
1.8.2.1  Trypanosome densities in natural infections 
Molecular studies such as detection of drug resistance genes, detection of infections and 
population genetics involving analysis by PCR of field samples, greatly depend on the 
quantity of available parasite material. Isolates collected from T. b. gambiense patients 
have been reported to have very low parasite densities ranging between 100-1000 
trypanosomes/ml (Simarro et al, 1999;Garcia et al, 2000). It is not known to date why the 
parasite density is persistently low it could possibly be associated with innate control 
mechanisms. The fluctuating low parasite levels are related to the presence of the variant 
surface glycoprotein coat (Cross G, 1975), which plays a huge role in the parasites evasion 
of the immune system (Cross, 1990;Clayton, 1992;Borst & Rudenko, 1994;Pays et al, 
1994;Cross, 1996). The low parasite densities in such isolates may result in insufficient 
material making it impossible to successfully detect the TbAT1/P2 gene by PCR, which is 
used as a drug resistance marker in T. brucei. The problem can also be enhanced if the 
primers used for PCR amplification are not so sensitive. This low-density problem may 
result in false negatives which, although they can be avoided, make the whole mutant 
detection process more labour intensive. An example of such a false negative would be 
lack of detection of the DNA of a trypanosome whose TbAT1 has been deleted (tbat1
-/-), 
even though such a result would not be associated with low parasite densities.  
1.8.2.2  Other methods to detect additional mutations 
The PCR/SfaNI RFLP method can be used to detect only two of the ten mutations that 
were found in to melarsoprol resistant strains (Mäser et al, 1999). Other alternative 
methods like the single stranded DNA conformation polymorphism (SSCP)/ Heteroduplex 
(HD) analysis used in the detection of human diseases (Orita et al, 1989;Liechti-Gallati et 
al, 1999) have also been used (Matovu et al, 2001b). This sensitive method can be used to 
detect the difference in the mobility on a polyacrylamide gel of a single stranded DNA 
whose conformation has been altered by a single mutation. SSCP screening results for the 
detection of TbAT1 mutants in T. b. gambiense field isolates showed three patterns which 
corresponded to the wild type, mutant and the mixed patterns observed with the PCR/SfaNI 
RFLP method indicating a correlation between the two methods (Matovu et al, 2001b) 
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mutations in a T. congolense adenosine transporter (TcoAT1) gene with high similarity to 
TbAT1/P2 when comparing diminazene resistant and sensitive T. congolense isolates 
characterised in mice by the single dose mouse test of 20 mg/kg (Delespaux et al, 2006).  
Direct sequencing (without subcloning into a vector) of DNA (Sanger et al, 1977) and 
sequencing by DNA cloning (Sambrook et al, 1989) are the methods most widely used for 
identifying the position and type of mutation in DNA isolates suspected of being mutated. 
Changes within the coding region of a sequence as a result of mutations may change the 
function of the protein or alter its affinity for the inhibiting drug. Direct sequencing of 
TbAT1 PCR products from the T. b. gambiense isolates of melarsoprol relapsed patients 
from NW Uganda (with mutant TbAT1 pattern by PCR/RFLP and SSCP), revealed that 
eight of the mutations detected were identical to mutations present in the melarsoprol 
resistant reference stock STIB777R although STIB 777R was found to contain two 
additional mutations (one synonymous and one non-synonymous) (Matovu et al, 2001b). 
Alternatively, sequencing of the TbAT1 gene from relapse patient isolates (with wild type 
TbAT1 pattern by PCR/RFLP and SSCP) showed that they lacked any of the mutations 
present in STIB 777R and were confirmed as identical to STIB 777S(Matovu et al, 2001b). 
Sequencing was also carried out for the TbAT1 gene from T. b. gambiense patient isolates 
from South Sudan (with wild type TbAT1 pattern by PCR/RFLP), and all of the isolates 
were almost identical to the melarsoprol sensitive reference stock STIB777S. Although 
direct sequencing of PCR products revealed one mutation, sequencing of subcloned PCR 
products revealed 3 more mutations which might have been introduced during PCR by Taq 
polymerase (Maina et al, 2007). 
1.8.3 FTA    Card Technology 
T. brucei drug resistance field studies especially those involving T. b. gambiense rely on 
very little parasite material as highlighted earlier (section 1.8.2.1). Moreover the 
convenient storage and transport of such material is crucial for later laboratory analysis. 
Whole blood samples, often preserved in heparinised capillary tubes, are stored at 4°C 
before being transported to the laboratory. This may lead to the irrecoverable loss of 
material in poorly resourced field settings where the power supply may not be constant. 
The development of a new sampling technology using the FTA card (Whatman 
Biosciences) has been a breakthrough. FTA technology is a simple, practical, economical 
and sensitive method for sampling, storage and retrieval of DNA from parasites or other Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 1, 55 
biological samples for PCR analysis. The FTA card method involves application of T. 
brucei infected patient blood samples by spotting on a special card filter or matrix on 
which the trypanosomes are lysed leading to their DNA being fixed and stabilized on the 
card matrix for long periods of time. The air dried FTA card samples can be stored at 
room temperature in a less humid environment or kept at 4°C before use for DNA 
extraction as will be described later in chapter 2. Low parasite densities, which are 
characteristic of T. b. gambiense, may result in little amplification material and the use of 
insensitive PCR primers are some of the drawbacks of the method. However, molecular 
studies on T. brucei amongst many other organisms have shown FTA technology to be an 
effective method (Becker et al, 2004;Picozzi et al, 2005;Morrison et al, 2007;MacLean et 
al, 2007;Morrison et al, 2008). 
1.8.4 Fluorescence tests 
Fluorescence assays have proved to be important regarding studies on T. brucei related to 
cross resistance to arsenicals and diamidines. A rapid fluorescence assay has been 
developed as a phenotypic diagnostic tool for the early detection of arsenical and 
diamidine resistance in T. brucei (Stewart et al, 2005). The method which was validated on 
T. brucei reference stocks characterised in mice utilises a fluorescent diamidine compound 
2,5-bis(4-amidinophenyl)-3,4-dimethylfuran (DB99) which targets the DNA containing 
compartments and has a TbAT1/P2 mode of uptake. The nucleus and kinetoplast of 
sensitive parasites with TbAT1/P2 activity were shown to fluoresce within 1 minute under 
a fluorescence microscope unlike the resistant parasites lacking P2 transport (Stewart et al, 
2005). A similar study performed by Lanteri and others, (2006) was used to demonstrate 
the absence of fluorescence in the TbAT1 null mutant and the T. brucei line selected for 
resistance to the fluorescent diamidine DB75 (prodrug DB289) in comparison to the wild 
type T. brucei 427 parasites. Another fluorescence assay utilising the fluorescent 
fluorophore 4,6-Diamidino-2-phenylindole dihydrochloride (DAPI) has also been taken 
advantage of (Frommel & Balber, 1987). Resistance to pentamidine, whose uptake occurs 
via multiple transporters, has been assessed by utilising DAPI fluorescence and it has been 
demonstrated that appearance of fluorescence occurred much later (after 30 minutes) in a 
laboratory derived pentamidine resistant KO-B48 line lacking both TbAT1/P2 and HAPT1 
activity while fluorescence occurred much earlier in the wild type T. brucei 427 (which has 
P2 activity) compared to the TbAT1 null mutant (which lacks P2 activity) (Bridges et al, Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 1, 56 
2007). Fluorescence microscopes suitable for use in African field settings are also under 
development (Jones et al, 2007). 
1.9 Background: Project Objectives 
The project aims to investigate risk factors, in an African field setting, that might lead to 
selection of drug resistance in African trypanosomes. This involves four complementary 
approaches: 
1.9.1 Approach 1 
To investigate the usefulness of genotyping for mutations in TbAT1/P2 as a predictive 
diagnostic and epidemiological tool for the early detection of drug resistance in T. brucei. 
This will offer a lead for making important clinical decisions aimed at reducing the burden 
of Human African Trypanosomiasis. Moreover, the investigation will be used to extend 
earlier findings that indicated that mutations in TbAT1 (related to loss of P2 activity) 
correlate with melarsoprol treatment outcome in clinical isolates from T. b. gambiense 
sleeping sickness patients in North Western Uganda. 
1.9.2 Approach 2 
To investigate, by microsatellite analysis, the general population structure of existent T. b. 
gambiense from NW Uganda as a possible way of identifying trypanosome strains that 
could be associated with drug resistance. Furthermore, to investigate how population 
structure in NW Uganda compares with other affected areas across Africa. 
1.9.3 Approach 3 
To investigate, by PCR typing the identity of trypanosome species infective to dogs and 
humans with the possibility of a veterinary link to human disease. This is a possible route 
that can lead to selection of drug resistant parasites and cross resistance between human 
and animal trypanocides which may result in serious implications for disease management. Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 1, 57 
1.9.4 Approach 4 
To investigate, by in vitro induction of drug resistance in T. brucei the possibility of 
identifying and characterising other possible markers of resistance to the drugs diminazene 
aceturate and DB75 both of which enter via the P2 transporter but for which other routes of 
uptake might exist. 
 Anne Juliet Nalunkuma Kazibwe    Chapter 2, 58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 Anne Juliet Nalunkuma Kazibwe    Chapter 2, 59 
 
2  Adaptation of the FTA technology for use in genotypic 
studies involving T. brucei  
2.1 Summary 
The specific aims of this study were to investigate whether collection of T. brucei-infected 
blood from sleeping sickness patients spotted on to FTA cards (Whatman) using the FTA 
method would enable the successful amplification by PCR and analysis of T. brucei 
microsatellite markers, the T. brucei drug resistance gene TbAT1/P2 and the presence of T. 
brucei in blood. Oligonucleotide primer pairs specific for the T. brucei multicopy locus 
(TBR) (Moser et al, 1989), the single copy T. brucei microsatellite flanking the 
Phospholipase C (PLC) gene (Tait et al, 2002), the T. brucei gambiense-specific 
glycoprotein gene (TgsGP) (Radwanska et al, 2002b) and the T. brucei adenosine 
transporter 1 gene (TbAT1/P2) (Mäser et al, 1999) were used in the sensitivity assay. 
The results revealed that the method was very sensitive with the T. brucei multicopy locus 
(TBR) primers and allowed detection of a T. brucei infection from a DNA disc punched 
from an FTA card spotted with the lowest parasite dilution of 1 trypanosome/ml. However, 
it was observed that the high parasite density required for amplification of the single copy 
TbAT1 gene, would be a limitation of the method if T. b. gambiense patient samples, which 
are known to have very low parasitaemia were to be spotted on FTA cards. Otherwise 
the method was found to be very useful. 
2.2 Introduction 
Genotypic studies on T. brucei, which involve the determination of parasite population 
structures, detection of mutations in parasite genes related to drug resistance and diagnosis 
of parasite infections, require the collection of field isolates. However, the material 
obtained from these isolates is often of very poor quality. Currently investigations of 
population genetics and in vitro drug susceptibility tests rely on propagation of parasites 
collected from patients in rodents or the KIVI kit for in vitro isolation (Truc et al, 
1992;Aerts et al, 1992). Success in the retrieval of the parasites using these methods has 
yielded varying results (Jamonneau et al, 2002;Jammonneau et al, 2003). Detection of Anne Juliet Nalunkuma Kazibwe    Chapter 2, 60 
drug resistance, the study of specific mutations in marker genes and the diagnosis of 
disease all rely on patient isolates which are collected in heparinised vials and stored at 4 
°C before transportation to the laboratory for downstream analysis. However, such storage 
conditions may not be guaranteed under field conditions in the resource-poor setting of 
sub-Saharan Africa as a result of many factors including an inconsistent power supply. 
This may lead to the loss of precious material, which may never be recoverable. It is 
therefore important that any isolates are collected in the most reliable way that will enable 
the successful retrieval of the material needed later for genotypic analysis in the laboratory. 
The FTA card (Whatman) method is a new sampling technology that has been shown to 
be effective for analysis of human pathogens (Wang et al, 2005;Zhong et al, 2001), human 
viruses (Beck et al, 2001) and plant viruses (Ndunguru et al, 2005) and even specifically 
for T. brucei (Becker et al, 2004;Picozzi et al, 2005;MacLean et al, 2007;Morrison et al, 
2008). However, I set out to evaluate the sensitivity of this approach independently, in 
order to investigate whether this technique is suitable for the PCR-based analysis of 
trypanosome DNA from T. b. gambiense-infected patients, many with low parasitaemia. 
2.3 Materials and Methods 
Study area and population 
This section includes a description of the study regions in Central Africa, where the 
samples for this thesis were collected. This was through collaborations established between 
Dr. Michael Barrett and Dr. Annette MacLeod (University of Glasgow) and other 
researchers from Central Africa. Human African Trypanosomiasis (HAT) patient samples 
from Chad, Cameroon, Ivory Coast and the Democratic Republic Congo were kindly 
provided to us by Dr. Phillipe Truc (OCEAC, Cameroon) 
Field surveys on HAT were carried out in Bodo village (GPS coordinates not available) in 
Chad in Central Africa during the month of December 2002. Similar activities were carried 
out in the month of May 2003 in Campo village (GPS coordinates not available) in 
Southern Cameroon, which is located near the border with Equatorial Guinea. During the 
month of October 2003, a medical field survey was carried out in the village in Bandundu 
around Maluku, and Maluku clinical centre (GPS coordinates not available), which is 
located north of Kinshasa in the Democratic Republic of Congo (Figure 2.1).  
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Figure 2.1 Map of Africa showing the locations of this thesis sample study regions 
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The polymerase chain reaction (PCR) is a basic molecular method that enables the 
amplification of target genes or DNA fragments along a sequence of interest. FTA 
sensitivity and detection limit PCR assays using the FTA cards spotted with known 
dilutions of infected mouse blood was performed to assess the utility of the FTA method 
for T. brucei sample collection and storage. 
T. brucei sample preparation from mice 
A female adult ICR mouse was injected intraperitoneally with 2 × 10
6 trypanosomes/ml of 
bloodstream form trypanosomes of the T. brucei brucei strain 427 (Cross, 1975). At peak 
parasitaemia (4-5 days post infection) following microscopic examination of smears from 
tail blood, infected blood was collected through cardiac puncture in a 15 ml falcon tube on 
ice. Using a start cell density of 1 × 10
10 trypanosomes/ml as determined by microscopy 
with an improved Neubauer counting chamber (WSI, Division of Hawksley Technology, 
England), the infected blood was diluted in 10-fold serial dilutions in CBSS buffer 
(Appendix I). 1 × 10
9 trypanosomes/ml and 1 trypanosome/ml were the highest dilution 
and lowest dilutions respectively. 500 µl from each blood dilution was spotted directly 
onto an FTA card (Whatman), which was allowed to air dry and then stored at room 
temperature. 
Patient sample collection 
Blood samples (n=74) from patients from Central Africa were collected as blood spots 
using the FTA card (n=54) and whole blood preps (n=20) by trained personnel in the 
respective regions. The blood preps had been pre-treated with guanidinium chloride for 
protein denaturation prior to RNA extraction before transportation. The dried cards sealed 
in plastic bags were transported at room temperature while the whole blood preps were 
transported on dry ice for molecular analysis at the Institute of Biomedical and Life 
Sciences, University of Glasgow, UK. 
DNA extraction from whole blood spotted on FTA cards 
Extraction and purification of trypanosome DNA from infected blood samples spotted on 
FTA cards (Whatman) was performed as described in the FTA protocols 
(www.whatman.com/repository/documents/s7/FTAProtocolBook602.pdf). Briefly, a 2.0 
mm disc was punched from a dried blood spot using a Harris micro punch (Whatman). The 
disc was collected in a microfuge tube and washed three times using 200 µl of FTA Anne Juliet Nalunkuma Kazibwe    Chapter 2, 63 
purification reagent with incubation and mixing by inversion at intervals for 5 minutes at 
room temperature between each wash. The FTA purification reagent was removed and the 
disc was rinsed twice using 200 µl of TE buffer (Appendix I) with incubation mixing for 5 
minutes at room temperature. The TE buffer was discarded and the DNA disc air-dried at 
room temperature for 1 hour. The air dried DNA disk was used immediately in PCR or 
kept at 4°C.  
DNA extraction from whole blood-preps using the Phenol-chloroform method 
Genomic DNA of isolates from Chad was extracted from 200 µl of infected whole blood 
pre-treated with guanidinium chloride, using the phenol-chloroform-isoamyl alcohol 
method and precipitated using 100% ethanol (Sambrook et al, 1989). Extracted DNA was 
suspended in 50 µl of sterile distilled water. Up to 5 µl of DNA was used immediately in 
PCR or kept at -20°C. 
Polymerase chain reaction amplification 
PCR amplification of the T. brucei multicopy locus (177 bp repeat or TBR), the T. brucei 
single copy GPI-specific Phospholipase C gene (PLC) associated microsatellite and the 
single copy T. brucei adenosine transporter 1 gene (TbAT1/P2) was performed. However, 
for the sensitivity assay, PCR amplification of the T. b. gambiense specific glycoprotein 
gene (TgsGP) was not included in the assay since the mouse blood used was infected only 
with T. b. brucei. The sequence properties of the TBR multicopy primers TBR-F and TBR-
R (Moser et al, 1989), the PLC gene microsatellite primers PLC-G and PLC-H3 (Tait et al, 
2002;MacLeod et al, 2005a;MacLean et al, 2007;Morrison et al, 2008) and the specific 
TbAT1 primers with their various combinations are shown in (Table 2.1). TbAT1 ant-s and 
TbAT1 ant-as (Mäser et al, 1999), TbP2F and TbP2R (Mhairi Stewart., PhD Thesis 2003, 
University of Glasgow) were designed within the 3’ and 5’ of the TbAT1 untranslated 
regions. Primer pairs P2F(RB1) and P2R(RB2) (Dr. R J S Burchmore, personal 
communication, University of Glasgow) and TbP2m-3 and TbP2m-4 (Mhairi Stewart, PhD 
Thesis 2003, University of Glasgow) were designed to amplify within the TbAT1 ORF as 
displayed in Figure 2.2. 
The analysis of the T. b. gambiense patient samples from the Democratic Republic of 
Congo, Chad and Cameroon stored as blood spots on FTA cards (Whatman) and whole 
blood preps followed. Amplification by PCR was performed using the TBR multicopy 
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the T. b. gambiense specific glycoprotein gene (TgsGP) primers TgsGP-F and TgsGP-R 
(Radwanska et al, 2002b). 
Each extracted DNA disc on an FTA card or 1-5 µl of whole blood prep DNA was PCR 
amplified in a total volume of 20 µl containing a 1 × Custom PCR mastermix (45 mM 
Tris-HCl (pH 8.8), 4.5 mM MgCl2, 11 mM (NH4)2SO4, 0.113 mg/ml BSA, 4.4 µl EDTA 
and 1 mM each deoxynucleotide triphosphate- dATP, dCTP, dGTP, dTTP) (ABgene®, 
Advanced Biotechnologies Ltd, UK). Oligonucleotide primer pairs (Table 2.1) synthesised 
by MWG Biotech-AG each at 0.4 µM and 1.25 units of GoTaq DNA polymerase enzyme 
(Promega Corporation, Madison, USA) were added to the reaction. TbAT1 primers were 
added at a concentration of 1 µM. Amplifications were carried out in a PTC-200
TM DNA 
Engine (MJ Research, inc., Waltham, MA, USA) using the following amplification 
conditions: initial denaturation at 94°C for 4 minutes, followed by denaturation at 94°C for 
30seconds, annealing at 50°C for 30 seconds, and extension at 72°C for 1 minute for 30 
cycles. This was followed by a last extension at 72°C for 7 minutes. Genomic DNA from 
the reference strain T. b. brucei 427 (Cross, 1975) or the T. b. gambiense strain ELIANE 
(Pays et al, 1983) was included in the PCR run were relevant as a positive control. Sterile 
water with no DNA template was included in the run as a negative control. To increase the 
sensitivity of each reaction, a second round of PCR, using the same oligonucleotide primer 
pair, was carried out using 1 µl of the primary PCR product as template under the same 
conditions. 
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Primer pair  Primer sequence (5’-3’)  Tm  Product 
size 
TBR-F 
TBR-R 
5’-tgc gca gtt aac gct att ata ca-3’ 
5’-aaa gaa cag cgt tgc aaa ctt-3’ 
57.1°C 
54.0° 
177 bp  
repeat 
PLC-G 
PLC-H3 
5’-caa cga cgt tgg aag agt gtg aac-3’ 
5’-cca ctg acc ttt cat ttg atc gct ttc-3’ 
62.7°C 
63.4°C 
177 bp 
TgsGP-F 
TgsGP-R 
5’-gct gct gtg ttc gga gag c-3’ 
5’-gcc atc gtg ctt gcc gct c-3’ 
61.0°C 
63.1°C 
308 bp 
TbAT1 ant-s* 
TbAT1 ant-as 
5’-gcc cgg atc cgg ctg gtt ttt aga caa aag tga t-3’ 
5’-gcc cct cga gcc gca tgg agt aag tct ga-3’ 
70.7°C 
72.3°C 
1840 bp 
TbP2F* 
TbP2R 
5’-cat gcg ctt tgg tgg agg-3’ 
5’-ttg gcg aat cgg tgt acg-3’ 
58.2°C 
56.0°C 
≈2000 bp 
TbP2m-3* 
TbP2m-4 
5’-cag agt tcc gat atg cag c-3’ 
5’- tca tcg cct ccg tgg ggg tc-3’ 
56.7°C 
65.5°C 
≈100 bp 
P2F(RB1)* 
P2R(RB2) 
5’-gac tgt cga cat gct cgg gtt tga ctc agc c-3’ 
5’-gac tct gca gta gtg cta ctt ggg aag ccc c-3’ 
72.1°C 
72.1°C 
1400 bp 
TbP2m-3* 
TbP2R 
5’-cag agt tcc gat atg cag c-3’ 
5’-ttg gcg aat cgg tgt acg-3’ 
56.7°C 
56.0°C 
≈1000 bp 
TbP2m-3* 
P2R(RB2) 
5’-cag agt tcc gat atg cag c-3’ 
5’-gac tct gca gta gtg cta ctt ggg aag ccc c-3’ 
56.7°C 
72.1°C 
≈700 bp 
P2F(RB1)* 
TbP2m-4 
5’-gac tgt cga cat gct cgg gtt tga ctc agc c-3’ 
5’- tca tcg cct ccg tgg ggg tc-3’ 
72.1°C 
65.5°C 
≈800 bp 
TbP2F* 
TbP2m-4 
5’-cat gcg ctt tgg tgg agg-3’ 
5’- tca tcg cct ccg tgg ggg tc-3’ 
58.2°C 
65.5°C 
≈1000 bp 
Table 2.1 Oligonucleotide primer sequences, properties and the expected product sizes. 
The TbAT1 primer pairs* used in the sensitivity assay in different combinations. Tm refers to 
melting temperature as calculated by the oligonucleotide manufacturer. 
 
 
Figure 2.2 A schematic showing the TbAT1 open reading frame (ORF). 
(Genbank accession number AF152369). Also shown are the positions of the forward and 
reverse primers used for PCR along the entireTbAT1 sequence from the 5’-3’ end. 
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Agarose gel electrophoresis and UV transillumination 
10 µl of each primary or second round PCR product was mixed with 1-2 µl of 6 × Blue 
loading dye (Appendix I) and separated by electrophoresis on either a 2% or 3% Agarose 
gel stained with 0.7 µg/ml ethidium bromide in 1 × TAE buffer (Appendix I). PCR 
products were visualised using a high performance ultraviolet transilluminator (Ultraviolet 
Laboratory Products Ltd, UK) and a digital photograph taken using a digital graphic printer 
(Sony, UP-D890). The band sizes were determined by comparison with a standard 1-Kb 
plus DNA size marker (Invitrogen, Life technologies, USA) and then compared to the 
expected band sizes (Table 2.1). 
2.4 Results 
2.4.1 Sensitivity and detection limit FTA PCR assays 
T. brucei brucei-infected mouse blood prepared in 10-fold serial dilutions and spotted onto 
FTA cards (Whatman) as described (section 2.3) was used to determine the sensitivity of 
the FTA method. Lack of mouse blood infected with T. b. gambiense made it impossible to 
use the TgsGP primers in this sensitivity assay. PCR reactions set up using reference 
control DNA from the T. b. brucei strain 427 (Cross, 1975) and T. b. gambiense (ELIANE) 
(Pays et al, 1983) yielded products of the predicted size with the TBR, the T. brucei PLC-
linked microsatellite, TgsGP and TbAT1 primer sets (Table 2.2). The method was specific 
with a signal observed only for the T. b. gambiense control strain (ELIANE) on 
amplification with the TgsGP primers set and not for the T. b. brucei control strain 427. 
Amplification was observed for both reference strains with the TBR primer set (Table 2.2). 
Primer pairs  T. brucei brucei 427  T. b. gambiense ELIANE 
TBR-F and TBR-R  Positive (177 bp repeat)  Positive (177 bp repeat) 
PLC-H and PLC-G3  Positive (177 bp)  Positive (177 bp) 
TgsGP-R and TgsGP-R  Negative   Positive (308 bp) 
TbAT1 ant-s and TbAT1ant-as  Positive (1800 bp)  Positive (1800 bp) 
Table 2.2 Control DNA PCR results showing the specificity of the primers. 
Positive; refers to right size PCR product as observed on agarose gel, with expected size 
given in brackets. Negative; refers to no PCR product observed on agarose gel. 
 
The TBR primer set was found to be highly sensitive as an amplicon was detected in 
agarose gel by electrophoresis for the PCR product generated from a DNA disc punched 
from an FTA card spotted with the lowest dilution of 1 trypanosome/ml. The TbAT1 and Anne Juliet Nalunkuma Kazibwe    Chapter 2, 67 
the PLC-linked microsatellite primer sets had detection limits of 10
4 trypanosomes/ml and 
10
6 trypanosomes/ml respectively (Table 2.3). It was also observed that the different 
TbAT1 based primers had varying sensitivities for this single copy gene and the PLC-
linked microsatellite as another single copy gene target was also a bit less sensitive (Table 
2.3). However, the sensitivity was observed to increase by 10-fold when a second round 
reaction of PCR was performed as shown (Figure 2.3) for the TbAT1 primer pair 
P2F(RB1) and P2R(RB2). 
The observed results indicate that the TBR primers are highly sensitive with the FTA 
method at a parasitaemia as low as 1 trypanosome/ml. They can effectively be used for the 
detection of T. brucei in very low parasitaemic samples. The use of the TBR primers has 
been reported in other studies (Masiga et al, 1992;Solano et al, 2002;Enyaru et al, 2006). 
 
Dilutions (Trypanosomes/ml)  Primer pair 
10
9  10
8  10
7  10
6  10
5  10
4  10
3  10
2  10
1  1 
Positive 
control 
strain 
TBR-F 
TBR-R 
+++  +++  +++  +++  ++  ++  ++  ++  ++  ++  ++ 
PLC-G 
PLC-H3 
-  ++  ++  +  -  -  -  -  -  -  ++ 
TbAT1 ant-s 
TbAT1 ant-as 
-  *  *  *  *  *  -  -  -  -  ++ 
TbP2F 
TbP2R 
-  -  -  -  -  -  -  -  -  -  ++ 
P2F(RB1) 
P2R(RB2) 
-  ++++  +++  +++  ++  +  -  -  -  -  ++ 
TbP2m-3 
TbP2m-4 
-  ++++  +++  ++  +  -  -  -  -  -  ++ 
TbP2m-3 
TbP2R 
-  ++++  +++  +++  ++  +  -  -  -  -  ++ 
TbP2m-3 
P2R(RB2) 
-  +++  ++  ++  -  -  -  -  -  -  ++ 
P2F(RB1) 
TbP2m-4 
-  *  *  *  *  *  -  -  -  -  ++ 
TbP2F 
TbP2m-4 
-  ++++  +++  ++  +  -  -  -  -  -  ++ 
Table 2.3 PCR assay primer sensitivities and T. brucei DNA detection limits. 
Trypanosome dilutions as displayed from the highest (10
9cells/ml) to the lowest (1 cell/ml). 
+, positive result showing gel intensity of the PCR product on agarose gel. 
-, negative result indicating no signal on agarose gel. *, wrong size product. 
TbAT1 primers are listed in bold type. 
Positive control reference strain (T. b. brucei 427). 
Negative control (sterile water with no template) results were not included in the Table. 
All results based on second round PCR using the same primer pairs and PCR conditions. Anne Juliet Nalunkuma Kazibwe    Chapter 2, 68 
 
Figure 2.3 The agarose PCR sensitivity results for primers P2F(RB1) and P2R(RB2). 
Lanes 2-11 are from the highest parasite density (10
9cells/ml) to the lowest dilution (1 
cell/ml). 
The detection limit increased by 10-fold from 10
5 to 10
4 trypanosomes/ml in a second round 
PCR using the same primers and PCR conditions.  
+, positive control (T. b. brucei strain 427). -, negative control (sterile water with no 
template). 
M, 1 Kb plus DNA size marker (Invitrogen, Life technologies, USA). 
 
2.4.2 PCR analysis of T. b. gambiense patient samples 
Field samples from Chad (n=20), Cameroon (n=9) and the Democratic Republic of Congo 
(n=45) provided to us by Dr. Phillipe Truc (OCEAC), were derived from patients 
confirmed positive by screening using the card agglutination test for trypanosomiasis 
(CATT) (Magnus et al, 1978) as described later in section 3.3 and were analysed by 
polymerase chain reaction (section 2.3). The patients had also been confirmed 
parasitologically positive by microscopy using a wet smear of their glandular aspirate and 
the haematocrit centrifugation technique (HCT) (Woo & Rogers, 1974) on their whole 
blood as described (section 3.3). The microscopic diagnosis results obtained from Dr. Truc 
are shown in Table 2.4 and Table 2.5. Out of a total of 74 samples analysed, 54 were blood 
spots on FTA cards (Whatman) and 20 were whole blood preps. A total of 53 out of 54 
(98%) samples on FTA cards were successfully amplified for the T. brucei multicopy 
locus (TBR) in comparison to 43 out of 54 (80%) for the single copy T. brucei PLC 
microsatellite (Table 2.4). This result appears to corroborate the earlier finding that TBR 
primers are more sensitive than the PLC microsatellite primers. A tentative conclusion 
could also be that 80% of the patients whose samples were observed to be positive with the 
PLC microsatellite primers likely had a peak parasite density at the time of sampling. In 
the case of the whole blood prep samples, only 9 out of 20 (45%) and 2 out of 20 (10%) Anne Juliet Nalunkuma Kazibwe    Chapter 2, 69 
were successfully amplified for the T. brucei multicopy locus and the single copy T. brucei 
PLC microsatellite respectively although the diagnosis results provided indicated that the 
wet smears were positive (Table 2.5). This finding was an indication that the FTA 
technology is superior to other sampling methods in terms of preserving parasite DNA 
material. Amplification of the TgsGP gene was unsuccessful for all the FTA cards 
(n=54) and whole blood prep (n=20) samples although the assay was positive with the T. b. 
gambiense (ELIANE) reference strain DNA. This result might indicate that the TgsGP 
gene is likely not ubiquitous in T. b. gambiense samples. But previous studies have 
indicated the gene is conserved in T. b. gambiense strains (Berberof et al, 2001) even those 
reported earlier to lack the LiTat 1.3 variant surface glycoprotein used in the CATT 
serological test (Dukes et al, 1992). An opportunity to perform an FTA sensitivity assay 
using the TgsGP primers was not possible as we were unable to successfully grow the T. b. 
gambiense (ELIANE) reference isolate in mice. 
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Sample code  Origin  Wet smear  HCT (T/ml)  TBR PCR  PLC PCR  
MAL 1  D.R of Congo  N/A  251  ++  ++ 
MAL 2  D.R of Congo  N/A  251  ++  ++ 
MAL 3  D.R of Congo  N/A  251  ++  +++ 
MAL 4  D.R of Congo  N/A  1000  ++  +++ 
MAL 5  D.R of Congo  N/A  251  ++  +++ 
MAL 6  D.R of Congo  N/A  1000  ++  +++ 
MAL 7  D.R of Congo  N/A  251  ++  - 
MAL 8  D.R of Congo  N/A  251  ++  + 
MAL 9  D.R of Congo  N/A  251  ++  ++ 
MAL 10  D.R of Congo  N/A  251  ++  - 
MAL 11  D.R of Congo  N/A  251  ++  +++ 
MAL 12  D.R of Congo  N/A  501  ++  + 
MAL 13  D.R of Congo  N/A  501  ++  + 
MAL 14  D.R of Congo  N/A  251  ++  ++ 
MAL 15  D.R of Congo  N/A  501  ++  ++ 
MAL 16  D.R of Congo  N/A  1000  -  +++ 
MAL 17  D.R of Congo  N/A  251  ++  +++ 
MAL 18  D.R of Congo  N/A  501  ++  +++ 
MAL. 19  D.R of Congo  N/A  501  ++  +++ 
MAL 20  D.R of Congo  N/A  501  ++  - 
MAL 21  D.R of Congo  N/A  1000  ++  ++ 
MAL 22  D.R of Congo  N/A  501  ++  + 
MAL 23  D.R of Congo  N/A  1000  ++  ++ 
MAL 24  D.R of Congo  N/A  251  ++  - 
MAL 25  D.R of Congo  N/A  501  ++  ++ 
MAL 26  D.R of Congo  N/A  501  ++  +++ 
MAL 32  D.R of Congo  Positive  N/A  ++  +++ 
MAL 1b  D.R of Congo  Positive  251  ++  + 
MAL 2b  D.R of Congo  Positive  251  ++  + 
MAL 3b  D.R of Congo  Positive  501  ++  + 
MAL 4b  D.R of Congo  Positive  Non   ++  + 
MAL 5b  D.R of Congo  Positive  501  ++  + 
MEN 1  D.R of Congo  Positive  251  ++  +++ 
MEN 2  D.R of Congo  Negative  501  ++  + 
MEN 3  D.R of Congo  Positive  106  ++  + 
MEN 4  D.R of Congo  Positive  215  ++  + 
MEN 5  D.R of Congo  Negative  501  ++  +++ 
MEN 6  D.R of Congo  Negative  501  ++  +++ 
MEN 7  D.R of Congo  Negative  251  ++  + 
MEN 8  D.R of Congo  Negative  251  ++  - 
MEN 9  D.R of Congo  Negative  251  ++  + 
MEN 10  D.R of Congo  Negative  251  ++  +++ 
MEN 11  D.R of Congo  Negative  251  ++  - 
MEN 12  D.R of Congo  Positive  501  ++  + 
MEN 13  D.R of Congo  Positive  251  ++  + 
CPO-01  Cameroon  Positive  Not done  ++  - 
CPO-02  Cameroon  Positive  Not done  ++  + 
CPO-03  Cameroon  Positive  Not done  ++  - 
CPO-04  Cameroon  Positive  Not done  ++  + 
CPO-05  Cameroon  Positive  Not done  ++  + 
CPO-06  Cameroon  Positive  Not done  ++  + 
CPO-07  Cameroon  Positive  Not done  ++  - 
CPO-08  Cameroon  Positive  Not done  ++  - 
CPO-09  Cameroon  Negative  Positive  ++  - 
Table 2.4 Microscopic diagnosis and PCR results for the FTA    card field samples.  
Each PCR reaction was performed on one 2-mm FTA disc. The results were obtained using 
one round of PCR amplification. 
D.R, Democratic Republic. HCT, Haematocrit centrifugation test. TBR, T. brucei repeat.  
PLC, T. brucei PLC microsatellite. +++, very strongly positive. ++, strongly positive. +, faintly 
positive. -, negative result. T/ml, number of trypanosomes /ml. N/A, result not available. 
Wet smear and HCT results as provided by Dr. P.Truc (OCEAC). PCR positive and negative 
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Sample code  Origin  Wet smear  HCT (T/ml)  TBR PCR  PLC PCR  
TCD 01a  Chad  Positive  Positive  -  - 
TCD 01 b  Chad  Positive  Positive  ++  - 
TCD 07a  Chad  Positive  Positive  +  - 
TCD 07b  Chad  Positive  Positive  -  - 
TCD 08a  Chad  Positive  Positive  -  - 
TCD 08b  Chad  Positive  Positive  -  - 
TCD 09a  Chad  Positive  Positive  +  - 
TCD 09b  Chad  Positive  Positive  +  - 
TCD 10a  Chad  Positive  Positive  ++  - 
TCD 10b  Chad  Positive  Positive  -  - 
TCD 11a  Chad  Positive  Positive  ++  - 
TCD 11b  Chad  Positive  Positive  -  - 
TCD 12a  Chad  Positive  Positive  -  - 
TCD 12b  Chad  Positive  Positive  -  - 
TCD 14a  Chad  Positive  Positive  -  - 
TCD 14b  Chad  Positive  Positive  -  - 
TCD 15a  Chad  Positive  Positive  +  - 
TCD 15b  Chad  Positive  Positive  -  - 
TCD 16a  Chad  Positive  Positive  ++  + 
TCD 16b  Chad  Positive  Positive  ++  ++ 
Table 2.5 Microscopic diagnosis and PCR results for the Whole blood prep field samples. 
Each PCR reaction was performed twice on each sample. The results were obtained using 
two rounds of PCR amplification 
HCT, Haematocrit centrifugation test. TBR, T. brucei repeat. PLC, T. brucei PLC 
microsatellite. ++, strongly positive. +, faintly positive. -, negative result. 
Wet smear and HCT results as provided by Dr. P. Truc (OCEAC). PCR positive and negative 
control results were not shown in the Table. 
 
2.5 Discussion 
Collection of trypanosomes on FTA cards is increasingly proving a reliable method to 
preserve DNA for analysis (Picozzi et al, 2005;MacLean et al, 2007;Pinchbeck et al, 
2008;Morrison et al, 2008). In our hands, the method was highly sensitive with the T. 
brucei multicopy locus (TBR) primers. With the exception of the TBR primers, no 
amplification was observed for any of the other primers at the highest concentration of 10
9 
trypanosomes/ml. This may have been due to too there being too much DNA in the 
sample, which resulted in a general failure of the PCR reaction. The TBR primers, which 
detected an infection from an FTA disc punched from a spot with the lowest dilution of 1 
trypanosome/ml, were thought to be highly sensitive because of the presence of several 
tens of thousands of copies of the repeat sequence in the genome. The FTA method was 
100-fold more sensitive in comparison to the whole blood method which could detect 10% 
of DNA in a single parasite as the lowest limit with TBR primers (Moser et al, 1989). 
However, by Real-time PCR, using DNA extracted from the FTA card with redesigned 
TBR primers, a detection limit of 10
2 trypanosomes/ml was observed for detection of T. Anne Juliet Nalunkuma Kazibwe    Chapter 2, 72 
brucei (Becker et al, 2004). Our result indicates the method is more sensitive with TBR 
primers in detecting a T. brucei infection in comparison to 1 trypanosome/ 10 ml of cattle 
blood or 25 trypanosomes/ml of human blood (Fevre et al, 2006b). Another new method 
by PCR followed by oligochromatography using a dipstick is also less sensitive with a 
detection limit of 1 trypanosome/180 µl of blood (Deborggraeve et al, 2006). However, a 
just recently concluded study has indicated a higher sensitivity with the FTA method using 
the TBR primers at a detection limit as low as 0.025 of a trypanosome/PCR. This quantity 
of material using this FTA method is equivalent to 1 µl of DNA that is whole genome 
amplified from one 2.0-mm disc punched from an FTA card (Morrison et al, 2007). 
The negative result obtained for one of the 54 FTA card field samples (MAL16) using 
the TBR primers (Table 2.4) was an indication that the sample lacked amplifiable material. 
The FTA card was designed in such a way that the parasite material spotted on the matrix 
is immobilised, fixed in place and does not spread elsewhere over the card. The same 
sample amplified with a positive result using the T. brucei single copy PLC microsatellite 
primers indicating presence of amplifiable material. The most plausible explanation for the 
negative TBR result could be lack of amplifiable T. brucei material on the FTA card 
position where the disc used in the PCR assay was punched. Repeating the PCR assay with 
another disc(s) may be required on the samples for reproducibility and to rule out sampling 
errors but this was not done. With the PLC microsatellite primers, it was observed that a 
high parasite density was required to be able to detect a signal even after performing a 
second round PCR reaction. This suggested the PLC primers were vastly less sensitive than 
the TBR primers and therefore required high parasitaemic samples. Results obtained for 
the FTA card field samples indicated a similar trend for both TBR and PLC 
microsatellite primers when compared with FTA sensitivity assay results. Of concern 
however, was the observation that the PLC-linked microsatellite primers had a detection 
limit of 10
6 trypanosomes/ml (Table 2.3), which is never achieved in patients and yet these 
primers were able to clearly detect trypanosomes in the FTA card field samples (80%) 
provided to us by Dr. Phillipe Truc. It is a possibility that the primer sensitivity was higher 
than the initial results indicated.  
Amplification of whole blood prep samples with both sets of primers was low. Eleven of 
twenty and 18/20 samples were negative with the TBR and PLC primers respectively. But 
the wet smear and HCT field diagnosis by microscopy indicated positive samples and yet 
the PCR technique is more sensitive. It is possible that the DNA extraction may not have 
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chloride, which was used to denature protein in the samples prior to RNA and DNA 
extraction, may have contributed to inhibiting the Taq polymerase enzyme during PCR 
(Reviewed by (Radstrom et al, 2004)). Alternatively, the sample DNA material could have 
been degraded or lost due to improper storage conditions prior to transportation to the 
laboratory;  but this was not tested using primers for a human repeat sequence. 
The TbAT1 primers used for amplification of the single copy TbAT1 gene were observed 
to be slightly more sensitive (10
5-10
4 trypanosomes/ml) than the PLC microsatellite 
primers used for amplification of the single copy T. brucei PLC microsatellite in the FTA 
sensitivity assay (Table 2.3). The TbAT1 ant primer set amplified different size products 
than expected, although it gave the right size product (approximately 2000 bp) with the 
reference strains (Table 2.2) and also for the DNA extracted from a T. b. gambiense relapse 
patient isolate (R015) from NW Uganda (Matovu et al, 2001a). It is possible that this set of 
primers may amplify other T. brucei related nucleoside transporters leading to different 
size products. However, a study performed using this set of TbAT1 ant primers revealed 
successful amplification of the TbAT1 gene by nested PCR of DNA extracted from CSF of 
65/75 T. b. gambiense patient isolates (Matovu et al, 2001b). These observations suggest 
that amplification of the right size fragment of TbAT1 is less likely to be successful in 
comparison to smaller size fragments of the gene as shown (see Table 2.1 and Table 2.3). 
Our results also suggested that PCR detection of TbAT1 from samples on FTA cards 
(Whatman) could be successful at a parasitaemia ≥ 10
4 trypanosomes/ml. But patient 
isolates with T. b. gambiense infections frequently have very low fluctuating parasitaemia 
between 10
2 and 10
3 trypanosomes/ml (Garcia et al, 2000;Simarro et al, 1999). As 
observed from our results, it was likely that the low parasite densities in the field isolates 
would make the amplification of TbAT1 from infected blood spotted on FTA cards more 
difficult. However, amplification of the T. brucei PLC microsatellite with PLC primers 
was good for the FTA field samples (Table 2.4) even though less sensitive than the TbAT1 
primers, which suggested the patients had a high parasitaemia. Although the development 
work indicated that TbAT1 primers were more sensitive than the PLC microsatellite 
primers (section 2.4.1), it was decided not to investigate the TbAT1 status in these samples 
although the PLC results indicated this was feasible. This was due to the fact Dr. P. Truc 
was obliged to leave Central Africa prior to having collected any follow up data on treated 
patients; hence it was not possible to determine whether samples were from treated or 
relapsed patients and thus no correlation of regarding TbAT1 status and treatment outcome 
was possible. The isolates have, however, proven invaluable with regard to development 
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sensitivity of the FTA method using the TbAT1 and PLC primers, which were observed to 
be less sensitive than the TBR primers, could possibly be increased by nested PCR. 
The TgsGP oligonucleotide primer pair was not capable of amplifying the TgsGP gene 
from DNA extracted from any of the FTA cards (Whatman) and whole blood prep field 
samples (not even for DNA diluted 1:10, 1:100 or 1:1000 in water). However, the gene 
was successfully amplified using DNA from the reference T. b. gambiense strain 
(ELIANE) and R015 which is a known T. b. gambiense relapse patient isolate from 
Uganda. The TgsGP primers have successfully been used for amplification of T. b. 
gambiense isolates from Côte d’Ivoire, Democratic Republic of Congo and Cameroon 
(Radwanska et al, 2002b;Agbo et al, 2003). The field isolates used in our study were 
collected from T. b. gambiense cases confirmed positive by CATT and parasitologically 
positive by microscopy. Since the TgsGP primers were not used in the FTA sensitivity 
assay, as this used T. brucei brucei DNA from rodent blood, it was not possible to establish 
their detection threshold. An alternative could be that these samples were possibly not T. b. 
gambiense type I and therefore did not contain TgsGP. The TgsGP primers were confirmed 
to specifically amplify from T. b. gambiense type I strains (Radwanska et al, 2002b). It is 
likely that our samples could have been T. b. gambiense type II strains, which are distinct 
from T. b. gambiense type I (Gibson, 1986;Paindavoine et al, 1986). T. b. gambiense type 
II strains were shown to be negative by PCR with the TgsGP primers (Radwanska et al, 
2002b). Yet the TgsGP gene was earlier shown to be specific to and conserved in T. b. 
gambiense strains from Cameroon, Côte d’Ivoire, Uganda and the Democratic Republic of 
Congo (Berberof et al, 2001). Possibly even low parasitaemia could have led to lack of 
amplification but this could not be resolved as explained earlier. However, since 
amplification of the single copy T. brucei PLC microsatellite was successful in many 
cases, the lack of success with the TgsGP gene requires consideration, for example the use 
of nested PCR. 
2.6 Conclusion 
Overall, the FTA method was found to be very sensitive with successful amplification of 
the T. brucei multicopy locus (TBR) and this could be useful in detection of infections due 
to T. brucei species. However, the low parasite densities limit the usefulness of the primer 
sets for the single copy T. brucei PLC microsatellite and the single copy TbAT1 gene. This 
could potentially restrict the usefulness of TbAT1 as a putative marker for arsenical and 
diamidine resistance in the field. The method has so far been utilised for detection of T. Anne Juliet Nalunkuma Kazibwe    Chapter 2, 75 
brucei infections and distinguishing between infections due to T. b. gambiense and T. b. 
rhodesiense in patient isolates collected from Uganda and Sudan (Picozzi et al, 2005). 
However, a more recent technical advance using the whole genome amplification method 
has been shown to increase the PCR sensitivity of T. b. gambiense blood samples spotted 
on FTA cards by 20-fold (Morrison et al, 2007).  
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3  Microsatellite Marker analysis 
3.1 Summary 
The aim of this part of the thesis was to investigate the population structure of T. b. 
gambiense using patient isolates collected during August 2005-August 2006 from two 
separate districts, Arua and Moyo, which are located in the same sleeping sickness focus in 
NW Uganda. A study indicating mutations in the TbAT1 gene (encoding the P2 
transporter) associated with melarsoprol treatment failure in Arua, Omugo (Matovu et al, 
2001a;Matovu et al, 2001b) associated with 30% failure rate (Legros et al, 1999) led to a 
change of treatment to eflornithine as first line treatment for stage II disease. However, 
melarsoprol is still used in Moyo as first line treatment since no high treatment failure rates 
have been recorded. The PCR/Sfa NI analysis suggested that the TbAT1 mutations 
associated with melarsoprol treatment failure were no longer present (Chapter 4). PCR 
typing of T. b. gambiense patient isolates from Arua (N=54) and Moyo (N=17) using 1 
minisatellite and 7 microsatellite markers as described (section 3.3) has been attempted to 
determine the genetic diversity and any existing genotypic differences in these samples. 
The findings suggest the two T. b. gambiense populations are distinct, although the small 
sample number for Moyo did not enable further statistically significant analysis. Analysis 
of the genotype frequencies of the T. b. gambiense population from Arua, Omugo, showed 
a deviation from the Hardy-Weinberg model (P<0.05) for all markers with evidence for 
alleles at all loci except one in linkage disequilibrium suggesting a non random mating 
population. There was evidence for an excess in homozygotes (Fis=0.315). This barrier to 
genetic exchange leading to a reduction in heterozygosity might be due to inbreeding or a 
number of other factors such as population sub-structuring or migration. In conclusion 
these data suggests that T. b. gambiense from Arua is not panmictic, clonal or epidemic but 
there is evidence of some level of genetic exchange. 
3.2 Introduction 
Background 
Genetics analysis of T. brucei is important in determining parasite population structures 
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exchange are necessary in order to determine how the parasites adapt to the different 
environments with-in the human and animal host. It is currently hypothesised that T. brucei 
strains with non-desirable selectable traits such as drug resistance (e.g. melarsoprol) or 
human serum resistance (e.g. T. b. rhodesiense and T. b. gambiense) could easily spread 
with in a population as a result of high rates of genetic exchange. In addition, this is of 
great importance regarding the choice of treatment should there be an overlap of the two 
diseases given the limited number of drugs used for the treatment of human disease due to 
T. b. gambiense and T. b rhodesiense. Moreover, the genetic diversity of T. brucei in the 
natural population is not fully understood. Results from laboratory and field studies give 
conflicting results (Gibson W & Stevens J, 1999). The population structure has been 
studied more extensively in T. b. brucei and T. b. rhodesiense than in T. b. gambiense. This 
is because of the ease with which the former two can be isolated and propagated in mice 
and culture unlike T. b. gambiense, which manifests with low level parasite densities in 
natural infections. Owing to the current advances in technology, which include the FTA 
method for sample collection (Chapter 2), population genetic studies involving T. b. 
gambiense in natural populations using microsatellite marker analysis can now be carried 
out with ease.  
Genetic exchange 
T. brucei is capable of undergoing genetic exchange. Generation of hybrids resulting from 
crosses between a reference T. b brucei strain (STIB 247) from an animal and a type II T. b 
gambiense strain (STIB 386) from man was first demonstrated to occur in tsetse (Jenni et 
al, 1986). More studies revealed that hybrids could be obtained from successful crosses in 
tsetse flies between reference strains of T. b. brucei with either T. b. brucei (Turner et al, 
1990;Gibson & Garside, 1991;Schweizer et al, 1994;Degen et al, 1995) or type II T. b. 
gambiense (Paindavoine et al, 1986;Sternberg et al, 1988) isolated from man, animals or 
tsetse. Successful crosses were shown to occur between T. b. rhodesiense isolated from 
man with either T. b. brucei strains isolated from animals (Gibson, 1989;Gibson & 
Garside, 1990;Gibson & Whittington, 1993;Gibson & Bailey, 1994;Gibson et al, 1992) or 
type II T. b. gambiense from man (Gibson et al, 1997). It was also demonstrated that 
successful crossing can occur as a result of a back cross (Gibson et al, 1995) and self-
fertilisation (selfing) can occur in the presence of another strain, as demonstrated for the T. 
b. brucei strain STIB 247 (Tait et al, 1996) and the human T. b. gambiense strain TH2N 
(Gibson et al, 1997). While genetic exchange can occur under laboratory conditions it is 
not clear to what extent it occurs in natural populations. A prerequisite for genetic 
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investigate if mixed infections are common, hypervariable T. brucei minisatellite markers 
were used to examine the isolates made from salivary glands of tsetse flies from SE 
Uganda (Lugala) and Kenya (Kiboko). More than two alleles were observed at each locus 
in several uncloned field isolates (36% Lugala and 47% Kiboko) corresponding to the 
presence of several trypanosome genotypes. Analysis of the isolates from one of the two 
cloned stocks yielded 7 genotypes further supporting the idea that large numbers of alleles 
were due to mixed infections in the field. In addition the genotypes observed in the isolates 
from tsetse were more diverse than those observed in man and animals (MacLeod et al, 
1999). 
Different genetic structures 
Three different genetic structures have been earlier described for T. brucei (Tait, 
1980;Tibayrenc et al, 1990;Maynard-Smith et al, 1993). Unlike the panmictic structure, 
the clonal and epidemic structures are characterised by linkage disequilibrium between 
alleles. The panmictic structure was described for T. b. brucei, where extensive 
unrestricted mating occurs (Tait, 1980) and the frequencies of the resulting genotypes of 
this type of structure follows the Hardy-Weinberg model with the alleles at different 
unlinked loci always in linkage equilibrium. The clonal structure was demonstrated for T. 
b. rhodesiense (Tibayrenc et al, 1990), where mating is limited i.e. little or no 
recombination occurs. The epidemic structure described for T. brucei (Maynard-Smith et 
al, 1993) is an intermediate between the panmictic and clonal type structures where the 
clonal expansion of a particular genotype conceals most of the underlying unrestricted 
mating leading to the detection of the deviation from the Hardy-Weinberg model and a 
lack of association of alleles.  
Methods and case studies analysing genetic diversity in African trypanosomes 
To investigate the level of diversity in T. brucei populations, different molecular methods 
such as isoenzyme analysis, restriction fragment length polymorphism (RFLP) (Hide et al, 
1994), random amplification of polymorphic DNA (RAPD) (Stevens and Tibayrenc, 
1995), repetitive DNA probes for southern blotting (Hide et al, 2000), minisatellite (Barrett 
et al, 1997;MacLeod et al, 1999;MacLeod et al, 2000;MacLeod et al, 2005a) and 
microsatellite markers (Biteau et al, 2000;MacLeod et al, 2005a;MacLean et al, 
2007;Morrison et al, 2008) have been applied. Population genetic studies can also be used 
to reveal variability between parasite strains or species within the same or different foci. 
This can lead to the identification of new strains associated with different transmission 
levels or disease patterns. A study by Hide and colleagues (1994), using RFLP, isoenzyme 
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isolates (n=88) from man, pigs, cattle and tsetse flies collected during a sleeping sickness 
epidemic in S.E Uganda revealed considerable diversity in the cattle isolates as observed 
from the different genotypes. The human isolates were found to be genotypically different 
from the cattle isolates and less diverse. This observation led to the conclusion that 
extensive genetic exchange was occurring between the cattle strains in comparison to the 
human infective strains an indication that possibly the transmitting flies had a feeding 
preference for cattle in comparison to humans (Hide et al, 1994). Since genetic exchange 
occurs in the fly, and mixed infections are necessary for genetic exchange, a feeding 
preference for cattle could result in mixed cattle genotypes rather than mixed human 
genotypes. However, it was not clear whether in the same focus the parasite genotypes 
circulating during an epidemic period are maintained during an endemic period. Other 
studies were carried out to address this issue. Analysis of animal T. b. brucei and T. b. 
rhodesiense (n=47) and human T. b. rhodesiense (n=7) isolates collected during an 
endemic period (1989, 1993-94) from Busia (Uganda-Kenya border) and during an 
epidemic period (1988, 1990) from Tororo (Uganda) was performed using the RFLP 
method (Hide et al, 1998). The results indicated limited genetic exchange between the 
animal strains which was in contrast to the previous findings (Hide et al, 1998). However, 
similar genotypes were observed in strains from Tororo (Uganda) suggesting that these 
strains were common to this region (Hide et al, 1998). Another study using RFLP/DNA 
probes was performed to compare T. b. rhodesiense and T. b. brucei isolates collected from 
infected tsetse in a sleeping sickness free region in Kiboko Kenya (n=7) with T. brucei 
isolates from old stocks collected from man and animals in a sleeping sickness foci in 
Busoga ,Uganda and Zambia (Hide et al, 2000). The findings revealed that the genotypes 
of the trypanosomes transmitted to man in the Busoga focus were similar to those found in 
Kiboko indicating a persistence of a common genotype. The non-human infective 
trypanosomes isolated from tsetse flies in this region were more diverse than the human 
infective trypanosomes. This suggested that circulation of trypanosomes did occur between 
geographically different foci (Hide et al, 2000). But, this did not rule out the existence of 
similar trypanosome strains occurring in different geographical regions. Observations from 
these studies seemed to suggest that T. b. rhodesiense had a clonal structure while T. b. 
brucei had either a panmictic or an epidemic type of structure. It was not clear whether T. 
brucei can have only one or more than one type of structure within the same or 
geographically distinct foci at different time points.  
Significant work has been carried out assessing Plasmodium population structure and 
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which is also a human parasite although their genetic systems are different. For example a 
study using microsatellite markers to determine the population structure of Plasmodium 
falciparum isolates from humans (n=468) collected from South America, Africa, South 
Asia/ Pacific from 5 regions of high transmission intensity and 4 regions of low level 
transmission revealed surprising results (Anderson et al, 2000). P. falciparum was 
demonstrated to exhibit different population structures with variations in diversity in each 
of the different geographical regions (Anderson et al, 2000). These differences were 
associated with either geographical factors such as differences in the epidemiological 
patterns of this species in different foci or thought to be due to migration. 
A similar approach was undertaken using minisatellite markers to compare the population 
structure of T. b. rhodesiense and T. b. brucei by analysis of isolates collected from three 
geographically distinct sleeping sickness foci; Uganda (n=64), Zambia (n = 19) and 
Nyanza (n = 24) (MacLeod et al, 2000). The findings suggested T. b. brucei had an 
epidemic structure which was in contrast to earlier findings where T. b. rhodesiense was 
observed to be clonal (MacLeod et al, 2000). Such variation in the apparent population 
structure may be due to differences in the epidemiological patterns of these species. The 
observed differences which led to that conclusion differentiated between the two sub-
species using the human serum resistance test (Jenni & Brun, 1982) prior to the analysis 
(unlike earlier analyses in which the two sub-species were grouped as one species 
(MacLeod et al, 2000). 
New methodologies applied to analysis of population genetics  
New methods for analysing population structure have recently become available. These 
include identification of novel markers for differentiating between T. b. rhodesiense 
(Welburn et al, 2001a;Gibson et al, 2002;Radwanska et al, 2002a) and T. b. gambiense 
(Radwanska et al, 2002b), sequencing of the T. brucei genome (Berriman et al, 2005), 
novel T. brucei microsatellite markers (MacLeod et al, 2005b) and the increased sensitivity 
of the FTA method for sampling T. b. gambiense field isolates (Morrison et al, 2007). The 
AFLP clustering method has been used to analyse laboratory derived T. brucei clones 
(n=6) and uncloned stocks (n=22) isolated from pigs (T. b. brucei), cattle (T. b. brucei) and 
man (T. b rhodesiense) from a sleeping sickness focus in Mukono, S.E Uganda and old 
reference stocks (T. b. brucei (n=5), T. b. rhodesiense (n = 2) and type I T. b. gambiense 
(n=6) from East, West and Central Africa. Relatedness existed between the stocks from the 
same region and small observable differences existed between stocks from different 
regions (Agbo et al, 2003). This gave an insight into the T. b. gambiense structure but the Anne Juliet Nalunkuma Kazibwe    Chapter 3, 82 
sample numbers used for this analysis were far too small to draw a firm conclusion. It was 
reported earlier that T. b. gambiense had a clonal type of structure (Tibayrenc et al, 1990). 
With the novel FTA sampling method which avoids selection of parasites when compared 
to other parasite isolation methods (Aerts et al, 1992;Truc et al, 1992), it was 
demonstrated, using microsatellite markers, that T. b. gambiense from the Democratic 
Republic of Congo (n=37) and Cameroon (n=9) was sub-structured, genetically distinct 
and clonal (Morrison et al, 2008). This was in agreement with previous studies. Using 
microsatellite markers to examine the population structure of T. brucei may act as a lead to 
the identification of specific genotypic strains that may be clonal and possibly responsible 
for drug resistance, disease virulence or human infectivity. Results from a recent study on 
T. b. rhodesiense isolates from two different sleeping sickness regions in the same focus in 
E Uganda revealed the isolates to be genotypically distinct (MacLean et al, 2007). Further 
analysis, using levels of inflammatory response as a marker for disease virulence indicated 
separate disease progression patterns for the isolates from the two regions (MacLean et al, 
2004;MacLean et al, 2007). Using a similar approach it was attempted to investigate the 
structure of T. b. gambiense from NW Uganda and to compare with the findings from the 
Central African study. 
3.3 Materials and Methods 
Study area and population 
This section includes a description of the study regions in NW Uganda from where the 
samples for this chapter were collected. The NW Uganda patient samples were collected 
during a field survey that was coordinated by Dr. Enock Matovu (Makerere University, 
Uganda). 
Field activities in areas of Arua and Moyo districts in North Western Uganda were carried 
out during the period August 2005 to August 2006. Arua and Moyo district neighbour each 
other and are separated by Yumbe district. Arua district was bordered by the Republic of 
Sudan in the north, the Democratic Republic of Congo in the west, Yumbe district in the 
northeast, Nebbi district in the south and Gulu district in the east. Omugo Health Centre 
(03.27641°N; 31.11522°S), the main sleeping sickness control centre within Arua, is 
located in Terego County. It is currently divided into three districts; Arua, Nyadri and 
Koboko (Figure 3.1). Moyo district is bordered by the River Nile in the south and east, 
Sudan in the north, and Yumbe district in the west (Figure 3.1). Moyo hospital 
(03.65055°N; 31.68872°S), the main sleeping sickness control centre within this locality, is Anne Juliet Nalunkuma Kazibwe    Chapter 3, 83 
located in Obongi County. In 2002, the population in Arua and Moyo districts was 
estimated at 860,000 and 200,000 respectively (District information Portal, 
http://www.dip.go.ug). Currently the figures are higher due to the settlement of displaced 
refugees from Sudan in N Uganda and Chad as result of civil war.(Hovil & Bagenda, 
2003;United Nations Report, 2004). Ethnic groups in this area comprise of the Nilotics 
(Alur), Nilohamites (Kakwa) and the Sudanic (Lugbara, Lendu and Madi). The main 
economic activity in the two regions is subsistence agriculture. 
Former Arua
district
Moyo district
 
Figure 3.1 Regional Map of Uganda showing the location of the study sites. 
Moyo district (shaded red) and former Arua district (shaded dark grey). 
The district map of NW Uganda showing the current location of Arua and two other created 
districts (Nyadri and Koboko).  
Omugo Health Centre, the HAT control unit in Omugo (black arrow) is located in Terego 
County.(www.newvision.co.ug/D/8/13/549160). 
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Patient screening and diagnosis 
In NW Uganda, active surveillance of populations at risk of HAT as determined from 
hospital records was carried out at designated screening centres in areas of active 
transmission by Mobile teams made up of personnel from the National Agricultural 
Livestock Health Research Institute, Vector Control Office, Omugo Health Centre and 
Moyo Hospital with the help of Sleeping Sickness Assistants (SSAs) and local village 
leaders. I was not personally involved in the diagnosis of the HAT patients. However, 
below is a description of the protocol that was used for the diagnosis of the patients that 
were used for my studies. Screening and diagnosis of patients in northwest Uganda was 
carried out according to an established diagnostic tree, which was adapted from the 
Medecens San Frontiers (Figure 3.2). All presenting persons were screened for presence of 
trypanosome antibodies using the Card Agglutination Test for Trypanosomiasis-CATT 
(Magnus et al, 1978). The cards were obtained from the Institute of Tropical Medicine 
Antwerp, Belgium (ITM) and provided as a donation by the World Health Organisation 
(WHO). Whole blood tested by CATT was taken by finger prick and later collected by 
venipuncture in heparinised vacutainer tubes. The test has been used in a number of studies 
for the serodiagnosis of T. b gambiense sleeping sickness (Blum et al, 2005;Robays et al, 
2004;Balasegaram et al, 2006;Garcia et al, 2000). Briefly, 50 µl of whole blood was 
dropped onto a plastic card. A drop of reconstituted CATT reagent (suspension of fixed 
stained and stabilised blood form trypomastigotes of well-defined serotypes) was added to 
the blood and mixed well. The card was agitated for 5 minutes at room temperature. 
Positive and negative controls from the kit were included. Agglutination indicated the 
presence of trypanosome antibodies suggestive of T. b. gambiense while absence of 
agglutination indicated absence of a trypanosome infection. Antibody levels of the CATT 
positive individuals were also determined using 1/4 and 1/8 dilutions of their blood plasma 
diluted in CATT buffer. 
Diagnosis of CATT positive persons was carried out using parasitological methods 
(Microscopy) for the detection of trypanosomes at the respective health unit; Omugo 
Health Centre (Arua) and Moyo Hospital (Moyo). Wet smears of gland aspirates from 
individuals with swollen lymph nodes were examined for motile trypanosomes using 
bright field microscopy under oil immersion at 400 × magnification.  Anne Juliet Nalunkuma Kazibwe    Chapter 3, 85 
 
Figure 3.2 A Schematic showing the screening and diagnostic tree used in NW Uganda. 
CATT, Card Agglutination Test for Trypanosomiasis. HCT, Haematocrit Centrifugation Test. 
Wet smears were performed on swollen lymph node aspirates and lumbar punctures were 
for obtaining cerebral spinal fluid.  
+ve, positive result for trypanosome antibodies by CATT and/or +ve result for trypanosomes 
by microscopy. -ve, negative result for trypanosomes by microscopy.  
SSI, sleeping sickness stage I. SSII, sleeping sickness stage II. 
WBC, white blood cell cerebral spinal fluid count.  
(Adapted from Médecins Sans Frontièrs- (Chappuis et al, 2005). 
 
Blood from individuals with or without swollen lymph glands was subjected to the 
Haematocrit Centrifugation Technique (HCT) (Woo & Rogers, 1974). Briefly, blood was 
drawn into capillary tubes, which were sealed with plasticine and centrifuged in a 
haematocrit centrifuge at 9000 × g for 5 minutes. The capillaries were examined for the 
presence of motile parasites by microscopy under oil immersion at 160 × magnification. 
Presence of trypanosomes in the lymph aspirates or blood was taken as confirmation that 
the sero-reactive individual was indeed a HAT case. A lumbar puncture for collection of 
cerebrospinal fluids (CSF) to check for central nervous system (CNS) invasion was 
performed. Briefly, 3 ml of the CSF was centrifuged at 300 × g for 5 minutes and the pellet 
was drawn into capillary tubes which were sealed for the second centrifugation followed 
by microscopic examination. In addition, a 50 µl aliquot of CSF was applied on the Anne Juliet Nalunkuma Kazibwe    Chapter 3, 86 
Rosenthal chamber to estimate the white blood cell count (WBC). Patients with 
demonstrated presence of trypanosomes in CSF or with an elevated WBC of > 5/mm
3 were 
considered to be late stage cases otherwise they were considered as early stage cases if 
they had no trypanosomes in CSF and a CSF WBC of ≤ 5/mm
3. Staging of the confirmed 
HAT patients was used to determine the drug to be administered. Passive surveillance was 
carried out when individuals feeling unwell reported to the respective health units and 
found positive after screening and diagnosis. Most of the late stage cases were detected by 
this mode. Sero-reactive but parasitologically negative individuals were asked to report for 
re-testing after 3 months. Informed consent was obtained from all confirmed HAT patients 
before enrollment in this study, who were admitted and hospitalized for the whole duration 
of treatment. 
Patient sample collection 
Blood samples for molecular analysis were collected before treatment from 
parasitologically confirmed HAT patients from NW Uganda from whom informed consent 
was obtained before enrolment in the study. A total of 133 samples were collected from 
NW Uganda of which 120 were collected on my behalf by trained personnel. The samples 
were collected in at least two different forms as either whole blood spotted onto FTA 
cards (n=89) or whole blood (n=83) or cerebral spinal fluid (n=90). Briefly, 2 ml of the 
infected whole blood from each patient was spotted onto 4 spots (500 µl per spot) of an 
FTA card (Whatman), air dried and stored in a self-sealing plastic bag at room 
temperature for later molecular analysis. All samples were then stored at room temperature 
to await transportation for analysis to the Molecular Biology Laboratory, Makerere 
University, Kampala, Uganda and the Institute of Biomedical and Life Sciences, 
University of Glasgow, UK. 
DNA extraction 
Extraction of DNA from blood spotted on FTA cards was carried out as described (section 
2.3). Genomic DNA extraction from whole blood and cerebral spinal fluid was carried out 
partially for easy transportation to the laboratory using a commercial kit (Puregene, 
Gentra Systems, MN, USA). Briefly, to 500 µl of whole blood in a 2 ml microfuge tube 
was added 1.5 ml of red blood cell (RBC) lysis solution mixed and incubated at room 
temperature for 10 minutes. This was followed by centrifugation in a desktop centrifuge at 
13,000 × g for 5 minutes, the supernatant was discarded and the pellet resuspended in 300 
µl of cell lysis solution. The quantity of CSF collected determined how much cell lysis Anne Juliet Nalunkuma Kazibwe    Chapter 3, 87 
solution was added. To 50 µl of CSF was added 550 µl of cell lysis solution directly or 300 
µl of cell lysis solution was used to resuspend the pellet recovered after centrifugation of 
the CSF. Extraction was completed using the commercial Puregene® purification kit 
following the manufacturer’s instructions (Gentra Systems, MN, USA). Proteinase K (100 
µg/ml) was added to the samples in cell lysis buffer, mixed by pipetting and incubated at 
55°C for 1 hour. For removal of protein, 200 µl of protein precipitation solution was 
added, mixed gently by inversion and the sample was incubated on ice for 5 minutes. After 
centrifugation of the suspension at 13,000 × g for 5 minutes, the supernatant was collected 
into a sterile microfuge tube and DNA precipitation and pellet washing was carried out by 
adding 400 µl each of isopropanol then 70% ethanol and centrifuged at 13,000 × g for 1 
min. After air- drying the DNA pellet for 15 minutes, it was dissolved in 20 µl of DNA 
hydration solution and left to rehydrate overnight at room temperature or at 65°C for 1 
hour. Up to 5 µl of the rehydrated DNA was used immediately in PCR or kept at -20°C.  
Whole genome amplification 
To increase the PCR sensitivity of the DNA samples on FTA cards (Whatman) and 
genomic DNA from whole blood or CSF, the whole genome amplification method was 
carried out as described (Morrison et al, 2007) using a commercial kit (GenomiPhi, 
Amersham, Biosciences Co., Piscataway, NJ, USA). Reactions were carried out in 
triplicate for each individual sample following the manufacturer’s instructions. Briefly, a 
DNA sample was denatured prior to amplification. To a DNA sample on an FTA card 
disc was added 10 µl of sample buffer in a sterile microfuge tube, which was heated to 
95°C for 3 minutes in a heating block and then cooled to 4°C on ice. Alternatively, to 1 µl 
of DNA sample from whole blood or CSF (at least 1 ng/µl) was added 9 µl of sample 
buffer. For each amplification reaction, 9 µl of reaction buffer was combined with 1 µl of 
enzyme mix on ice added to the cooled sample. The sample was then incubated at 30°C in 
a heating block for 16-18 hours. Following the overnight incubation, the sample was 
heated to 65°C for 10 minutes in a heating block to inactivate the enzyme and immediately 
cooled to 4°C. The 3 separate reactions for each individual sample were pooled. 1-2 µl of 
whole genome amplified DNA was ready for use in PCR or kept at -20°C. 
Microsatellite marker typing of NW Uganda field isolates 
Microsatellite analysis is a molecular method that has proved useful in determining the 
genotypic differences or similarities between parasite populations leading to understanding 
of their population structures (Biteau et al, 2000;Hide et al, 2000;MacLeod et al, Anne Juliet Nalunkuma Kazibwe    Chapter 3, 88 
2000;MacLeod et al, 2005a). 182 chromosome markers which span all of the 11 megabase 
chromosomes that make up the T. brucei genome have been identified (MacLeod et al, 
2005b). PCR primers based on some of these individual chromosome markers have been 
used (MacLeod et al, 2005a;MacLean et al, 2007;Morrison et al, 2008). Nested PCR 
amplifications of the chromosome (Ch) markers Ch1/18, Ch5/JS2, Ch1/D2/7, Ch11/110 
and Ch3/IJ15/1 were carried out using outer and inner microsatellite oligonucleotide 
primers (MacLean et al, 2007;Morrison et al, 2008). Amplifications were also carried out 
for two new microsatellite markers Ch11/51, Ch7/B and one new minisatellite marker 
Ch10/3778. Outer and nested oligonucleotide primer sequences and the different allele 
sizes for each chromosome marker are shown in. One of every 5’-primer of each inner 
primer pair with an exception of the minisatellite marker Ch10/3778, was FAM modified 
by labelling with a fluorescent dye to enable accurate sizing of products by computer 
analysis as described below under allele size determination. Out of 133 patient samples 
collected from NW Uganda, 54 samples from Arua district and 17 from Moyo district were 
successfully analysed.  
In a primary PCR, 2 µl of whole genome amplified DNA was PCR amplified in a total 
volume of 20 µl containing a custom PCR mastermix (45 mM Tris-HCl (pH 8.8), 4.5 mM 
MgCl2, 11 mM (NH4)2SO4, 0.113 mg/ml BSA, 4.4 µl EDTA and 1 mM each 
deoxynucleotide triphosphate- dATP, dCTP, dGTP, dTTP) (ABgene®, Advanced 
Biotechnologies Ltd, UK ). For each chromosome marker an outer primer pair (Table 3.1) 
synthesised by MWG Biotech-AG, each at 1 µM and 1.25 units of GoTaq DNA 
polymerase enzyme (Promega Corporation, Madison, USA) were added to the reaction. 
The amplification conditions for the PCR reactions were as follows: initial denaturation at 
94°C for 4 minutes, followed by denaturation at 94°C for 30seconds, annealing at 50°C for 
30 seconds, and extension at 72°C for 1 minute for 25 cycles. This was followed by a last 
extension at 72°C for 7 minutes. Amplifications were carried out in a PTC-200
TM DNA 
engine (MJ Research, inc., Waltham, MA, USA). Genomic DNA from reference strains T. 
b. gambiense reference isolate (ELIANE) (Pays et al, 1983) or T. b. brucei reference 
isolate (427) (Cross, 1975) was included in each PCR run. An inner PCR was performed 
for each chromosome marker with a nested oligonucleotide primer pair (Table 3.1) using 
1µl of undiluted primary PCR product or 1µl of 1:100 dilution as template under the same 
primary PCR and amplification conditions. 
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Primer pair  Sequence (5’-3’)  Tm  Allele sizes 
(approx.) 
Ch1/18-outside C 
Ch1/18-outside D 
Ch1/18-nestedA FAM 
Ch1/18-nested B 
5’-tataatgcgtttgtgagaat-3’ 
5’-gaagggagggaacagaagcaggg-3’ 
5’-tgtgagaatggtactcacgcgctg-3’ 
5’-cctgttggccgcattattcgatgc-3’ 
49.1°C 
66.0°C 
64.4°C 
64.4°C 
145-224bp 
Ch5/JS2-ourtside C 
Ch5/JS2-outside D 
Ch5/JS2-nested A FAM 
Ch5/JS2-nested B 
5’-agtaatgggaatgagcgtcaccag-3’ 
5’-gatcttcgcttacacaagcggtac-3’ 
5’-gattggcgcaacaactttcacatacg-3’ 
5’-ccctttcttccttggccattgttttactat-3’ 
62.7°C 
62.7°C 
63.2°C 
64.0°C 
89-253bp 
Ch1/D2/7-outside C 
Ch1/D2/7-outside D 
Ch1/D2/7-nested CC FAM 
Ch1/D2/7-nested DD 
5’-acattttggttgtcctgttgg-3’ 
5’-gatcgaagataataaatgcacat-3’ 
5’-gttggtcgcattattcgatgc-3’ 
5’-gacaaataacacacaggtgcacca-3’ 
55.9°C 
53.5°C 
57.9°C 
61.0°C 
121-246bp 
Ch11/110-outsideC 
Ch11/110-outsideD 
Ch11/110-nested A FAM 
Ch11/110-nested B 
5’-tttctacgtctcatttcaacg-3’ 
5’-actgcacaaacaggtaagcag-3’ 
5’-gatgcgaggattatgactgtagcg-3’ 
5’-ccaatcttatgcatacatgcaagc-3’ 
54.0°C 
57.9°C 
62.7°C
59.3°C 
168-228bp 
Ch3/IJ15/1-outside C 
Ch3/IJ15/1-outside D 
Ch3/IJ15/1-nested A FAM 
Ch3/IJ15/1-nested B 
5’-aggcttagacgagtgtcagg-3’ 
5’-gtaaatagacacagtgaaaccg-3’ 
5’-gttaggttacgcaagtcagt-3’ 
5’-gaaacactcagttccacacc-3’ 
59.4°C 
56.5°C 
55.3°C 
57.3°C 
102-154bp 
Ch11/51-outside A 
Ch11/51-outside B 
Ch11/51-nested A 
Ch/51-nested B FAM 
5’-cttacccacagggccaaa-3’ 
5’-tgagatggtacttgaagaaag-3’ 
5’-aaccgatcattcctgttcc-3’ 
5’-tgagatggtacttgaagaaag-3’ 
56°C 
54.0°C 
54.5°C 
54.0°C 
92-104 bp 
Ch7/B-outside A 
Ch7/B-outside B 
Ch7/B-nested A 
Ch7/B-nested B FAM 
5’-aagtggttgcgatgcggt-3’ 
5’-cctagcgcataggaatgaaacc-3’ 
5’-tatgaaatgaagtgaagtg-3’ 
5’-ctcgcagaagtaaattaaata-3’ 
56.0°C 
60.3°C 
48.0°C 
52.8°C 
133-156 bp 
*Ch10/3778-outside A 
*Ch10/3778-outside B 
*Ch10/3778-nested A 
*Ch10/3778-nested B 
5’cataagacaccactctccag-3’ 
5’-cctttgtctgacttaatgcg-3’ 
5’-caacagtgcccggaggaggtacg-3’ 
5’-gcggtgactcgtccgtcttcttgc-3’ 
57.3°C 
55.3°C 
67.8°C 
67.8°C 
Approx. 100 
bp size 
repeats (10) 
Table 3.1 T. brucei oligonucleotide PCR micro/*mini satellite primers and their properties.  
The Table shows the outside PCR primer pairs (C and D) or (A and B) and the inner or 
nested primer pairs (A and B or CC and DD) for the different chromosome markers.  
New chromosome markers (text in green). FAM, fluorescently labelled 5’ inner–primer.  
Tm, primer melting temperature as calculated by the oligonucleotide manufacturer. 
 
Agarose gel electrophoresis and allele size determination 
A volume of 8 µl of each inner PCR product, mixed with 1-2 µl of 6 × Blue loading dye 
(Appendix I), was separated by Agarose gel electrophoresis on a 3% Agarose gel stained 
with 0.7 µg/ml ethidium bromide in 1 × TAE buffer (Appendix I) and visualised as 
described (section 2.3). The approximate product band sizes as displayed in Table 3.1 and Anne Juliet Nalunkuma Kazibwe    Chapter 3, 90 
were determined by comparison with a standard 100 bp molecular weight DNA marker 
(Promega Corporation, Madison, USA). For accurate allele size determination to a level of 
1 bp, 1µl of each PCR product, which was fluorescent as a result of the FAM-labelled 
primer was diluted in water (1: 500, 1:250, 1:100 or 1:50 depending on its in gel-intensity) 
and gene scanned at the Dundee Sequencing services unit. Briefly, 15 µl of diluted PCR 
product was put in each run and separated in a capillary sequencer (ABI 3100 Genetic 
Analyser, Applied Biosystems). Fluorescent ROX-labelled standard size markers (GS500 
markers, Applied Biosystems) were included in each run for comparison with the product 
sizes. The Peak Scanner software version 1.0 (Applied Biosystems) was used for reading 
the peak traces corresponding to each sample allele product size. For each chromosome 
locus, a single peak represented a homozygous allele while a double peak represented 
heterozygous alleles for that particular marker. 
Microsatellite data analysis 
For each isolates’ peak trace results at each of the 7 out of 8 chromosome loci, an allele or 
alleles present were binned in groups according to given specific numbers (Table 3.2). 
Briefly, a specific allele number was designated to each PCR product or allele (size not 
always exactly the same for different samples) as detected by the Peak scanner for each 
locus. For the two populations in NW Uganda, Arua and Moyo, analysis was performed 
for the 8 chromosome loci using the bin data. To determine the similarities between the 
genotypes for the two populations, the data analysis was performed using the free Genetic 
Data Analysis (GDA) program (Lewis & Zaykin, 1999) for the input data to calculate the 
allele frequencies for each genotype at each loci and to calculate Nei’s genetic distance (D) 
between the Arua (N=54) and Moyo (N=17) populations. The statistical analysis was 
limited to only the Arua population, which had a reasonable sample size. Using the GDA 
program, the Fixation index (Fis) or inbreeding coefficient for the genotypes at each of the 
8 heterozygous chromosome loci (He-Ho)/Ho (where He is the expected allele frequency 
of heterozygosity and Ho is the observed frequency of heterozygosity) was calculated. 
Linkage analysis between genotypes at individual loci and the 23 pairwise locus 
combinations for Hardy-Weinberg equilibrium and linkage disequilibrium to determine the 
probability of whether mating was random or due to chance was tested using the GDA 
program. Further comparison between sample genotypes was done using the clustering 
calculator program http://www2.biology.ualberta.ca/jbrzusto/cluster.php, which generated 
the bootstrap values and the Phylip drawtree string values for only 29 samples with 5 
complete chromosome loci data sets. The TreeView free downloadable program, which 
converted the drawtree string values, was used for drawing the dendogram Anne Juliet Nalunkuma Kazibwe    Chapter 3, 91 
http://taxonomy.zoology.gla.ac.uk/rod/treeview.html. Linkage disequilibrium was also 
tested using another program Linkage Analysis 3.0 (LIAN) (Haubold and Hudson, 2000) 
to calculate the Standardised index of Association (I
SA) as a measure of the level of 
mating. 
 
Allele 
No. 
1/18 
 
5/JS2 
 
1/D2/7 
 
11/110 
 
3/IJ15/1 
 
10/3778  11/51  7/B 
1  160-4 bp  127-34 
bp 
227-228 
bp 
168-72 
bp 
136 bp  300 bp  97-8 bp  133 bp 
2  167-71 
bp 
167-171 
bp 
298-301 
bp 
210-2 
bp 
115 bp  400 bp  104 bp  142 bp 
3  224 bp  204-6 bp  231-4 bp  179 bp  144-146 
bp 
800 bp  92 bp  137-9 bp 
4  175-8 bp  95-101 
bp 
307-308 
bp 
200 bp  126 bp  900 bp    147-8 bp 
5  145-6 bp  107-110 
bp 
219-224 
bp 
174 bp  154 bp      156 bp 
6  153-4 bp  123-5 bp  147-148 
bp 
191 bp  102-104 
bp 
     
7  219 bp  156 bp  137-139 
bp 
187-8 
bp 
132 bp       
8  158 bp  89-92 bp  280 bp  182 bp  120 bp       
9    162-4 bp  167-73 
bp 
228 bp         
10    182-3 bp  247-51 
bp 
197 bp         
11    104 bp  190 bp  204 bp         
12    115 bp  194 bp  185 bp         
13    137 bp  202 bp           
14    214-18 
bp 
242-6 bp           
15    141-3 bp  180 bp           
16    237-9 bp  213 bp           
17    241-2 bp  140-2 bp           
18    253 bp  176-9 bp           
19    137 bp  162 bp           
20    221 bp  207 bp           
21    158 bp  262 bp           
22      107 bp           
23      121 bp           
Table 3.2 Alleles present at each loci and their specific allele bin number (No.)  
New microsatellite alleles (black bold) and old existing alleles (not bold) encountered at 7 
chromosome loci from the peak scan traces. Alleles encountered at minisatellite loci 
10/3778 based on signal as observed in agarose. 
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3.4 Results 
3.4.1 Genetic analysis for variation or diversity 
Sleeping sickness patient’s trypanosome DNA fixed on FTA cards (Whatman) was 
extracted as described (section 2.3) and whole genome amplified to increase the sensitivity 
(section 3.3). The trypanosome DNA was used in microsatellite/minisatellite analysis to 
identify those alleles present in parasites in the population. For both populations, Arua, 
Omugo (n=54) and Moyo (n=17), two or more alleles were observed at each of the eight 
loci for all of the isolates analysed by PCR typing of microsatellite and minisatellite 
markers (section 3.3). Determination of accurate allele sizes was performed by the Dundee 
sequencing services using a capillary based sequencer (ABI 3100 Genetic Analyser, 
Applied Biosystems) and a Peak Scanner software version 1.0 (Applied Biosystems) was 
used for reading the peak sizes as described (section 3.3). However, one marker 
(Ch10/3778) was analysed by agarose gel electrophoresis because it amplified about ten 
100 bp repeats, which are difficult to size accurately using the Peak Scanner software. For 
both populations, the alleles observed for each isolate at each chromosome locus were 
grouped together by binning and given specific numbers as detailed in Table 3.2. The 
genotypes present for each individual sample from the Arua and Moyo populations for 
each of the 8 markers are shown in Table 3.3 and Table 3.4 respectively. A summary of the 
different genotypes and their frequency for both populations is shown in Table 3.5 and 
Table 3.6 respectively. Anne Juliet Nalunkuma Kazibwe    Chapter 3, 93 
 
Genotype present at each chromosome locus  Sample
code  Ch1/18  Ch5/JS2  Ch1/D2/7  Ch11/110  Ch3/IJ15/1  Ch10/3778  Ch11/51  Ch7/B 
OM46  1/2  1/1  n.d  7/2  7/7  1/1  1/1  n.d 
OM48  1/1  1/1  10/10  1/1  1/1  1/2  2/2  n.d 
OM51  1/2  1/14  13/13  n.d  n.d  2/2  1/1  n.d 
OM55  1/2  15/16  14/14  1/1  1/7  1/2  1/1  1/1 
OM58  1/2  1/1  14/14  n.d  1/1  1/1  n.d  n.d 
OM62  1/2  15/16  10/10  1/7  1/7  1/2  1/2  2/2 
OM66  1/2  15/15  10/10  8/8  7/7  n.d  n.d  n.d 
OM69  1/1  15/15  10/10  1/7  1/1  2/2  1/1  3/3 
OM70  1/2  15/15  10/10  7/7  n.d  n.d  n.d  n.d 
OM72  2/2  1/14  14/14  1/1  7/7  n.d  2/2  n.d 
OM77  1/1  1/1  10/10  1/1  1/7  n.d  n.d  1/1 
OM79  1/2  n.d  9/9  7/7  1/1  2/2  3/1  n.d 
OM80  1/1  8/4  n.d  9/9  8/8  n.d  3/3  3/4 
OM81  1/1  n.d  15/15  1/10  1/1  n.d  2/2  n.d 
OM83  1/1  8.4  9/16  9/9  8/8  3/3  n.d  4/5 
OM85  1/1  8/4  n.d  n.d  8/1  n.d  n.d  n.d 
OM86  1/1  15/14  9/16  1/7  7/1  1/2  1/2  2/2 
OM87  1/2  15/17  17/14  1/1  7/1  1/2  1/2  2/2 
OM88  1/1  8/4  9/16  9/9  8/8  3/3  3/3  4/5 
OM89  n.d  17/17  14/14  1/1  1/1  1/1  2/2  n.d 
OM90  1/2  15/17  14/14  1/7  7/7  3/3  n.d  2/2 
OM92  1/8  8/4  9/16  1/7  7/7  1/2  1/2  2/2 
OM93  1/1  n.d  9/16  1/1  7/7  2/2  2/2  n.d 
OM95  1/2  4/4  n.d  7/7  n.d  n.d  n.d  n.d 
OM96  1/1  18/18  9/16  1/7  7/7  1/1  1/2  2/2 
OM97  1/1  4/4  10/10  1/7  7/1  1/1  n.d  n.d 
OM100  1/2  15/15  n.d  1/7  7/7  n.d  1/2  2/2 
OM105  1/1  1/1  n.d  7/7  1/1  n.d  1/2  n.d 
OM106  2/2  4/4  n.d  7/7  n.d  1/2  n.d  2/2 
OM108  1/1  8/4  15/15  n.d  1/1  n.d  n.d  2/2 
OM110  1/1  n.d  9/9  1/7  7/7  1/2  n.d  2/2 
OM112  1/1  4/4  9/16  9/9  8/8  3/3  3/3  4/5 
OM115  1/1  15/16  9/16  1/7  1/7  1/2  1/2  2/2 
OM116  1/2  n.d  10/10  1/7  1/7  1/2  1/2  2/2 
OM117  1/2  n.d  14/14  1/7  1/7  1/2  1/2  2/2 
OM118  1/2  16/16  19/18  7/7  7/7  2/2  2/2  n.d 
OM119  1/2  15/14  7/7  1/7  7/7  1/1  1/2  2/2 
OM120  n.d  n.d  3/3  n.d  1/1  2/2  1/1  n.d 
OM121  1/2  1/1  17/20  1/7  1/1  n.d  n.d  n.d 
OM122  1/2  15/14  14/14  1/7  1/7  1/2  n.d  2/2 
OM123  1/2  15/16  14/14  1/7  1/7  2/2  n.d  2/2 
OM126  1/2  15/15  14/14  1/7  1/7  1/2  1/2  n.d 
OM127  1/2  19/20  14/14  1/7  1/7  1/2  1/2  2/2 
OM129  1/2  n.d  10/10  1/7  1/7  n.d  1/2  2/2 
OM130  1/2  n.d  10/10  1/7  1/7  2/2  1/2  2/2 
OM131  1/2  16/16  10/10  1/7  1/7  1/1  n.d  2/2 
OM132  1/1  1/20  10/10  7/7  7/7  n.d  n.d  n.d 
OM133  1/2  15/15  21/21  7/7  n.d  n.d  n.d  2/2 
OM140  1/2  15/16  14/14  7/7  n.d  1/1  n.d  n.d 
OM142  1/2  15/15  n.d  1/1  7/7  n.d  n.d  n.d 
OM143  1/2  15/15  10/10  1/7  1/1  1/2  1/2  n.d 
OM145  1/2  21/21  10/10  7/7  7/7  1/2  n.d  n.d 
OM147  1/2  15/15  10/10  1/7  n.d  n.d  1/1  n.d 
OM148  1/2  15/21  10/10  1/7  1/7  1/1  1/2  2/2 
Table 3.3 Multilocus allele genotype data for the Arua population (N=54) at 8 loci. 
Allele types for 7 loci (after binning based on signals as determined from Peak scanner 
trace results) with the exception of locus Ch10/3778 (after binning based on signals as 
observed in agarose). 
Specific allele numbers as allocated to the different size PCR products after binning (Table 
3.2). n.d, no product detected in agarose (or missing data). 
 
 Anne Juliet Nalunkuma Kazibwe    Chapter 3, 94 
 
Genotype present at each Chromosome locus  Sample
code  Ch1/18  Ch5/JS2  Ch1/D2/7  Ch11/110  Ch3/IJ15/1  Ch10/3778  Ch11/51  Ch7/B 
M117  1/2  n.d  n.d  n.d  n.d  2/2  ½  2/2 
M135  n.d  n.d  n.d  11/11  n.d  2/2  n.d  1/1 
M139  1/1  4/4  22/23  10/10  1/7  n.d  2/2  1/1 
M140  1/1  n.d  n.d  n.d  1/1  n.d  1/2  2/2 
M145  n.d  n.d  n.d  n.d  n.d  n.d  n.d  n.d 
M146  2/2  8/6  n.d  n.d  n.d  4/4  n.d  2/2 
M148  1/1  n.d  n.d  1/1  1/1  2/2  2/2  2/2 
M152  1/2  8/5  n.d  n.d  1/1  n.d  1/1  n.d 
M153  1/2  1/1  14/14  10/10  1/1  1/1  n.d  n.d 
M155  1/2  n.d  14/14  1/7  n.d  1/2  1/2  n.d 
M156  1/1  1/14  n.d  7/7  1/1  n.d  2/2  2/2 
M167  1/2  n.d  n.d  n.d  n.d  n.d  n.d  n.d 
M169  n.d  4/4  n.d  1/1  n.d  n.d  n.d  n.d 
M175  2/2  4/4  10/10  n.d  3/3  n.d  n.d  n.d 
M176  1/2  19/19  14/14  n.d  n.d  2/2  n.d  n.d 
M177  1/1  1/1  14/14  7/7  1/1  1/1  n.d  n.d 
M181  1/2  4/1  n.d  1/1  1/1  1/1  n.d  2/2 
Table 3.4 Multilocus allele genotype data for the Moyo population (N=17) at 8 loci  
Allele types for 7 loci (after binning based on signals as determined from Peak scanner 
trace results) with the exception of locus Ch10/3778 (after binning based on signals as 
observed in agarose).  
Specific allele numbers as allocated to the different size PCR products after binning (Table 
3.2). n.d, no product detected in agarose (or missing data). 
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Region  Genotypes at each chromosome locus / (number of samples) 
Arua  1/18  5/JS2  1/D2/7  11/110  IJ15/1  3778  11/51  7/B 
  1/1(18)  1/1(6)  10/10(16)  7/2(1)  7/7(13)  1/1(9)  1/1(6)  1/1(2) 
  1/2(31)  1/14(2)  13/13(1)  1/1(8)  1/1(11)  1/2(16)  2/2(6)  2/2(22) 
  2/2(2)  15/16(5)  14/14(11)  1/7(25)  1/7(18)  2/2(8)  1/2(17)  3/3(1) 
  1/8(1)  15/15(9)  9/9(2)  8/8(1)  8/8(4)  3/3(4)  3/1(1)  3/4(1) 
    8/4(6)  15/15(2)  7/7(9)  8/1(1)    3/3(3)  4/5(3) 
    15/14(3)  9/16(8)  9/9(4)         
    15/17(2)  17/14(1)  1/10(1)         
    17/17(1)  19/18(1)           
    4/4(4)  7/7(1)           
    18/18(1)  3/3(1)           
    16/16(2)  17/20(1)           
    19/20(1)  21/21(1)           
    1/20(1)             
    21/21(1)             
    15/21(1)             
total(N)  52  45  46  49  47  37  33  29 
Table 3.5 Genotypes present in Arua at each individual chromosome locus. 
Genotypes unique within the Arua T. b. gambiense population (Bold red). 
Genotypes present in both Arua and Moyo T. b. gambiense populations (not bold). 
N, total number of samples successfully analysed for each chromosome marker. 
 
Region  Genotypes at each chromosome locus / (number of samples) 
Moyo  1/18  5/JS2  1/D2/7  1/110  IJ15/1  3778  11/51  7/B 
  1/1(5)  1/1(2)  10/10(1)  1/1(3)  1/1(1)  1/1(3)  1/1(1)  1/1(2) 
  1/2(7)  1/14(1)  14/14(4)  1/7(1)  1/7(7)  1/2(1)  2/2(3)  2/2(6) 
  2/2(2)  4/4(3)  22/23(1)  7/7(2)  3/3(1)  2/2(4)  1/2(3)   
    8/6(1)    10/10(2)    4/4(1)     
    8/5(1)    11/11(1)         
    19/19(1)             
    4/1(1)             
total (N)  14  10  6  9  9  9  7  29 
Table 3.6 Genotypes present in Moyo at each individual chromosome locus. 
Genotypes unique within the T. b. gambiense Moyo population (Bold black). 
Genotypes present in both Arua and Moyo T. b. gambiense populations (not bold). 
N, total number of samples successfully analysed for each chromosome marker. Anne Juliet Nalunkuma Kazibwe    Chapter 3, 96 
Microsatellite markers Ch1/18, Ch3/IJ15/1, Ch10/3778, and Ch11/51 were observed to be 
relatively homogenous for both populations with one or two predominant alleles present in 
all of the isolates. Markers Ch5/JS2, Ch1/D2/7, Ch11/110 and Ch7/B were more 
polymorphic, especially within the Arua population, indicating a high level of diversity as 
observed from the number of alleles and genotypes as summarised (Table 3.7). This 
difference in the populations could be due to the different sample sizes. 
Population  Locus  Sample number  
(n) 
Number of alleles  
(Na) 
Number of 
genotypes (Ng) 
Moyo  Ch1/18  14  2  3 
(N=17)  Ch5/JS2  10  7  7 
  Ch1/D2/7  6  4  3 
  Ch11/110  9  4  5 
  Ch3/IJ15/1  9  3  3 
  Ch10/3778  9  3  4 
  Ch11/51  7  2  3 
  Ch7/B  8  2  2 
Arua   Ch1/18  52  3  4 
(N=54)  Ch5/JS2  45  11  15 
  Ch1/D2/7  46  13  12 
  Ch11/110  49  6  7 
  Ch3/IJ15/1  47  3  4 
  Ch10/3778  37  3  4 
  Ch11/51  33  3  5 
  Ch7/B  29  5  5 
Table 3.7 Diversity of alleles and genotypes observed at each locus in both populations. 
The data shows the polymorphism of the different markers.  
N, Population sample size. n, number of samples with a positive signal. 
Na, number of alleles observed based on peak scan traces (7 loci) and in agarose (locus 
10/3778). Ng, number of genotypes present at each loci. 
 
The frequencies of the alleles present within each population at each locus which were 
calculated using the Genetic Data Analysis (GDA) program (Lewis & Zaykin, 1999) 
http://hydrodictyon.eeb.uconn.edu/people/plewis/software.php and are presented in Table 
3.8 and displayed as histograms in Figure 3.3, Figure 3.4 and Figure 3.5. 
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Locus   Allele   Arua 
Allele frequency 
Moyo 
Allele frequency 
Ch1/18  1  0.654  0.607 
  2  0.337  0.393 
  8  0.010  0.000 
Ch5/JS2  1  0.167  0.300 
  4  0.156  0.350 
  5  0.000  0.050 
  6  0.000  0.050 
  8  0.067  0.100 
  14  0.056  0.050 
  15  0.322  0.000 
  16  0.100  0.000 
  17  0.044  0.000 
  18  0.022  0.000 
  19  0.011  0.100 
  20  0.022  0.000 
  21  0.033  0.000 
Ch1/D2/7  3  0.022  0.000 
  7  0.022  0.000 
  9  0.130  0.000 
  10  0.348  0.167 
  13  0.022  0.000 
  14  0.250  0.667 
  15  0.043  0.000 
  16  0.087  0.000 
  17  0.022  0.000 
  18  0.011  0.000 
  19  0.011  0.000 
  20  0.011  0.000 
  21  0.022  0.000 
  22  0.000  0.083 
  23  0.000  0.083 
Ch11/110  1  0.418  0.389 
  2  0.010  0.000 
  7  0.459  0.278 
  8  0.020  0.000 
  9  0.082  0.000 
  10  0.010  0.222 
  11  0.000  0.111 
Ch3/IJ15/1  1  0.436  0.833 
  3  0.000  0.111 
  7  0.468  0.056 
  8  0.096  0.000 
Ch10/3778  1  0.459  0.389 
  2  0.432  0.500 
  3  0.108  0.000 
  4  0.000  0.111 
Ch11/51  1  0.455  0.429 
  2  0.439  0.571 
  3  0.106  0.000 
Ch7/B  1  0.069  0.250 
  2  0.759  0.750 
  3  0.052  0.000 
  4  0.069  0.000 
  5  0.052  0.000 
Table 3.8 Allele frequencies at each locus for both Arua and Moyo T. b. gambiense 
populations. Anne Juliet Nalunkuma Kazibwe    Chapter 3, 98 
 
Figure 3.3 Allele frequencies for Ch1/18, Ch5/JS2 and Ch1/D2/7 within Arua and Moyo T. b. 
gambiense populations. 
n, number of samples that amplified with a product for each particular marker. 
Population size Arua (N=54) and Moyo (N=17). 
Allele, specific number allocated to a particular size PCR product after binning based on the 
peak scanner traces (Table 3.2). 
 Anne Juliet Nalunkuma Kazibwe    Chapter 3, 99 
 
Figure 3.4 Allele frequencies for Ch3/IJ15/1, Ch10/3778 and Ch11/51 within Arua and Moyo T. 
b. gambiense populations. 
n, number of samples that amplified with a product for each particular marker. 
Population size Arua (N=54) and Moyo (N=17). 
Allele, specific allele number allocated to a particular size PCR product after binning based 
on the peak scanner traces with an exception of minisatellite marker Ch10/3778 (size of PCR 
products were determined as observed in agarose) [Table 3.2] 
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Figure 3.5 Allele frequencies for Ch11/110 and Ch7/B within Arua and Moyo T. b. gambiense 
populations. 
n, number of samples that amplified with a product for each particular marker. 
Population size Arua (N=54) and Moyo (N=17). 
Allele, specific allele number allocated to a particular size PCR product after binning based 
on peak scanner traces (Table 3.2)  Anne Juliet Nalunkuma Kazibwe    Chapter 3, 101 
 
Comparison of the Arua and Moyo T. b. gambiense populations 
To determine whether a genetic difference existed between the two T. b. gambiense 
populations, the averaged genetic difference was obtained for all the 8 markers. The 
Genetic Data Analysis (GDA) software program (Lewis & Zaykin, 1999) 
http://hydrodictyon.eeb.uconn.edu/people/plewis/software.php was used to calculate 
genetic distance (Nei 1978) using a matrix type input data generated from the multilocus 
genotype results for Arua and Moyo populations (Table 3.3 and Table 3.4). The result 
suggested that the two populations were genetically different with a moderate genetic 
distance (D=0.176). Because of the limitation of the small sample size for the Moyo 
population (N=17), it has been excluded from further genetic analysis other than for 
comparison with the Arua population as, after exclusion of samples with missing data at 
each locus, the sample number was too low. 
By comparing the two populations (Table 3.5 and Table 3.6), it is clear that there are a 
number of alleles unique to each population, referred to as private alleles at each individual 
locus. These were observed to occur at a very low frequency (<0.1) although five of these 
(allele 15 and 16 for Ch5/JS2, allele 9 for Ch1/D2/7, allele 3 for Ch10/3778 and allele 3 for 
Ch11/51) were observed to occur at a frequency ≥0.1 which was suggestive of population 
sub-structuring (Table 3.9) and is consistent with the moderate genetic distance between 
the two populations. Anne Juliet Nalunkuma Kazibwe    Chapter 3, 102 
 
Locus   Allele   Frequency 
Ch1/18  8  0.009615 
Ch1/18  2  0.336538 
Ch1/18  1  0.653846 
Ch5/JS2  21  0.033333 
Ch5/JS2  20  0.022222 
Ch5/JS2  19  0.011111 
Ch5/JS2  18  0.022222 
Ch5/JS2  17  0.044444 
Ch5/JS2  16  0.100000 
Ch5/JS2  15  0.322222 
Ch5/JS2  14  0.055556 
Ch5/JS2  8  0.066667 
Ch5/JS2  4  0.155556 
Ch5/JS2  1  0.166667 
Ch1/D2/7  21  0.021739 
Ch1/D2/7  20  0.010870 
Ch1/D2/7  19  0.010870 
Ch1/D2/7  18  0.010870 
Ch1/D2/7  17  0.021739 
Ch1/D2/7  16  0.086957 
Ch1/D2/7  15  0.043478 
Ch1/D2/7  14  0.250000 
Ch1/D2/7  13  0.021739 
Ch1/D2/7  10  0.347826 
Ch1/D2/7  9  0.130435 
Ch1/D2/7  7  0.021739 
Ch1/D2/7  3  0.021739 
Ch11/110  10  0.010204 
Ch11/110  9  0.081633 
Ch11/110  8  0.020408 
Ch11/110  7  0.459184 
Ch11/110  2  0.010204 
Ch11/110  1  0.418367 
Ch3/IJ15/1  8  0.095745 
Ch3/IJ15/1  7  0.468085 
Ch3/IJ15/1  1  0.436170 
Ch10/3778  3  0.108108 
Ch10/3778  2  0.432432 
Ch10/3778  1  0.459459 
Ch11/51  3  0.106061 
Ch11/51  2  0.439394 
Ch11/51  1  0.454545 
Ch7/B  5  0.051724 
Ch7/B  4  0.068966 
Ch7/B  3  0.051724 
Ch7/B  2  0.758621 
Ch7/B  1  0.068966 
Table 3.9 Private alleles (shaded grey) at each locus within the Arua gambiense population. 
Private alleles (Bold italics) with an allele frequency ≥ ≥ ≥ ≥0.1. 
Arua T. b. gambiense population size (N=54). Anne Juliet Nalunkuma Kazibwe    Chapter 3, 103 
3.4.2 Genetic analysis for Hardy-Weinberg (HW) and linkage 
disequilibrium 
To be able to determine the how frequently genetic exchange was occurring in the T. b. 
gambiense from Arua, statistical analysis was performed on the microsatellite and 
minisatellite genotype data at each individual locus to test for Hardy-Weinberg equilibrium 
and whether linkage equilibrium existed between alleles at different loci. The Hardy-
Weinberg model predicts random mating should occur in diploid organisms within or 
between populations under no restrictions (which are either biological or geographical), 
leading to extensive genetic variation as a result of genetic exchange (Hartl & Clark, 
1997). A recently performed study using microsatellite marker analysis on T. b. gambiense 
patient isolates from the Democratic Republic of Congo and Cameroon indicated that very 
limited genetic exchange goes on between the T. b. gambiense populations from within and 
between the different regions (Morrison et al, in press). Apart from being clonal, the T. b. 
gambiense populations from both regions were also clustered or sub-structured in groups 
based on their hosts geographical locations (Morrison et al, in press). It is not yet clear 
whether T. b. gambiense from other geographical regions exhibit the same characteristics 
in natural populations. A similar approach was used to determine the population structure 
of T. b. gambiense isolates from Arua district, Omugo in NW Uganda. 
Determination of the level of heterozygosity in T. b. gambiense from Arua 
The Genetic Data Analysis (GDA) software program (Lewis & Zaykin, 1999) 
http://hydrodictyon.eeb.uconn.edu/people/plewis/software.phpwas used for the input data 
in the form of a matrix generated from the genotype data (Table 3.3) to determine the level 
of heterozygosity as described under data analysis (section 3.3) and secondly to test for 
Hardy-Weinberg (HW) equilibrium. The level of heterozygosity is defined by the fixation 
index (Fis), which is the measure of reduction in the observed heterozygosity (Ho) due to 
inbreeding compared to the expected heterozygosity (He) assuming the HW model. A 
value Fis >0 indicates an excess of homozygotes (Ho>He) and a negative value Fis<0 
indicates an excess of heterozygotes (Ho<He). This analysis was carried out on the Arua 
data (Table 3.7) as a whole population (i.e. total number of samples and alleles observed at 
all the 8 chromosome loci) and the result yielded a calculated value greater than 0 
(Fis=0.315; Ho=0.421<He=0.613) (Table 3.10). This implied an excess of homozygotes 
and a deviation from the HW model. When the analysis was performed for each locus 
individually for the Arua population, all loci had an excess of homozygotes except locus Anne Juliet Nalunkuma Kazibwe    Chapter 3, 104 
Ch1/18 (Fis=-0.332) as shown in Table 3.11. The possible reasons for the deviation from 
the HW model include inbreeding or other factors will be discussed later. 
Population  Sample 
number 
(n) 
Number 
of alleles 
(Na) 
Observed 
heterozygosity 
(Ho) 
Expected 
heterozygosity 
(He) 
In breeding 
coefficient 
(Fis) 
Mean  42.25  5.875  0.421  0.613  0.315 
Table 3.10 The level of heterozygosity or inbreeding in Arua T. b. gambiense population. 
The results are based on the mean of all alleles (Na) present at all 8 loci. 
n, size obtained as an average of all the sample numbers present for each locus (Table 3.7). 
Total number of samples for the Arua T. b. gambiense population (N=54). 
 
 
Locus  Sample 
number 
(n) 
Number 
of alleles 
(Na) 
Observed 
heterozygosity 
(Ho) 
Expected 
heterozygosity 
(He) 
In breeding 
coefficient 
(Fis) 
Ch1/18  52  3  0.615  0.464  -0.332 
Ch5/JS2  45  11  0.467  0.832  0.441 
Ch1/D2/7  46  13  0.239  0.796  0.701 
Ch11/110  49  6  0.531  0.613  0.136 
Ch3/IJ15/1  47  3  0.404  0.588  0.315 
Ch10/3778  37  3  0.432  0.598  0.280 
Ch11/51  33  3  0.545  0.598  0.089 
Ch7/B  29  5  0.138  0.417  0.673 
mean  42.25  5.875  0.421  0.613  0.315 
Table 3.11 The level of heterozygosity or inbreeding at each individual locus. 
The table shows the level of polymorphism at each locus. 
n, number of samples analysed for each locus. 
Na, number of alleles present at each locus. 
Total number of samples for the Arua T. b. gambiense population (N=54). 
 
Hardy-Weinberg disequilibrium in T. b. gambiense population from Arua 
Deviation from HW equilibrium at each individual locus was tested using the GDA 
program for the Arua population data (Table 3.3), and the results indicated a deviation 
from the HW model with P<0.05 at all loci although Ch1/18 was not so highly significant 
(Table 3.12). This was in agreement with the calculated Fis values (Table 3.11) and 
suggests a non random mating population structure (not panmictic).  Anne Juliet Nalunkuma Kazibwe    Chapter 3, 105 
Locus  Sample number (n)  Probability (P) 
Ch1/18  52  0.031250 
Ch5/JS2  45  0.000000* 
Ch1/D2/7  46  0.000000* 
Ch11/110  49  0.000000* 
Ch3/IJ15/1  47  0.000000* 
Ch10/3778  37  0.000000* 
Ch11/51  33  0.000937* 
Ch7/B  29  0.000000* 
Table 3.12 Analysis for Hardy-Weinberg (HW) disequilibrium at each locus. 
n, number of samples analysed for each locus. 
* very highly significant (P<0.001) deviation from HW (P<0.05). 
Total number of samples for the Arua T. b. gambiense population (N=54). 
 
Testing for Linkage disequilibrium in the T. b. gambiense from Arua 
To determine whether no association existed between alleles at unlinked loci, linkage 
equilibrium was tested on the matrix input generated from the Arua population multilocus 
genotype data (Table 3.3) using the GDA program. This was first done by breaking up 
multilocus genotypes in all different possible allele combinations for two paired loci 
combinations (23 pairs) and the analysis was performed using 3200 reiterations and 
Fisher’s exact test for significance. As shown in Table 3.13, a lack of random association 
between alleles or linkage disequilibrium was evident at all the 23 loci combinations with 
P<0.05. The conclusion was in agreement with the Fis values indicating a deviation from 
HW. However, when the analysis for linkage disequilibrium between alleles was 
performed while preserving the genotypes (not breaking up the multilocus allele 
genotypes) of those markers which were not in Hardy-Weinberg there was evidence for 
linkage equilibrium between alleles at 16 out of the 23 paired loci combinations (P>0.05) 
as shown in Table 3.14. This indicated some level of genetic exchange.  Anne Juliet Nalunkuma Kazibwe    Chapter 3, 106 
 
 
Locus combination  Sample number 
(n) 
Probability  
(P) 
Ch1/18 and Ch5/JS2  44  0.000000 
Ch1/18 and Ch1/D2/7  41  0.000000 
Ch1/18 and Ch11/110  48  0.000000 
Ch1/18 and Ch3/IJ15/1  45  0.000313 
Ch1/18 and Ch10/3778  35  0.001563 
Ch1/18 and Ch11/51  31  0.002500 
Ch1/18 and Ch7/B  31  0.000000 
Ch5/JS2 and Ch1/D2/7  37  0.000000 
Ch5/JS2 and Ch11/110  41  0.000000 
Ch5/JS2 and Ch3/IJ15/1  38  0.000000 
Ch5/JS2 and Ch10/3778  30  0.000000 
Ch5/JS2 and Ch11/51  25  0.000000 
Ch5/JS2 and Ch7/B  25  0.000000 
Ch1/D2/7 and Ch11/110  42  0.000000 
Ch1/D2/7 and Ch3/IJ15/1  41  0.000000 
Ch1/D2/7 and Ch10/3778  35  0.000000 
Ch1/D2/7 and Ch11/51  29  0.000000 
Ch1/D2/7 and Ch7/B  35  0.000000 
Ch11/110 and Ch3/IJ15/1  35  0.000000 
Ch11/110 and Ch10/3778  34  0.000000 
Ch11/110 and Ch11/51  31  0.000000 
Ch11/110 and Ch7/B  28  0.000000 
Ch3/IJ15/1 and Ch10/3778  34  0.000000 
Ch3/IJ15/1 and Ch11/51  31  0.000000 
Ch3/IJ15/1 and Ch7/B  27  0.000000 
Ch10/3778 and Ch11/51  26  0.000000 
Ch10/3778 and Ch7/B  23  0.000000 
Ch11/51 and Ch7/B  19  0.000000 
Table 3.13 Results for the analysis for linkage equilibrium between paired loci. 
n, number of samples statistically analysed for each locus combination. 
All multilocus broken genotype combinations in linkage disequilibrium P<0.05. 
Total number of samples for the Arua T. b. gambiense population (N= 54). 
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Pair wise  
Locus combination 
Sample number 
(n) 
Probability  
(P) 
Ch1/18 and Ch5/JS2  44  0.022187 
Ch1/18 and Ch1/D2/7  41  0.000625 
Ch1/18 and Ch11/110  48  0.073125* 
Ch1/18 and Ch3/IJ15/1  45  0.061562* 
Ch1/18 and Ch10/3778  35  0.722187* 
Ch1/18 and Ch11/51  31  0.059062* 
Ch1/18 and Ch7/B  31  0.120313* 
Ch5/JS2 and Ch1/D2/7  37  0.068125* 
Ch5/JS2 and Ch11/110  41  0.409375* 
Ch5/JS2 and Ch3/IJ15/1  38  0.084687* 
Ch5/JS2 and Ch10/3778  30  0.680312* 
Ch5/JS2 and Ch11/51  25  0.466562* 
Ch5/JS2 and Ch7/B  25  0.794375* 
Ch1/D2/7 and Ch11/110  42  0.100937* 
Ch1/D2/7 and Ch3/IJ15/1  41  0.059687* 
Ch1/D2/7 and Ch10/3778  35  0.517813* 
Ch1/D2/7 and Ch11/51  29  0.157188* 
Ch1/D2/7 and Ch7/B  35  0.740625* 
Ch11/110 and Ch3/IJ15/1  35  0.000000 
Ch11/110 and Ch10/3778  34  0.044687 
Ch11/110 and Ch11/51  31  0.000000 
Ch11/110 and Ch7/B  28  0.000000 
Ch3/IJ15/1 and Ch10/3778  34  0.004375 
Ch3/IJ15/1 and Ch11/51  31  0.000000 
Ch3/IJ15/1 and Ch7/B  27  0.000000 
Ch10/3778 and Ch11/51  26  0.002812 
Ch10/3778 and Ch7/B  23  0.014687 
Ch11/51 and Ch7/B  19  0.000000 
Table 3.14 Analysis of Arua samples for linkage equilibrium between 23 paired loci. 
n, number of samples statistically analysed for each locus combination. 
*Preserved multilocus genotype combinations (Bold) in agreement with linkage equilibrium 
P>0.05. 
Total number of samples for the Arua T. b. gambiense population (N= 54). Anne Juliet Nalunkuma Kazibwe    Chapter 3, 108 
To further determine whether linkage disequilibrium existed between alleles on unlinked 
loci, another linkage analysis program (LIAN) (Haubold & Hudson, 2000), which is able 
to determine differences between the predicted and observed frequency of each pair of 
haplotypes was used for the analysis of the Arua population generated from the multilocus 
genotype data (Table 3.3). The measure of linkage disequilibrium between genotypes at all 
paired loci combinations is determined as the Standardisation Index of Association (I
S
A). A 
value I
S
A ≤0 suggests frequent genetic exchange while I
S
A >0 suggests little or a lack of 
genetic exchange. The I
S
A at the 5% critical value was calculated from the comparison of 
the variance of the differences between the paired loci combinations (VD), to the variance 
expected (Ve) for linkage equilibrium. The results indicated little linkage disequilibrium 
(I
S
A=0.0856, VD=2.2438, Ve=1.4031) with P<0.01. Since the I
S
A value is close to zero, 
which is the limit for linkage equilibrium, this is suggestive of some genetic exchange. 
 
Further population analysis of the Arua T. b. gambiense  
Further comparisons of the different multilocus genotypes (Table 3.3) to determine the 
level of differentiation was undertaken using a free downloadable CLUSTERING 
CALCULATOR program http://www2.biology.ualberta.ca/jbrzusto/cluster.php for the 
input data (Appendix II) to produce a matrix of pairwise differences as a draw string of 
values. To calculate the bootstrap values and generate a dendogram (Figure 3.6) of 
similarity from the draw string of values (Appendix II), the free downloadable TREE 
VIEW program http://taxonomy.zoology.gla.ac.uk/rod/treeview.html was used. The 
calculated bootstrap values were used to determine the statistical robustness of the nodes 
and the level of similarity or differentiation that existed between the multilocus genotypes 
generated for each sample analysed.  
Only five of the loci (Ch1/18, Ch5/JS2, Ch1/D2/7, Ch11/110 and Ch3/IJ15/1) were 
considered. Three markers were not included in this analysis due to the high level of 
missing data for these loci. For the purposes of comparison in this analysis was included 
three samples from the Moyo population (M139, M153 and M177) (Table 3.4), which had 
complete multilocus genotype data sets for the five loci. Almost all of the T. b. gambiense 
isolates from the Arua, Omugo (OM) population were closely similar to each other and to 
the reference strain type I T. b. gambiense (ELIANE) with bootstrap values below 60 at the 
different nodes (not shown). Only nodes with bootstrap values >70 were shown (Figure 
3.6). It can be concluded that they probably evolved from the same trypanosome species as 
the reference strain type I T. gambiense which was isolated from a woman in Cote d’Ivoire 
(Pays et al, 1983). The three T. b. gambiense samples from Moyo included in this analysis Anne Juliet Nalunkuma Kazibwe    Chapter 3, 109 
did not cluster as a separate group and so were not any different from the Arua population 
but the sample size of three was too low to draw firm conclusions. The earlier result of the 
genetic difference (D=0.176) between the two populations obtained in the initial analysis is 
moderate enough to suggest a difference and the presence of some unique alleles found in 
one population and not in the other further supports this.  
While linkage disequilibrium has been detected in the Arua T. b. gambiense population, 
only two isolates OM83 and OM88 were found to have identical genotypes. This is in 
contrast to the clonal nature of T. b. gambiense found in the Democratic Republic of 
Congo and Cameroon (Morrison et al, in press), where a common genotype was repeatedly 
sampled. The T. b. gambiense population from Arua is definitely not clonal. The possible 
reasons for the linkage disequilibrium detected could be inbreeding, substructuring, null 
alleles, or migration as will be discussed. The two identical samples (OM83, OM88) and 
one other sample OM112 were observed to be distinct from the rest of the samples and the 
reference strain type I T. b. gambiense (ELIANE) with bootstrap values of 99-100 (Figure 
3.6), which is a significant level of differentiation. It is possibility that the two clustering 
isolates (OM83 and OM88) and OM112 are a result of recent migration from a different 
focus of disease for example southern Sudan. These samples are not similar to the T. b. 
gambiense reference control (ELIANE) used in this analysis. This finding is similar to an 
observation made in a recent study where T. b. gambiense isolates from Cameroon were 
demonstrated to be distinct from type I T. b. gambiense (ELIANE) strains and type II T. b. 
gambiense 386 reference strains with bootstrap values of 86 and 91 respectively (Morrison 
et al, in press). As in the Cameroon study, the samples used in this study were all collected 
from patients who were confirmed seropositive for the presence of the T. b. gambiense 
VSG antigen LiTat 1.3 which is the basis of the card agglutination test for trypanosomiasis 
(Magnus et al, 1978). The samples were also parasite-positive using the highly sensitive 
TBR multicopy primers (Moser et al, 1989) for the trypanozoon group as indicated 
(Chapter 4, Table 4.2). However, a type II T. b. gambiense control was not included in the 
analysis in the current study. Therefore it cannot be ruled out that the three Arua samples 
could possibly be type II T. b. gambiense. Further studies may be required using larger 
sample numbers to confirm this finding. Alternatively, these three isolates could be 
responsible for the observed linkage disequilibrium observed in this population. However, 
exclusion of these samples from the analysis may be required to test whether this is the 
case.  Anne Juliet Nalunkuma Kazibwe    Chapter 3, 110 
 
Figure 3.6 Comparison of different Arua sample T. b. gambiense genotypes at five loci. 
The dendogram shows the level of differentiation between the Arua samples. 
Bootstrap values are indicated at the relevant t node. 
OM, T. b. gambiense isolates from Omugo, Arua district and their respective hosts’ 
counties. 
Control, type I T. b. gambiense (ELIANE) (Pays et al, 1983).  
M139, M153 and M177, T. b. gambiense isolates from Moyo with complete data sets. 
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3.5 Discussion 
This aim of the study was to investigate the population structure of T. b. gambiense using 
samples collected from sleeping sickness patients from Arua and Moyo districts both 
located in NW Uganda. The simple method of sampling using the FTA cards (Whatman) 
(rather than propagation in mice and culture) and the availability of microsatellite and 
minisatellite markers has made this kind of analysis possible. Only one study has 
previously used this approach and the findings indicated a clonal structure for T. b. 
gambiense isolates from the Democratic Republic of Congo (DRC) and Cameroon taken 
from patients presenting at a clinic and during a field survey in 2003 (Morrison et al, in 
press). However, it is still not clear whether T. b. gambiense from East Africa has a similar 
or distinct structure. With regard to another protozoan parasite, a study performed by 
Anderson and colleagues (2000) clearly showed that P. falciparum from regions with 
different disease endemic levels was capable of exhibiting different structures in the same 
and different geographical foci. It is therefore hypothesised that T. b. gambiense from the 
same or different foci may have distinct structures during an epidemic and a post-epidemic 
period. This implies that the structure may change over time and it is therefore necessary to 
determine the structure at various time points in order to make proper comparisons 
between populations from within the same and distinct geographical foci. The samples 
used for this study were collected from patients during field surveys (where most patients 
were in stage I) and from patients reporting to health units (where most patients were in 
stage II) between 2005 and 2006. The collections were from two regions within a focus of 
high endemicity during a post epidemic period. Both populations were observed to share at 
least two alleles between them for all of the markers, with an exception of the Ch5/JS2 
marker, which had five alleles in common between the two populations (Figure 3.3). The 
presence of private alleles at each of the loci especially for Ch5/JS2 and Ch1/D2/7 revealed 
considerable genetic variation between the two populations.  
The Arua and Moyo populations were genetically distinct as determined by the value 
obtained for the genetic distance. More meaningful analysis could not be done to compare 
the two populations because of the limitation of the small population sample size for Moyo 
(N=17), which was reduced further on exclusion of samples with missing data at each 
locus. Low parasite levels, despite using the whole genome amplification method 
(Morrison et al, 2007), were mostly considered responsible for this lack of microsatellite 
PCR amplification. Moreover, for both populations the samples that could be amplified for 
some of the loci could not be amplified alleles for other loci, which led to a further Anne Juliet Nalunkuma Kazibwe    Chapter 3, 112 
reduction of sample numbers, especially for the Moyo population. This precluded further 
analyses on this population. The failure of some markers to amplify was attributed to the 
low parasite numbers present or the presence of null alleles, possibly due to point 
mutations in the PCR primer targets such that the primers could not anneal to the template 
(Jarne & Lagoda, 1996). It is also possible that allele-drop-out occurred during the whole 
genome amplification process leading to lack of amplification of some alleles. Spotting of 
the buffy coat on FTA cards from concentrated trypanosome isolates could be used to 
overcome the low parasitaemia while pooling of whole genome amplified DNA from three 
individual FTA discs instead of two could reduce on allele drop-out.  
Deviation from the Hardy-Weinberg equilibrium (with an excess of homozygotes) and 
linkage disequilibrium between alleles of paired loci was detected in the Arua population. 
Hardy-Weinberg and linkage equilibrium was restored at 16 of 23 locus combinations 
when genotypes that had markers in linkage disequilibrium were preserved without 
breaking them up. The homozygous excess and linkage disequilibrium observed could be 
due to a lack of genetic recombination or a number of other reasons as discussed below.  
The first reason null alleles associated with genetic differences between samples (Hartl & 
Clark, 1997) could be among the factors responsible for the excess in homozygosity 
leading to the deviation from the Hardy-Weinberg equilibrium as observed for the Arua 
population. Sequence divergence especially at the 3’ end of the primer site could also lead 
to poor primer annealing leading to only one size allele being amplified resulting in the 
locus being scored a homozygous rather than heterozygous (Reviewed by Dakin & Avise, 
2004). Although this may be unlikely since comparison of the sequences of the primers 
used for the amplifications with the sequences of the relevant loci along the 11 megabase 
size chromosomes available from the T. b. brucei genome project (Berriman et al, 2005) or 
the T. b. gambiense genome http://www.genedb.org/ indicated no mismatches. However, 
sequence differences in the primer sites cannot be ruled out considering the diversity of the 
genotypes in the natural population coupled with the incomplete sequence of the T. b. 
gambiense genome. 
Inbreeding (selfing) or mating between relatives, which is a biological property of a 
population is another factor which could have played a role in the observed excess of 
homozygotes. Selfing has been demonstrated to occur in T. brucei under laboratory 
conditions (Tait et al, 1996;Gibson et al, 1997). However, the extent to which selfing can 
occur in T. brucei under natural field conditions has not been fully explored.  Anne Juliet Nalunkuma Kazibwe    Chapter 3, 113 
Sub-structuring associated with inbreeding is another possibility for the reduction of 
heterozygosity. Although all Arua T. b. gambiense samples were collected from the same 
geographical region over the same time period thus reducing the possibility of detecting 
linkage disequilibrium due to geographical sub-structuring, it is still possible that the 
population is substructured , possibly due to micro-geographical barriers or host vector 
dynamics. This substructuring has also been detected in T. b. gambiense populations from 
the Democratic Republic of Congo and Cameroon (Morrison et al, in press) 
Sampling errors could also lead to a reduction in hetereozygosity especially if there is an 
animal reservoir within the population. Sampling of the T. b. gambiense isolates used in 
the analysis was by both active and passive surveillance of patients. While the majority of 
stage II cases were identified at the health units when they turned up on their own 
(passive), the majority of stage I cases were identified during the field surveys (active) 
(Patient Raw data, Appendix II). The majority of samples from Arua used in this analysis 
(N=54) were collected from stage II cases (n=47) already suffering central nervous 
infection. Only 7 isolates in the analysis were from patients in stage I disease. This may 
introduce a bias in the data set as possibly only virulent genotypes were sampled. The 
isolates from stage I cases were also not observed to cluster. The observed reduction in 
heterozygosity leading to alleles in linkage disequilibrium could also occur as a result of 
lack of informativeness of the markers e.g. due to the predominance of an allele.  
An alternative explanation for the linkage disequilibrium detected and deviation from 
Hardy-Weinberg equilibrium could possibly be due to migration, (Hartl & Clark, 1997). 
This is another factor that can contribute to a reduction in heterozygosity due to the 
introduction of new alleles in the population leading to genetic divergence as observed in 
the Arua population. Migration is a likely scenario which cannot be ruled out since NW 
Uganda where Arua and Moyo are located, borders with S Sudan where there is another T. 
b. gambiense focus and a large number of Sudanese refugees have migrated and settled in 
Northern Uganda as a result of the long term civil war (Hovil & Bagenda, 2003;United 
Nations Report, 2004). The human populations in Arua and Moyo regions are of different 
ethnic backgrounds. It is possible that host differences exist between the two populations, 
which may enable some trypanosome genotypes to survive in one host population and not 
the other leading to the difference in diversity. This may require further investigation with 
larger sample numbers and also looking at isolates from tsetse flies in these regions. Anne Juliet Nalunkuma Kazibwe    Chapter 3, 114 
3.6 Conclusion 
I tested the overall genotypes using microsatellite and minisatellite markers in samples 
collected in Arua and Moyo. Using 8 different markers it can tentatively be concluded that 
the T. b. gambiense population from Arua seems to be different from the T. b. gambiense 
population from Moyo although this may necessitate further investigations with larger 
sample numbers to confirm this finding. Deviation from the Hardy-Weinberg equilibrium 
with an excess of homozygotes and the evidence for alleles at pairs of loci in linkage 
disequilibrium points to the fact that the T. b. gambiense population from Arua is not 
panmictic. The lack of a high frequency common genotype indicates that the population is 
not epidemic or clonal. The most parsimonious explanation for the observed linkage 
equilibrium is that some degree of genetic exchange is occurring within the Arua T. b. 
gambiense population. The observed linkage disequilibrium could be due to factors such as 
bias sampling (due to predominance of late stage), cryptic population sub-structuring, 
migration or selfing. 
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4  Genotypic status of the TbAT1/P2 of T. b. gambiense 
isolates from NW Uganda 
4.1 Summary 
The aim of this study was to investigate the current status of TbAT1 alleles in T. b. 
gambiense isolates collected from sleeping sickness patients from areas within Arua and 
Moyo districts of NW Uganda. This was carried out using the PCR/RFLP based method to 
determine if it can be useful as a predictive tool for the early detection of treatment failure 
or developing drug resistance and hence guide the decision making process regarding the 
treatment of Human African Trypanosomiasis. Moreover, not only can the method be used 
for predicting melarsoprol treatment failures but it may also be utilised in the case of 
diamidines including pentamidine whose uptake is also mediated partly through the same 
P2 transporter (de Koning & Jarvis, 2001;de Koning, 2001b). Out of a total of 133 isolates 
(collected as either blood spots on FTA cards, whole blood or CSF) analysed, 91 (68 %) 
were successfully amplified by PCR using TbAT1 primers and all possessed the TbAT1 
wild type alleles after RFLP analysis with Sfa NI endonuclease, implying that 
trypanosomes in circulation have TbAT1 alleles which showed normal melarsoprol 
transport as far as can be assessed with the Sfa NI analysis. This finding indicates a shift 
from previous results (58.5%) of the presence of tbat1 mutant alleles or melarsoprol 
resistant alleles in Omugo, NW Uganda (Matovu et al, 2001b). It could be speculated that 
this reduction of TbAT1 mutant alleles in the field might be linked with the withdrawal of 
the drug from Omugo health centre. The melarsoprol TbAT1 resistant alleles may have a 
fitness cost disadvantage and therefore cannot compete against wild type for long in the 
absence of drug pressure. In a recent study in South Sudan, where melarsoprol was 
withdrawn, the findings revealed the presence of only tbat1 wild type alleles (Maina et al, 
2007), which is in agreement with our findings. This also led these authors’ to conclude 
that the tbat1 mutant alleles associated with melarsoprol resistance did not occur in S. 
Sudan. However, they did not collect samples for analysis at the peak of relapses before 
drug withdrawal as in the case of NW Uganda situation. Anne Juliet Nalunkuma Kazibwe    Chapter 4, 117 
4.2 Introduction 
The Trypanosome brucei adenosine transporter 1 gene encoding P2 activity (TbAT1/P2) is 
known to mediate the cellular uptake of melaminophenyl arsenicals and diamidines. 
Moreover, loss of drug uptake by this P2 purine transporter as a result of alterations in the 
transporter has been associated with the development of arsenical and diamidine resistance 
in Trypanosoma brucei (Carter & Fairlamb, 1993;Carter et al, 1995;Carter et al, 
1999;Barrett et al, 1995;Scott et al, 1997). Resistance has also been suggested to occur 
through other mechanisms (see section 1.4.2). The TbAT1/P2 gene was identified by 
complementation in the yeast Saccharomyces cerevisiae as a single copy gene encoding 
463 amino acids that should fold into 11 transmembrane domains (Mäser et al, 1999). 
Identification of this drug transporter gene has led to elucidation of many mechanisms 
responsible for development of drug resistance in T. brucei. Mäser and colleagues (1999) 
were able to demonstrate, by sequencing, that ten point mutations which were homozygous 
were present in the open reading frame of the cloned TbAT1 gene of the laboratory-derived 
melarsen oxide cysteamine (Melcy) resistant stock (STIB 777R) when compared to the 
TbAT1 gene of the T. brucei drug sensitive parent stock (STIB 777S). This further 
implicated TbAT1 involvement in drug resistance. One of the mutations caused an amino 
acid change [alanine to threonine (A178T)] associated with a base change (G to A) at 
position 532 and another [asparagine to serine (A286S)] associated with a base change (A 
to G) at position 857. The former mutation destroyed a Sfa NI site in the TbAT1 of the wild 
type T. brucei and the latter created a new Sfa NI site. Some of the remaining mutations 
caused amino acid substitutions while others were silent (Mäser et al, 1999). 
These two mutations were used to differentiate between the drug sensitive and resistant T. 
brucei stocks by a PCR/RFLP-based method using the restriction endonuclease Sfa NI 
(Mäser et al, 1999). This development offers a potential tool for the diagnosis of drug 
resistance in T. brucei. The method required validation by determining whether the same 
mutations occurred in field isolates. Analysis of T. b. gambiense isolates (n=65) from 
Omugo, NW Uganda, collected from sleeping sickness patients who relapsed after 
melarsoprol treatment as well as isolates from newly infected patients, using the PCR/Sfa 
NI based method indicated the presence of TbAT1 mutant alleles in 50% of the melarsoprol 
treatment failure patient isolates (Matovu et al, 2001b). However, the presence of only 
TbAT1 wild type alleles in 30% of the isolates from relapsed patients which was also 
confirmed by sequencing, was an indication that other factors such as biochemically 
mediated resistance could also play a role in the development of melarsoprol treatment Anne Juliet Nalunkuma Kazibwe    Chapter 4, 118 
failure (Matovu et al, 2001a;Matovu et al, 2001b). The isolates analysed were collected 
from patients treated in Omugo, Arua district, during an outbreak when melarsoprol 
relapses had reached alarming levels (30%) (Legros et al, 1999). Such treatment failure 
levels were not observed in Moyo, a neighbouring district also located in NW Uganda. 
These findings led to the replacement of melarsoprol with DFMO (Eflornithine) as first 
line treatment for stage II disease at Omugo health centre located in Arua district and this 
took effect in 2001. 
In South Sudan, where melarsoprol treatment failures were reported at 20% (Moore & 
Richer, 2001), melarsoprol was also withdrawn. Two years later, isolates were collected 
from T. b. gambiense sleeping sickness patients (n=18) from the same region and a study 
carried out using the same PCR/RFLP approach to determine the existence of such TbAT1 
mutant alleles which were reported in NW Uganda (Maina et al, 2007). The results 
indicated only the presence of TbAT1 wild type alleles and sequencing the TbAT1 from 
these isolates confirmed their finding which led the authors to suggest that the TbAT1 
mutant alleles had never occurred (Maina et al, 2007). In this study, I revisited NW 
Uganda where melarsoprol was withdrawn to determine the TbAT1 status by PCR/RFLP 
and sequencing and to confirm earlier findings of its role in melarsoprol treatment failure. 
4.3 Materials and Methods 
Study area and population 
As described in chapter 3 (see section 3.3). 
Patient sample collection 
Blood samples from confirmed stage I and stage II HAT patients (Table 4.1) were 
collected as described (section 3.3).  Anne Juliet Nalunkuma Kazibwe    Chapter 4, 119 
 
Disease Stage  Arua district (n) 
(Omugo health Centre) 
Moyo district (n) 
(Moyo hospital) 
Total (N) 
Early stage (SSI)  11  0  11 
Late stage (SSII)  88  34  122 
Total (N)  99  34  133 
Table 4.1 T. b. gambiense sleeping sickness isolates collected from NW Uganda. 
Omugo health centre and Moyo hospital are the sleeping sickness control centres located in 
Arua and Moyo district respectively. 
SSI, sleeping sickness stage I disease. SSII, sleeping sickness stage II.  
N, total number of isolates collected in both districts. 
n, number of isolates collected in each district under each respective group. 
Patients screening by the Card agglutination test for trypanosomiasis (Magnus et al, 1978)  
Diagnosis confirmed by microscopy using wet smear, haematocrit centrifugation technique 
(Woo & Rogers, 1974) and lumbar puncture (section 3.3). 
Patient treatment and follow-up 
Qualified medical personnel at Omugo Health Centre and Moyo Hospital in NW Uganda 
carried out the monitored drug administration. The drugs used were a donation by the 
World Health Organisation (WHO). Stage I patients at both health units were treated with 
pentamidine isethionate (4 mg/kg body weight/day) administered intramuscularly for 10 
days. Stage II patients at Moyo Hospital were treated with a melarsoprol schedule of 3 
series each as four daily injections administered intravenously with an increasing dosage 
from 1.2 to 3.6 mg/kg body weight with a 7-day rest interval between each series. Unlike 
in Moyo, stage II patients at Omugo Health Centre, were treated with 400 mg/kg body 
weight/day of eflornithine (DFMO), which was administered at 100 mg/kg body weight 
intravenously with 4 daily infusions each lasting 6 hours for 14 days. On completion of 
treatment, patients were discharged and requested to return every 6 months for follow up 
for a period of 2 years. 
Follow up post treatment was supposed to take place at 6, 12, and 24 months to monitor for 
any treatment failures. During this time patients were retested by microscopy for presence 
of trypanosomes in any of their body fluids. Patients showing signs of infection were re-
admitted and retreated with an appropriate drug, which depended on the stage of the 
disease and the region of readmitting health unit. An individual can be declared fully 
recovered with no signs of infection after two years of follow up. 
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DNA extraction 
Extraction of DNA from blood spotted on FTA cards (Whatman) was performed as 
described (section 2.3). 
DNA extraction from whole blood and CSF 
Partial extraction of trypanosome genomic DNA for easy transportation to the laboratory 
was performed using a commercial kit (Puregene, Gentra Systems, MN, USA) on CSF 
and whole blood samples. Briefly, 1.5 ml of red blood cell (RBC) lysis solution was added 
to 500 µl of whole blood in a 2 ml microfuge tube, mixed and incubated at room 
temperature for 10 minutes. This was followed by centrifugation in a desktop centrifuge at 
13,000 × g for 5 minutes, the supernatant was discarded and the pellet resuspended in 300 
µl of cell lysis solution. The quantity of CSF collected determined how much cell lysis 
solution wad added. To 50 µl of CSF was added 550 µl of cell lysis solution directly or 
300 µl of cell lysis solution was used to resuspend the pellet recovered after centrifugation 
of the CSF. Extraction was completed using the commercial purification kit following the 
manufacturer’s instructions (Puregene®, Gentra Systems, MN, USA). Proteinase K (100 
µg/ml) was added to the samples in cell lysis buffer, mixed by pipetting and incubated at 
55°C for 1 hour. For removal of protein, 200 µl of protein precipitation solution was 
added, mixed gently by inversion and the sample was incubated on ice for 5 minutes. After 
centrifugation of the suspension at 13,000 × g for 5 minutes, the supernatant was collected 
into a sterile microfuge tube and DNA precipitation and pellet washing was carried out by 
adding 400 µl each of isopropanol then 70% ethanol and centrifuged at 13,000 × g for 1 
min. After air-drying the DNA pellet for 15 minutes, it was dissolved in 20 µl of DNA 
hydration solution and left to rehydrate overnight at room temperature or at 65°C for 1 
hour. Up to 5 µl of the rehydrated DNA was used immediately in PCR or kept at -20°C.  
TbAT1 genotyping by PCR amplification 
Detection of TbAT1 mutants associated with melarsoprol treatment failures in NW Uganda 
was performed in Uganda during the period July 2006 to September 2006 using the PCR 
/RFLP method as described (Mäser et al, 1999;Matovu et al, 2001b). The TbAT1 RFLP 
fragment was successfully amplified from extracted DNA by nested PCR (Mäser et al, 
1999;Matovu et al, 2001b). The method has also been used on samples from Moyo, NW 
Uganda (Nerima et al, 2007) and in South Sudan to clarify the existence of TbAT1 mutant 
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In a primary PCR to amplify the TbAT1 gene each DNA disc on an FTA card or 5 µl of 
whole blood or CSF genomic DNA was amplified in a total volume of 25 µl, containing a 
1 × Custom PCR Mastermix (45 mM Tris-HCl (pH 8.8), 4.5 mM MgCl2, 11 mM 
(NH4)2SO4, 0.113 mg/ml BSA, 4.4 µM EDTA and 1 mM of each deoxynucleotide 
triphosphate- dATP, dCTP, dGTP, dTTP) (ABgene®, Advanced Biotechnologies Ltd, 
UK). The oligonucleotide primer pair TbAT1 ant-s (5’-gcc cgg atc cgg ctg gtt ttt aga caa 
aag tga t-3’) and TbAT1 ant-as (5’-gcc cct cga gcc gca tgg agt aag tct ga-3’) (Mäser et al, 
1999) (MWG Biotech-AG) each at 1 µM, and 1.25 units of Taq DNA polymerase 
(Promega Corporation, Madison, USA) were added to the reaction. The reaction was 
performed in a PTC-100
TM DNA Engine (MJ Research, inc., Waltham, MA, USA) under 
the following conditions: initial denaturation at 94°C for 4 minutes; denaturation at 94°C 
for 30 seconds, annealing at 50°C for 30 seconds, and extension at 72°C for 1 minute for 
30 cycles with a final extension at 72°C for 7 minutes. Genomic DNA of a T. brucei 
reference clone STIB 950 (isolated from a cow in Somalia, resistant to diminazene, 
isometamidium and quinapyramine) (Kaminsky et al, 1989) and sterile water (no template) 
were included in each run as a positive and negative control respectively. To amplify the 
TbAT1 RFLP 677 bp fragment, 2 µl of primary PCR product was used as template in an 
inner PCR with the oligonucleotide primer pair Sfa-s or ATF-2 (5’-cgc cgc act cat cgc ccc 
gtt-3’) and Sfa-as or ATR-2 (5’-cca ccg cgg tga gac gtg at-3’) (Mäser et al, 1999;Matovu 
et al, 2001b) under the same conditions with the annealing temperature increased to 65°C 
(Matovu et al, 2001b). 
RFLP analysis using SfaNI endonuclease 
The RFLP analysis of TbAT1 with the restriction endonuclease enzyme Sfa NI was shown 
to distinguish between melarsoprol sensitive and resistant T. brucei (Mäser et al, 
1999;Matovu et al, 2001b). For each individual sample, 5 µl of a successfully amplified 
TbAT1 677 bp PCR product analysed by agarose gel electrophoresis was digested with the 
enzyme SfaNI. The reaction which was incubated at 37°C overnight was carried out in a 
total volume of 20 µl containing 1 × NEBuffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM 
MgCl2, 1 mM DTT) (pH 7.9) and 1 unit of Sfa NI enzyme (New England Biolabs). 
Agarose gel electrophoresis and UV transillumination 
A volume of 10 µl of each TbAT1 nested PCR product was mixed with 1-2 µl of 6 × Blue 
loading dye (Appendix I) and separated by electrophoresis on a 3% Agarose gel stained 
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visualised under an ultraviolet transilluminiscence box (Synegene GelVue model no. 
GVM20, Synoptics Ltd. UK) and pictures taken on polaroid film (Polaroid 667, Polaroid 
corporation, Mexico) with a polaroid camera (DS34 Polaroid). The product band size was 
determined by comparison with a standard 1-Kb (Gene Ruler
TM, Fermentas, Life Sciences) 
molecular weight DNA marker. A 677 bp size fragment should be observed in agarose. 
20 µl of each SfaNI digested reaction was analysed by electrophoresis on a 2% Agarose gel 
and the different size fragments visualised under UV light as described above. Any of the 
three patterns signifying wild type TbAT1 alleles (566 bp and 111 bp) or mutant TbAT1 
alleles (435 bp and 242 bp) or a mixture of both patterns (wild type TbAT1 together with 
mutant TbAT1) should be observed in agarose. 
Cloning and sequencing 
The TbAT1 RFLP fragments (677 bp) of 5 randomly selected samples from NW Uganda 
were sub-cloned (Sambrook et al, 1989) and the sequencing was performed by MWG 
Biotech AG (Germany). Preparation of the samples for sequencing was carried out as 
described below. 
Agarose purification of PCR products 
Briefly, two independent 25 µl PCR reactions for each individual sample were pooled and 
separated on an Agarose gel as described above. The PCR fragment was purified from an 
Agarose gel using a Qiaquick gel purification kit (Qiagen) following the manufacturer’s 
instructions.  
Ligation into a vector 
In a sterile microfuge tube, 7 µl of each purified PCR product was ligated with 25 ng of 
pGEM
-T Easy vector (Promega corporation, Madison, USA) in a total reaction volume of 
20 µl containing 1 × ligation buffer (30 mM Tris-HCl pH 7.8, 10 mM MgCl2, 10 mM 
DTT, 1mM ATP 5% PEG), and 1 unit of ligase enzyme (10 mM Tris-HCl pH 7.4, 50 mM 
KCl, 1 mM DTT, 0.1 mM EDTA. 50% glycerol (Promega). The reaction was incubated at 
room temperature overnight.  
Transformation into bacteria 
Transformation of the ligated purified PCR products was carried out using competent 
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competent E. coli strain DH5-α cells (donation from G. Campbell, University of Glasgow) 
in a sterile microfuge tube on ice and the reaction incubated for 30 minutes. Following 
incubation the reaction was heat-shocked at 42°C for 45 seconds followed by immediate 
cooling on ice for 2 minutes. 1 ml of SOC medium (Appendix I) was added and the 
reaction incubated at 37°C with shaking for 45-60 minutes. 
Plating on Luria Broth (LB) Agar under blue/white selection 
Following incubation, the reaction was centrifuged briefly at 13,000 × g. Most of the 
medium was removed leaving behind about 100 µl in which the pellet was resuspended. 
Under sterile conditions the suspension was plated onto LB agar/Ampicillin (50 µg/ml) 
prepared on a petri dish (Appendix I) and spread with 100 µl X-Gal (100 mM) and 50 µl 
IPTG (50 mg/ml) blue/white marker compounds. The plate was incubated at 37°C for 15-
16 hours (preferably overnight) for colony growth. 
Plasmid DNA preparation 
Under sterile conditions, two colonies of the transformed bacteria containing insert were 
picked from the plate and each inoculated separately into 5 ml of sterile LB medium 
(Appendix I) containing Ampicillin (50 µg/ml). The cultures were incubated for 15-16 
hours at 37°C. Following incubation, plasmid DNA was prepared from the two cultures 
using a plasmid purification kit following the manufacturer’s instructions (Qiagen). To 
check for the presence of the plasmid DNA, 2 µl was analysed on an agarose gel. To check 
for successful cloning of the TbAT1 fragment, 10 µl of plasmid DNA was digested with the 
endonuclease Not I enzyme (Promega Corporation, Madison, USA) in a total volume of 20 
µl containing 1 × Buffer D (6 mM Tris-HCl (pH 7.9), 0.15 M NaCl, 6.0 mM MgCl2 and 1 
mM DTT) 10 µg/µl BSA, and 5 units of enzyme. The reactions were incubated at 37°C for 
3 hours. 20 µl of the digested reaction was analysed by electrophoresis on a 2.0% Agarose 
gel and visualised as described (section 2.3). The two independent plasmid DNA 
preparations were pooled. 20µl of plasmid DNA in duplicate were vacuum-dried in a speed 
vac concentrator (Thermo Electronic Corporation, model DNA Speed Vac System 120-
230, USA) and sent off for T7 and SP6 promoter sequence determination at MWG Biotech 
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4.4 Results 
4.4.1 PCR amplification of the TbAT1 gene 
PCR amplification of DNA extracted from the samples was performed to confirm whether 
the patients were infected with T. brucei using the highly sensitive T. brucei multicopy 
repeat (TBR) primers specific for the trypanozoon group (Moser et al, 1989) as described 
(section 2.3). PCR amplification of the ubiquitous single copy T. brucei Phospholipase C 
linked microsatellite was also performed as a control using PLC linked microsatellite based 
primers ( Tait et al, 2002;MacLeod et al, 2005b) as described (section 2.3).  
The RFLP bearing fragment (677 bp) of the TbAT1 gene (Figure 1.5) was amplified by 
nested PCR using primers specific for the TbAT1 gene as described (section 4.3). The 
TbAT1 677 bp fragment was successfully PCR amplified from 65 of the 133 samples 
analysed and, when the whole genome amplification method was employed (Morrison et 
al, 2007) as described in section 4.3, the number of samples from which the TbAT1 gene 
was amplified increased giving a total of 91 samples analysed. 
The PCR results with the TBR primers revealed that all of the isolates (99.3%) except one 
isolate from Moyo were positive for the T. brucei group (Table 4.2). It is unclear why the 
single isolate was not positive for the T. brucei repeat and it is proposed that the analysis 
should be repeated and if necessary checked for other markers, rather than suggest, on the 
basis of this one piece of evidence, that this patient was infected with a non-brucei 
trypanosome species. Using the single copy PLC–linked microsatellite primers, only 
45.8% of the isolates were detectable by PCR post whole genome amplification while 
68.4% were successfully amplified for the single copy TbAT1 gene (Table 4.2).  Anne Juliet Nalunkuma Kazibwe    Chapter 4, 125 
 
PCR target  Arua district 
SSI (n=11)      SSII (n=88) 
Moyo district 
SSII (n=34) 
Total 
(N=133) 
T. brucei repeat  11  88  33  132 (99.3%) 
T. brucei PLC  8  42  11  61 (45.8%) 
TbAT1 (677 bp)  8  74  9  91 (68.4%) 
Table 4.2 PCR analysis positive results of the NW Uganda T. b. gambiense patient isolates. 
The Table shows a summary of the results following amplification of the T. brucei 177 bp 
repeat, the single copy T. brucei Phospholipase C-linked microsatellite and the adenosine 
transporter gene (TbAT1). 
SSI, sleeping sickness stage I. SSII, sleeping sickness stage II. N, total number of samples 
analysed. n, number of samples analysed under each group.  
TBR-F and TBR-R primers (Moser et al, 1989) used to amplify the T. brucei repeat (section 
2.3). 
PLC-G and PLC-H3 primers (Tait et al, 2002) used to amplify the T. brucei Phospholipase C 
microsatellite (section 2.3).  
TbAT1 ant-s and TbAT1 ant-as outer primers and ATF-2 and ATR-2 nested primers (Mäser et 
al, 1999;Matovu et al, 2001b) used to amplify the TbAT1 677 bp fragment (section 4.3) 
 
These results are consistent with our earlier findings from the sensitivity assay (Chapter 2) 
which indicated that the high sensitivity of the T. brucei repeat (TBR) primers makes them 
better at reporting on infection. Even in this study, the TbAT1 primers are more sensitive 
than the PLC-linked microsatellite primers. Only one isolate from Moyo failed 
amplification with the highly sensitive TBR primers following two attempts of DNA 
extraction from two separate discs punched from the blood spot on an FTA card. This was 
possibly due to lack of trypanosome DNA on the cut FTA card discs used for DNA 
extraction or presence of extremely little amplifiable material. The finding also suggested 
that the isolates that failed to amplify for the single copy T. brucei PLC -linked 
microsatellite and the TbAT1 gene most likely had very low parasite densities below the 
threshold for detection by PCR. However, on comparison of the PCR results for each of 
the isolates with both sets of primers, 42 isolates (Arua n=37and Moyo n=5) had been 
successfully amplified for the TbAT1 gene but not for the T. brucei PLC like microsatellite 
(Table 4.3). And yet 12 isolates (Arua n=5 and Moyo n=7) were successfully amplified for 
the T. brucei PLC-linked microsatellite but not for the TbAT1 gene (Table 4.3). While low 
parasite densities may be responsible for the former situation, it could not be ruled out that 
the complete loss or deletions within the TbAT1 gene could be responsible for the later 
situation which is likely. An example is the complete loss of the TbAT1 gene which was 
demonstrated in 1 Angolan T. brucei stock (K001) isolated from a melarsoprol relapsed Anne Juliet Nalunkuma Kazibwe    Chapter 4, 126 
patient (Matovu et al, 2001b). However, some of the PCRs were done only once and some 
twice. Alternatively, other point mutations that influence the ability of the primers to bind 
template DNA could have affected the results.  
 
PCR target  Arua district (n=99) 
PLC (+ ve)         PLC (-ve) 
Moyo district (n=33) 
PLC (+ve)            PLC (-ve) 
Total 
(N=132) 
TbAT1 (+ ve)  45  37  4  5  91 
TbAT1 (-ve)  5  12  7  17  41 
Total  50  49  11  22  132 
Table 4.3 The TbAT1 and the single copy T. brucei PLC microsatellite PCR results. 
The Table shows how lack of amplification of the T. brucei Phospholipase C (PLC) like gene 
possibly due to low parasite densities influenced the amplification of T. brucei adenosine 
transporter gene (TbAT1). 
+ve, PCR product detected in agarose gel. –ve, no PCR product detected in agarose gel. 
N, total number of samples analysed. n, number of samples from each respective district. 
Cells (shaded grey), no TbAT1 PCR product detected (possibly lost or deleted TbAT1).  
Cells (diagonal pattern), no PLC PCR product detected (most probably due to low 
parasitaemia)  
TbAT1 PCR results based on one experiment and PLC PCR results based on two 
experiments. 
 
4.4.2 Sfa NI analysis of the TbAT1 gene 
The 677 bp PCR fragment (Figure 4.1) of the TbAT1 gene from each of the 91 successfully 
amplified isolates (Table 4.2) was digested with the Sfa NI restriction endonuclease 
enzyme as described (section 4.3) to determine the TbAT1 genotype based on the fragment 
sizes generated. All of the 91 isolates (Arua n=82 and Moyo n=9) possessed TbAT1 wild 
type alleles corresponding to the presence of the 566 bp and 111 bp band size pattern 
similar to that shown earlier for the T. brucei melarsoprol sensitive stock STIB 777 (Figure 
4.2). The TbAT1 mutant positive control a T. brucei reference clone STIB 950 (multidrug 
resistant to diminazene aceturate, isometamidium chloride and quinapyramine) (Kaminsky 
et al, 1989), displayed the TbAT1 mutant pattern (425 bp and 242 bp) (Figure 4.2) similar 
to that reported for the T. brucei melarsoprol resistant reference clone STIB 777R (Mäser 
et al, 1999). These results suggested the patients were infected with trypanosomes 
possessing TbAT1 melarsoprol sensitive alleles. 
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Figure 4.1 A representative Agarose gel showing the TbAT1 nested PCR results. 
The Figure shows the 677 bp TbAT1 gene RFLP fragment (White arrow head). 
Lanes 2, 4, 5, 7, 9 and 10-13 representative patient samples positive for the TbAT1 gene. 
Lanes 1, 3, 6 and 8 patient samples negative for the TbAT1 gene. 
M, 1 Kb molecular weight DNA marker (Gene Ruler
TM, Fermentas, Life Sciences). 
+, TbAT1 mutant positive control (multidrug resistant reference clone STIB 950 identical to 
STIB 777R). 
-, negative control (sterile water no template). 
A TbAT1 wild type positive control e.g. the melarsoprol sensitive reference clone (STIB 
777S) was not included in the PCR run. 
 
 
Figure 4.2 A representative Agarose gel showing the TbAT1 (677 bp) Sfa NI digest results. 
The Figure shows the TbAT1 wild type pattern (566 bp and 111 bp) and the TbAT1 resistant 
pattern (425 bp and 242 bp) size bands.  
Lanes 1-9 and 12-14 representative patient samples with tbat1 wild type alleles.  
M, 1 Kb molecular weight DNA marker (Gene Ruler
TM, Fermentas, Life Sciences).  
+, TbAT1 mutant positive control, a multidrug resistant reference clone STIB 950 identical to 
STIB 777R 
A TbAT1 wild type positive control was not included in the SfaNI RFLP digest reaction 
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4.4.3 Sequencing of the TbAT1 gene 
In a previous study, Matovu and others (2001b) demonstrated by sequencing 13 isolates 
from melarsoprol relapsed patients from Omugo, the presence of TbAT1 wild type alleles 
confirming the PCR/RFLP results. In the current study, only TbAT1 wild type alleles were 
observed by PCR/RFLP in all the 91 patient isolates successfully analysed (section 4.4.2). 
Sequencing was therefore carried out on a few samples to confirm this observation.  
The TbAT1 PCR products (677 bp fragment) from 5 randomly selected patient isolates 
were cloned as described (section 4.3) and the plasmid DNA sequenced at MWG Biotech 
from the forward and reverse directions using the T7 and SP6 primers. The 677 bp 
fragment of TbAT1 of the positive control reference strain STIB 950 (Kaminsky et al, 
1989) used in the RFLP analysis was cloned as well and sequenced for comparison with 
the sequences of the patient isolates. The cloning and sequencing was carried out once for 
each patient isolate. Using the blast analysis tool from the National Centre for 
Biotechnology Institute (NCBI) database http://www.ncbi.nih.gov/, the patient isolate 
TbAT1 sequences were 99% identical to the TbAT1 gene sequence of the wild type T. 
brucei reference strain STIB 427 (Genbank Accession number AF152369). The TbAT1 
sequence of the positive control STIB 950 was 99% identical to the TbAT1 gene of the 
melarsen oxide cysteamine resistant T. brucei reference strain STIB 777R (Genbank 
Accession number AF152370). A multiple alignment of the sequences was performed 
using the alignment tool at http://www.expasy.ch/ (Figure 4.4). Four of the five isolates 
lacked the 10 mutations reported earlier to be present in the TbAT1 gene sequence of the 
drug resistant stock STIB777R. This included the two mutations Ala178Thr and 
Asn276Ser at nucleotide positions G532A and A858G respectively, which were used in the 
PCR/RFLP analysis as the basis for differentiating between the TbAT1 genes of the 
melarsoprol sensitive (STIB777S) and resistant (STIB777R) trypanosomes (Mäser et al, 
1999;Matovu et al, 2001b). The fifth isolate OM62 was found to possess one of the silent 
mutations C502T reported to be present in STIB777R but not any of the other reported 
mutations including those that could be detected by PCR/RFLP. This however, indicated it 
had one characteristic of a mutant. The RFLP analysis, which detects only the two 
mutations Ala178Thr and Asn276Ser, indicated it was wild type. Moreover all the isolates 
had other changes compared to the original wild type occurring in different positions in 
their TbAT1 sequences (Figure 4.3 and Table 4.4). Isolate OM72 had a mutation C1062T Anne Juliet Nalunkuma Kazibwe    Chapter 4, 129 
causing amino acid change Ser354Leu. Another mutation led to a dinucleotide deletion in 
isolate OM62 at positions 1087 and 1088, while isolate M148 had one nucleotide deletion 
at position 1088. However these deletions may or may not alter the conformation of amino 
acid Leu 363 since a base change T1089A observed in the rest of the isolates that occurred 
within the same codon did not code for another amino acid (Table 4.4). Another mutation 
A1090T occurred in all the isolates causing amino acid change Thr364Ser. The tbat1 
mutant control used in this analysis (STIB950) was also found to have a mutation in its 
sequence at nucleotide positions 950-952 leading to the deletion of an entire codon Phe317 
which was similar to the deletion observed in field isolates from melarsoprol relapsed 
patients but not in the mutated TbAT1 gene sequence of STIB777R (Matovu et al, 2001b). 
This result is in agreement with earlier findings (Mäser et al, 1999;Matovu et al, 2001b). 
Some of the observed changes in these isolates like the deletions would change the open 
reading frame by frame shift therefore altering the protein and its function or they may not 
necessarily affect the function of the protein. The new mutations may also be due to 
sequencing errors or changes introduced during the amplification process by Taq 
polymerase. However, the sequencing, which was performed at MWG Biotech was carried 
out only once so reamplification and reanalysis would be required to confirm these results. Anne Juliet Nalunkuma Kazibwe    Chapter 4, 130 
 
Figure 4.3 The positions of mutations present in the RFLP fragment of field isolates and 
STIB950. 
The schematic shows (in bold black) mutations in sequenced STIB950 also present in 
STIB777R including G543A and A858G used for tbat1 mutant allele detection in RFLP. 
(in bold blue), deletion observed only in STIB950 but reported absent in STIB777R 
(in bold green), silent mutation observed in OM62 but reported to exist in STIB777R. 
(in bold red), mutation present in isolate OM 72. 
(in bold purple), mutations/deletions present in OM62 & M148 or silent mutation in OM72, 
OM141 and M176. 
(in bold brown) mutation present in all isolates (OM62, OM72, OM141, M148 and M176). 
[Adapted from (Matovu et al, 2001b)] 
 
Base positions in the TbAT1 gene  ∗ ∗ ∗ ∗Reference clone/ 
• • • •Field sample code 
502  1062  1087  1088  1089  1090 
∗STIB427 wild type  C  C  C  T  T  A 
∗STIB950 mutant  C  C  C  T  A*  T** 
•OM62  T*  C  ∆  ∆  A*  T** 
•OM72  C  T**  C  T  A*  T** 
•OM141  C  C  C  T  A*  T** 
•M148  C  C  C  ∆  A*  T** 
•M176  C  C  C  T  A*  T** 
Table 4.4 Comparison TbAT1 gene sequences at positions 503, 1063 and 1087-1090. 
The Table shows base changes at the different positions in the TbAT1 of the field isolates in 
comparison to the TbAT1 of the reference clones, STIB 427 wild type (Genbank accession 
number AF152639) and STIB 950 mutant (identical to STIB 777R Genbank accession number 
AF152370). 
OM, Omugo (patient sample code for Arua, Omugo health centre). 
M, Moyo (patient sample code for Moyo hospital). 
*, silent mutation. **, coding mutation. ∆, base deletion. Anne Juliet Nalunkuma Kazibwe    Chapter 4, 131 
 
STIB427_wildtype TGCTGGAAACGCCGCACTCATCGCCCCGTTTCCAACGAAATTTTATAGCTCCGTCGTGTG 480 
OM141            --------TCGCCGCACTCATCGCCCCGTTTCCAACGAAATTTTATAGCTCCGTCGTGTG 52 
M148             --------TCGCCGCACTCATCGCCCCGTTTCCAACGAAATTTTATAGCTCCGTCGTGTG 52 
OM62             --------TCGCCGCACTCATCGCCCCGTTTCCAACGAAATTTTATAGCTCCGTCGTGTG 52 
M176             --------TCGCCGCACTCATCGCCCCGTTTCCAACGAAATTTTATAGCTCCGTCGTGTG 52 
OM72             AATTCGATTCGCCGCACTCATCGCCCCGTTTCCAACGAAATTTTATAGCTCCGTCGTGTG 62 
STIB950_mutant   --------TCGCCGCACTCATCGCCCCGTTTCCAACGAAATTTTATAGCTCTGTCGTGTG 52 
                          ****************************************** ******** 
 
STIB427_wildtype GGGTATCGCTGTGTGCGGCGTCGTCACATCTTTCTTCTCGATCGTCATAAAAGCATCCAT 540 
OM141            GGGTATCGCTGTGTGCGGCGTCGTCACATCTTTCTTCTCGATCGTCATAAAAGCATCCAT 112 
M148             GGGTATCGCTGTGTGCGGCGTCGTCACATCTTTCTTCTCGATCGTCATAAAAGCATCCAT 112 
OM62             GGGTATCGCTGTGTGCGGCGTTGTCACATCTTTCTTCTCGATCGTCATAAAAGCATCCAT 112 
M176             GGGTATCGCTGTGTGCGGCGTCGTCACATCTTTCTTCTCGATCGTCATAAAAGCATCCAT 112 
OM72             GGGTATCGCTGTGTGCGGCGTCGTCACATCTTTCTTCTCGATCGTCATAAAAGCATCCAT 122 
STIB950_mutant   GGGTATCGCTGTGTGCGGCGTCGTCACATCTTTCTTCTCGATCGTCATAAAAACATCCAT 112 
                 ********************* ****************************** ******* 
 
STIB427_wildtype GGGAGGCGGTTATCACAACATGCTCATACAGTCGCGCATATACTTTGGATTGGTCATGTT 600 
OM141            GGGAGGCGGTTATCACAACATGCTCATACAGTCGCGCATATACTTTGGATTGGTCATGTT 172 
M148             GGGAGGCGGTTATCACAACATGCTCATACAGTCGCGCATATACTTTGGATTGGTCATGTT 172 
OM62             GGGAGGCGGTTATCACAACATGCTCATACAGTCGCGCATATACTTTGGATTGGTCATGTT 172 
M176             GGGAGGCGGTTATCACAACATGCTCATACAGTCGCGCATATACTTTGGATTGGTCATGTT 172 
OM72             GGGAGGCGGTTATCACAACATGCTCATACAGTCGCGCATATACTTTGGATTGGTCATGTT 182 
STIB950_mutant   GGAAGGCGGTTATCACAACATGCTCATACAGTCGCGCATATACTTTGGATTGGTCATGTT 172 
                 ** ********************************************************* 
 
STIB427_wildtype TATGCAGGTGATATCTTGCGCCCTTTTAGTGTTGCTAAGGAAGAACCCTTACGCCCAAAA 660 
OM141            TATGCAGGTGATATCTTGCGCCCTTTTAGTGTTGCTAAGGAAGAACCCTTACGCCCAAAA 232 
M148             TATGCAGGTGATATCTTGCGCCCTTTTAGTGTTGCTAAGGAAGAACCCTTACGCCCAAAA 232 
OM62             TATGCAGGTGATATCTTGCGCCCTTTTAGTGTTGCTAAGGAAGAACCCTTACGCCCAAAA 232 
M176             TATGCAGGTGATATCTTGCGCCCTTTTAGTGTTGCTAAGGAAGAACCCTTACGCCCAAAA 232 
OM72             TATGCAGGTGATATCTTGCGCCCTTTTAGTGTTGCTAAGGAAGAACCCTTACGCCCAAAA 242 
STIB950_mutant   TATGCAGGTGATATCTTGCGCCCTTTTAGTGTTGCTAAGGAAGAACCCTTACGCCCAAAA 232 
                 ************************************************************ 
 
STIB427_wildtype GTACGCGGCAGAGTTCCGATATGCAGCGAGGAAAGGGATTGATGATAAGGGCGCAGATGG 720 
OM141            GTACGCGGCAGAGTTCCGATATGCAGCGAGGAAAGGGATTGATGATAAGGGCGCAGATGG 292 
M148             GTACGCGGCAGAGTTCCGATATGCAGCGAGGAAAGGGATTGATGATAAGGGCGCAGATGG 292 
OM62             GTACGCGGCAGAGTTCCGATATGCAGCGAGGAAAGGGATTGATGATAAGGGCGCAGATGG 292 
M176             GTACGCGGCAGAGTTCCGATATGCAGCGAGGAAAGGGATTGATGATAAGGGCGCAGATGG 292 
OM72             GTACGCGGCAGAGTTCCGATATGCAGCGAGGAAAGGGATTGATGATAAGGGCGCAGATGG 302 
STIB950_mutant   GTACGCGGCAGAGTTCCGATATGCAGCGAGGAAAGGGATTGATGATAAGGGCGCAGGTGG 292 
                 ******************************************************** *** 
 
STIB427_wildtype TGACGAAGGAAACGGCGCAGCAAAAGGGCCGGCCGATCAGGATGATGACCCCCACGGAGG 780 
OM141            TGACGAAGGAAACGGCGCAGCAAAAGGGCCGGCCGATCAGGATGATGACCCCCACGGAGG 352 
M148             TGACGAAGGAAACGGCGCAGCAAAAGGGCCGGCCGATCAGGATGATGACCCCCACGGAGG 352 
OM62             TGACGAAGGAAACGGCGCAGCAAAAGGGCCGGCCGATCAGGATGATGACCCCCACGGAGG 352 
M176             TGACGAAGGAAACGGCGCAGCAAAAGGGCCGGCCGATCAGGATGATGACCCCCACGGAGG 352 
OM72             TGACGAAGGAAACGGCGCAGCAAAAGGGCCGGCCGATCAGGATGATGACCCCCACGGAGG 362 
STIB950_mutant   TGACGAAGGAAACGGCGCAGCAAAAGGGCCGGCCGATCAGGATGATGACCCCCACGGAGG 352 
                  ************************************************************ 
 
STIB427_wildtype CGATGATACTGACAAAGGAAATGTAATGACCGCCACTGTAGATCCTGACACAATGAAGGA 840 
OM141            CGATGATACTGACAAAGGAAATGTAATGACCGCCACTGTAGATCCTGACACAATGAAGGA 412 
M148             CGATGATACTGACAAAGGAAATGTAATGACCGCCACTGTAGATCCTGACACAATGAAGGA 412 
OM62             CGATGATACTGACAAAGGAAATGTAATGACCGCCACTGTAGATCCTGACACAATGAAGGA 412 
M176             CGATGATACTGACAAAGGAAATGTAATGACCGCCACTGTAGATCCTGACACAATGAAGGA 412 
OM72             CGATGATACTGACAAAGGAAATGTAATGACCGCCACTGTAGATCCTGACACAATGAAGGA 422 
STIB950_mutant   CGATGATACTGACAAAGGAAATGTAATGACCGCCACTGTAGATCCTGACACAATGAAGGA 412 
                  ************************************************************ 
 
STIB427_wildtype CATGGACCAGGTGGAAAACATCACGACTTCGCAGCAGATGTTAATGGCAAGGGTATGGAA 900 
OM141            CATGGACCAGGTGGAAAACATCACGACTTCGCAGCAGATGTTAATGGCAAGGGTATGGAA 472 
M148             CATGGACCAGGTGGAAAACATCACGACTTCGCAGCAGATGTTAATGGCAAGGGTATGGAA 472 
OM62             CATGGACCAGGTGGAAAACATCACGACTTCGCAGCAGATGTTAATGGCAAGGGTATGGAA 472 
M176             CATGGACCAGGTGGAAAACATCACGACTTCGCAGCAGATGTTAATGGCAAGGGTATGGAA 472 
OM72             CATGGACCAGGTGGAAAACATCACGACTTCGCAGCAGATGTTAATGGCAAGGGTATGGAA 482 Anne Juliet Nalunkuma Kazibwe    Chapter 4, 132 
STIB950_mutant   CATGGACCAGGTGGAAAGCATCACGACTTCGCAGCAGATGTTAATGGCAAGGGTATGGAA 472 
                 ***************** ****************************************** 
 
STIB427_wildtype TGTGTTCTGGCGCGTTTGGCCCATGCTGTTCGCATGCTTCATGGTTTTCTTCACCACATT 960 
OM141            TGTGTTCTGGCGCGTTTGGCCCATGCTGTTCGCATGCTTCATGGTTTTCTTCACCACATT 532 
M148             TGTGTTCTGGCGCGTTTGGCCCATGCTGTTCGCATGCTTCATGGTTTTCTTCACCACATT 532 
OM62             TGTGTTCTGGCGCGTTTGGCCCATGCTGTTCGCATGCTTCATGGTTTTCTTCACCACATT 532 
M176             TGTGTTCTGGCGCGTTTGGCCCATGCTGTTCGCATGCTTCATGGTTTTCTTCACCACATT 532 
OM72             TGTGTTCTGGCGCGTTTGGCCCATGCTGTTCGCATGCTTCATGGTTTTCTTCACCACATT 542 
STIB950_mutant   TGTGTTCTGGCGCGTTTGGCCCATGCTGTTCGCATGCTTCATGGTTTTC---ACCACATT 529 
                 *************************************************   ******** 
 
STIB427_wildtypeTCTCGTCTACCCTGCCGTGTACTTCGCCATCAAGGCAGATACGGGTGACGGCTGGTACTT 1020 
OM141           TCTCGTCTACCCTGCCGTGTACTTCGCCATCAAGGCAGATACGGGTGACGGCTGGTACTT 592 
M148            TCTCGTCTACCCTGCCGTGTACTTCGCCATCAAGGCAGATACGGGTGACGGCTGGTACTT 592 
OM62            TCTCGTCTACCCTGCCGTGTACTTCGCCATCAAGGCAGATACGGGTGACGGCTGGTACTT 592 
M176            TCTCGTCTACCCTGCCGTGTACTTCGCCATCAAGGCAGATACGGGTGACGGCTGGTACTT 592 
OM72            TCTCGTCTACCCTGCCGTGTACTTCGCCATCAAGGCAGATACGGGTGACGGCTGGTACTT 602 
STIB950_mutant  TCTCGTCTACCCTGCCGTGTACTTCGCCATCAAGGCAGATACGGGTGATGGCTGGTACTT 589 
                ************************************************ *********** 
 
STIB427_wildtypeGACGATCGCTGCCGCATTGTTCAATTTGGGTGATTTCTTGTCGCGTCTTTGCCTTCAGTT 1080 
OM141           GACGATCGCTGCCGCATTGTTCAATTTGGGTGATTTCTTGTCGCGTCTTTGCCTTCAGTT 652 
M148            GACGATCGCTGCCGCATTGTTCAATTTGGGTGATTTCTTGTCGCGTCTTTGCCTTCAGTT 652 
OM62            GACGATCGCTGCCGCATTGTTCAATTTGGGTGATTTCTTGTCGCGTCTTTGCCTTCAGTT 652 
M176            GACGATCGCTGCCGCATTGTTCAATTTGGGTGATTTCTTGTCGCGTCTTTGCCTTCAGTT 652 
OM72            GACGATCGCTGCCGCATTGTTCAATTTGGGTGATTTCTTGTTGCGTCTTTGCCTTCAGTT 662 
STIB950_mutant  GACGATCGCTGCCGCATTGTTCAATTTGGGTGATTTCTTGTCGCGTCTTTGCCTTCAGTT 649 
                ***************************************** ****************** 
 
STIB427_wildtypeCAAAGCCTTACACGTCTCACCGCGGTGGGTTCTGATTGGGACATTTGCGCGTATGCTGCT 1140 
OM141           CAAAGCCTATCACGTCT------------------------------------------- 669 
M148            CAAAGCC-ATCACGTCTCACCGCGGTGGA------------------------------- 680 
OM62            CAAAGC--ATCACGTCTCACCGCGGTGGA------------------------------- 679 
M176            CAAAGCCTATCACGTCTCACCGCGGTGGA------------------------------- 681 
OM72            CAAAGCCTATCACGTCTCACCGCGGTGGA------------------------------- 691 
STIB950_mutant  CAAAGCCTATCACGTCTCACCGCGGTGGAA------------------------------ 679 
                ******    *******                                            
Figure 4.4 Comparison of TbAT1 gene sequences (RFLP fragment) by multiple alignments. 
OM62, OM72 and OM141 are isolates from sleeping sickness patients treated at Omugo 
health centre. 
M148 and M176 are isolates from sleeping sickness patients treated at Moyo hospital. 
wild type T. brucei TbAT1 (STIB427 Genbank accession number AF152369)  
mutant T. brucei TbAT1 STIB950 identical to (STIB777R Genbank accession number 
AF152370). 
 
4.4.4 TbAT1 genotype and patient treatment outcome 
Patients had to be followed according to protocol at 6, 12 and 24 months after treatment to 
detect any treatment failures or relapses (section 4.3). However, correlation of the TbAT1 
genotype with treatment outcome would only apply to melarsoprol and pentamidine-
treated cases and not eflornithine where, unlike the other two drugs, resistance is not 
mediated through the TbAT1/P2 transporter (Delespaux & De Koning, 2007). The 
correlation greatly depends on the patient follow up data and successful amplification of 
the TbAT1 gene. By the time of writing this thesis follow up data from Omugo, Arua was 
available for 25 of 88 stage II patients (Table 4.5) and 5 of 11 stage I patients (Table 4.6). 
Follow up data was available for only 2 patients M135 and M177 (Table 4.7) out of 34 Anne Juliet Nalunkuma Kazibwe    Chapter 4, 133 
patients from Moyo who had at most attended only one follow up visit (Patient Raw data, 
Appendix II). However the patient follow up diagnosis results for one of the patients 
(OM95) treated with eflornithine indicated an increase in the cerebral spinal fluid (CSF) 
white blood cell count (WBC) from 10 to 81/mm
3 in the CSF but with no detectable 
trypanosomes in the CSF (Table 4.5). A cut-off of 5WBC/mm
3 in the CSF and/or presence 
of trypanosomes in any of the body fluid is considered a late stage case at Omugo, Arua 
NW Uganda. No trypanosomes were observed in the CSF possibly because of very low 
parasitaemia and the low sensitivity of microscopy. The result would suggest that the 
patient failed treatment. For eflornithine to be effective, it requires an intact immune 
system that can recognise and fight infection after it has exerted its trypanostatic effect 
(Burri & Brun, 2003). It is possible that this patient was Immune-suppressed or had 
another secondary infection e.g. with Human Immune deficiency Virus (HIV) rendering 
the drug ineffective (Pepin et al, 1992). HIV is known to be prevalent in Uganda. It is also 
a possibility that the patient was infected with drug resistant trypanosomes. However, HIV 
does attack the T-lymphocytes (CD4 cells) in the immune system while trypanosome 
resistance may be due to B cells and innate factors. The drug is also difficult to administer 
since it requires 4 daily infusions of 100 mg/kg body weight for 14 days, which in some 
instance may be unbearable particularly if the patient is a child. Anne Juliet Nalunkuma Kazibwe    Chapter 4, 134 
 
Patient 
code 
Date 
Admitted 
CSF WBC 
& tryps 
yes or no 
Date 
followed 
CSF WBC 
& tryps 
yes or no 
TbAT1 
PCR/SfaNI 
PLC 
 PCR 
OM46  Aug `05  205/ yes  Feb `06  5/ no  Wild type  n. d 
OM47  Aug `05  247/ yes  Mar `06  43/ no  n. d  n. d 
OM50  Aug `05  363/ yes  Mar `06  16/ no  n. d  n. d 
OM54  Sep `05  283/ yes  Mar `06  20/ no  Wild type  n. d 
OM55  Sep `05  45/ yes  Apr `06  22/ no  Wild type  Positive 
OM56  Sep `05  383/ yes  Jun `06  12/ no  Wild type  n. d 
OM57  Sep `05  99/ yes  Apr `06  1/ no  n. d  n. d 
OM62  Oct `05  295/ yes  May `06  7/ no  Wild type  Positive 
OM64  Nov `05  93/ yes  Jun `06  3/ no  Wild type  n. d 
OM68  Nov `05  170/ yes  Jun `06  5/ no  Wild type  n. d 
OM69  Nov `05  529/ yes  Aug `06  9/ no  Wild type  Positive 
OM73  Nov `05  571/ yes  Jun `06  7/ no  Wild type  n. d 
OM75  Nov `05  318/ yes  Aug `06  9/ no  Wild type  n. d 
OM79  Jan `06  107/ yes  Aug `06  2/ no  Wild type  Positive 
OM82  Jan `06  20/ yes  Aug `06  5/ no  n. d  n. d 
OM83  Jan `06  617/ yes  Aug `06  3/ no  Wild type  n. d 
OM84  Jan `06  963/ no  Jun `06  7/ no  Wild type  n. d 
OM85  Jan `06  1025/ no  Aug `06  7/ no  Wild type  n. d 
OM86  Jan `06  7/ no  Aug `06  0/ no  Wild type  Positive 
OM89  Jan `06  21/ no  Aug `06  3/ no  n. d  n. d 
OM90  Jan `06  103/ no  Aug `06  74/ no  Wild type  Positive 
OM94  Jan `06  61/ no  Aug `06  3/ no  Wild type  n. d 
OM95*  Jan `06  10/ no  Aug `06  81/ no  n. d  n. d 
OM96  Jan `06  259/ no  Aug `06  64/ no  Wild type  Positive 
OM101  Jan `06  137/ no  Jul `06  39/ no  Wild type  n. d 
Table 4.5 Follow up and PCR results for stage II patients (n=25) treated with DFMO at 
Omugo, Arua. 
“CSF WBC”, cerebral spinal fluid-white blood cell count (number of cells/mm
3 CSF). 
tryps, trypanosomes. 
yes, presence of trypanosomes detected by microscopy  
no, no trypanosomes detected by microscopy.  
Haematocrit centrifugation results by microscopy were negative at follow up 
Parasitological tests as determined by trained personnel at Omugo health centre 
n. d, no PCR product detected in agarose. 
*Patient (OM95) had an increased CSF WBC count (10 to 81/mm
3) post treatment and was 
readmitted and treated with melarsoprol. Anne Juliet Nalunkuma Kazibwe    Chapter 4, 135 
 
Of the 11 pentamidine treated stage I patients from Omugo health centre in Arua, follow-
up data 6 months post treatment, was available for only 5 patients (Table 4.6). Of these 
patients, 4 had no trypanosomes in their body fluids with <5WBC/mm
3 in the CSF or none 
after parasitological diagnosis. Isolates from these patients possessed TbAT1 wild type 
alleles according to the Sfa NI enzyme analysis (Table 4.6). This suggested the TbAT1/P2 
transporter was not defective which may be in agreement with the hypothesis that the 
TbAT1 genotype should correlate with the treatment outcome if the transporter is 
responsible for treatment failure or resistance.  
 
Patient 
code 
Date 
Admitted 
CSF WBC 
& tryps 
yes or no 
Date 
followed 
CSF WBC 
& tryps  
yes or no 
TbAT1 
PCR/SfaNI 
PLC  
PCR 
OM65*  Nov `05  3/ no  Jul. `06  39/ yes  n. d  n. d 
OM88  Jan. `06  5/ no  Aug. `06  3/ no  Wild type  Positive 
OM93  Jan. `06  1/ no  Aug. `06  0/ no  Wild type  Positive 
OM97  Jan. `06  4/ no  Aug. `06  1/ no  Wild type  Positive 
OM98  Jan. `06  1/ no  Aug. `06  3/ no  Wild type  Positive 
Table 4.6 TbAT1 status and diagnosis results post treatment of Arua stage I patients. 
The Table shows results of the comparison between pentamidine treatment outcome at 6 
months follow up and the PCR/RFLP results.  
The T. brucei Phospholipase C linked microsatellite (PLC) PCR was used as a single copy 
gene control. 
Haematocrit centrifugation test follow up results all negative by microscopy (not shown).  
“CSF WBC”, cerebral spinal fluid-white blood cell count (number of cells/mm
3 CSF).  
tryps, trypanosomes. 
yes, presence of trypanosomes detected by microscopy. no, no trypanosomes detected by 
microscopy.  
Parasitological tests as determined by trained personnel at Omugo health centre.  
n. d, no PCR product detected in agarose.  
*Patient (OM65) failed treatment during follow up and was readmitted and retreated with 
eflornithine. 
 
The problem of low parasite densities encountered with most isolates (Table 4.3) made it 
impossible to determine the TbAT1 status of the isolate from patient OM65 who had 
progressed to stage II disease. This patient who had an elevated CSF cell count (from 3 to 
39 WBC/mm
3) also had trypanosomes in CSF after diagnosis by microscopy (Table 4.6). 
This patient was readmitted and treated with eflornithine. This patient’s follow-up results 
after retreatment are not yet available. It was not possible to draw any conclusions from Anne Juliet Nalunkuma Kazibwe    Chapter 4, 136 
these results regarding the role of TbAT1 in relation to pentamidine. Pentamidine resistance 
in the field is not considered a problem because it is imported via multiple transporters, 
which is considered a rationale for the observed high efficacy in the field (de Koning & 
Jarvis, 2001;de Koning, 2001b;Matovu et al, 2003). It is therefore more likely that this 
pentamidine relapse patient (OM65) was a misdiagnosed late stage case which is a 
possibility especially if the cell counts are at the borderline. The weakness of this argument 
though, is from a study that indicated that patients in the early late stage of phase II are 
likely to benefit from pentamidine therapy (Doua et al, 1996), invoking the consideration 
that this observed failure as is the case with Omugo in NW Uganda could as well be a 
result of genuine pentamidine resistance. Indeed, results from a more recent study 
demonstrated increased resistance to pentamidine in vitro following the loss of both 
TbAT1/P2 and HAPT1 transport in a laboratory pentamidine resistance induced strain B48 
(Bridges et al, 2007). However, there is no evidence to date of the loss of HAPT1 in field 
trypanosome isolates because the molecular characterisation of HAPT1 is not yet 
undertaken. Moreover, at least in mice, the B48 strain was of greatly reduced virulence and 
could only infect if given at a greatly elevated inoculum (Bridges et al, 2007). 
Follow up data (6 months) was available for 2 out of the 34 melarsoprol treated stage II 
patients enrolled in the study from Moyo hospital. The problem of low parasite densities, 
made it impossible to determine the TbAT1 status by PCR/RFLP of most of the isolates 
and yet for the isolates (n=9) whose TbAT1 genotype was determined their follow up data 
was unavailable except for one (M135) which was wild type (Table 4.7). Patient M135 had 
no trypanosomes in any of the body fluids and the CSF cell count had decreased from 240 
to 2/mm
3 following diagnosis by microscopy (Table 4.7). It was not possible to draw 
conclusions from this data. Otherwise, it would have been of interest to compare the 
melarsoprol treatment outcome results and TbAT1 PCR/RFLP results of isolates from two 
patients M173 (relapsed earlier after melarsoprol treatment) and M174 (reinfected after 4 
years of first admission) who were enrolled in this study from a previous survey (Table 
4.7). For melarsoprol, a 9% treatment failure rate is regarded as normal (Legros et al, 
1999). One would suggest that patient M173 might not be a treatment failure in this study 
based on the TbAT1 genotype by PCR/RFLP further suggesting that the initial situation 
falls among the expected treatment failure cases regarded as normal. On the other hand, 
knowing the results for two other patients (M165 and M166) who had earlier failed 
treatment with pentamidine would have ruled out whether they were misdiagnosed late 
stage cases as explained earlier on for patient OM65 (Table 4.6) or genuine pentamidine 
resistant.  Anne Juliet Nalunkuma Kazibwe    Chapter 4, 137 
 
Patient 
code 
Date 
Admitted 
CSF WBC 
& tryps 
Yes or no 
Date 
followed 
CSF WBC 
& tryps 
Yes or no 
TbAT1 
PCR/SfaNI 
PLC  
PCR 
M117  Feb `05  186/ yes  N/A  N/A  Wild type  Positive 
M135  Apr `05  240/ yes  Nov `05  2/ no  Wild type  n. d 
M146  Jul `05  88/ yes  N/A  N/A  Wild type  n. d 
M148  Aug. `05  66/ yes  N/A  N/A  Wild type  Positive 
M150  Aug `05  122/ yes  N/A  N/A  Wild type  n. d 
M160  Sept `05  82/ yes  N/A  N/A  Wild type  Positive 
M162  Oct `05  16/ yes  N/A  N/A  Wild type  n. d 
M168  Dec `05  116/ yes  N/A  N/A  Wild type  Positive 
M161*  Oct `05  15/ yes  N/A  N/A  n. d  n. d 
M165*  Oct `05  10/ yes  N/A  N/A  n. d  n. d 
M173§  Feb `06  13/ yes  N/A  N/A  Wild type  n. d 
M174†  Feb `06  16/ yes  N/A  N/A  n. d  n. d 
M177  Feb `06  136/ yes  N/A  1/ no  n. d  n. d 
Table 4.7 TbAT1 status and diagnosis results post-treatment of Moyo stage II patients. 
The Table shows PCR/RFLP results but comparison with melarsoprol treatment outcome 
not conclusive due to the unavailability of adequate data.  
The T. brucei Phospholipase C (PLC) microsatellite PCR was used as a single copy gene 
control.  
CSF, cerebral spinal fluid. WBC, white blood cell count. tryps, trypanosomes. 
no, no trypanosomes detected by microscopy. yes, trypanosomes detected by microscopy. 
Parasitological results as determined by trained personnel at Moyo hospital.  
N/A, follow up results not available. n.d, PCR product not detected in agarose possibly due 
to low parasitaemia.  
*Patient relapsed earlier following pentamidine treatment and was readmitted.  
†Patient relapsed earlier following melarsoprol treatment and was readmitted.  
§Patient reinfected (2
nd admission 4 years after first admission following melarsoprol 
treatment) (Dr.E Matovu, personal communication). 
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4.5 Discussion 
The alarming increase in incidence of treatment failure following the use of melarsoprol, in 
several HAT foci, has led to concerns that drug resistance has emerged and may be 
spreading (Legros et al, 1999;Moore & Richer, 2001;Stanghellini & Josenando, 2001). 
Resistance to melarsoprol has been linked to mutations in the TbAT1 gene that encodes the 
P2 amino purine transporter that can also carry melaminophenylarsenical and diamidine 
drugs (Carter & Fairlamb, 1993;Carter et al, 1995;Carter et al, 1999;Mäser et al, 
1999;Matovu et al, 2001b). Melarsoprol was replaced, in 2001, by eflornithine (DFMO) as 
first-line treatment for late stage disease at Omugo health centre, Arua due to high levels of 
treatment failure in this area (Legros et al, 1999). However, this was not the case in Moyo 
and therefore melarsoprol is still used at this centre as first-line treatment for late stage 
disease. Moreover, detection of treatment failures or developing drug resistance relies on 
the diagnosis of the presence of trypanosomes in body fluids using microscopy, a 
notoriously insensitive technique and dependent on long-term follow-up of patients, which 
is logistically fraught. A PCR/Sfa NI RFLP based method was devised by Mäser and 
colleagues (1999) to demonstrate the presence of two of the mutations in the TbAT1 gene 
of the arsenical resistant T. b. brucei stock STIB 777R. Similar mutations were identified 
in isolates from T. b. gambiense melarsoprol relapsed (n=30) and patients infected for the 
first time (n=8) who were hospitalised at Omugo health centre. These manifested mainly as 
mixed banding patterns (26/38) reflecting the presence of both mutant and wild genotypes 
in the same patient (Matovu et al, 2001b). However, the presence of the wild type pattern 
alone observed in a limited number of isolates from melarsoprol relapsing patients (n=13) 
was suggestive that the method failed to detect all relapse cases (Matovu et al, 2001b). It 
remains possible that trypanosome numbers in the relapse cases were below detection 
levels, thus preventing detection of the so-called resistance alleles. One would also suggest 
that these wild type drug failures are due to inadequate administration or poor drug batches 
implying failure may not be due to true drug resistance but possibly other biochemically 
mediated factors. But the patients were treated under careful supervision by trained 
medical personnel for the whole duration of hospitalisation and only drugs donated by 
WHO were used. Further analyses using in vitro drug susceptibility assays on the isolates 
from NW Uganda revealed that treatment failures in this region were most likely due to 
decreased melarsoprol susceptibility (Matovu et al, 2001a) although results from a 
pharmacokinetic study suggested melarsoprol treatment failures in this region could be due 
to other factors (Brun et al, 2001). The treatment policy was changed through mediation by 
the Médecins Sans Frontières (MSF), who then worked with Ministry of Health, which Anne Juliet Nalunkuma Kazibwe    Chapter 4, 139 
granted permission for the replacement of melarsoprol with DFMO for Omugo Health 
centre, and Yumbe hospital which took effect in 2001. However, monitoring of the 
TbAT1/P2 status in the T. b. gambiense isolates continued in order to investigate possible 
changes in genotypic composition over time. Furthermore, although eflornithine does not 
utilize the P2 transporter, monitoring of TbAT1/P2 status was deemed important for 
pentamidine (therapy for T. b. gambiense stage I disease) whose uptake occurs via the 
same P2 transporter (Carter et al, 1995;Barrett & Fairlamb, 1999) in addition to other 
transporters (de Koning & Jarvis, 2001;de Koning, 2001b;Matovu et al, 2003) whose loss 
has been shown to lead to high level resistance in vitro (Bridges et al, 2007). Besides, the 
same P2 transporter is the targeted route for delivery of furamidine [DB75 (2,5-bis(4-
amidinophenyl)furan] a diamidine whose prodrug DB289 is the O-methyl amidoxime 
derivative (pafuramidine) oral drug that was until recently undergoing phase III clinical 
trials for the treatment of early stage disease (Lanteri et al, 2006;Jannin & Cattand, 2004). 
While the previous study(Matovu et al, 2001b) utilized isolates from one HAT focus 
(Omugo), this study has been performed using isolates from the same region as well as 
from the neighbouring foci in Moyo district. The PCR/Sfa NI RFLP based method was 
used, to determine the current status of TbAT1/P2 in isolates from Omugo and whether the 
TbAT1 mutant type alleles observed previously are still in existence after a prolonged 
absence of treatment with melarsoprol. We further aimed to generate more evidence of a 
correlation between the TbAT1 genotype and treatment outcome, using isolates collected 
from Moyo where melarsoprol is still used as first-line treatment for stage II disease. Equal 
importance was also attached to observation of pentamidine treatment outcome. 
In the present study, analysis of all the successfully amplified 677bp TbAT1 fragments 
revealed one banding pattern with 566 and 111bp fragments matching with the wild type 
TbAT1 of the melarsoprol sensitive strain (STIB 777S) which was present in all samples 
from Arua, Omugo (n=82) and Moyo (n=9). It is clear that the TbAT1 mutant alleles at 
Omugo have dwindled (0%) compared to about 30% overall prevalence observed earlier 
when the treatment failure rate (also 30%) was at its highest (Matovu et al, 2001b). This 
absence of the TbAT1 mutant type alleles may be due to a shift in Arua (currently Nyadri 
district) foci from Terego where most cases previously originated, to Koboko that is the 
current source of patients treated at Omugo (Figure 3.1). A more recent report did indicate 
TbAT1 mutant alleles were present in isolates collected from Moyo in the period 2003-
2004 albeit at low prevalence that coincides with the relatively low melarsoprol relapse 
rates (9%) at the focus (Nerima et al, 2007). Their approach was based on using an allele-Anne Juliet Nalunkuma Kazibwe    Chapter 4, 140 
specific PCR but the results were in agreement with the PCR/RFLP based method. This 
method is worth considering, since it eliminates the problem of differentiating between a 
single infection due to a trypanosome that is TbAT1 heterozygous for wild type and mutant 
alleles and a mixed infection due to a trypanosome that is either TbAT1 
homozygous/hemizygous for wild type or mutant alleles. The current analysis using the 
PCR/RFLP method had been completed by the time tbat1 allele specific PCR report was 
published and therefore I did not take a similar approach. Comparison of the current 
findings with the results from previous studies does suggest a decline in TbAT1 PCR/SfaNI 
mutant alleles over the years with a possibility of few or no mutant alleles in circulation 
now (Table 4.8).  
 
Study period/ 
sample number (N) 
Melarsoprol 
relapse rate 
(%) 
TbAT1 mutant 
alleles prevalence 
(%) 
References 
1999-2001 (65)  30  59  Matovu et al, 
2001b 
2003-2004 (80)  10  14  Nerima et al, 
2007 
2005-2006 (91)  ***  0  Kazibwe A,  
this Thesis 
Table 4.8 The observed prevalence of TbAT1 mutant alleles in NW Uganda T. b. gambiense. 
The Table shows a declining trend in the number of PCR/RFLP mutant alleles when results 
from previous studies and this study are compared for patient samples (N) collected in the 
presence and absence of melarsoprol at the different time periods. 
***; Relapse rate not registered since follow up data incomplete at the time of writing this 
thesis. 
 
To determine whether a difference existed between the results obtained during each study 
period, and the sample numbers, the different TbAT1 alleles were either grouped separately 
(wild type alleles pure, mutant alleles pure and mixed alleles) or combined (wild type total 
or mutant total) and analysed using the Chi square test. There was a significant difference 
(i.e. P<0.05) with X
2=87.5, P=0.000 and X
2=57.1, P=0.000 respectively (Table 4.9 and 
Table 4.10). The result suggests a difference exists between the sample numbers analysed 
for the different alleles results obtained during each study period. 
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Study period  *TbAT1 wild 
type alleles pure  
*TbAT1 mutant 
alleles pure 
Mixed alleles 
(WT & Mut) 
Total 
(N) 
1999-2001  27  12  26  65 
2003-2004  69  0  11  80 
2005-2006  91  0  0  91 
Total (N)  187  12  37  236 
Table 4.9 TbAT1 alleles and corresponding sample numbers analysed over three study 
periods. 
X
2=87.5 (P=0.000) when alleles are grouped separately.  
WT, TbAT1 wild type alleles. Mut, TbAT1 mutant alleles.  
*Analysis based on PCR/Sfa NI analysis. 
 
 
Study period  *TbAT1 wild 
type alleles total 
*TbAT1 mutant 
alleles total 
Total 
(N) 
1999-2001  53  38  91 
2003-2004  80  11  91 
2005-2006  91  0  91 
Total (N)  224  49  273 
Table 4.10 TbAT1 alleles present (by PCR/Sfa NI) grouped together over three study periods  
X
2=57.1, (P=0.000)  
 
The low relapse rates reported for Moyo (9%) in comparison to Omugo (30%) suggest that 
the Moyo trypanosome population may be entirely different from the Omugo, Arua 
population since such high relapse rates were never observed at Moyo. Findings from the 
microsatellite analysis study in Chapter 3 gave an indication that the two populations are 
different (Nei’s genetic distance 0.176). However, this result is based on the analysis of 
low sample numbers for Moyo (N=17). It is possible, given the known focal nature of 
HAT, that even the populations within the different Arua regions Terego, Koboko are 
different. Although the Arua trypanosome genotypes were observed to be diverse by 
microsatellite marker analysis, the trypanosomes isolated from the regions within Arua are 
not any different or clustered based on location (Figure 3.6) but a difference does exist 
between the Arua and Moyo populations. It was observed that there were villages within Anne Juliet Nalunkuma Kazibwe    Chapter 4, 142 
the endemic areas where CATT reactions were negative, while other villages only a few 
kilometres away had positive patients in abundance (Dr E. Matovu, personal 
communication). It is therefore possible that just a few tsetse flies concentrated around a 
watering hole may propagate an epidemic within a limited geographical range. Genetic 
exchange between parasites occurs through mating within the tsetse populations. This 
might be of concern based on the finding of tbat1 mutants in some of the isolates as 
revealed by the sequencing results, which would suggest that such trypanosomes might be 
able to repopulate the region quickly. This might have implications for treatment with ‘P2 
drugs’ especially if the identified mutations alter the function of TbAT1/P2 and/or have a 
fitness cost to the trypanosomes, either in the mammalian host or in the tsetse fly. The 
results from the microsatellite analysis (Chapter 3) however, indicated some degree of 
genetic exchange within the Arua population based on analysis of samples collected 
between 2005 and 2006 period. The situation may be different now. 
The results from this PCR/RFLP analysis also suggest that the patients treated at Omugo 
and Moyo were exclusively infected with potentially melarsoprol sensitive trypanosomes. 
The absence of the PCR/RFLP TbAT1 mutant type alleles from the area seems to correlate 
with withdrawal of melarsoprol from Omugo health centre, although this could be a result 
of the coincidental shift of the focus to Koboko. The majority of the patients used to come 
from the immediate surroundings of Terego sub-county during the late 1990s, when 
melarsoprol treatment failures where common but from 2003, the majority of the patients 
who received treatment at Omugo originated from Koboko which is 40 km away. 
Drug resistance-associated alleles can carry a fitness cost and can thus be lost from a 
population when selective drug pressure is removed. For example Plasmodium falciparum 
having mutations in the genes (Pfmdr1 and Pfcrt) associated with chloroquine resistance 
was observed in vivo and in vitro in the absence of drug (Walliker et al, 2005;Hayward et 
al, 2005). This observation had been noted earlier in the field following the withdrawal of 
chloroquine which corresponded with disappearance of the resistance genotype (Pfcrt 76T) 
and reversal of resistance within 10 years of this strategy in Malawi (Kublin et al, 2003). It 
should be noted that in the case of P. falciparum this is possible since resistant parasites 
can be easily spread by mosquito bites to treated patients thereby encouraging development 
of resistance by transmission of drug exposed pathogens. In the case of HAT, this is less 
likely since patients are treated under carefully monitored hospital settings and do not 
resume normal activities that would expose them to tsetse flies, at least not to such a 
degree as to mosquitoes, which is in contrast to tsetse infest indoors, in the case of malaria. Anne Juliet Nalunkuma Kazibwe    Chapter 4, 143 
Further Plasmodium undergoes obligate sexual reproduction in the mosquito whereas 
genetic exchange between trypanosomes in the tsetse vector is optional and thought to be 
relatively rare. It is therefore unlikely that the vector plays a significant role in the spread 
of trypanocidal resistance mutants arising from drug exposure. The most probable 
explanation may be consistent with the hypothesis that melarsoprol resistant trypanosomes 
that possess these TbAT1 mutant alleles are unstable in the field or declining in the 
population in the absence of drug pressure. In South Sudan where the drug was withdrawn 
in 2001 because of high failure rates (Moore & Richer, 2001), a similar situation was 
observed. No TbAT1 mutant alleles were detected by PCR/RFLP and sequencing in any of 
the T. b. gambiense collected in 2003 (Maina et al, 2007) which led to the authors to 
speculate that TbAT1 mutants never occurred. However, in the previous study in Omugo, 
NW Uganda, (Matovu et al, 2001b), “mutant” alleles, were present but they appear to have 
disappeared since treatment with melarsoprol was terminated. It is therefore possible that 
“resistant” alleles could also have been circulating in South Sudan when melarsoprol acted 
as a selective force although this cannot be proven either way as no samples were collected 
at that time. A recent report indicates the presence of TbAT1 mutant alleles at a prevalence 
of 14% in isolates collected between 2003 and 2004 from Moyo, NW Uganda where 
melarsoprol is still in use to the present day further supporting the existence of such alleles 
(Nerima et al, 2007). The small sample number successfully analysed by PCR/RFLP from 
Moyo (9 of 34) may possibly be responsible for the lack of observation or current absence 
of resistant alleles from this region. 
The PCR/Sfa NI RFLP based method is useful as a field tool for detection of TbAT1/P2 
defective trypanosomes especially to monitor for emerging resistance to drugs that use the 
same P2 transporter. However, the method does not reveal anything about other mutations 
and deletions. The PCR/RFLP analysis reported here, based on the Sfa NI profiles 
indicated that all the parasites identified here were wild type at that marker. However, 
sequence analysis (verified on both strands) indicated other changes. For example in the 
TbAT1 sequence of isolate OM72 at position 1062 is a base change from C to T but more 
dramatically are two nucleotides missing at positions 1087 and 1088 in isolate OM62, 
which should yield a frame shift. This would dramatically alter the protein most likely 
leading to a loss of activity. A single base deletion in M148 would create a similar frame 
shift. Sequencing was performed on both strands but just once. It would require re-
amplification and reanalysis to confirm these important results that further expand the 
ways to which diverse alterations to TbAT1 may contribute to loss of P2 activity in clinical 
settings. Since the PCR/RFLP method does not detect other mutations which could also Anne Juliet Nalunkuma Kazibwe    Chapter 4, 144 
lead to loss of P2 function, phenotypic tests such as a-fluorescence based test would be 
useful. One such test for detection of loss of P2 function has been developed (Stewart et al, 
2005). 
A limitation of this study was the low patient return for follow up visits especially in 
Moyo, making the analysis difficult. In a previous field survey taking into account all 
patients that were followed up at least once, patients who felt better after treatment had to 
be convinced to return for another lumbar puncture (Dr. E. Matovu personal 
communication). Similar problems have been encountered in related field studies where 
patients are impossible to follow through the 24 months leading to a lack of complete post 
treatment data (Lejon & Buscher, 2005;Burri et al, 2000). This has been associated with 
waiting periods, which stretch beyond 3 months. Yet 49.3% of patients at discharge not 
attending any of the 4 scheduled follow up visits and 50.7% of the patients attending only 
1 visit have been reported (Schmid et al, 2005). Follow up numbers have been reported to 
drop from 64% at 6 months to 46% at 12 months post treatment (Chappuis et al, 2005), 
which has resulted in restricting the treatment outcome analysis to 12 months in particular 
studies since the numbers drop even lower beyond this period (Balasegaram et al, 2006).  
4.6 Conclusion 
The PCR/RFLP method detected only TbAT1 wild type alleles and not the mutant allele 
that was in circulation in 1999. The limited number of followed up patients means that the 
correlation between the TbAT1 genotype and treatment outcome do not permit tests for 
statistical significance. However, the data suggests that melarsoprol sensitive 
trypanosomes are in circulation and therefore melarsoprol could still be a useful drug in the 
treatment of stage II disease, possibly even at Omugo where it was withdrawn 6 years ago. 
But to ascertain its usefulness at the centre, a rapid and specific test easily adaptable to a 
field setting is required to identify potential melarsoprol treatment outcome. Results from 
the use of such a test would guide the clinical decision process regarding treatment using 
this drug. The detection of homozygous resistance alleles would be grounds for treatment 
failures with either eflornithine or with nifurtimox as a compassionate treatment, or with a 
combination of both (Matovu et al, 2001a). However, the absence of the particular 
mutation detected by the PCR-RFLP method (apparent wild type alleles) would not 
necessarily guarantee the presence of a functional P2 transport activity, due to the 
possibility of other mutations or the low abundance of resistant parasites in a mixed 
population. Nifurtimox/Eflornithine Combination Trials (NECT) are on-going in Uganda Anne Juliet Nalunkuma Kazibwe    Chapter 4, 145 
and Congo. On the other hand, (Bisser et al, 2007) have demonstrated successful 
combination of melarsoprol with Nifurtimox, although this may not be a lasting solution at 
foci where melarsoprol is already failing. A fluorescence based method for detection of P2 
transport activity (Stewart et al, 2005) appears to be a promising option for assisting in the 
determination of the specific drug treatment.  
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5  Detection of animal and human infective trypanosome 
species in dogs as possible reservoirs 
5.1 Summary 
As discussed in the introduction (section 1.4.1) diminazene enters trypanosomes 
predominantly via the P2 transporter and loss of P2 correlates to drug resistance. There is a 
risk that treatment of animals with diminazene aceturate (to clear babesiosis or 
trypanosomiasis) could therefore contribute to selection of P2 defective trypanosomes, 
resistant to other drugs should human infectious trypanosomes infect these animals. 
Species typing by PCR is the most sensitive tool for the detection of trypanosome 
infections including those caused by T. b gambiense, which is known to manifest at very 
low parasite densities making microscopic detection insensitive. Apart from confirming 
presence of trypanosomes by microscopy, distinguishing between human and animal 
trypanosomes is dependent on qualified personnel whose work is made particularly 
difficult if faced with low parasitaemic infections. With the availability of species specific 
markers, PCR typing using species specific primers can now be used to identify the 
presence of the human infective T. b. gambiense in isolates from animals capable of acting 
as a reservoir (Radwanska et al, 2002b). The aim of this study was to use species specific 
PCR typing to detect the different trypanosome species known to be infective to dogs (T. 
brucei, T. vivax, T. congolense) and humans (T. b. gambiense) in samples (N=190) 
collected from dogs (Mongrels) from the tsetse fly endemic areas of the Jos High Plateau 
area, North Central Nigeria, West Africa. These were provided to us by our collaborator 
the late Dr. E. Yanan (NITOR). The success rate for the detection of animal trypanosomes 
(T. brucei, T. vivax, T. congolense) in this region has been recorded at 27.9% by 
microscopy using the wet smear and the haematocrit centrifugation technique (Dede et al, 
unpublished). Samples were collected in a field survey as dried blood spots on FTA 
cards (Whatman) between the months of August and November 2006 from the local 
government areas of the plateau state during an animal trypanosomiasis outbreak (Dede et 
al, unpublished). Field diagnosis results by microscopy carried out by qualified personnel 
were later provided and these indicated an absence of trypanosomes (Appendix III). The 
dog samples were also analysed by PCR for infection due to babesiosis since field 
diagnosis of the dogs indicated they had clinical symptoms. This was confirmed using Anne Juliet Nalunkuma Kazibwe    Chapter 5, 148 
 
microscopy which indicated infections due to Babesia gibsoni by thin smear (23/190). 
Some of the dogs were domestic and used for hunting, guarding or kept as pets while some 
were free roaming and originated from typical rural, urban or near urban areas. Unlike 
dogs from around urban areas, which are near veterinary clinics, dogs from the typical 
rural areas do not have access to treatment (Dr. E Yanan, personal communication). All the 
sampled dogs were treated for babesiosis or trypanosomiasis using a single dose of 
diminazene aceturate (Trypadim, Merial, France) at 3.5 mg/Kg body weight. The PCR 
results indicated that 180 of 190 (95%) of the analysed dog samples were infected with 
trypanosomes from the T. brucei group and 169 of 180 (94%) were co-infected with T. 
vivax. 59.5% and 51% of the 190 dog samples were, also infected with T. congolense 
subtypes (savannah (59.5%) or forest (51%)). None of the dogs sampled (N=190) was 
positive for T. b. gambiense. 73 of the 190 (38%) samples were found to be PCR positive 
for Babesia using non species-specific babesiosis primers. Sequencing for Babesia species 
confirmation of four samples, positive by PCR, indicated that two of the samples were 
99% similar to the reference Babesia canis rossi 18s ribosomal RNA gene sequence 
(GenBank accession number DQ111760.1) by blast search. The remaining two samples 
were 99% similar to the reference Hepatozoon canis 18s ribosomal RNA gene sequence 
(GenBank accession number DQ439543). The analysis revealed that the dogs were co-
infected with several parasite species, which may complicate the successful treatment of 
the disease. Moreover, using the same treatment for both trypanosomiasis and babesiosis as 
was the case for these dogs might result in selection for resistance to diminazene especially 
if the dogs are treated for only babesiosis. This is likely to be a problem due to the lack of 
sensitivity of detection of trypanosomes by microscopy. I was interested to learn to what 
extent misdiagnosis could underlie introduction of inappropriate treatment options. 
5.2 Introduction 
The control and management of Human African Trypanosomiasis involves screening of 
people at risk, diagnosis of the disease, treatment of infected people and reducing tsetse fly 
numbers. However, animals acting as a reservoir represents one of the ways in which these 
trypanosomes are maintained in circulation (Gibson et al, 1978;Mehlitz et al, 1982;Zillman 
et al, 1984). Most important are domestic animals which include cattle, pigs, goats,(Njiru 
et al, 2004;Waiswa et al, 2003;Welburn et al, 2001a) and even dogs (Gibson & Gashumba, 
1983). Of the three T. brucei sub-species only T. b. brucei does not infect humans but does 
infect animals. T. b. rhodesiense infects both humans and domestic animals especially 
cattle (Welburn et al, 2001a). T. b. rhodesiense is typically known to cause acute disease in Anne Juliet Nalunkuma Kazibwe    Chapter 5, 149 
 
humans but there is evidence that it can cause different disease patterns as either acute (SE 
Uganda) or mild (Malawi) in humans (MacLean et al, 2004). This is an indication that 
animals and humans can both act as major reservoirs. Humans are the major reservoir of T. 
b. gambiense which typically causes the chronic form of the disease (Welburn et al, 
2001b). It is of concern that the same vector Glossina palpalis transmits T. b. gambiense to 
both humans and animals (Waiswa et al, 2003). Studies looking at T. brucei isolates from 
man and animals have revealed more mammalian hosts acting as reservoirs for T. b. 
gambiense (Gibson et al, 1978;Mehlitz, 1986;Penchenier et al, 1999). It has also been 
speculated that animals could have a veterinary link to human T. b. gambiense disease 
(Barrett, 2001). Diagnosis of these parasites has always depended on microscopy, which 
apart from being less sensitive is unable to differentiate T. b. brucei, T. b. rhodesiense and 
T. b. gambiense morphologically. The diagnosis of both animal and human trypanosomes 
has improved over time with new methods which include use of species specific PCR 
primers based on markers to specifically identify each trypanosome group or species 
(Moser et al, 1989;Masiga et al, 1992;MacLeod et al, 1999;Welburn et al, 2001a;Gibson et 
al, 2002;Radwanska et al, 2002a;Radwanska et al, 2002b;Simo et al, 2008a). The T. b. 
gambiense specific glycoprotein (TgsGP) PCR primers (Radwanska et al, 2002b) have 
been used to demonstrate the presence of T. b. gambiense in wild (rodents, ungulates, 
primates, carnivores, reptiles) and domestic animals especially pigs from Cameroon and 
Central Africa (Nkinin et al, 2002;Herder et al, 2002;Simo et al, 2006;Simo et al, 2005). 
Moreover these animals were also found co-infected with other animal trypanosome 
species, as demonstrated by the use of species specific primers for T. b. brucei, T. vivax, 
and T. congolense (Herder et al, 2002;Simo et al, 2006). Genetic analysis using a recently 
developed method, Amplified Fragment Length Polymorphism (AFLP) has been used to 
demonstrate that T. b. gambiense isolates collected in Central Africa from pigs were of the 
same genotype as T. b. gambiense isolated from man in the same and different 
geographical regions (Simo et al, 2008a).  
The animal trypanocide diminazene aceturate like the human trypanocides melarsoprol and 
pentamidine is known to have a dependency on the same T. brucei adenosine transporter 
(TbAT1/P2) for uptake (Matovu et al, 2003;de Koning et al, 2004) (section 1.4.2). 
Moreover, it has been demonstrated that the same transporter is the major route of uptake 
of furamidine (DB75) whose prodrug DB289 was until recently under development for the 
treatment of human disease (Jannin & Cattand, 2004;Lanteri et al, 2006). Different sub-
Saharan African countries are experiencing parasite resistance to animal trypanocides 
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from tsetse endemic regions in Nigeria are mostly treated using diminazene aceturate, but 
the problem of resistance has rendered treatment less effective leading to the use of 
isometamidium chloride in some regions (Kalu, 1995;Anene et al, 2001;Anene et al, 
2006). This continuous treatment of infected animals that are capable of acting as 
reservoirs of human infection with such trypanocides has been considered as a possible 
route that may lead to selection of human infective P2 drug resistant trypanosomes. This 
may eventually result in cross resistance between animal and human trypanocides which 
utilize the same P2 transporter (Barrett & Fairlamb, 1999). Not only is diminazene 
aceturate used for treatment of animal canine trypanosomiasis but it is also used for 
treatment of babesiosis which is another parasitic disease that affects animals (Brüning, 
1996), including dogs http://www.addl.purdue.edu/newsletters/1999/fall/cb.shtml. It is 
likely that animals treated for Babesia canis may also harbour human infective 
trypanosomes, which could result in the selection of drug resistant human infective 
trypanosomes. In a recent study a T. b. brucei stock resistant to diminazene aceturate was 
isolated from an infected dog in Nigeria and was found to be cross-resistant to pentamidine 
when tested in vivo in albino rats (Anene et al, 2006). A more recent study has indicated 
that melarsoprol resistant T. b. rhodesiense isolates from sleeping sickness patients from 
Kenya and Uganda were found to be cross resistant to diminazene aceturate when tested in 
vivo in mice (Kagira & Maina, 2007). Melarsoprol resistant parasites which resulted from 
selection pressure were also found cross-resistant to diminazene possibly due to loss of the 
same transporter system. The concept of licensing diminazene aceturate for treatment of 
human disease should be considered with caution and preferably not implemented.  
5.3 Materials and Methods 
Study area and population 
This section includes a description of the study regions in Nigeria from where the samples 
for this chapter were collected. This was through collaborations established between Dr. 
Michael Barrett and other researchers from West Africa. Dr. Everestus Yanan-Deceased 
(NITOR, Nigeria) provided us with samples collected from trypanosomiasis and babesiosis 
infected dogs in Jos High Plateau, North Central Nigeria.  
A pilot survey of Canine Trypanosomiasis in dogs was carried out in Jos East, Bassa, 
Riyom, Barkin Ladi and Mangu Local Government areas which are located between 
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1600 metres above sea level on the of Jos High Plateau of Northern Nigeria. Some of these 
regions are urban and others are typically rural. The region is comprised of the semi 
nomadic (Fulani) ethnic group whose main occupation is hunting. Most of the dogs in the 
survey were hunting dogs, guard dogs or kept as pet dogs. These dogs had owners or some 
were in transit for sale to hunters and people who wished to keep pets or guard dogs. 
However, although these dogs had owners, some could move freely in search of prey.  
Sample collection 
Blood samples were taken before treatment from all the dogs examined during the survey 
in Nigeria, Jos Plateau. The blood samples (N=190) were collected using the FTA card 
method by field personnel. The air-dried FTA card samples were transported for analysis at 
the Institute of Biomedical and Life Sciences, University of Glasgow, UK. The dogs 
diagnosed as positive for trypanosomaisis or babesiosis were treated using the same dosage 
of diminazene aceturate (Berenil) at 3.5 mg/kg body weight. 
DNA extraction 
Extraction of DNA from dog blood spotted on FTA cards was performed as described 
(section 2.3). 
Species typing by PCR of dog samples from Nigeria 
It was of interest to investigate whether T. b. gambiense might be present in domestic 
animals from the collection of dog derived blood in Nigeria. Microscopy is the main 
method used for diagnosis of T. brucei infections in the field. However, its lack of 
sensitivity means it may fail to detect some infections. Moreover, microscopy cannot 
distinguish T. brucei brucei and T. b. gambiense and other trypanosome species (T. 
congolense and T. vivax) can only be distinguished by trained personnel. Analysis using a 
more sensitive method by PCR on infected dog samples from Nigeria was performed to 
identify the presence of any infection due to human infective T. b. gambiense parasites 
using specific primers (Radwanska et al, 2002b). These dog samples were also analysed 
for detection of infective trypanosome species T. brucei, T. vivax, and T. congolense 
(Masiga et al, 1992) and infection due to Babesia (Foldvari et al, 2005) since many of the 
dogs were presented at the clinic with suspected babesiosis. 
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Detection of the T. vivax West Africa, T. congolense forest and T. congolense savannah by 
PCR amplification of satellite DNA repeats 
In a first round PCR, a DNA disc on an FTA card was PCR amplified in a total volume 
of 20 µl containing a 1 × PCR buffer (10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 50 mM 
KCl) and 200 µM each deoxynucleotide triphosphate- dATP, dCTP, dGTP, dTTP) 
(Promega Corporation, Madison, USA). Species-specific oligonucleotide primer pairs 
(Figure 5.1) synthesised by MWG Biotech-AG each at 1 µM and 1.25 units of GoTaq 
DNA polymerase enzyme (Promega Corporation, Madison, USA) were added to the 
reaction. The reaction was performed in a PTC-200
TM DNA Engine (MJ Research, inc., 
Waltham, MA, USA) under the following conditions: initial denaturation at 94°C for 3 
minutes, followed by denaturation at 94°C for 1 minute, annealing at 60°C for 2 minutes, 
and extension at 74°C for 30 seconds for 30 cycles. 1 µl of genomic DNA from reference 
strain T. vivax (Y486) (Masiga et al, 1992), T. congolense forest (TSW 103) (Masiga et al, 
1992) and T. congolense savannah (WG 81) (Masiga et al, 1992) was included in each 
respective PCR run as a positive control otherwise it was included as a negative control. 
Sterile water without DNA template was also included in each run as a negative control. 
To increase the sensitivity of the reaction, a second round PCR was performed using 1 µl 
of the first round PCR product as template with the same oligonucleotide primer pair under 
the same PCR and amplification conditions.  
Detection of T. brucei group species by PCR amplification of the T. brucei repeat 
PCR amplification of the T. brucei multicopy locus (177 bp repeat) was performed as 
described (section 2.3) using the T. brucei group oligonucleotide primer pair TBR-F and 
TBR-R (Moser et al, 1989) (Table 2.1). 
Attempts to detect T. b. gambiense by PCR amplification of TgsGP 
Each DNA disc on an FTA card was amplified in a total volume of 20 µl containing 1 × 
PCR buffer (20 mM Tris-HCl (pH 8.7), 100 mM KCl, 50 mM (NH4)2SO4, 1.5 mM MgCl2 
and Q solution) (Qiagen), and 200 µM each dinucleotide triphosphate- dATP, dCTP, 
dGTP, dTTP) (Promega Corporation, Madison, USA). T. b. gambiense specific 
oligonucleotide primer pair TgsGP-F and TgsGP-R (Radwanska et al, 2002b) (Table 2.1) 
synthesised by MWG Biotech-AG each at 0.5 µM and 1.25 units of HotStarTaq DNA 
polymerase (Qiagen) were added to the reaction. The reaction was performed in a PTC-
200
TM DNA Engine (MJ Research, inc., Waltham, MA, USA) under the following 
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for 1 minute, annealing at 63°C for 1 minute, and extension at 72°C for 1 minute for 45 
cycles. This was followed by a last extension at 72°C for 10 minutes. 1 µl of genomic 
DNA (5 ng/µl) or a DNA disc from an FTA card (Whatman) from T. b. gambiense 
reference strain (ELIANE) (Pays et al, 1983) was included in the PCR run as a positive 
control. 1µl (1:100 dilution) of genomic DNA from a T. b. brucei reference strain (427), T. 
b. rhodesiense reference strain (Nyanza-1052) (Baldry, 1972), P. falciparum reference 
strain (7G8) (Su et al, 1997) and sterile water (no DNA template) were included in the run 
as negative controls. To increase the sensitivity of the reaction 1 µl of the primary PCR 
product was used as template in a second round reaction under the same PCR and 
amplification conditions.  
Detection of Babesia species by PCR amplification of the 18S ribosomal RNA gene 
Each DNA disc on an FTA card (Whatman) was amplified in a total volume of 20 µl 
containing 1 × PCR buffer (10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 50 mM KCl) and 
200 µM each dinucleotide triphosphate-dATP, dCTP, dGTP, dTTP) (Promega 
Corporation, Madison USA). A non species-specific oligonucleotide primer pair (Table 
5.1) synthesised by MWG Biotech-AG each at 0.5 µM and 1.25 units of GoTaq DNA 
polymerase (Promega Corporation, Madison, USA) were added to the reaction. The 
reaction was performed in a PTC-200
TM DNA Engine (MJ Research, inc., Waltham, MA, 
USA) under the following conditions: initial denaturation at 94°C for 10 minutes, followed 
by denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds and extension at 
72°C for 30 seconds for 30 cycles. This was followed by a last extension at 72°C for 5 
minutes. T. b. gambiense reference strain (ELIANE) DNA from an FTA card (Whatman) 
disc and sterile water (no template) was included in the PCR run as a negative control. 
Because of the difficulty encountered in acquiring a known Babesia reference strain, it was 
not possible to include a positive control in the assay. Four PCR products from the Babesia 
amplified samples were sequenced following the protocol as described (section 4.3) to 
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Species/sub 
species 
Primer 
pair 
Sequence (5’-3’)  Tm  Product 
size 
T. vivax 
West Africa 
TVW1 
TVW2 
5’-ctg agt gct cca tgt gcc ac-3’ 
5’-cca cca gaa cac caa cct ga-3’ 
61.4°C 
59.4°C 
≈150 bp 
T. congolense 
forest 
TCF1 
TCF2 
5’-gga cac gcc aga agg tac tt-3’ 
5’-gtt ctc gca cca aat cca ac-3’ 
59.4°C 
57.3°C 
≈350 bp 
T. congolense 
savannah 
TCS1 
TCS2 
5’-cga gaa cgg cac ttt gcg a-3’ 
5’-gga caa aca aat ccc gca ca-3’ 
61.4°C 
57.3°C 
316 bp 
Babesia   PIRO A1 
PIRO B 
5’-agggagcctgagagacggctacc-3’ 
5’-ttaaatacgaatgcccccaac-3’ 
65.2°C 
42.9°C 
≈ 450 bp 
Table 5.1 Animal trypanosome oligonucleotide PCR primer sequences and their properties.  
The Babesia primer pair PIRO A1 and PIRO B is non-species specific. 
Tm, primer melting temperature as calculated by the oligonucleotide manufacturer. 
Agarose gel electrophoresis and UV transillumination 
A volume of 18 µl of each TgsGP PCR product and 10-15 µl of each of the PCR products 
from the rest of the amplification reactions was analysed on a 2.0% Agarose gel and 
visualised as described (section 2.3). 
5.4 Results 
5.4.1 PCR species typing for detection of T. vivax, and T. 
congolense satellite DNA in dog isolates 
The dogs originated from areas with a high prevalence (approximately 27.9%) of animal 
trypanosomiasis as detected by microscopy (Dede et al, unpublished). The PCR technique, 
which is more sensitive than microscopy, was therefore utilised to detect the presence of 
trypanosome infections and to differentiate between the infecting trypanosome species. 
DNA extracted from FTA cards (Whatman) from dog samples (N=190) collected by Dr. 
Yanan was performed as described (section 2.3). Detection of T. vivax and T. congolense 
infections was performed by PCR amplification of satellite DNA from dog samples 
(N=190) using species specific primer pairs TVW1 and TVW2 for T. vivax (Masiga et al, 
1992), TCS1 and TCS2 or TCF1 and TCF2 for the T. congolense subtypes savannah and 
forest (Masiga et al, 1992) respectively as described (section 5.3). Results indicated that 
infection due to T. vivax showed the highest prevalence (91%), followed by infection due 
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(Table 5.2). The findings also revealed that the dogs infected with T. vivax were also co-
infected with either one or both of the T. congolense subtypes (Table 5.2). 
5.4.2 Detection of T. brucei by PCR in dog isolates 
Trypanozoon detection was carried out prior to PCR typing for the T. b. gambiense 
infections to determine if the dogs were infected with any trypanosomes from the T. brucei 
group other than the tested animal trypanosomes (section 5.3). DNA extraction from 
FTA cards (Whatman) containing dog blood samples (N=190) was performed as 
described (section 2.3). PCR amplification of the T. brucei 177 bp repeat using the specific 
trypanozoon group multicopy T. brucei primers TBR-F and TBR-R (Moser et al, 1989) 
was performed as described (section 2.3). These primers were demonstrated to be highly 
sensitive and therefore useful for reporting on T. brucei infections in samples with a low 
parasite density (1 trypanosome /ml) using the FTA method (Chapter 2). Separation of the 
PCR products in agarose by electrophoresis followed by observation under U.V light 
showed signals corresponding to the T. brucei 177 bp repeat for 180 of 190 (94.7%) dog 
(Table 5.2 and Table 5.4). This result confirmed the dogs were infected with T. brucei 
species and at the same time co-infected with the other animal trypanosome species. T. 
brucei co-infections with T. vivax had the highest prevalence of 89% (Table 5.2 and Table 
5.4). Lack of amplification material was ruled out for the ten TBR PCR negative samples, 
which were found positive for infections from the non T. brucei group or babesia (Table 
5.4). The presence of multiple animal trypanosome species as observed in this study is in 
agreement with findings from other studies (Herder et al, 2002;Simo et al, 2006;Pinchbeck 
et al, 2008).  
5.4.3 PCR typing for detection of the TgsGP gene in dog isolates 
This was carried out to determine if there could be a possibility of this human infective 
parasite being present in these dog samples. DNA extracted from FTA cards (Whatman) 
containing blood from dog samples (N=190) was performed as described (section 2.3). 
PCR analysis was performed to amplify a 306 bp fragment of the T. brucei gambiense 
specific glycoprotein gene (Berberof et al, 2001) using the PCR T. b. gambiense specific 
glycoprotein primers TgsGP-F and TgsGP-R (Radwanska et al, 2002b) as described 
(section 2.3). Preliminary results indicated that three of the first 50 samples analysed were 
possibly positive for the TgsGP gene on amplification. However, these results were not 
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using the whole genome amplification method (Morrison et al, 2007). The same T. b. 
gambiense (ELIANE) reference strain used as a control, along with FTA cards 
(Whatman) containing human blood (Chapter 2) was used. The preliminary results were 
therefore disregarded. Overall, all of the dog samples (N=190) were found to be negative 
by PCR of the TgsGP gene, which suggested that these dogs were not infected with T. b. 
gambiense parasites. Amplification of the single copy T. brucei PLC microsatellite linked 
gene as a positive control was not performed in this study. Determination of the presence 
of human disease in this region is currently under investigation. The samples were not 
analysed using the serum resistance antigen (SRA) primers specific for T. b. rhodesiense 
(Welburn et al, 2001a;Radwanska et al, 2002a;Gibson et al, 2002) since their source of 
origin is Nigeria, West Africa where only T. b. gambiense is found (Figure 1.1). Lack of T. 
b. gambiense in the dog samples therefore indicated that the observed TBR PCR positive 
T. brucei infections were due to T. b. brucei. Dogs have been shown to carry T. b. 
gambiense in other regions (Gibson et al, 1978;Mehlitz et al, 1982;Zillman et al, 
1984;Schares & Mehlitz, 1996) but not, to date, in the Jos Plateau of Nigeria. 
Trypanosome species or subspecies  Sample number 
(Prevalence) 
T. brucei  180 (94.7%) 
T. vivax  171 (90%) 
T. congolense forest  113 (59.5%) 
T. congolense savannah  97 (51%) 
T. b. gambiense  0 
T. brucei & T. vivax  169 (89%) 
T. brucei & T. congolense forest  102 (53.7%) 
T. brucei & T. congolense savannah  96 (50.5%) 
T. brucei & T congolense forest & T. congolense savannah  46 (24.2%) 
T. brucei & T. vivax & T. congolense forest  94 (49.5%) 
T. brucei & T. vivax & T. congolense savannah  89 (46.8%) 
T. brucei & T. vivax & T. congolense savannah & forest  41 (21.6%) 
Table 5.2 Prevalence of animal and human trypanosomes in Nigerian dogs by PCR typing. 
Results show the number of dogs infected with one or more than one trypanosome species. 
Total number of dog samples analysed by PCR (N=190). 
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5.4.4 PCR typing for detection of the Babesia 18s rRNA gene in 
dog isolates 
It is speculated that treatment of animals with diminazene aceturate for babesiosis without 
knowing whether they could be infected with trypanosomiasis (which is likely to be missed 
on detection by microscopy) could provide a stronger selection for P2 drug resistant 
trypanosomes. The dogs in this study had signs of babesiosis infection which was later 
identified by laboratory microscopic diagnosis of the dog samples by qualified personnel at 
the veterinary clinic in Nigeria to be due to Babesia gibsoni in 23 of 190 (12%) dog 
samples (Table 5.5). Diagnosis of infection by the more sensitive PCR amplification 
technique was therefore applied to detect and confirm the presence of infection due to 
babesiosis (By Clare McCann, Project student, University of Glasgow). It was not possible 
in this study to use Babesia (B. canis canis, B canis rossi, B. canis vogeli or B. gibsoni) 
species specific primers but instead universal Babesia parasite 18s rRNA specific primers 
were used. DNA extraction from FTA cards (Whatman) containing dog blood samples 
(N=190) was performed as described (section 2.3). The DNA from the dog samples was 
PCR amplified for an approximately 450 bp size fragment of the 18s ribosomal RNA gene 
using Babesia parasite 18s rRNA specific primers PIRO-A1 and PIRO B (Foldvari et al, 
2005) as described (section 5.3). However, different size products between 450-700 bp 
were obtained for different samples (Table 5.3) and (Babesia PCR data, Appendix III). 
38.4% (73/190) of the dog samples were positive by PCR compared to 12% by microscopy 
indicating a 3-fold increase in sensitivity by the PCR method. The results also revealed that 
the dogs infected with babesiosis were also infected with animal trypanosomes (Table 5.4). Anne Juliet Nalunkuma Kazibwe    Chapter 5, 158 
 
 
Dog samples 
(n) 
PIRO-A1 and PIRO B 
PCR product size (bp) 
32  450 
33  500 
5  600 
3  700 
Table 5.3 18s rRNA PCR amplification product sizes obtained for the dog samples. 
Total number of dog samples positive (N=73) (Data from Clare McCann). 
 
 
Species or subspecies  Sample number 
(Prevalence) 
T. brucei  180 (94.7%) 
T. vivax  171 (90%) 
T. congolense forest  113 (59.5%) 
T. congolense savannah  97 (51%) 
Babesia  73 (38.4%) 
T. brucei & T. vivax  169 (89%) 
T. brucei & Babesia  70 (36.8%) 
T. brucei & T. vivax & Babesia  64 (33.7%) 
T. brucei & T. vivax & T. congolense & Babesia  53 (27.9%) 
Table 5.4 Prevalence of animal trypanosomes and babesia parasites in dogs by PCR. 
Results show number of infections due to one or more parasite species 
Total number of isolates analysed by PCR (N=190)  Anne Juliet Nalunkuma Kazibwe    Chapter 5, 159 
 
 
Sample no.  HCT  Thin smear  TBR  TVW  TCS  TCF  PIRO 
138  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
139  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
140  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
141  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
142  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
143  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
144  -ve  -ve  +ve  +ve  -ve  -ve  -ve 
145  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
146  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
147  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
148  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
149  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
150  +/mf  -ve  +ve  +ve  +ve  -ve  -ve 
151  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
152  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
153  -ve  B. gibsoni+  +ve  +ve  +ve  -ve  -ve 
154  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
155  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
156  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
157  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
158  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
159  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  +ve 
160  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
161  -ve  -ve  +ve  -ve  -ve  +ve  +ve 
162  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
163  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
164  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
165  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
166  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
167  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
168  -ve  -ve  +ve  -ve  +ve  -ve  -ve 
169  -ve  -ve  +ve  -ve  +ve  +ve  -ve 
170  -ve  B. gibsoni+  +ve  +ve  -ve  -ve  -ve 
171  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
172  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
173  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
174  -ve  -ve  +ve  -ve  +ve  +ve  +ve 
175  -ve  -ve  +ve  -ve  +ve  +ve  -ve 
176  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
177  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
178  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
179  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
180  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
181  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
182  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
183  -ve  -ve  +ve  +ve  -ve  -ve  -ve 
184  -ve  -ve  +ve  +ve  -ve  -ve  -ve 
185  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
186  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
187  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
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Sample no.  HCT  Thin smear  TBR  TVW  TCS  TCF  PIRO 
189  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
190  -ve  B. gibsoni+  +ve  -ve  -ve  +ve  +ve 
191  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
192  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
193  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
194  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
195  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  +ve 
196  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
197  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  -ve 
198  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
199  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
200  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
201  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  -ve 
202  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
203  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  -ve 
204  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
205  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  -ve 
206  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
207  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
208  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
209  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
210  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  -ve 
211  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
212  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
213  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  +ve 
214  -ve  -ve  +ve  +ve  -ve  -ve  -ve 
215  -ve  -ve  +ve  +ve  -ve  -ve  -ve 
216  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
217  -ve  -ve  +ve  -ve  -ve  -ve  -ve 
218  -ve  -ve  +ve  +ve  -ve  -ve  -ve 
219  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
220  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
221  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  -ve 
222  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
223  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
224  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
225  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
226  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
227  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
228  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
229  -ve  B. gibsoni+  -ve  -ve  -ve  +ve  -ve 
230  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
231  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
232  -ve  -ve  +ve  -ve  -ve  +ve  -ve 
233  -ve  -ve  +ve  +ve  -ve  -ve  -ve 
234  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
235  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  -ve 
236  -ve  -ve  +ve  -ve  -ve  +ve  -ve 
237  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
238  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
239  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
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Sample no.  HCT  Thin smear  TBR  TVW  TCS  TCF  PIRO 
241  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  -ve 
242  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
243  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
244  -ve  -ve  -ve  -ve  -ve  +ve  -ve 
245  -ve  -ve  -ve  -ve  -ve  +ve  -ve 
246  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
247  -ve/mf  B. gibsoni+  +ve  +ve  +ve  +ve  -ve 
248  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
249  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
250  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
251  -ve  -ve  -ve  +ve  +ve  +ve  -ve 
252  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
253  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
254  ve/mf++  B. gibsoni+  +ve  -ve  +ve  +ve  -ve 
255  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
256  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
257  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
258  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
259  -ve  -ve  -ve  +ve  -ve  +ve  -ve 
260  -ve  B. gibsoni+  +ve  +ve  -ve  +ve  -ve 
261  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
262  -ve  -ve  -ve  +ve  -ve  +ve  -ve 
263  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
264  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
265  -ve  -ve  -ve  -ve  -ve  +ve  -ve 
266  -ve  -ve  -ve  +ve  +ve  -ve  -ve 
267  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
268  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
269  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
270  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
271  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
272  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
274  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
275  +ve  -ve  +ve  +ve  +ve  +ve  -ve 
276  -ve  N/A  +ve  +ve  +ve  -ve  -ve 
277  -ve  B. gibsoni+  +ve  +ve  +ve  +ve  -ve 
278  -ve  B. gibsoni+  +ve  +ve  +ve  +ve  +ve 
279  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
280  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
281  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
282  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
283  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
284  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
285  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
286  -ve  -ve  -ve  -ve  -ve  +ve  -ve 
287  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
288  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
289  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
290  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
291  -ve  B. gibsoni+  +ve  +ve  +ve  -ve  -ve 
292  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
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Sample no.  HCT  Thin smear  TBR  TVW  TCS  TCF  PIRO 
294  -ve  -ve  +ve  +ve  -ve  -ve  -ve 
295  -ve  -ve  +ve  +ve  -ve  +ve  -ve 
296  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
297  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
298  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
299  -ve  -ve  +ve  +ve  -ve  -ve  -ve 
300  -ve  B. gibsoni+  +ve  +ve  +ve  -ve  +ve 
301  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
302  N/A  N/A  +ve  +ve  +ve  -ve  -ve 
303  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
304  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
305  -ve  -ve  +ve  +ve  -ve  -ve  -ve 
306  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
307  -ve  -ve  -ve  +ve  -ve  +ve  -ve 
308  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
309  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
310  -ve  -ve  +ve  +ve  -ve  +ve  +ve 
311  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
312  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
313  -ve  -ve  +ve  +ve  -ve  -ve  +ve 
314  -ve  -ve  +ve  +ve  +ve  +ve  +ve 
315  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
316  -ve  -ve  +ve  -ve  +ve  -ve  +ve 
317  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
318  -ve  -ve  +ve  +ve  +ve  -ve  +ve 
319  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
320  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
321  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
322  -ve  B. gibsoni+  +ve  +ve  +ve  +ve  -ve 
323  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
324  -ve  -ve  +ve  +ve  -ve  -ve  -ve 
325  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
326  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
327  -ve  -ve  +ve  +ve  +ve  +ve  -ve 
328  -ve  -ve  +ve  +ve  +ve  -ve  -ve 
Table 5.5 PCR analysis results of the dog isolates in comparison to microscopy results. 
HCT; haematocrit centrifugation test (parasites/ml), +ve; positive result, -ve; negative result, 
no.; number, N/A; microscopy result not available; mf; microfilaria 
TBR; T. brucei repeat PCR (section 2.3) 
TVW; T. vivax satellite DNA PCR (section 5.3),  
TCS; T. congolense savannah satellite DNA PCR (section 5.3) 
TCF; T. congolense forest satellite DNA PCR (section 5.3) 
PIRO; Babesia 18s ribosomal RNA PCR (section 5.3) 
Microscopy diagnosis results provided by Dr. Yanan.  Anne Juliet Nalunkuma Kazibwe    Chapter 5, 163 
 
 
Amplification of different size bands ranging between 450-700 bp was observed in 
different samples with one sample amplifying both the 450 and 600 bp amplicons. One 
sample amplified both 450 and 700 bp amplicons, 6 samples amplified both 500 and 700 
bp amplicons and 4 samples amplified both 600 and 700 bp amplicons. The difficulty in 
obtaining Babesia parasite reference strains made it impossible to have them included in 
the PCR as positive controls in order to confirm the PCR results. Amplicons from samples 
JSK177 and JNK219 (approximately 450 bp), JNK166 (approximately 500 bp) and 
JSK189 (approximately 600 and 700 bp) were sequenced. Sub-cloning of the PCR 
products of the 18s rRNA gene prior to sequencing was carried out as described (section 
4.3). Blast search analysis of the National Centre for Biotechnology Information data base 
http://www.ncbi.nih.gov/ showed that nucleotide sequences of the cloned amplicons from 
DNA samples JSK177 and JNK219 (500 bp after purification) were 99% similar with the 
reference sequence of the 18s ribosomal RNA gene of Babesia canis rossi (GenBank 
accession number DQ111760.1) by (Figure 5.1). Surprisingly nucleotide sequences for 
cloned amplicons from DNA samples JNK166 and JSK189 (550 bp after purification) 
were 99% similar to the reference sequence of the 18s ribosomal RNA gene of Hepatozoon 
canis (GenBank accession number DQ439543) (Figure 5.2). However, very few samples 
were cloned and sequenced but the sequencing results possibly indicated that the dogs 
were not only infected with Babesia canis but also Hepatozoon canis. The presence of 
Hepatozoon canis in these dog isolates is in agreement with a study by Foldavari and 
others (2005) in which they demonstrated infection due to both Babesia canis canis and 
Hepatozoon canis in dogs from Hungary following amplification using the same set of 
primers and sequencing. Ticks as the major vector transmit these two parasite species. 
According to the symptoms and results from the field diagnosis (Nigerian dog sample Raw 
data, Appendix III), Babesia parasite or trypanosome infections were suspected. The 
identification of both Babesia and Hepatozoon parasite species in addition to multiple 
animal trypanosome species has revealed that dogs can harbour several parasites species, 
which might compromise the unsuccessful treatment for animal trypanosomiasis. Anne Juliet Nalunkuma Kazibwe    Chapter 5, 164 
 
 
DQ439543.1  GGGTTCGATTCCGGAGAGGGAGCCTGAGAAACGGCTACCACATCTAAGGAAGGCAGCAGG 420 
JSK_189     ----------------AGGGAGCCTGAGAGACGGCTACCACATCTAAGGAAGGCAGCAGG 44 
                            ************* ****************************** 
 
DQ439543.1  CGCGCAAATTACCCAATTCTAACAGTTTGAGAGAGGTAGTAACAAGAAATAACAATACAA 480 
JSK_189     CGCGCAAATTACCCAATTCTAACAGTTTGAGAGAGGTAGTAACAAGAAATAACAATACAA 104 
            ************************************************************ 
 
DQ439543.1  GGCAATTAAAATGCTTTGTAATTGGAATGATAGAAATTTAAACCCTTTTTAAAGTATCAA 540 
JSK_189     GGCAATTAAAATGCTTTGTAATTGGAATGATAGAAATTTAAACCCTTTTTAAAGTATCAA 164 
            ************************************************************ 
 
DQ439543.1  TTGGAGGGCAAGTCTGGTGCCAGCAGCCGCGGTAATTCCAGCTCCAATAGCGTATATTAA 600 
JSK_189     TTGGAGGGCAAGTCTGGTGCCAGCAGCCGCGGTAATTCCAGCTCCAATAGCGTATATTAA 224 
            ************************************************************ 
 
DQ439543.1  AATTGTTGCAGTTAAAAAGCTCGTAGTTGAAGTTCTGCTAAAAGTAACCGGTCTGCTTTT 660 
JSK_189     AATTGTTGCAGTTAAAAAGCTCGTAGTTGAAGTTCTGCTAAAAGTAACCGGTCTGCTTTT 284 
            ************************************************************ 
 
DQ439543.1  AATAAAAGTGGTATCTTGGTGTGTATTTAGCAATGATGTCCTTTGAAGTGTTTTTTACTT 720 
JSK_189     AATAAAAGTGGTATCTTGGTGTGTATTTAGCAATGATGTCCTTTGAAGTGTTTTTTACTT 344 
            ************************************************************ 
 
DQ439543.1  TATTGTAATAAAGCATATTCAGGACTTTTACTTTGAGAAAATTAGAGTGTTTCTAGCAGG 780 
JSK_189     TATTGTAATAAAGCATATTCAGGACTTTTACTTTGAGAAAATTAGAGTGTTTCTAGCAGG 404 
            ************************************************************ 
 
DQ439543.1  CCGACGCTTTGAATACTGCAGCATGGAATAATAAGATAGGATTTTAGTTCTACATTATTG 840 
JSK_189     CCGACGCTTTGAATACTGCAGCATGGAATAATAAGATAGGATTTTAGTTCTACATTATTG 464 
            ************************************************************ 
 
DQ439543.1  GTTTTAAGAGCTAAATTAATGATTGATAGGGACAGTTGGGGGCATTTGTATTTAACTGTC 900 
JSK_189     GTTTTAAGAGCTAAATTAATGATTGATAGGGACAGTTGGGGGCATTCGTATTTAAA-ATC 523 
            ********************************************** ********   ** 
 
DQ439543.   AGAGGTGAAATTCTTAGATTTGTTAAAGACAAACTACTGCGAAAGCATTTGCCAAAGATG 960 
JSK_189     ACTAGTG----------------------------------------------------- 530 
            *   ***                                                      
Figure 5.1 Sequence alignments between a dog isolate and the reference Hepatozoon canis 
isolate (Genbank accession number DQ439543) Anne Juliet Nalunkuma Kazibwe    Chapter 5, 165 
 
 
DQ111760.1  AGCAACGGGTAACGGGGAATTAGGGTTCGATTCCGGAGAGGGAGCCTGAGAGACGGCTAC 360 
JSK_177     -------------------------------------TAGGGAGCCTGAGAGACGGCTAC 23 
                                                 ********************** 
 
DQ111760.   CACATCTAAGGAAGGCAGCAGGCGCGCAAATTACCCAATCCCGACACGGGGAGGTAGTGA 420 
JSK_177     CTCATCTAAGGAAGGCAGCAGGCGCGCAAATTACCCAATCCCGACACGGGGAGGTAGTGA 83 
            * ********************************************************** 
 
DQ111760.   CAAGAAATAACAATACAGGGCTAATGTCTTGTAATTGGAATGATGGTGACTTAAACCCTC 480 
JSK_177     CAAGAAATAACAATACAGGGCTAATGTCTTGTAATTGGAATGATGGTGACTTAAACCCTC 143 
            ************************************************************ 
 
DQ111760.1  ACCAGAGTAGCAATTGGAGGGCAAGTCTGGTGCCAGCAGCCGCGGTAATTCCAGCTCCAA 540 
JSK_177     ACCAGAGTAGCAATTGGAGGGCAAGTCTGGTGCCAGCAGCCGCGGTAATTCCAGCTCCAA 203 
            ************************************************************ 
 
DQ111760.   TAGCGTATATTAAACTTGTTGCAGTTAAAAAGCTCGTAGTTGTATTTTTGCTTGGCGGTT 600 
JSK_177     TAGCGTATATTAAACTTGTTGCAGTTAAAAAGCTCGTAGTTGTATTTTTGCTTGGCGGTT 263 
            ************************************************************ 
 
DQ111760.   TGTTGCCTTTGTGGCTTGATTCCGCTTGGCTTTTGGCTTTTTGCCTTATTACTTTGAGAA 660 
JSK_177     TGTTGCCTTTGTGGCTGTATCCCGCTTGGCTTTTGGCTTTTTGCCTTATTACTTTGAGAA 323 
            ****************  ** *************************************** 
 
DQ111760.1  AATTAGAGTGTTTCAAGCAGACTTTTGTCTTGAATACTGTAGCATGGAATAATAGAGTAG 720 
JSK_177     AATTAGGGTGTTTCAAGCAGACTTTTGTCTTGAATACTGTAGCATGGAATAATAGAGTAG 383 
            ****** ***************************************************** 
 
DQ111760.   GACTTTGGTTCTATTTTGTTGGTTTGGGAACCTTGGTAATGGTTAATAGGAACGGTTGGG 780 
JSK_177     GACTTTGGTTCTATTTTGTTGGTTTGGGAACCTTGGTAATGGTTAATAGGAACGGTTGGG 443 
            ************************************************************ 
 
DQ111760.1  GGCATTCGTATTTAACTGTCAGAGGTGAAATTCTTAGATTTGTTAAAGACGAACTACTGC 840 
JSK_177     GGCATTCGTATTTAAA-ATCACTAGTG--------------------------------- 469 
            ***************   ***   ***                                  
Figure 5.2 Sequence alignments between a dog isolate and the reference Babesia canis 
isolate (Genbank accession number DQ111760.1) Anne Juliet Nalunkuma Kazibwe    Chapter 5, 166 
 
 
5.5 Discussion 
Domestic animals acting as a reservoir of human infective T. b. gambiense parasites, pose 
a risk to humans in disease endemic regions. This might also have serious implications 
regarding the control and management of the human disease if it involves transmission of 
P2 transporter lacking trypanosomes selected as a result of drug pressure to animals. 
However, in this study, none of the dog samples had T. b. gambiense parasites, which 
indicated these human infecting parasites may not be involved in the animal-tsetse 
transmission cycle in this Jos Plateau region of Nigeria. Alternatively, the T. b. gambiense 
parasites may currently not be in circulation in this part of Nigeria. The status of human 
disease in these areas is not known due to lack of adequate surveillance systems, although 
the surrounding areas Quan-Pan, Bachit and Wamba in the Kaduna region were previously 
known to be endemic HAT foci (Ukah, 1989, NITR Unpublished). Determination of 
human disease status in the study areas is currently under investigation as a result of efforts 
initiated by Dr. M. Barrett (University of Glasgow) and our recently deceased collaborator 
Dr. E. Yanan (NITOR). According to the analysis all of the dogs infected with babesiosis 
were also infected with animal trypanosomes. Moreover, both diseases are treated using 
the same dosage (3.5 mg/Kg body weight) of diminazene aceturate which has been 
reported as less effective in Nigeria for treatment of domestic animals (Anene et al, 2006). 
Imidocarb dipropionate is an alternative drug used for treatment of babesiosis in this part 
of Nigeria but this depends on its availability. Diminazene aceturate is the drug mostly 
commonly used. Because of the low sensitivity of parasite detection by microscopy as 
observed from the negative wet smear and HCT results (Nigerian dog sample Raw data, 
Appendix III), trypanosome parasites are most likely to be missed and instead the animals 
could be treated only for babesiosis. There is a likelihood that this could also lead to 
selection of drug resistant, TbAT1/P2 defective, trypanosomes as a result of the treatment. 
Although the chance that this may happen is low, since generally only animals near or 
within urban centres have access to treatment in comparison to animals from the typical 
rural areas which have no access at all. Nevertheless, the possibility of a veterinary link 
associated with selection of drug resistant P2 defective trypanosomes cannot be ruled out 
since in previous and recent studies it was demonstrated that T. b. gambiense species 
identified in dogs, pigs, wild animals and bovids in Liberia, Cote d’Ivoire and Burkina 
Faso. Moreover, pigs in Cameroon were found to carry T. b. gambiense identical to the 
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can act as a reservoir for T. b. gambiense ( Mehlitz et al, 1982;Mehlitz, 1986;Simo et al, 
2008a).  
PCR technology, using specific primers, is a more sensitive method that has successfully 
been used for detection of various infections and species (Moser et al, 1989;Masiga et al, 
1992;Morlais et al, 1998;Penchenier et al, 2000;Herder et al, 2002;Nkinin et al, 2002;Njiru 
et al, 2004;Radwanska et al, 2002a;Radwanska et al, 2002b;Picozzi et al, 2005;Simo et al, 
2006). From the PCR analysis, every trypanosome positive sample had previously been 
observed to be negative by wet smear and HCT which might possibly suggest problems 
with the PCR method (i.e. false positives as a result of contamination). Reference control 
strains and a no template (water) control were included in the analysis (section 5.3) but a 
parasitologically diagnosed control was unavailable for inclusion in the assays. However, 
microscopy has a low sensitivity in comparison to the PCR method and is therefore likely 
to miss the detection of trypanosome parasites as observed in this case. On the other hand, 
some dogs diagnosed as positive for Babesia parasites by microscopy were found negative 
by PCR which could also be due to methodology problems, degradation or improper 
storage of sample material during transportation to the laboratory. A reference control 
strain to resolve this issue was lacking. However, sequencing of a few Babesia PCR 
positive samples (negative by microscopy) was carried out for confirmation as indicated 
earlier. 
Overall, the study revealed that dogs were infected with multiple species of animal 
trypanosomes which is consistent with findings from previous and recent studies involving 
other wild animals and other domestic animals such as pigs, horses and donkeys (Njiokou 
et al, 2004;Simo et al, 2006;Pinchbeck et al, 2008). The findings indicated that most of the 
dogs were co-infected with both T. brucei and T. vivax. The dogs infected with these two 
species were also observed to be co infected with either subtypes of T. congolense 
savannah or T. congolense forest or both.  
In addition to animal trypanosomes, the dogs were also infected with Babesia canis and 
Hepatozoon canis parasite species. Due to the nature of the survey it was not possible to 
determine the exact proportions of the dogs that recovered, relapsed or died after treatment 
with diminazene aceturate although earlier communication indicated four of the dogs did 
not survive while more than 90% of the dogs improved clinically apart from those infected 
with both trypanosome and Babesia parasites (follow-up data not available). Because of 
this information gap it has not been possible to have a definitive answer on whether both Anne Juliet Nalunkuma Kazibwe    Chapter 5, 168 
 
the relapsed and dead dogs were infected with drug resistant trypanosomes to necessitate 
molecular typing the isolates for drug resistance. Therefore the PCR/SfaNI analysis for 
detection of TbAT1/P2 mutant alleles associated with drug resistance could not be done. 
Comparison of the treatment outcome data for each dog sampled with the type and number 
of infective parasite species obtained from the PCR typing results could possibly have 
revealed whether successful treatment is compromised by the type or number of infective 
parasite species.  
5.6 Conclusion 
The PCR method was able to show that the dog isolates were lacking T. b. gambiense 
parasites. The method was able detect the presence of T. b brucei, T. vivax and T. 
congolense animal trypanosomes and Babesia parasite infections which were not detected 
by microscopy. This confirms the supremacy of PCR based diagnostics over microscopy. 
The findings also revealed the presence of mixed parasite infections. Simultaneous 
infection with several parasite species, as observed in the dog samples in this study, may 
complicate the determination of correct clinical diagnosis, which might affect the success 
of treatment. Moreover, although T. b. gambiense were not identified in this small study it 
is certainly of importance to consider that treatment of babesiosis with diminazene would 
risk selection of P2 deficient (and drug resistant) trypanosomes should it emerge that T. b. 
gambiense infection is more widespread than suspected hitherto. 
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6  In vitro selection for resistance to high levels of 
diminazene aceturate and DB75 resistance in T. brucei 
6.1 Summary 
The problem of drug resistance is a threat to the successful treatment of animal and human 
African trypanosomiasis. The development of new trypanocides is dependent on 
understanding the mechanisms of drug resistance. Trypanosomes with a deleted TbAT1 
gene that encodes the P2 transporter, although significantly resistant to diminazene and 
DB75 (furamidine), are relatively sensitive to some diamidines suggesting other routes of 
entry. The aim of this study was to select for increased levels of diminazene and DB75 
resistance in trypanosomes lacking the TbAT1 gene, for the purpose of identifying 
additional markers for drug resistance. A T. brucei line (ABR) that was more resistant to 
diminazene than the parent tbat1
-/- strain, (Matovu et al, 2003) was isolated. This strain 
also proved to be highly resistant to DB75. Uptake of radiolabeled pentamidine in the ABR 
strain was significantly reduced and this was shown to be the result of loss of the High 
Affinity Pentamidine Transporter (HAPT1) while the Low Affinity Pentamidine 
Transporter (LAPT1) was not affected. However, transport of radiolabeled diminazene was 
still possible at 1 µM in the ABR line, implicating LAPT1 as another possible uptake 
route. Selection for DB75 resistance proved difficult. The findings from this study revealed 
that selection for high level resistance to diminazene in the T. brucei line lacking 
TbAT1/P2 transport resulted into the loss of HAPT1 which suggested HAPT1 was a 
secondary route for diminazene transport. The in vitro drug selection for resistance in T. 
brucei resulted into a phenotype similar to the B48 strain with increased resistance and 
reduced uptake of pentamidine (Bridges et al, 2007) but with a different diminazene and 
DB75 resistance profile. 
6.2 Introduction 
The uptake of trypanocidal melaminophenyl arsenicals and diamidines in T. brucei 
involves the P2 adenosine transporter, encoded by TbAT1. The development of resistance 
to the arsenicals and the diamidine group of compounds is associated with the loss of this Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 6, 171 
 
membrane transporter as previously reviewed (Maser et al, 2003;Delespaux & De Koning, 
2007). However, using the 72 hour Alamar blue assay only a 2-3–fold resistance to 
melarsoprol and the diamidine pentamidine was observed in T. brucei with a deleted 
TbAT1 gene that encodes P2 transport (Raz et al, 1997;Matovu et al, 2003). The slightly 
resistant T. brucei with the deleted TbAT1 gene were still sensitive (at sub micromolar 
concentrations) to these drugs, which suggested other routes of uptake (Matovu et al, 
2003). However, T. brucei lacking the TbAT1 gene were previously shown to be 
significantly resistant to the diamidine diminazene (approximately 18-fold compared to 
wild type T. brucei with P2 transport) with hardly any detectable transport of radiolabeled 
diminazene, which confirmed its dependency on TbAT1/P2 transport (Matovu et al, 
2003;de Koning et al, 2004).  
Pentamidine has been shown to utilise TbAT1/P2 and two other transporters (HAPT1 and 
LAPT1) which accounts for the slight 2-3 fold resistance observed in the tbat1
-/- strain (de 
Koning & Jarvis, 2001;de Koning, 2001b;Matovu et al, 2003). On the other hand, DB75 
(furamidine) has been demonstrated to have a major dependency on the TbAT1/P2 
transport (10-fold resistance in the tbat1
-/- strain) although another uptake route is 
suspected since resistance was increased to 20-fold in a T. brucei line selected against 
DB75 (Lanteri et al, 2006). However, the increased resistance could be based on other 
modifications than reduced uptake across the plasma membrane. In vitro selection for high 
level resistance using pentamidine in the laboratory has been shown to lead to 130-fold 
increase in resistance in a T. brucei B48 line that was derived from tbat1
-/- (Bridges et al, 
2007). This pentamidine resistant line was found to have lost HAPT1 activity but not 
LAPT1 (Bridges et al, 2007). Unlike HAPT1 and LAPT1, which have not yet been 
characterised at the molecular level, TbAT1/P2 has been characterised and targeted as a 
route for the uptake of the novel diamidine DB75 (Mäser et al, 1999;Barrett & Gilbert, 
2006). Identifying resistance markers for diminazene or DB75 by selecting for high level 
resistance in vitro in T. brucei will aid to determine whether a secondary route exists for 
the transport of these drugs and whether this can possibly be exploited for the delivery of 
new drugs into trypanosomes. It will also provide essential insights into the likelihood of 
resistance developing against new diamidine drugs. Moreover, given the fact that 
diminazene is used in treating animals, further insight into possible cross-resistance risks 
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6.3 Materials and Methods 
Cultivation of bloodstream T. brucei in vitro has contributed greatly to the understanding 
of trypanosomes cell and their molecular biology (Baltz et al, 1985). Previously it has been 
shown that trypanosomes deleted in the TbAT1 gene that encodes the P2 transporter 
develop significant resistance to diminazene and to furamidine in a 72 hour Alamar blue 
assay (Lanteri et al, 2006;Matovu et al, 2003). However, even these “resistant” cells are 
relatively sensitive (at sub micromolar minimum inhibitory concentrations) to some 
diamidines. Thus we aimed to select higher level resistance with an aim to detect markers 
of high level resistance. 
Briefly, to a sterile 25 cm
3 vented tissue culture flask (Corning Incorporation) containing 5 
ml of pre-warmed (room temperature) HMI-9 medium (Appendix I) with 10% fetal calf 
serum (FCS) (Biosera) was inoculated with bloodstream form T. brucei from an existing 
cell line tbat1
-/- (Matovu et al, 2003) culture at a start cell density of 0.5 × 10
6 cells/ml as 
determined using an improved Neubauer counting chamber (WSI, Division of Hawksley 
Technology, England). Bloodstream form T. brucei from the wild type reference strain 427 
were set up in a similar manner and the flasks incubated in a low pressure CO2 incubator at 
37°C and 5% CO2. The cells were left to grow to a density of 2-3 × 10
6 cell/ml before they 
were seeded into fresh HMI-9 medium with 10% FCS. 
To confirm the identity of the strain, a series of short experiments as described below were 
performed prior to starting the in vitro drug selection process. 
Analysis of the tbat1
-/- cell line 
Under sterile conditions, 500 µl from an established culture of T. brucei trypanosomes 
from the tbat1
-/- cell line and wild type s427 was each spotted on a separate FTA card 
(Whatman). The cards were allowed to air dry at room temperature and extraction of DNA 
following the FTA protocol was performed as described (section 2.3). 
Detection of the neomycin resistance marker gene by PCR 
Generation of the tbat1
-/- cell line by gene knock out were constructed in a plasmid 
containing antibiotic resistance markers neomycin and puromycin (Matovu et al, 2003) 
Based on this, PCR amplification using primers designed to amplify the NEO gene was Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 6, 173 
 
carried out on the tbat1
-/- cell line. Briefly each extracted DNA disc on an FTA card was 
amplified in a total volume of 25 µl containing 1 × custom PCR mastermix (45 mM Tris-
HCl (pH 8.8), 4.5 mM MgCl2, 11 mM (NH4)2SO4, 0.113 mg/ml BSA, 4.4 µl EDTA and 1 
mM each deoxynucleotide triphosphate-dATP, dCTP, dGTP, dTTP) (ABgene®, Advanced 
Biotechnologies Ltd, UK). Neomycin oligonucleotide primer pair (Neo-s 5’-atg att gaa caa 
gat gga ttg c- 3’ and Neo-as 5’-tca gaa gaa ctc gtc aag aag-3’ (Dr. P Alibu, personal 
communication, University of Glasgow), synthesised by MWG Biotech-AG each at 1 µM 
and 1.25 units of GoTaq DNA polymerase (Promega Corporation, Madison, USA) were 
added to the reaction. PCR conditions were initial denaturation at 95°C for 4 minutes, 
followed by denaturation at 94°C for 1 minute, annealing at 55°C for 1 minute, and 
extension at 72°C for 2 minute for 30 cycles. This was followed by a last extension at 72°C 
for 7 minutes. DNA on an FTA card (Whatman) disc from T. brucei wild type 427 and 
sterile water (no DNA template) were included in the run as negative controls.  
Testing for resistance of tbat1
-/- trypanosomes to neomycin in culture 
Culturing of the T. brucei tbat1
-/- cell line in presence of neomycin antibiotic was 
performed in parallel with the neomycin PCR assay. A start cell density of 0.5 × 10
6 
cells/ml from an on-going culture of the tbat1
-/- cell line was inoculated into 10 ml of fresh 
HMI-9 medium containing 10% FCS and 1.5 µg/ml of neomycin (G418 sulphate) in a 25 
ml culture flask. A T. brucei wild type 427 culture was set up under the same conditions as 
a negative control. Both cultures in flasks were incubated at 37°C and 5% CO2 for 3-5 
days. After 3 to 5 days incubation, the flasks containing the cultures were viewed under a 
light microscope (Leitz Wietzler, Germany) at 20 × magnification. Observation of motile 
trypanosomes in the tbat1
-/- cell culture flask should confirm their resistance to antibiotic. 
Absence of motile trypanosomes in the T. brucei wild type 427 culture flask should 
confirm their susceptibility to antibiotic. 
Detection of the TbAT1/P2 gene by PCR 
To confirm absence of the TbAT1 gene in the tbat1
-/- cell line, PCR amplification of the 
entire TbAT1 using an outer oligonucleotide primer pair TbAT1 ant -s and TbAT1 ant-as 
(Mäser et al, 1999) was performed as described (section 4.3). An FTA card (Whatman) 
DNA disc from the T. brucei wild type strain 427 was included in the run as a positive 
control. Sterile water (no template) was used as a negative control. A nested PCR using 5 
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ATF-1 5’-gaa agc tta atc aga agg atg ctc ggg ttt gac tca-3’and ATR-1 5’-gag gat cct gaa 
cag tat tcg tat gac gat tag tgc tac-3’ to amplify the TbAT1 open reading frame (ORF) was 
performed (Matovu et al, 2001b). The PCR and amplification conditions were similar but 
the annealing temperature was increased to 60°C for the inner reaction.  
Agarose gel electrophoresis and UV transillumination 
10 µl of each of the PCR products was analysed by electrophoresis on a 2.0% Agarose gel 
as described (section 2.3). Amplification of the TbAT1 and NEO genes should yield 1400 
bp and 800 bp size products on agarose respectively. 
Initiation of T. brucei drug resistance selection in vitro 
In vitro drug selection in T. brucei has made possible the understanding of possible 
resistance mechanisms, leading to the identification of putative resistance markers such as 
TbAT1, HAPT1, LAPT1, TbMRPA (Carter & Fairlamb, 1993;Barrett et al, 1995;Carter et 
al, 1999;Mäser et al, 1999;de Koning et al, 2000;de Koning & Jarvis, 2001;de Koning, 
2001b;Shahi et al, 2002;Matovu et al, 2003;de Koning et al, 2004;Luscher et al, 
2006;Lanteri et al, 2006). A similar approach of subjecting T. brucei brucei already 
deficient in the TbAT1 (P2) transporter was attempted for diminazene aceturate (berenil) 
and furamidine [2,5-bis (4-amidinophenyl) furan (DB75)], which both enter via P2 (De 
Koning et al, 2004; Lanteri et al, 2006). This aimed to lead to an increased level of 
resistance for these diamidines and possibly to the identification of the unknown additional 
route postulated for DB75 uptake (Lanteri et al, 2006). 
In vitro drug selection in the presence of P2-mediated trypanocides diminazene and DB75 
in stepwise small increments was carried out in duplicate on T. brucei bloodstream 
trypanosomes from the tbat1
-/- cell line (Matovu et al, 2003). The selection process was 
initiated using the doubling dilution method on a 96 well plate. The drugs were prepared 
by dissolving in sterile water and kept at stock concentrations of 50 mM and 0.5 mM for 
diminazene and DB75 respectively. Diminazene aceturate was used at a start concentration 
of 1.6 µM and DB75 at 0.85 µM - both concentrations equivalent to their respective IC50 
values. Briefly, 1.6 µM of diminazene aceturate and 0.85 µM of DB75, each made up in 
200 µl of HMI-9 medium with 10% FCS (Appendix I), was each added to one of the first 
wells in the first column of a 96-well culture plate (Corning Incorporation) in duplicate. To 
the following 11 wells along each row was added 100 µl of HMI-9 medium with 10% 
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well and the doubling dilution process repeated to the 11
th well leaving out the last well (no 
drug control). The tbat1
-/- cells at a start cell density of 0.5 × 10
6cells/ml were aliquoted 
into each of these wells. The plates were incubated at 37°C and 5% CO2. After 3-5 days, 
incubation, cell growth was monitored by observation of the plates under an inverted light 
microscope (Motic, AET31) at 20 × magnification. Motile cells with a normal morphology 
were seeded again in fresh HMI-9 medium with 10% FCS at the same drug concentration 
of that particular well into a fresh well and incubated under the same conditions. The same 
cells were also seeded at twice, a-half, and a tenth of that drug concentration in fresh HMI-
9 medium with 10% FCS. Cells established as growing stably in drug were transferred and 
seeded into 1 ml volume cultures on 24 well plates and the selection continued with 
gradual increase in drug concentration. The drug selected cells were later transferred into 5 
ml volumes of HMI-9 medium with 10% FCS containing drug in sterile 25 cm
3 vented 
tissue culture flasks and incubated as before. The whole selection process took a period of 
5 months for each of the two independent lines. The two tbat1
-/- diminazene selected lines 
each at 0.1µM and the tbat1
-/- DB75 selected lines each at 0.08 µM were then tested for 
their susceptibility to drug using the Alamar Blue assay as described below. 
In vitro drug testing using the Alamar Blue assay 
In vitro drug testing using a derivative the 72-hour Alamar Blue method (Raz et al, 1997) 
was carried out after 5 months of selecting the tbat1
-/- lines in diminazene and the 
furamidine DB75 to measure their susceptibility to the drugs. This was done to determine 
the inhibitory concentration of the drugs that affect viability by 50% (IC50). The assay 
utilizes a blue coloured dye (Resazurin or Alamar Blue), which is used to measure the level 
of survival of the trypanosomes. This dye (Appendix I) is non fluorescent and when added 
to the medium containing live trypanosomes a reduction process due to an unspecified 
cellular dehydrogenase takes place leading to a colour change from blue to pink 
(Resofurin). Resofurin is fluorescent and therefore the amount of fluorescence due to this 
process can be measured in a fluorimeter at a wavelength of 530 nm excitations and 
emission of 590 nm. Since conversion of the dye is a function of cell viability, the degree 
to which the non-fluorescent compound is converted is taken as a measure of viability (but 
confirmation by microscopy is required). 
The reference strain, wild type 427, and the parent tbat1
-/- line were used as controls in 
each assay, which was carried out three separate times. Each assay was set up in duplicate 
using the serial doubling dilution method. Briefly, 200 µl of a 200 µM working drug stock Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 6, 176 
 
concentration was aliquoted into the first well of a white 96-well flat-bottomed plate 
(Greiner-bio-one, Germany). 100 µl of sterile HMI-9 medium with 10% FCS was 
aliqouted into the following wells in a row from well 2 to 23. 100 µl of drug from the first 
well was added with mixing to the next well bringing the concentration of the drug in the 
second well to 100 µM. This serial dilution was repeated across the plate leaving the last 
well free with no drug as a negative control. To each of the wells was added 100 µl of 
bloodstream form trypanosomes in HMI-9 medium with 10% FCS at a density of 2 × 10
5 
cells/ml bringing the final cell density to 1 × 10
5 cells/ml. The plate was incubated at 37°C 
and 5% CO2 for 48 hours at which time, 20 µl of Alamar Blue dye (10% resazurin (Sigma) 
was added to each well and the plate incubated for another 24 hours at 37°C and 5% CO2. 
The fluorescence was measured using a fluorescence spectrophotometer at an excitation 
wavelength of 530 nm and emission wavelength of 590 nm. The same assay was also 
performed using a lower cell density of 4 × 10
4 cells/ml bringing the final density to 2 × 
10
4 cells/ml after addition of 100 µl of cells. Using the high and low cell densities was 
done to compare the IC50 values obtained for each drug in order to determine whether an 
off set in P2 expression is a likely factor that could lead to the low increment in the IC50 
value observed in wild type cells in comparison to the P2-deficient cells which had 
pronounced elevated IC50 values at high cell densities especially for diminazene (Dr. C 
Ward, University of Glasgow, personal communication). 
The assays were repeated on the lines selected against high concentration of diminazene 
after several passages in drug free HMI-9 medium with 10% FCS for a period of 3 months 
to determine whether the acquired resistance was stable. 
Alamar Blue assay data analysis 
The fluorescence data was analysed using the Prism software package version 5.0 for 
determination of the IC50 values. The IC50 value for each test drug, which is referred to as 
the inhibitory concentration that reduces the fluorescence by 50% was calculated by 
nonlinear regression. Graphs were generated which showed the amount of absorbed 
fluorescence as a function of the trypanosomes’ response to the test drug plotted against 
the log10 values of each of the different test drug concentrations. 
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Cross-resistance using the Alamar Blue assay 
Testing for cross-resistance to other P2 drugs pentamidine, cymelarsan (melarsoprol), and 
the furamidine DB75, was carried out for one of the tbat1
-/- lines selected against increased 
diminazene concentration (ABR) using the Alamar Blue assay as described earlier in this 
section. Diminazene was included among the P2 drugs and a non-P2 trypanocide 
phenylarsine oxide (PAO), which diffuses across the trypanosome membrane (Scott et al, 
1997) was included in each assay as a drug control. T. brucei 427 (P2 wild type), tbat1
-/- 
(P2-deficient) whose susceptibility profiles to the mentioned P2 drugs are known (Lanteri 
et al, 2006) and the pentamidine resistant stock KO-B48 which is another P2-deficient line 
but also lacking HAPT1 activity (Bridges et al, 2007) were included in each of the three 
independent assays as controls. This was carried out to compare their drug susceptibility 
profiles with that of the tbat1
-/- cell line selected against diminazene (ABR).  
Pentamidine transport assays 
Pentamidine transport assays using high and low concentrations of radiolabeled 
pentamidine and propamidine have been used to assess the status of the high affinity and 
low affinity pentamidine transporters (HAPT1 and LAPT1) in T. brucei (de Koning & 
Jarvis, 2001;de Koning, 2001b). In the laboratory T. b. brucei line KO-B48 (derived from 
the tbat1
-/- line through selection for pentamidine resistance), uptake of [
3H]-pentamidine 
label was reduced and HAPT1 was demonstrated to be missing (de Koning, 2001b;Bridges 
et al, 2007). The KO-B48 cell line was also shown to be highly cross resistant (15-fold less 
susceptible than wild type T. brucei 427) to the arsenical melarsoprol in comparison to 
tbat1
-/- (2-3 fold less susceptible than wild type T. brucei 427) (Bridges et al, 2007). 
Due to time constraints, I could not personally perform the transport assays, which were 
instead carried out by Dr. Nasser El Sabbagh, University of Glasgow. However, the assays 
were performed as described below.  
Assays involving the uptake of [
3H]-pentamidine label (Appendix I) by the T. b. brucei 
tbat1
-/- diminazene selected line were performed using the rapid oil–stop method (Figure 
6.1) as described (de Koning, 2001b;Bridges et al, 2007). Assays were carried out in 
triplicate and on the same day for the diminazene-selected line and bloodstream form wild 
type T. brucei brucei 427 which was used as a control. Briefly, tbat1
-/- cells adapted to 
increased diminazene concentrations (ABR) cultured to a high density in HMI-9 with 10% 
FCS were aliquoted in 50 ml falcon tubes and centrifuged at 2,500g for 10 minutes at room Anne Juliet Nalunkuma Kazibwe, 2008    Chapter 6, 178 
 
temperature. The medium was aspirated off and the cells were washed twice in assay 
buffer pH 7.3 (Appendix I) by spinning under the same conditions. The cells were 
resuspended in assay buffer at a cell density of 1 × 10
8 cells/ml as determined by 
microscopy using an improved Neubauer counting chamber (WSI, Division of Hawksley 
Technology, England). 100 µl of the cell suspension at room temperature was added to 
each microfuge tube already containing a mixture of 200 µl of dibutyl-phthalate 
oil/mineral oil (v/v 7:1) (Sigma) and 100 µl of assay buffer with [
3H]-pentamidine label at 
60 nM for HAPT1 determinations and 2 µM for LAPT1 assays, as well as any competitive 
inhibitors being tested, such as unlabelled pentamidine and propamidine. The uptake 
reactions were initiated by the addition of 100 µl of assay buffer containing 10
7 
trypanosomes and terminated after 60 seconds using 1 ml of ice cold unlabelled 
pentamidine stop solution (Appendix I) at a saturation concentration of 4 mM. The cells 
were centrifuged through oil at 13,000 rpm for 30 seconds in a microfuge. The tubes were 
snap frozen immediately in liquid nitrogen and the bottom end, containing the cell pellet, 
cut off and the pellet solubilised in 2% SDS (Appendix I). A volume of 3 ml of 
scintillation fluid (Optiphase HiSafe III) was added to the reactions, mixed and incubated 
overnight at room temperature. Control reactions to measure the radiolabel associated with 
the cell pellet at zero-uptake conditions (T0) were determined by adding cells kept on ice to 
a mix of [
3H]-pentamidine label and unlabelled pentamidine also kept on ice simultaneous 
with stop solution and spinning the cells immediately through oil. Radioactivity in the 
pellet, as a measure of uptake, was determined using a scintillation counter (1450 
MicroBeta Trilux). Transport values expressed as pmol(10
7 cells)
-1)s
-1 were determined 
after non-mediated transport values at time zero (T0) were subtracted. 
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Figure 6.1 A schematic of the rapid oil-stop method used in the pentamidine transport 
assays. 
(Adapted from Al Salabi Mohammed, PhD Thesis, 2006, University of Glasgow) Anne Juliet Nalunkuma Kazibwe    Chapter 6, 175  
 
6.4 Results 
6.4.1 In vitro selection process 
T. brucei bloodstream form trypanosomes lacking the TbAT1 gene were chosen for the in 
vitro selection process. To confirm their identity, DNA extracted from an FTA card 
(Whatman) spotted with a bloodstream form culture was PCR amplified for the neomycin 
gene, which is one of the markers that was used in the plasmid construction of the TbAT1 
knock-out cell line (Matovu et al, 2003). Amplification of the TbAT1 gene was also carried 
out as described (section 6.3). The TbAT1 knock-out cell line was also tested against 
neomycin in culture as described (section 6.3). Wild type T. brucei (s427) with TbAT1/P2 
activity was included in each test as a control. Amplification of the 800 bp size fragment of 
the neomycin gene (Figure 6.2 panel A) and lack of amplification of the 1400 bp fragment 
which corresponds to the TbAT1 gene open reading frame (Figure 6.2 panel B) confirmed 
the identity of the T. brucei TbAT1 knock-out cell line. The T. brucei TbAT1 knock-out cell 
line was resistant to 1.5 µg/ml of neomycin in culture, unlike wild type T. brucei which 
was susceptible, thus confirming its identity. Anne Juliet Nalunkuma Kazibwe    Chapter 6, 176  
 
 
Figure 6.2 PCR amplification results to confirm identity of T. brucei tbat1
-/-  
Panel A, a neomycin 800 bp PCR product (white arrow head). 
Panel B, a TbAT1 1400 bp PCR product (white arrow head). 
Lane 1, T. brucei s427 (wild type with P2 activity). 
Lane 2, tbat1
-/- (mutant lacking P2 activity). 
-ve, no template (water) control. 
M, 1 Kb plus DNA size marker (Invitrogen, Life technologies, USA). 
M’, 100 bp DNA size marker (Promega). Anne Juliet Nalunkuma Kazibwe    Chapter 6, 177  
 
 
The in vitro selection for high level resistance against the diamidine drugs diminazene and 
DB75 was carried out for 5-6 months on two independent T. brucei tbat1
-/- cell cultures in 
a stepwise manner with gradual increment of drug as described (section 6.3). The tbat1
-/- 
cell cultures selected against high level resistance to diminazene (ABR) and DB75 
(ADB75) were then tested for their susceptibility to the two drugs using the Alamar Blue 
assay after a total of 55-60 passages in diminazene and 49-58 passages in DB75. The tbat1
-
/- cultures in diminazene were observed to be more resistant compared to wild type strain 
427 (Figure 6.3) and the tbat1
-/- parent strain possibly indicating an additional resistance 
mechanism. The cultures grown in DB75 were passaged about the same number of times 
as the cultures grown in diminazene. However, the tbat1
-/- cultures in DB75 did not acquire 
any significant increase in the level of resistance in comparison to the parent strain tbat1
-/-. 
The same level of resistance as for the parent strain was observed for these tbat1
-/- cultures 
in DB75 in comparison to wild type strain 427 (Figure 6.3). Alamar Blue assays were 
performed using both a high and low cell density (Table 6.1 and Table 6.2) to determine if 
the IC50 values vary as a result of different seeding densities. The experiment might further 
address the possibility that P2 expression is down regulated in captured trypanosomes, 
(observation by Dr. C. Ward and Dr. Pui Wong) leading to a low estimate of resistance 
compared to in vivo studies, especially for diminazene which is known to be highly 
dependent on P2 (Matovu et al, 2003;de Koning et al, 2004). As observed from the results 
(Table 6.1 and Table 6.2), the IC50 values were slightly increased for both drugs at the high 
cell seeding density for the wild type strain 427 and tbat1
-/- strain but more pronounced  for 
diminazene than DB75 which is suspected to have a secondary import route independent of 
P2 (Lanteri et al, 2006). These results were obtained directly after the selection process 
was complete without allowing the cells to proliferate without drug. Anne Juliet Nalunkuma Kazibwe    Chapter 6, 178  
 
 
Figure 6.3 Selection for resistance in the tbat1
-/- cell line cultured under drug pressure. 
Observed increments in resistance in the tbat1
-/-.cell line in comparison to wild type s427 
when cultured in increasing drug concentrations over a 6 month period. 
The obtained IC50 values are not shown.  
 
Drug  Cell line  IC50 (µ µ µ µM)* 
(1x10
4cells/ml) 
IC50 (µ µ µ µM)∗ ∗ ∗ ∗ 
(1x10
5cells/ml) 
RF*  RF∗ ∗ ∗ ∗  RF 
(published) 
Diminazene  WT s427  0.00535 (n=2)  0.0343 (n=1)       
  tbat1
-/-  0.0121 (n=2)  0.0894 (n=1)  2.2  2.6  17.8 
  ABR  0.511 (n=2)  1.73 (n=1)  95.5  43   
Table 6.1 Summary of diminazene Alamar Blue results at different cell seeding densities. 
ABR, T. brucei tbat1
-/- cell line grown in high concentration of diminazene (up to 0.1 µM). 
RF, resistance factor in comparison to wild type (WT) s427. 
n, number of experiments performed.  ( *) refers to seeding cells at 10
4 cells per ml and ( ∗ ∗ ∗ ∗) 
refers to seeding cells and 10
5 per ml.  
 
 
Drug 
Cell line  IC50 (µ µ µ µM)* 
(1x10
4cells/ml) 
IC50 (µ µ µ µM)∗ ∗ ∗ ∗ 
(1x10
5cells/ml) 
RF*  RF∗ ∗ ∗ ∗  RF 
(published) 
DB75  WT s427  0.00581 (n=2)  0.00903 (n=1)       
  tbat1
-/-  0.0279 (n=2)  0.0746 (n=1)  4.79  8.26  10.6 
  ADB75  0.0395 (n=2)  0.111 (n=1)  6.79  12.3   
Table 6.2 Summary of DB75 Alamar Blue results at different cell seeding densities. 
ADB75, T. brucei tbat1
-/- cell line grown in high concentration of DB75 (up to 0.08 µM). 
RF, resistance factor in comparison to wild type (WT) s427. 
n, number of experiments performed. ( *) refers to seeding cells at 10
4 cells per ml and ( ∗ ∗ ∗ ∗) 
refers to seeding cells and 10
5 per ml.  
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Resistance phenotype 
The cultures selected against high level resistance to diminazene were withdrawn from 
drug and passaged 27 times in drug-free medium for a period of 3 months. To determine 
the cross-resistance profile and to compare with the tbat1
-/- strain, which is only slightly 
resistant to melarsoprol and pentamidine (2-3 fold) but significantly resistant (17.8 fold) to 
diminazene (Matovu et al, 2003), and the B48 strain, which lacks P2 and HAPT1 with no 
increased resistance to diminazene but significant resistance to pentamidine and 
melarsoprol (Bridges et al, 2007), the Alamar Blue assay was carried out. The results are 
summarised in Table 6.3. The raw data can be found in Appendix IV. The results indicated 
the resistance phenotype of the ABR cell line was somewhat different from the B48 cell 
line. The ABR cell line was more resistant to diminazene and DB75 than either the parent 
strain tbat1
-/- or the B48 cell line, although some variations (possibly due to technical 
errors) were observed for the tbat1
-/- and B48 cell lines with DB75 at the high cell seeding 
density (1 × 10
5 cells/ml). The ABR cell line was also found to be more resistant to 
pentamidine than to cymelarsan but not as highly resistant to pentamidine as B48 cell line. 
 
Cell line  Diminazene 
  Expt (n)  IC50(µ µ µ µM)  
1 x 10
5cells/ml 
RF  Expt (n)  IC50(µ µ µ µM)  
2 x 10
4cells/ml  
RF 
WT s427  6  0.63  1.0  6  0.224  1.0 
tbat1
-/-  5  6.40  10  4  2.58  11 
B48  5  8.98  14  5  1.58  7.1 
ABR  6  12.5  20  6  5.98  27 
  Pentamidine 
WT s427  6  0.00685  1.0  6  0.00206  1.0 
tbat1
-/-  5  0.0149  2.2  3  0.00491  2.4 
B48  5  0.368  54  5  0.278  135 
ABR  5  0.342  50  6  0.0529  26 
  DB75 
WT s427  5  0.279  1.0  6  0.0202  1.0 
tbat1
-/-  5  1.67  6  4  0.434  21 
B48  5  1.16  4.2  5  0.225  11 
ABR  5  4.56  16  6  0.753  37 
  Cymelarsan 
WT s427  6  0.00408  1.0  6  0.00222  1.0 
tbat1
-/-  6  0.0130  3.2  3  0.00938  4.2 
B48  6  0.0623  15  3  0.0294  13 
ABR  6  0.0268  6.6  3  0.0167  7.5 
Table 6.3 In vitro susceptibility Alamar Blue results comparing resistance phenotypes. 
WT s427, T. brucei (with TbAT1/P2 activity). B48, T. brucei (lacking TbAT1/P2 and HAPT1 
activity). ABR, T. brucei (lacking TbAT1/P2 activity) selected for high level resistance to 
diminazene. Expt (n), number of experiments performed. RF, resistance factor compared to 
WT s427. IC50 values are an average of each of the recorded number of experiments (n). Anne Juliet Nalunkuma Kazibwe    Chapter 6, 180  
 
The in vitro test results suggested an additional uptake route for diminazene in the ABR 
line already lacking P2 transport leading to the findings as below. 
6.4.2 Pentamidine and diminazene transport in the T. brucei ABR 
strain selected against high level diminazene 
Additional work was carried out using radiolabeled transport assays to determine whether 
HAPT1 and LAPT1 activity could be detected in the ABR line. The ABR cell line was 
similarly tested similarly for diminazene transport. Due to time constraints this work was 
carried out by Nasser El Sabbagh (Pentamidine transport) and Ibrahim Teka (Diminazene 
transport) but the results are included in this thesis (Appendix IV) as they offer an 
explanation to the phenotypes described in section 6.4.1. 
6.5 Discussion 
Alterations in drug targets or loss of drug uptake by membrane transporters is associated 
with development of trypanocidal resistance in T. brucei (Maser et al, 2003). Loss of 
TbAT1/P2 led to 2-3 fold resistance to melarsoprol and pentamidine but a significantly 
higher level of resistance to diminazene (18-fold) (Matovu et al, 2003) and DB75 (11-fold) 
(Lanteri et al, 2006). However, the tbat1
-/- mutant was still sensitive at sub-micromolar 
concentrations to diminazene and DB75 suggesting the drugs either get into the 
trypanosomes through other routes or by diffusion or endocytosis (or act at the cell 
surface). HAPT1 and LAPT1 are other routes for the uptake of pentamidine and possibly 
other diamidines (de Koning, 2001b;de Koning & Jarvis, 2001). Adaptation of ABR to a 
high concentration of diminazene resulted in more resistance to diminazene and cross-
resistance to pentamidine and DB75 in comparison to the parent tbat1
-/- strain. Pentamidine 
transport associated with loss of HAPT1 was abolished but pentamidine transport through 
LAPT1 was not affected. Diminazene transport was not totally abolished even in the B48 
strain which also lacks HAPT1 implicating another mode of entry which could be 
transporter related or by endocytosis or diffusion although the latter possibilities are less 
likely as uptake of 1 µM [
3H]-diminazene was saturable, i.e. completely inhibited by 1 mM 
unlabelled diminazene. Evidence has emerged that, at least in procyclic trypanosomes, 
which are used as a model, diminazene is primarily taken up by HAPT1 (De Koning, 
unpublished). While procyclics do not express TbAT1/P2 (de Koning et al, 1998) they do 
express HAPT1 (Km for diminazene 27 ± 5 µM (n=4) and LAPT1. Evidence for loss of Anne Juliet Nalunkuma Kazibwe    Chapter 6, 181  
 
HAPT1 in the ABR diminazene resistant derived line implicates HAPT1 as a second route, 
which is in agreement with the procyclic model. 
The in vitro selection of ABR thus appears to have led to loss of HAPT1 activity, which is 
a phenotype similar to B48. However, there is no increased diminazene resistance in the 
B48 strain as is observed in the ABR strain. This could be due to point mutations in the 
B48 strain that could have affected high affinity binding of pentamidine by HAPT1 but not 
the low affinity binding by diminazene. On the other hand, a different set of mutations 
could have affected binding by both pentamidine and diminazene in ABR although even in 
the ABR line the increase in pentamidine resistance was very much higher than the loss in 
diminazene sensitivity (Table 6.3). It was observed that the level of cross-resistance to 
pentamidine attained in the ABR strain was of a high level than the level of resistance to 
diminazene and DB75. Moreover, no increased resistance to diminazene or DB75 was 
reported for the highly pentamidine resistant strain B48 (Bridges et al, 2007) and (Table 
6.3). This difference may be due to differences in the 3-dimensional structures of the three 
compounds (Figure 6.4). Pentamidine, which displays has a significant level of resistance 
in the adapted tbat1
-/- lines is more flexible (frame C) and may owe its high affinity (Km = 
0.0035 ± 0.005 µM) to HAPT1 to its ability to engage in multiple hydrogen-bond 
interactions with the transporter. In contrast, the rigid (and very similar) structures of 
diminazene (Km=62.48 ± 3 µM) and DB75 (Km=38.25 ± 10 µM) allow the formation of 
fewer bonds (frame A and B), reflected in the much lower binding energy. Thus it is 
conceivable that some mutations in HAPT1 might affect pentamidine binding while not 
affecting diminazene binding, or to a far lesser extent. 
An alternative model that would also explain the non-reciprocal cross-resistance profiles 
seen in the B48 line compared with ABR line would relate to HAPT1 activity being 
dependent upon accessory factors. Loss of either of two accessory factors could yield 
pentamidine resistance while only loss of one particular factor would give diminazene 
resistance. Further work would be required to distinguish these models. Anne Juliet Nalunkuma Kazibwe    Chapter 6, 182  
 
 
Figure 6.4 Rigid structures of diminazene and DB75 and flexible structure of pentamidine. 
Images produced with Chem3D Ultra software version.10 (Cambridge soft) after 
minimalisation of energy. 
(Dr.Harry De Koning, University of Glasgow, with permission). 
6.6 Conclusion 
Adaptation of the tbat1
-/- line to a high concentration of diminazene leads to loss of 
HAPT1. This changes the previous model of P2 as the sole route for diminazene uptake 
and instead the new model shows HAPT1 as a secondary route (Figure 6.5). Uptake of 
diminazene in the ABR line is still possible in the absence of P2 and HAPT1, which 
indicates at least one additional means of drug entry. TbAT1/P2 has been cloned and is 
being exploited for the delivery of drugs such as DB75. Molecular characterisation of 
HAPT1 has not yet been accomplished and neither is the function and physiological 
substrate of both HAPT1 and LAPT1 known to date. Nevertheless, HAPT1 offers hope as 
a lead target for the delivery of new trypanocidal compounds into trypanosomes. Anne Juliet Nalunkuma Kazibwe    Chapter 6, 183  
 
 
 
Figure 6.5 Current model showing mechanisms for drug uptake in the trypanosome. 
TbAT1/P2, T. brucei adenosine transporter 1 encoding P2 activity. 
HAPT1, High Affinity Pentamidine Transporter. 
LAPT1, Low Affinity Pentamidine Transporter. 
TbMRPA, T. brucei multidrug resistance protein A. 
PTD, pentamidine. MelB, melarsoprol. MO, Melarsen oxide. T, trypanothione. 
MelT, melarsoprol-trypanothione complex. N, nucleus. K, kinetoplast. M, mitochondria. 
(De Koning, 2008, in press).Anne Juliet Nalunkuma Kazibwe    Chapter 7, 188  
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7  General discussion 
Human African Trypanosomiasis; a problem exacerbated by increasing drug 
resistance.  
HAT is a public health problem and occurs in 36 countries in sub-Saharan Africa with the 
most severely affected including Uganda, Angola, the Democratic Republic of Congo 
(DRC), Sudan, the Central African Republic (CAR), and the Republic of Congo. The 
disease, which mostly affects the rural poor, is fatal if left untreated and it has a major 
impact on social and economic development.  
The problem of drug resistance and the existence of an animal reservoir have made efforts 
to manage the disease difficult. The existence of parasite strains resistant to the cheapest 
and non-species specific drug melarsoprol recently led to the withdrawal of the drug as 
first-line therapy for stage II disease and its replacement with eflornithine in some regions 
of Uganda, Sudan and Angola. More alarming yet are anecdotal reports of eflornithine 
treatment failures in the field, which have started to emerge. 
This project thesis reports work aimed at studying several factors influencing the spread 
and selection of drug resistance in Human African Trypanosomiasis. 
FTA card technology and its application to the analysis of T. brucei in the field 
I have developed and expanded the FTA card (Whatman) technique, which was found 
effective for sampling and retrieval of DNA material for analysis from T. brucei blood 
isolates. Amplification by PCR of the multicopy T. brucei 177 bp repeat, the single copy T. 
brucei adenosine transporter 1 (TbAT1/P2) gene and the single copy T. brucei PLC-linked 
microsatellite was possible using serially diluted T. brucei blood from a rodent. 
T. b. gambiense patient samples from the Democratic Republic of Congo, Cameroon and 
Chad, provided to us by Dr. Phillipe Truc, were used in a pilot study to assess the 
effectiveness of the method for field studies. The results indicated that the method was 
useful in detecting T. brucei infections and low level parasitaemic infections with the 
highly sensitive multicopy T. brucei TBR primers. Anne Juliet Nalunkuma Kazibwe    Chapter 7, 189  
 
This work was important in establishing an experimental platform to enable me to study 
field isolates transferred to a laboratory setting. I adapted the method to study the 
population genetics and the TbAT1 gene status of sleeping sickness patient samples 
collected from Arua and Moyo districts in North-western Uganda, a region endemic for T. 
brucei gambiense disease. 
Population genetics analysis of T. b. gambiense from North-western Uganda  
Analysis of patient blood isolates revealed the population structure of T. b. gambiense to be 
stable with the level of genetic diversity more intra than inter regional. But some genetic 
exchange was observed to be taking place in the Arua T. b. gambiense population 
indicating some risk of transfer and spread of resistance genes. Conversely, the same 
mechanism could contribute to the loss of resistance alleles in the absence of drug 
pressure, especially if there is a fitness cost to the resistance. 
Melarsoprol was withdrawn from Arua, Omugo health centre in 2001 because of a high 
treatment failure rate (30%) associated with the problem of resistance, but the drug is still 
used in the neighbouring district in Moyo, where such a high treatment failure rate has not 
been registered. The population genetics analysis did indicate that the Arua and Moyo T. b. 
gambiense populations are genotypically distinct possibly accounting for the different 
patient responses to the drug melarsoprol although further work would be needed to verify 
this. 
T. brucei adenosine transporter 1 (TbAT1) status determination 
Alterations in TbAT1/P2 leading to the loss of drug uptake have been implicated in the 
development of resistance to melaminophenyl arsenicals and diamidines. Mutations in the 
TbAT1 gene associated with melarsoprol resistance were found to be present in isolates 
from melarsoprol relapsed patients from Omugo when treatment failures were at their 
peak. 
Determination of the TbAT1 gene status of T. b. gambiense patient isolates collected from 
Omugo, NW Uganda in 2005-2006 when melarsoprol was no longer in use revealed the 
absence of TbAT1 mutant alleles. This is an important finding which indicates that 
melarsoprol can possibly be reintroduced as first-line for treatment of stage II disease in 
Omugo. Since eflornithine resistance has been reported, this fact would be of great 
significance. With drug trials involving the use of combination therapies as a means of 
preserving the efficacy of the few existing drugs still underway, the rational use of Anne Juliet Nalunkuma Kazibwe    Chapter 7, 190  
 
melarsoprol with eflornithine in this region could be taken advantage of at this point 
because of the lack of new drugs. Meanwhile monitoring for TbAT1 status needs to 
continue, in order to avoid a return to the high relapse rates of the late 1990’s. 
Dogs as a potential reservoir of human T. b. gambiense 
Animals are known to act as host reservoirs of the zoonotic parasite T. b. rhodesiense, 
which implicates them in the transmission of the human disease. T. b. gambiense occurs in 
humans as the major reservoir, but it does also infect domestic animals (mostly pigs and 
dogs) and wild animals, since it is transmitted by the same tsetse fly vector, Glossina 
palpalis, that transmits to humans.  
Dogs acting as a host reservoir of T. b. gambiense (or other parasites e.g. Babesia) coupled 
with their treatment using “P2” trypanocides, raises a risk of a possible veterinary link to 
selecting resistance in human disease. The diamidine, diminazene aceturate, which is 
dependent on TbAT1/P2 transport, is becoming less effective in the tsetse-fly endemic Jos 
Plateau, Nigeria. The drug is also used to treat canine babesiosis. Continuous treatment of 
dogs with diminazene could eventually lead to selection and spread of P2-defective 
trypanosomes, which could end up being transmitted to humans, resulting in cross-
resistance to human trypanocides that utilise the same P2 transporter e.g. pentamidine and 
melarsoprol. 
Trypanosome-infected dog isolates from Nigeria collected on FTA cards, which were 
provided to us by the late Dr. Everestus Yanan were used in this study and the findings 
revealed the absence of T. b. gambiense in this particular region. However, the parasites 
could exist in animals in other places, which could complicate treatment of human disease. 
Multiple infections with other animal trypanosomes and other parasite species, which 
included Babesia canis and Hepatozoon canis, as revealed in the study, could complicate 
proper diagnosis and the successful treatment of animal trypanosomiasis. 
In vitro selection for high-level resistance in T. brucei 
TbAT1/P2 is a known and characterised marker associated with the development of 
diamidine resistance in T. brucei. However, its loss does not lead to the complete loss of 
sensitivity for some diamidines nor melamine-based arsenicals. Identification of additional 
markers for diamidine resistance is therefore required particularly since DB289 
(pafuramidine) and other diamidines are under consideration as next generation Anne Juliet Nalunkuma Kazibwe    Chapter 7, 191  
 
trypanocides. These markers can be exploited as possible routes for the delivery of new 
diamidine compounds into the trypanosomes and critically provide better diagnostics for 
field drug-resistance. 
The diamidine, diminazene aceturate, relies largely on P2 for its uptake but adaptation to 
high concentration of diminazene in the known T. brucei tbat1
-/- cell line, which is already 
significantly resistant to diminazene, resulted in increased diminazene resistance and cross-
resistance to pentamidine. The High Affinity Pentamidine Transporter (HAPT1) appeared 
to be lost in these cells. This finding suggested HAPT1 as a possible secondary route for 
diminazene uptake. The preliminary model emerging from this work is that diamidines 
may be taken up by P2 as well as HAPT1 and possibly LAPT1, but that different 
diamidines displaying different affinity for each transporter utilise the various uptake 
routes to a different extent.  
The next priority is the characterisation of HAPT1 at molecular level and the identification 
of more resistance markers as the basis for future work. 
7.1 Conclusion 
This work investigated a series of factors that can impact on the selection and propagation 
of drug resistance in trypanosomes and made some key findings. The absence of TbAT1 
mutant alleles associated with melarsoprol resistance following the withdrawal of 
melarsoprol from Omugo, NW Uganda shows the effect drug pressure possibly has on the 
selection of melarsoprol resistant TbAT1 alleles. Moreover, the finding that some low-level 
mating occurs in the Omugo T. b. gambiense population highlights the risk of spreading 
undesirable traits such as those associated with drug resistance should drug resistant 
trypanosomes exist in this population.  
The use of the PCR technique using the FTA method proved superior to microscopy for 
the identification of low parasitaemic trypanosome infections in dogs suspected of having a 
possible veterinary link to human T. b. gambiense disease. In vitro drug selection for drug 
resistance led to the identification of HAPT1 as a marker for diamidine resistance and 
offers hope for the development of new trypanocides targeting HAPT1 for uptake. It is 
anticipated that such drugs would display at most a modest cross-resistance with the 
current treatments that rely mostly on P2 for their activity. Anne Juliet Nalunkuma Kazibwe    Chapter 7, 192  
 
Most of the above insights have been made possible because of the simple and convenient 
FTA method of sampling. 
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Appendix I 
1 × × × × TE buffer (pH 8.0) (Tris-EDTA buffer) 
10 mM Tris-HCl pH 8.0,  
0.1 mM EDTA pH 8.0 
6 × × × × Blue loading dye  
0.25% bromophenol blue  
0.25% xylene cyanol FF  
30% glycerol in water 
50 × × × × TAE buffer (pH 8.5) (Tris acetate-EDTA buffer) (1 Litre) 
Tris- base      242 g 
Glacial acetic acid    57.1 ml 
0.5 M EDTA (pH 8.0)   100 ml 
1 × × × × TAE buffer (1 litre) 
50 × TAE buffer      20 ml 
Double distilled water     980 ml 
LB medium (Luria broth) pH 7.0 (1 Litre) 
LB powder (Sigma, USA)      25 g 
Double distilled water       1 L 
LB Agar (1 Litre) 
Luria Agar (Sigma, USA)      35 g 
LB medium          1 L 
SOC Medium pH 7.0 (500 ml) 
LB medium        482.5 ml 
250 mM KCl        5 ml Appendix     194 
 
2 M MgCl2        2.5 ml 
1 M Glucose        10 ml 
HMI-9 medium pH 7.4 (5 Litres) (Based on Hirumi and Hirumi, 1989) 
HMI-9 powder 1 sachet (Biosera)        500 g 
Double distilled water           4.5 L 
10% Heat inactivated fetal calf serum (FCS) (Biosera)  500 ml 
β-mercapto-ethanol (200 mM)        71.5 µl 
CBSS buffer pH 7.4 (1 Litre) 
25 mM Hepes    5.96 g 
120 mM Nacl   7.01 g 
5.4 mM KCl    0.4 g 
0.55 mM CaCl2  81 mg 
0.4 mM MgSO4  98.6 mg 
5.6 mM NaH2PO4  0.79 g 
11.1 mM D-Glucose  1.44 g 
TELT (Lysis buffer) 
50 mM Tris-Cl pH 8.0 
62.5 mM EDTA pH 9.0 
2.5 mM LiCl 
4% Triton × 100 
Alamar Blue dye (0.49 nM) (pH 7.4) 
Resazurin sodium salt (FW 251.18 g/ml)    12.5 mg 
1 × Phosphate buffered saline (PBS)      100 ml 
Transport assay buffer pH 7.3 (grams/Litre) 
Glucose      2.53 g 
HEPES      8.0 g 
MOPS       5.0 g Appendix     195 
 
NaHCO3      2.0 g 
KCl        347.5 mg 
MgCl.6H20      62.5 mg 
NaCl        5.7 g 
NaH2PO42H20     913.5 mg 
CaCl2.2H2O      40.7 mg 
MgSO4.7H2O      19.9 mg 
Transport assay stop solution 
4 mM unlabelled Pentamidine 
ImM diminazene aceturate 
2% SDS (Sodium Dodecyl Sulfate) (g/100ml) 
SDS      2 g 
Radiolabel 
[
3H] Pentamidine isethionate- specific activity 3.40 TBq/mmol; 92 Ci/mmol (Amersham) 
        Radioactive concentration 7.4 MBq/ml; 2 mCi/ml 
[
3H] diminazene aceturate  Radioactive concentration 83 Ci/mmol Appendix     196 
 
Appendix II 
Input for clustering data 
36 
  1  2  8  1  4  8  9  10  14  15  16
  17  18  19  20  21  7  9  10  14  16  17
  18  19  20  22  23  1  7  8  9  10  12  1
  7  8 
OM48 1  0  0  1  0  0  0  0  0  0  0  0
  0  0  0  0  0  0  1  0  0  0  0  0
  0  0  0  1  0  0  0  0  0  1  0  0 
OM55 1  1  0  0  0  0  0  0  0  1  1  0
  0  0  0  0  0  0  0  1  0  0  0  0
  0  0  0  1  0  0  0  0  0  1  1  0 
OM62 1  1  0  0  0  0  0  0  0  1  1  0
  0  0  0  0  0  0  1  0  0  0  0  0
  0  0  0  1  1  0  0  0  0  1  1  0 
OM66 1  1  0  0  0  0  0  0  0  1  0  0
  0  0  0  0  0  0  1  0  0  0  0  0
  0  0  0  0  0  1  0  0  0  0  1  0 
OM69 1  0  0  0  0  0  0  0  0  1  0  0
  0  0  0  0  0  0  1  0  0  0  0  0
  0  0  0  1  1  0  0  0  0  1  0  0 
OM72 0  1  0  1  0  0  0  0  1  0  0  0
  0  0  0  0  0  0  0  1  0  0  0  0
  0  0  0  1  0  0  0  0  0  0  1  0 
OM77 1  0  0  1  0  0  0  0  0  0  0  0
  0  0  0  0  0  0  1  0  0  0  0  0
  0  0  0  1  0  0  0  0  0  1  1  0 
OM83 1  0  0  0  1  1  0  0  0  0  0  0
  0  0  0  0  0  1  0  0  1  0  0  0
  0  0  0  0  0  0  1  0  0  0  0  1 
OM86 1  0  0  0  0  0  0  0  1  1  0  0
  0  0  0  0  0  1  0  0  1  0  0  0
  0  0  0  1  1  0  0  0  0  1  1  0 
OM87 1  1  0  0  0  0  0  0  0  1  0  1
  0  0  0  0  0  0  0  1  0  1  0  0
  0  0  0  1  0  0  0  0  0  1  1  0 
OM88 1  0  0  0  1  1  0  0  0  0  0  0
  0  0  0  0  0  1  0  0  1  0  0  0
  0  0  0  0  0  0  1  0  0  0  0  1 
OM90 1  1  0  0  0  0  0  0  0  1  0  1
  0  0  0  0  0  0  0  1  0  0  0  0
  0  0  0  1  1  0  0  0  0  0  1  0 
OM92 1  0  1  0  1  1  0  0  0  0  0  0
  0  0  0  0  0  1  0  0  1  0  0  0
  0  0  0  1  1  0  0  0  0  1  1  0 
OM96 1  0  0  0  0  0  0  0  0  0  0  0
  1  0  0  0  0  1  0  0  1  0  0  0
  0  0  0  1  1  0  0  0  0  0  1  0 Appendix     197 
 
OM97 1  0  0  0  1  0  0  0  0  0  0  0
  0  0  0  0  0  0  1  0  0  0  0  0
  0  0  0  1  1  0  0  0  0  1  1  0 
OM112  1  0  0  0  1  0  0  0  0  0  0
  0  0  0  0  0  0  1  0  0  1  0  0
  0  0  0  0  0  0  0  1  0  0  0  0
  1 
OM115  1  0  0  0  0  0  0  0  0  1  1
  0  0  0  0  0  0  1  0  0  1  0  0
  0  0  0  0  1  1  0  0  0  0  1  1
  0 
OM118  1  1  0  0  0  0  0  0  0  0  1
  0  0  0  0  0  0  0  0  0  0  0  1
  1  0  0  0  0  1  0  0  0  0  0  1
  0 
OM119  1  1  0  0  0  0  0  0  1  1  0
  0  0  0  0  0  1  0  0  0  0  0  0
  0  0  0  0  1  1  0  0  0  0  0  1
  0 
OM121  1  1  0  1  0  0  0  0  0  0  0
  0  0  0  0  0  0  0  0  0  0  1  0
  0  1  0  0  1  1  0  0  0  0  1  0
  0 
OM122  1  1  0  0  0  0  0  0  1  1  0
  0  0  0  0  0  0  0  0  1  0  0  0
  0  0  0  0  1  1  0  0  0  0  1  1
  0 
OM123  1  1  0  0  0  0  0  0  0  1  1
  0  0  0  0  0  0  0  0  1  0  0  0
  0  0  0  0  1  1  0  0  0  0  1  1
  0 
OM126  1  1  0  0  0  0  0  0  0  1  0
  0  0  0  0  0  0  0  0  1  0  0  0
  0  0  0  0  1  1  0  0  0  0  1  1
  0 
OM127  1  1  0  0  0  0  0  0  0  0  0
  0  0  1  1  0  0  0  0  1  0  0  0
  0  0  0  0  1  1  0  0  0  0  1  1
  0 
OM131  1  1  0  0  0  0  0  0  0  0  1
  0  0  0  0  0  0  0  1  0  0  0  0
  0  0  0  0  1  1  0  0  0  0  1  1
  0 
OM132  1  0  0  1  0  0  0  0  0  0  0
  0  0  0  1  0  0  0  1  0  0  0  0
  0  0  0  0  0  1  0  0  0  0  0  1
  0 
OM143  1  1  0  0  0  0  0  0  0  1  0
  0  0  0  0  0  0  0  1  0  0  0  0
  0  0  0  0  1  1  0  0  0  0  1  0
  0 
OM145  1  1  0  0  0  0  0  0  0  0  0
  0  0  0  0  1  0  0  1  0  0  0  0Appendix     198 
 
  0  0  0  0  0  1  0  0  0  0  0  1
  0 
OM148  1  1  0  0  0  0  0  0  0  1  0
  0  0  0  0  1  0  0  1  0  0  0  0
  0  0  0  0  1  1  0  0  0  0  1  1
  0 
M139  1  0  0  0  1  0  0  0  0  0  0  0
  0  0  0  0  0  0  0  0  0  0  0  0
  0  1  1  0  0  0  0  1  0  1  1  0 
M153  1  1  0  1  0  0  0  0  0  0  0  0
  0  0  0  0  0  0  0  1  0  0  0  0
  0  0  0  0  0  0  0  1  0  1  0  0 
M177  1  0  0  1  0  0  0  0  0  0  0  0
  0  0  0  0  0  0  0  1  0  0  0  0
  0  0  0  0  1  0  0  0  0  1  0  0 
control 1  1  0  0  0  0  0  0  1  0  0  0
  0  1  0  0  0  0  1  0  0  0  0  0
  0  0  0  0  0  0  0  0  1  1  0  0 
 
Tree Draw string 
((((((((OM48:0.08333333333333333,OM77:0.08333333333333333):0.1979166666666666
9,OM132:0.28125):0.040745751162417854,(OM121:0.28888888888888886,(M153:0.214
28571428571427,M177:0.21428571428571427):0.07460317460317459):0.033106862273
52899):0.02011537844871175,((((((((OM55:0.05555555555555555,OM123:0.055555555
55555555):0.048611111111111105,(OM122:0.05555555555555555,OM126:0.055555555
55555555):0.048611111111111105):0.055176767676767685,(OM87:0.15,OM90:0.15):0.
009343434343434348):0.04368686868686869,OM127:0.20303030303030303):0.0303030
3030303033,OM119:0.23333333333333336):0.007296927609427545,((((OM62:0.055555
55555555555,OM131:0.05555555555555555):0.06944444444444445,OM148:0.125):0.03
240740740740741,(OM69:0.07142857142857142,OM143:0.07142857142857142):0.0859
7883597883599):0.03787037037037036,OM97:0.19527777777777777):0.0453524831649
8314):0.05386720587613447,(((OM86:0.1,OM115:0.1):0.1,OM96:0.2):0.0146464646464
6463,OM92:0.21464646464646464):0.07985100217243074):0.03045618035697395,((OM
66:0.25,OM145:0.25):0.06388888888888888,OM118:0.3138888888888889):0.011064758
286980447):0.017157482435260274):0.02247479886368775,OM72:0.3645859284748173
6):0.008046201300169586,control:0.37263212977498694):0.01973584707574849,M139:
0.39236797685073543):0.05300211601935739,((OM83:0.0,OM88:0.0):0.0714285714285
7142,OM112:0.07142857142857142):0.3739415214415214) 
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NW Uganda Patient Raw data 
Code  Sex 
Age 
(yrs)  Village  Parish  County  DOA  GP  HCT  WBC 
CSF 
Tryps  Stage/F-up  DOD  Treatment 
OM46  F  25  Sinyaki  Alirubu  Koboko  09.08.05  + ve  N  205  + ve  SSII  02.09.05  DFMO 
                  13.02.06  N  N  5  - ve  TLA 6 mths       
                  08.08.06  N  N  2  - ve  TLA 1 yr       
OM47  F  12  Kumoyo  Erea  Terego  8.08.05                 05.09.05  DFMO 
                  9.08.05  + ve  N  247  + ve  SSII       
                  23.03.06  N  N  23  - ve  TLA 6 mths       
OM48  M  13  Luo  Ayuri  Terego  17.08.05                 08.09.05  DFMO 
                  09.08.05  + ve  N  452  + ve  SSII       
OM50  F  30  Jilla  Yiddu  Terego  11.08.05                 01.09.05  DFMO 
                  10.08.05  N  - ve  363  + ve  SSII       
                  03.03.05  N  N  16  - ve  TLA 6 mths       
OM51  M  25  Ndeku  Otumbari  Terego  11.08.05  N  + ve  293  + ve  SSII  29.08.05  DFMO 
OM52  F  38  Yosini  Lobule  Koboko  30.08.05  + ve  N  2075  + ve  SSII  15.09.05  DFMO 
OM53  M  8  Otumbari  Otumbari  Terego  13.09.05                 07.10.05  DFMO 
                  02.09.05  + ve  N  455  + ve  SSII       
OM54  F  30  Kimuru  Pabura  Maracha  09.09.05  N  + ve  283  + ve  SSII  27.09.05  DFMO 
                  07.03.06  N  N  20  - ve  TLA 6 mths       
OM55  M  19  Bamure  Gurepi  Koboko  12.09.05  + ve  N  41  + ve  SSII  01.10.05  DFMO 
                  10.04.06  N  N  22  - ve  TLA 6 mths       
OM56  F  21  Komindaku  Lobule  Koboko  23.09.05  N  + ve  383  + ve  SSII  29.09.05  DFMO 
                  21.06.06  N  N  12  - ve  TLA 6 mths       
OM57  F  27  Oduzia  Alirubu  Koboko  23.09.05  N  - ve  99  + ve  SSII  19.10.05  DFMO 
                  25.04.06  N  N  1  - ve  TLA 6 mths       
OM58  M  12  Ocea R/S  Ocea 
Madi-
Okolo  28.09.05  + ve  N  507  + ve  SSII  24.10.05  DFMO 
OM59  F  12  Yosini  Lurujo  Koboko  03.10.05  N  - ve  367  + ve  SSII  23.10.05 (Died)  DFMO 
OM60  F  45  Kigemero  Padrombu  Koboko  03.10.05  N  - ve  203  + ve  SSII  26.10.05  DFMO 
OM61  F  24  Kigemero  Padrombu  Koboko  03.10.06  N  - ve  165  - ve  SSII  26.10.06  DFMO Appendix     200 
 
Code  Sex 
Age 
(yrs)  Village  Parish  County  DOA  GP  HCT  WBC 
CSF 
Tryps  Stage/F-up  DOD  Treatment 
OM62  M  13  Adologo  Alirubu  Koboko  14.10.05                 07.11.05  DFMO 
                  13.10.05  + ve  N  295  - ve  SSII       
                  29.05.06  N  N  7  - ve  TLA 6 mths       
OM63  F  43  Gbogby  Lobule  Koboko  14.10.05  N  + ve  7  - ve  SSII  02.11.05  DFMO 
OM64  F  50  Alutura  Lurujo  Koboko  08.11.05  N  + ve  93  + ve  SSII  05.12.05  DFMO 
                  05.06.06  N  - ve  3  - ve  TLA 6 mths       
OM65  F  3  Alutura  Lurujo  Koboko  08.11.05  N  + ve  3  - ve  SSI  22.11.05  Pentamidine 
                  07.07.06  N  N  39  + ve 
SSII TLA 6 
mths  Re-admitted  DFMO 
OM66  F  32  Alutura  Lurujo  Koboko  08.11.05  + ve  N  2  - ve  SSI  23.11.05  Pentamidine 
OM67  F  9  Kabure  Lurujo  Koboko  19.09.03                 06.10.03  DFMO 
                  10.11.05  N  N  229  + ve  SSII  30.11.05    
OM68  F  19  Kolo  Lurujo  Koboko  10.11.05  N  - ve  170  + ve  SSII  05.12.05  DFMO 
                  05.06.06  N  - ve  5  - ve  TLA 6 mths       
OM69  F  23  Akua  Ayuri  Terego  11.11.05  + ve  N  529  + ve  SSII  05.12.05  DFMO 
                  22.08.06  N  - ve  9  - ve  TLA 6 mths       
OM70  M  14  Kabule  Lurujo  Koboko  11.11.05  + ve  N  243  + ve  SSII  30.11.05  DFMO 
OM71  F  9  Alutura  Lurujo  Koboko  15.11.05  + ve  N  5  - ve  SSI  27.11.05  Pentamidine 
OM72  M  13  Okele  Okuvu  Maracha  15.11.05  + ve  N  211  + ve  SSII  04.12.05  DFMO 
OM73  F  20  Bamure  Gurepi  Koboko  21.11.05                 09.12.05  DFMO 
                  16.11.05  + ve  N  571  + ve  SSII       
                  09.06.06  N  - ve  7  - ve  TLA 6 mths       
OM74  F  26  Erea  Ayuri  Terego  28.11.05  + ve  N  777  + ve  SSII  3.02.06  DFMO 
OM75  F  37  Ibia  Otumbari  Terego  29.11.05  N  + ve  318  + ve  SSII  17.12.05  DFMO 
                  28.11.06  N  - ve  9  - ve  TLA 6 mths       
OM76  F  6  Okele  Okuvu  Maracha  01.12.05  + ve  N  159  + ve  SSII  18.01.06  DFMO 
OM77  F  30  Radulu  Aliba 
Madi-
Okolo  02.12.05  + ve  N  359  + ve  SSII  13.02.06  DFMO 
OM78  M  22  Rugbuja  Ginyako  Koboko  05.12.05  + ve  N  483  + ve  SSII  07.02.06  DFMO 
OM79  M  7  Alio.N  Egamara  Maracha  25.01.06                 09.02.06  DFMO 
                  20.12.05  N  + ve  107  + ve  SSII       
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Code  Sex 
Age 
(yrs)  Village  Parish  County  DOA  GP  HCT  WBC 
CSF 
Tryps  Stage/F-up  DOD  Treatment 
OM80  F  55  Abaa  Anufira  Terego  20.12.05  N  - ve  429  + ve  SSII  Died before Txt    
OM81  F  47  Bamure  Gurepi  Koboko  06.01.06  N  + ve  554  + ve  SSII   Referred to Yumbe  DFMO 
OM82  M  22  Erea  Ogunu  Terego  17.01.06                 05.02.06  DFMO 
                  10.01.06  + ve  N  20  + ve  SSII       
                  22.08.06  N  - ve  5  - ve  TLA 6 mths       
OM83  F  23  Ayiziveko  Otumbari  Terego  12.01.06  - ve  + ve  617  + ve  SSII  11.02.06  DFMO 
                  22.08.06  N  - ve  3  - ve  TLA 6 mths       
OM84  M  15  Milia  Gojuru  Aringa 
.06.02 
(Yumbe)                 Re-admitted  Pentamidine 
                  13.01.06  N  - ve  963  + ve  SSII  31.01.06  DFMO 
                  30.06.06  N  N  7  - ve  TLA 6 mths       
OM85  F  35  Kimu  Lobule  Koboko  17.01.06  + ve  N  1025  + ve  SSII  05.02.06  DFMO 
                  10.08.06  N  - ve  7  - ve  TLA 6 mths       
OM86  F  35  Ija  Ludara  Koboko  20.01.06  + ve  + ve  7  - ve  SSII  05.02.06  DFMO 
                  16.08.06  N  N  0  - ve  TLA 6 mths       
OM87  F  12  Ija  Ludara  Koboko  20.01.06  N  + ve  4  - ve  SSI  31.01.06  Pentamidine 
OM88  M  9  Ija  Ludara  Koboko  20.01.06  N  + ve  5  - ve  SSI  31.01.06  Pentamidine 
                  16.08.06  N  N  3  - ve  TLA 6 mths       
OM89  F  34  Ija  Ludara  Koboko  20.01.06  + ve  + ve  21  - ve  SSII  13.02.06  DFMO 
                  16.08.06  N  - ve  3  - ve  TLA 6 mths       
OM90  F  9  Ija  Ludara  Koboko  20.01.06  + ve  + ve  103  - ve  SSII  06.02.06  DFMO 
                  16.08.06  N  N  74  - ve  TLA 3 mths       
OM91  F  49  Ija  Ludara  Koboko  20.01.06  + ve  + ve  3  - ve  SSI  31.01.06  Pentamidine 
OM92  F  10  Ija  Ludara  Koboko  23.01.06                 02.02.06  Pentamidine 
                  21.01.06  N  + ve  3  - ve  SSI       
OM93  F  40  Morodo  Gurepi  Koboko  23.01.06                 02.02.06  Pentamidine 
                  21.01.06  N  + ve  1  - ve  SSI       
                  16..08.06  N  N  0  - ve  TLA 6 mths       
OM94  M  20  Rukaku  Gichara  Aringa  23.01.06                 13.02.06  DFMO 
                  21.01.06  + ve  + ve  61  - ve  SSII       
                  18.08.06  N  - ve  3  - ve  TLA 6 mths       Appendix     202 
 
Code  Sex 
Age 
(yrs)  Village  Parish  County  DOA  GP  HCT  WBC 
CSF 
Tryps  Stage/F-up  DOD  Treatment 
OM95  M  9  Gimere  Gurepi  Koboko  23.01.06                 08.02.06  DFMO 
                  21.01.06  N  + ve  10  - ve  SSII       
                  18.08.06  N  - ve  81  - ve  TLA 6 mths  Re-admitted    
OM96  F  22  Ija  Ludara  Koboko  23.01.06  N  + ve  259  + ve  SSII  14.02.06  DFMO 
                  16.08.06  N  - ve  64  - ve  TLA 6 mths       
OM97  M  20  Ija  Ludara  Koboko  23.01.06  N  + ve  4  - ve  SSI  02.02.06  Pentamidine 
                  16.08.06  N  N  1  - ve  TLA 6 mths       
OM98  F 
8/12 
mths  Ija  Ludara  Koboko  25.01.06  N  + ve  1  - ve  SSI  02.02.06  Pentamidine 
                  16.08.06  N  N  3  - ve  TLA 6 mths       
OM99  M 
3 2/12 
yrs  Ayizeveku   Otumbari  Terego  01.02.06                 19.02.06  DFMO 
                  25.01.06  N  + ve  59  + ve  SSII       
OM100  F                 - ve  + ve  1  - ve  SSI     Pentamidine 
OM101  M  15  Lobule  Lobule  Koboko 
.05.04 
(Yumbe)                    DFMO 
                  27.01.06  N  - ve  137  - ve  SSII 
12.02.06  
Re-admitted  DFMO 
                  18.07.06  N  N  39  - ve  TLA 3 mths       
OM102  M  14  Nabogo  Aupi  Aringa 
.01.05 
(Yumbe)                    DFMO 
                  01.02.06                 15.02.06  DFMO 
                  30.01.06  N  N  119  + ve  SSII  Re-admitted    
OM104  M  29  Loronga  Gojuru  Yumbe  13.02.06  + ve  N  506  + ve  SSII  08.03.06  DFMO 
OM105  F  11  Pasulu  Luba 
Madi-
Okolo  16.02.06  - ve  + ve  77  + ve  SSII  07.03.06  DFMO 
OM106  M  39  Arina R/S    
Madi-
Okolo  02.03.06  N  + ve  672  + ve  SSII  18.03.06  DFMO 
OM107  M  25  Alutura  Lurujo  Koboko  03.03.06                 24.03.06  DFMO 
                  02.03.06  + ve  + ve  761  + ve  SSII       
OM108  M  25  Onzoro  Aroi  Maracha  08.03.06                 28.03.06  DFMO 
                  03.03.06  + ve  + ve  219  + ve  SSII       
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Code  Sex 
Age 
(yrs)  Village  Parish  County  DOA  GP  HCT  WBC 
CSF 
Tryps  Stage/F-up  DOD  Treatment 
OM109  M  14  Drandua  Ayuri  Terego  10.03.06                 26.03.06  DFMO 
                  06.03.06  + ve  N  1121  + ve  SSII       
OM110  M  9  Dondo  Lurujo  Koboko  07.03.06                 26.03.06  DFMO 
                  06.03.06  + ve  N  317  + ve  SSII       
OM111  M  18     Nyori  Yumbe  26.03.06                 16.04.06  DFMO 
                  09.03.06  + ve  N  251  + ve  SSII       
OM112  F  29  Drandua  Ayuri  Terego  18.03.06                 08.04.06  DFMO 
                  17.03.06  N  + ve  893  + ve  SSII       
OM113  F  26  Robu  Orinzi  Aringa  26.03.06                 16.04.06  DFMO 
                  21.03.06  N  + ve  90  - ve  SSII       
OM114  M  28  Ija  Ludara  Koboko 
2004 
(Yumbe)                      
                  21.03.06  N  - ve  58  - ve  SSII 
08.04.06  
Re-admitted  DFMO 
OM115  M  13  Elekele  Nyori  Aringa  26.03.06                 08.04.06  DFMO 
                  24.03.06  + ve  + ve  195  + ve  SSII       
OM116  F  21  Madikini  Ludara  Koboko  27.03.06  + ve  + ve  497  + ve  SSII  19.04.06  DFMO 
OM117  F 
1 5/12 
yrs  Madikini  Ludara  Koboko  27.03.07  + ve  N  6  + ve  SSII  13.04.06  DFMO 
OM118  M  18  Ilekile  Nyori  Aringa  08.04.06  - ve  + ve  183  + ve  SSII  03.05.06  DFMO 
OM119  M  16  Obayia  Okavu  Terego  10.04.06  - ve  + ve  434  + ve  SSII  28.04.06  DFMO 
OM120  F  11  Erekpea  Orivu  Terego  25.04.06                 10.05.06  DFMO 
                  10.04.06  N  + ve  99  + ve  SSII       
OM121  M  25  Okavu  Paranga  Terego  13.04.06                 30.04.06  DFMO 
                  11.04.06  - ve  + ve  948  + ve  SSII       
OM122  M  18  Oreku  Okuvu  Maracha  26.04.06                 17.05.06  DFMO 
                  21.04.06  + ve  + ve  1206  + ve  SSII       
OM123  F  40  Kimu  Kijiriba  Koboko  13.05.06     + ve  767  + ve  SSII  05.06.06  DFMO 
OM124  M  17  Kumiyo  Erea  Terego  30.06.05                 20.01.05  DFMO 
                  24.05.06  N  - ve  159  - ve  SSII 
11.06.06  
Re-admitted  DFMO 
OM125  M  24  Aliowaku  Ayuri  Terego  24.05.06  + ve  + ve  212  + ve  SSII  18.06.06  DFMO Appendix     204 
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OM126  F  22  Igamara  Olube  Aringa  29.05.06  + ve  + ve  372  + ve  SSII  18.06.06  DFMO 
OM127  M  19  R/S  Arina  Aringa 
.01.05 
(Yumbe)                    DFMO 
                  31.05.06  N  N  221  + ve  SSII 
11.06.06  
Re-admitted  DFMO 
OM128  M  34  Nakamure  Angazi  Terego  6.06.06                 23.06.06  DFMO 
                  5.06.06  N  - ve  238  + ve  SSII       
OM129  F  19  Nyatu  Lobule  Koboko  08.06.06  + ve  + ve  573  + ve  SSII  05.07.06  DFMO 
OM130  F 
2 1/2 
yrs  Egamara  Oluba  Aringa  09.06.06  + ve  + ve  163  + ve  SSII  23.06.06  DFMO 
OM131  F  34  Rigboa  Rogale  Aringa  09.06.06  - ve  - ve  578  + ve  SSII  09.07.06  DFMO 
OM132  M  4  Kwili  Aliba 
Madi-
Okolo  .12.04                    DFMO 
                  12.06.06  N  N  259  + ve  SSII 
13.06.06  
Re-admitted  DFMO 
OM133  F  6  Agodonga  Gurepi  Koboko  18.06.06  + ve  N  199  + ve  SSII  20.06.06  DFMO 
OM134  F  25  Guruki  Lurujo  Koboko  15.10.04                 05.11.04  DFMO 
                  19.06.06  N  N  193  + ve  SSII  Re-admitted  DFMO 
OM135  F  28  Nagulu  Ponyura  Koboko  05.07.06  N  + ve  137  + ve  SSII  01.08.06  DFMO 
OM136  M  15  K.T.C  K.T.C  Koboko 
.12.05 
(Sudan)                    Arsobal 
                  07.07.06  N  - ve  257  + ve  SSII 
24.07.06  
Re-admitted  DFMO 
OM137  F  32  Alutura  Lurujo  Koboko  07.07.06  - ve  + ve  169  - ve  SSII  28.07.06  DFMO 
OM138  F 
3 1/2 
yrs  Alutura  Lurujo  Koboko  08.11.05                 22.11.05  Pentamidine 
                  07.07.06  N  N  39  + ve  SSII 
26.07.06  
Re-admitted  DFMO 
OM139  F  12  Itia  Erea  Terego  14.07.06                 30.07.06  DFMO 
                  13.07.06  N  + ve  218  - ve  SSII       
OM140  F  30  Goromonye  Rugbuja  Koboko  17.07.06  N  + ve  99  - ve  SSII  08.08.06  DFMO 
OM141  F  6  Jamure  Alirubu  Koboko  21.12.04                 08.01.05  DFMO 
                  26.07.06  N  N  75  + ve  SSII  Re-admitted  DFMO Appendix     205 
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OM142  F  36  Jamure  Alirubu  Koboko  26.07.06  N  + ve  267  + ve  SSII  18.08.06  DFMO 
OM143  M  60  Kimiro  Olua  Terego  12.08.06  N  + ve  1995  + ve  SSII     DFMO 
OM144  M  9  Gimere  Gurepi  Koboko  23.01.06                 08.02.06  DFMO 
                  18.08.06  N  - ve  81  - ve  SSII  Re-admitted  DFMO 
OM145  F  24  Ija  Ludara  Koboko  18.08.06  N  + ve  6  - ve  SSII     DFMO 
OM146  M  31  Licobe  Gurepi  Koboko  22.08.06  N  + ve  793  + ve  SSII     DFMO 
OM147  M  19  Drandua  Ayuri  Terego  22.08.06  + ve  + ve  11  - ve  SSII     DFMO 
OM148  F  21  Drandua  Ayuri  Terego  22.08.06  N  + ve  1  - ve  SSI     Pentamidine 
M117  F  38  Patabo  Pamujo  N/A  25.02.05        186  + ve  SSII  13.03.05  Melarsoprol 
M135  M  49  Ramogi. N  Arra  N/A  15.04.05     + ve  240  + ve  SSII  8.05.05  Melarsoprol 
               N/A  9.11.05        2  - ve          
M138  M  13  Kendi  Vura  N/A  17.06.05  + ve     134  + ve  SSII  10.07.05  Melarsoprol 
M139  F  14  Erepi. E  Pameri  N/A  17.03.04     + ve  41  - ve  SSII  Re-admitted  Melarsoprol 
                          248  + ve  SSII  10.07.05    
M140  F  Adult  Central II  Central  N/A  22.06.05     + ve  48  - ve  SSII  16.07.05  Melarsoprol 
M145  F  13 
Erepi-
Loliwe  Pameri  N/A  15.07.05  + ve     78  - ve  SSII  9.08.05  Melarsoprol 
M146  M  22  Patabo  Pamujo  N/A  27.07.05  + ve     88  + ve  SSII  13.08.05  Melarsoprol 
M148  M  46  Ginyi East  Pamuyi  N/A  4.08.05     + ve  66  + ve  SSII  31.08.05  Melarsoprol 
M149  F  4  Elegu  Pamujo  N/A  12.08.05  + ve     2  - ve  SSI  3.09.05  Melarsoprol 
M150  F  28  Palorinya E  Palorinya  N/A  12.08.05     + ve  122  - ve  SSII  3.09.05  Melarsoprol 
M152  M  47  Aya  Pajakiri  N/A  24.08.05  + ve     164  + ve  SSII  16.09.05  Melarsoprol 
M153  M  6  Arra  Arra  N/A  24.08.05                 16.09.05  Melarsoprol 
M154  M  17  Parego  Ebihwa  N/A  24.08.05  + ve     88  - ve  SSII     Melarsoprol 
M155  F  36  Indridri  Dufile  N/A  2.09.05     + ve  42  + ve  SSII  25.09.05  Melarsoprol 
M156  M  28  Padiga  Pamujo  N/A  2.09.05                 25.09.05  Melarsoprol 
M160  F  24  Arapi  Pamujo  N/A  30.09.05     + ve  82  - ve  SSII  1.11.05  Melarsoprol 
M161  F  9  Erepi E  Pamujo  N/A  21.10.05  - ve  - ve  15  + ve  SSII  13.11.05  Melarsoprol 
                                Formerly SSI relapse    
M162  M  14  Gbari  Pamujo  N/A  21.10.05  + ve     16  - ve  SSII  13.11.05  Melarsoprol 
M163  M  28  Agugwe  Pajakiri  N/A  26.10.05     + ve  176  + ve  SSII  17.11.05  Melarsoprol Appendix     206 
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M165  M  8  Oruba  Pamujo  N/A  28.10.05  - ve  - ve  10  + ve  SSII  23.11.05  Melarsoprol 
                                Relapse       
M166  M  21  Parego  Ebihwa  N/A  23.11.05  + ve     130  - ve  SSII  16.12.05  Melarsoprol 
M167  F  16  Goopi W  Pamujo  N/A  29.11.05  + ve     348  + ve  SSII  2.01.06  Melarsoprol 
M168  F  10  Indridri  Dufile  N/A  29.12.05  + ve     116  + ve  SSII  22.01.06  Melarsoprol 
M169  F  16  Ibihwa  Ibihwa  N/A  4.01.06  + ve     86  - ve  SSII  29.01.06  Melarsoprol 
M170  M  21  Padiga  Pamujo  N/A  18.01.06  + ve     110  + ve  SSII  9.02.06  Melarsoprol 
M171  M  26  Ramogi N  Arra  N/A  18.01.06  + ve     38  - ve  SSII  9.02.06  Melarsoprol 
M172  M  39  Ramogi N  Arra  N/A  18.01.06  + ve     74  + ve  SSII  9.02.06  Melarsoprol 
M173  M  13  Oruba  Pamujo  N/A  8.02.06        13  + ve  SSII  5.03.06  Melarsoprol 
                  No control done after discharge, either a relapse or re-infection       
M174  F  17  Oruba  Pamujo  N/A  1.02.06        16  + ve  SSII  25.02.06  Melarsoprol 
               N/A                 Relapse       
M175  M  9  Indriba  Pameri  N/A  25.01.06  + ve     66  - ve  SSII  18.02.06  Melarsoprol 
M176  F  40  Oruba  Pamujo  N/A  17.02.06     + ve  54  - ve  SSII  17.03.06  Melarsoprol 
M177  M  20  Parego  Ebihwa  N/A  22.02.06  + ve     136  + ve  SSII  17.03.06  Melarsoprol 
                 14.10.06        1  - ve          
M178  M  13  Iyua  Pamujo  N/A  19.05.06     + ve  26  - ve  SSII  13.06.06  Melarsoprol 
M179  M  46  Kegburu  Kohci  N/A  2.06.06  + ve     480  + ve  SSII  29.06.06  Melarsoprol 
M180  M  6  Erepi E  Pamujo  N/A  23.06.06  + ve     49  + ve  SSII  24.07.06  Melarsoprol 
M181  F  30  Malingu  Ebwea  N/A  23.06.06  + ve     426  + ve  SSII  15.07.06  Melarsoprol 
NW Uganda, Omugo and Moyo T. b. gambiense Patients Raw data 
DOA, Date of admission. GP, glandular puncture. HCT, haematocrit centrifugation test. WBC, white blood cell count/mm
3. CSF, cerebral spinal fluid. 
F-up, follow up period. DOD, date of discharge. DFMO, eflornithine. +ve, positive result for trypanosomes by microscopy . –ve, negative result for 
trypanosomes by microscopy. N, test not performed. 
SSI, stage I disease. SSII, stage II disease. N/A, detail not available. 
Field surveys conducted by members of the mobile team: Margaret Akol, Charles Sebikali (National and Agricultural Livestock Health Research Institute-
NALIRI), Nicholas Ogweng the vector control officer (Moyo). Data collection and Microscopy diagnosis by Albino Louga (Omugo health centre) and Phillip 
Dravu (Moyo Hospital), Clinicians: Dr. Charles Wamboga (Omugo health centre) and Dr. Richard Mangwi, (Moyo hospital) Appendix     207 
 
Appendix III 
Nigerian Dog sample Raw data 
 
Sample No.  Origin  PCV  HCT  Thin smear  RBC(X10
4)  WBC 
138  JNK-9  39  -ve  -ve  471  1010 
139  JNK-9  41  -ve  -ve  486  1150 
140  JNK-9  40  -ve  -ve  407  1150 
141  JNK-9  41  -ve  -ve  431  815 
142  JNK-9  38  -ve  -ve  476  1300 
143  JNK-9  37  -ve  -ve  473  1950 
144  JNK-9  38  -ve  -ve  366  975 
145  JNK-9  40  -ve  -ve  443  930 
146  JNK-9  55  -ve  -ve  201  975 
147  JNK-9  43  -ve  -ve  315  1005 
148  JNK-9  39  -ve  -ve  317  1350 
149  JNK-9  30  -ve  -ve  415  1440 
150  JNK-9  43  +/mf  -ve  335  851 
151  JNK-9  35  -ve  -ve  325  1030 
152  JNK-9  33  -ve  -ve  195  940 
153  JNK-9  23  -ve  B. gibsoni+  305  1115 
154  JNK-9  30  -ve  -ve  335  850 
155  JNK-9  38  -ve  -ve  351  653 
156  JNK-9  37  -ve  -ve  470  758 
157  JNK-9  50  -ve  -ve  455  878 
158  JNK-9  47  -ve  -ve  295  735 
159  JNK-9  35  -ve  B. gibsoni+  359  187 
160  JNK-9  34  -ve  -ve  359  187 
161  JNK-9  34  -ve  -ve  431  755 
162  JNK-9  20  -ve  -ve  211  1105 
163  JNK-9  54  -ve  -ve  485  160 
164  JNK-9  57  -ve  -ve  490  402 
165  JNK-9  43  -ve  -ve  443  954 
166  JNK-9  49  -ve  -ve  435  957 
167  JNK-9  33  -ve  -ve  335  1035 
168  JNK-9  35  -ve  -ve  401  720 
169  JNK-9  30  -ve  -ve  395  865 
170  JNK-9  40  -ve  B. gibsoni+  388  735 
171  JNK-9  37  -ve  -ve  401  1115 
172  JNK-9  41  -ve  -ve  379  719 
173  JNK-9  37  -ve  -ve  201  198 
174  JNK-9  27  -ve  -ve  289  178 
175  JNK-9  51  -ve  -ve  301  335 
176  JSK-9  40  -ve  -ve  325  215 
177  JSK-9  53  -ve  -ve  488  701 
178  JSK-9  66  -ve  -ve  415  1001 
179  JSK-9  45  -ve  -ve  321  635 
180  JSK-9  43  -ve  -ve  401  875 
181  JSK-9  25  -ve  -ve  398  788 
182  JSK-9  34  -ve  -ve  198  753 
183  JSK-9  43  -ve  -ve  501  85 
184  JSK-9  44  -ve  -ve  515  987 Appendix     208 
 
Sample No.  Origin  PCV  HCT  Thin smear  RBC(X10
4)  WBC 
185  JSK-9  50  -ve  -ve  415  857 
186  JSK-9  42  -ve  -ve  498  874 
187  JSK-9  49  -ve  -ve  419  1116 
188  JSK-9  51  -ve  -ve  469  904 
189  JSK-9  37  -ve  -ve  289  830 
190  JSK-9  62  -ve  B. gibsoni+  541  780 
191  JSK-9  48  -ve  -ve  538  790 
192  JNK-9  47  -ve  -ve  411  895 
193  JNK-9  44  -ve  -ve  315  1011 
194  JNK-9  36  -ve  -ve  398  950 
195  JNK-9  40  -ve  B. gibsoni+  412  880 
196  JNK-9  48  -ve  -ve  398  795 
197  JNK-9  52  -ve  B. gibsoni+  491  585 
198  JNK-9  47  -ve  -ve  411  1025 
199  JNK-9  45  -ve  -ve  389  1015 
200  JNK-9  47  -ve  -ve  389  985 
201  JNK-9  11  -ve  B. gibsoni+  98  1105 
202  JNK-9  37  -ve  -ve  273  805 
203  JNK-9  25  -ve  B. gibsoni+  119  855 
204  JNK-9  45  -ve  -ve  385  890 
205  JNK-9  28  -ve  B. gibsoni+  291  750 
206  JNK-9  49  -ve  -ve  491  1225 
207  JNK-9  33  -ve  -ve  349  985 
208  JSK-9  35  -ve  -ve  325  730 
209  JNK-9  30  -ve  -ve  319  905 
210  JSK-9  40  -ve  B. gibsoni+  415  795 
211  JSK-9  37  -ve  -ve  373  975 
212  JSK-9  41  -ve  -ve  471  1150 
213  JSK-9  37  -ve  B. gibsoni+  354  1090 
214  JNK-9  27  -ve  -ve  231  775 
215  JNK-9  51  -ve  -ve  512  870 
216  JNK-9  40  -ve  -ve  419  740 
217  JNK-9  53  -ve  -ve  521  355 
218  JNK-9  66  -ve  -ve  611  1020 
219  JNK-9  45  -ve  -ve  412  885 
220  JNK-9  43  -ve  -ve  431  1065 
221  JNK-9  25  -ve  B. gibsoni+  213  850 
222  JNK-9  34  -ve  -ve  315  1015 
223  JNK-9  43  -ve  -ve  455  497 
224  JNK-9  44  -ve  -ve  395  350 
225  JNK-9  50  -ve  -ve  388  579 
226  JEK-9  42  -ve  -ve  488  185 
227  JEK-9  49  -ve  -ve  496  173 
228  JEK-9  51  -ve  -ve  401  505 
229  JEK-9  37  -ve  B. gibsoni+  599  1028 
230  JSK-9  62  -ve  -ve  418  350 
231  JSK-9  48  -ve  -ve  401  295 
232  JSK-9  47  -ve  -ve  398  915 
233  JSK-9  44  -ve  -ve  316  800 
234  JSK-9  36  -ve  -ve  415  420 
235  JSK-9  40  -ve  B. gibsoni+  417  858 
236  JNK-9  48  -ve  -ve  413  459 
237  JNK-9  52  -ve  -ve  413  720 Appendix     209 
 
Sample No.  Origin  PCV  HCT  Thin smear  RBC(X10
4)  WBC 
238  JNK-9  47  -ve  -ve  515  450 
239  JNK-9  45  -ve  -ve  401  965 
240  JNK-9  47  -ve  -ve  398  840 
241  JNK-9  11  -ve  B. gibsoni+  416  165 
242  JNK-9  37  -ve  -ve  101  972 
243  JNK-9  25  -ve  -ve  348  935 
244  BSAK-9  45  -ve  -ve  201  720 
245  BSAK-9  28  -ve  -ve  138  350 
246  BSAK-9  47  -ve  -ve  415  735 
247  BSAK-9  19  -ve/mf  B. gibsoni+  105  1120 
248  BSAK-9  55  -ve  -ve  498  845 
249  BSAK-9  46  -ve  -ve  387  749 
250  BSAK-9  50  -ve  -ve  599  738 
251  BSAK-9  44  -ve  -ve  405  813 
252  BSAK-9  65  -ve  -ve  897  915 
253  BSAK-9  57  -ve  -ve  491  815 
254  BSAK-9  47  ve/mf++  B.gibsoni+  435  1035 
255  BSAK-9  49  -ve  -ve  415  735 
256  BSAK-9  38  -ve  -ve  375  920 
257  BSAK-9  48  -ve  -ve  398  935 
258  BSAK-9  27  -ve  -ve  205  850 
259  BSAK-9  18  -ve  -ve  98  98 
260  BSAK-9  61  -ve  B. gibsoni+  587  870 
261  BSAK-9  63  -ve  -ve  594  789 
262  BSAK-9  60  -ve  -ve  598  1105 
263  BSAK-9  37  -ve  -ve  373  1031 
264  BSAK-9  33  -ve  -ve  401  950 
265  BSAK-9  28  -ve  -ve  139  101 
266  BSAK-9  59  -ve  -ve  485  1135 
267  BSAK-9  68  -ve  -ve  598  788 
268  JEK-9  36  -ve  -ve  356  1020 
269  JEK-9  58  -ve  -ve  489  1215 
270  BSAK-9  38  -ve  -ve  289  1025 
271  BSAK-9  52  -ve  -ve  445  1150 
272  BSAK-9  52  -ve  -ve  448  870 
274  JEK-9  50  -ve  -ve  511  1015 
275  JEK-9  38  +ve  -ve  298  1120 
276  JEK-9  68  -ve  N/A  589  870 
277  JEK-9  46  -ve  B. gibsoni+  416  1115 
278  JEK-9  31  -ve  B. gibsoni+  291  1115 
279  JEK-9  60  -ve  -ve  551  1025 
280  JEK-9  62  -ve  -ve  536  1030 
281  JEK-9  43  -ve  -ve  451  11400 
282  JEK-9  52  -ve  -ve  438  6800 
283  JEK-9  30  -ve  -ve  288  10400 
284  JEK-9  63  -ve  -ve  538  10250 
285  JEK-9  48  -ve  -ve  415  9200 
286  JEK-9  52  -ve  -ve  478  4600 
287  JEK-9  58  -ve  -ve  495  13250 
288  JEK-9  55  -ve  -ve  483  7420 
289  JEK-9  45  -ve  -ve  439  9400 
290  JEK-9  52  -ve  -ve  448  8505 
291  JEK-9  51  -ve  B. gibsoni+  479  8600 Appendix     210 
 
Sample No.  Origin  PCV  HCT  Thin smear  RBC(X10
4)  WBC 
292  JEK-9  61  -ve  -ve  589  7400 
293  JEK-9  45  -ve  -ve  491  1500 
294  JEK-9  55  -ve  -ve  498  2512 
295  JEK-9  64  -ve  -ve  551  3100 
296  JEK-9  53  -ve  -ve  485  6500 
297  JEK-9  47  -ve  -ve  457  7400 
298  JEK-9  65  -ve  -ve  589  5450 
299  JEK-9  55  -ve  -ve  480  1400 
300  JEK-9  17  -ve  B. gibsoni+  118  14500 
301  JEK-9  62  -ve  -ve  598  9510 
302  JEK-9  N/A  N/A  N/A  N/A  N/A 
303  JEK-9  18  -ve  -ve  145  784 
304  JEK-9  37  -ve  -ve  367  635 
305  JEK-9  42  -ve  -ve  389  867 
306  JEK-9  43  -ve  -ve  415  194 
307  JEK-9  38  -ve  -ve  401  1108 
308  JEK-9  43  -ve  -ve  389  1109 
309  JEK-9  48  -ve  -ve  391  718 
310  JEK-9  45  -ve  -ve  554  345 
311  JEK-9  31  -ve  -ve  309  665 
312  JEK-9  50  -ve  -ve  595  870 
313  JEK-9  50  -ve  -ve  68  780 
314  JEK-9  12  -ve  -ve  N/A  N/A 
315  JEK-9  33  -ve  -ve  434  984 
316  JEK-9  22  -ve  -ve  245  1030 
317  JEK-9  29  -ve  -ve  384  870 
318  JEK-9  37  -ve  -ve  398  720 
319  JEK-9  42  -ve  -ve  403  178 
320  JEK-9  45  -ve  -ve  389  350 
321  JEK-9  23  -ve  -ve  434  350 
322  JEK-9  18  -ve  B. gibsoni+  245  218 
323  JEK-9  57  -ve  -ve  384  1005 
324  JEK-9  62  -ve  -ve  398  870 
325  JEK-9  32  -ve  -ve  403  857 
326  JEK-9  45  -ve  -ve  389  874 
327  JEK-9  53  -ve  -ve  2423  795 
328  JEK-9  43  -ve  -ve  124  1025 
Microscopy data for the dog isolates from Nigeria (by Dr. Yanan-NITOR). 
HCT, haematocrit centrifugation test (parasites/ml). PCV, packed cell volume (%). 
RBC, red blood cell count (M/µL). WBC, white blood cell count (/µL). 
Mf, microfilariae. N/A, result not available. 
JNK, Jos North Kaduna. JSK, Jos south Kaduna. JEK, Jos East Kaduna. BSA, Bakin South 
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Nigerian dog Babesia PCR data 
 
PCR product size (bp) with Babesia spp. primers  Sample  
number  450  500  600  700 
138  -  -  -  - 
138  -  -  -  + 
139  -  -  -  - 
140  -  +  -  - 
141  -  -  -  - 
142  -  -  -  - 
142  -  +  -  - 
142  -  +  -  - 
143  -  -  -  - 
144  -  -  -  - 
145  -  -  -  - 
146  -  -  -  - 
147  -  -  +  + 
148  -  -  -  - 
149  +  -  -  - 
150  -  -  -  - 
151  -  -  -  - 
152  +  -  -  - 
153  -  -  -  - 
154  +  -  +  - 
155  -  -  -  - 
156  -  -  -  - 
157  -  -  -  - 
158  -  -  -  - 
159  +  -  -  - 
160  +  -  -  - 
161  +  -  -  - 
162  -  -  -  - 
163  -  -  -  - 
164  -  -  -  - 
165  -  +  -  - 
166  -  +  -  - 
167  -  -  -  - 
168  -  -  -  - 
169  -  -  -  - 
170  -  -  -  + 
171  -  -  -  - 
172  +  -  -  - 
173  +  -  -  - 
174  -  +  -  - 
175  -  -  -  - 
176  -  -  -  - 
177  +  -  -  - 
178  -  -  -  - 
179  -  +  -  - 
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PCR product size (bp) with Babesia spp. primers  Sample  
number  450  500  600  700 
180  -  -  -  - 
181  -  +  -  - 
182  -  -  -  - 
183  -  -  -  - 
184  -  -  -  - 
185  -  +  -  + 
186  -  -  +  + 
187  -  -  -  - 
188  -  -  -  - 
189  -  -  +  + 
190  -  -  +  + 
191  -  -  -  + 
192  -  -  +  - 
193  -  +  -  + 
194  +  -  -  + 
195  -  +  -  - 
196  -  -  -  - 
197  -  -  -  - 
198  -  -  -  - 
199  -  -  -  - 
200  -  -  -  - 
201  -  -  -  - 
202  -  -  -  - 
203  -  -  -  - 
204  -  -  -  - 
205  -  -  -  - 
206  -  -  -  - 
207  -  -  -  - 
208  +  -  -  - 
209  +  -  -  - 
210  -  -  -  - 
211  -  -  -  - 
212  -  +  -  - 
213  -  +  -  - 
214  -  -  -  - 
215  -  -  -  - 
216  +  -  -  - 
217  -  -  -  - 
218  -  -  -  - 
219  +  -  -  - 
220  -  -  -  - 
221  -  -  -  - 
222  -  -  -  - 
223  -  -  -  - 
224  -  -  -  - 
225  +  -  -  - 
226  -  +  -  - 
227  -  -  -  - 
228  -  +  -  - Appendix     213 
 
PCR product size (bp) with Babesia spp. primers  Sample  
number  450  500  600  700 
229  -  -  -  - 
230  -  -  -  - 
231  +  -  -  - 
232  -  -  -  - 
233  -  -  -  - 
234  -  -  -  - 
235  -  -  -  - 
236  -  -  -  - 
237  -  -  -  - 
238  -  +  -  - 
239  +  -  -  - 
240  -  -  -  - 
241  -  -  -  - 
242  -  +  -  + 
243  +  -  -  - 
244  -  -  -  - 
245  -  -  -  - 
246  +  -  -  - 
247  -  -  -  - 
248  -  +  -  + 
249  -  +  -  - 
250  +  -  -  - 
251  -  -  -  - 
252  +  -  -  + 
253  -  +  -  + 
254  -  -  -  - 
255  -  -  -  - 
256  -  -  -  - 
257  -  -  -  - 
258  -  -  -  - 
259  -  -  -  - 
260  -  -  -  - 
261  +  -  -  - 
262  -  -  -  - 
263  -  +  -  + 
264  -  +  -  - 
265  -  -  -  - 
266  -  -  -  - 
267  -  -  -  - 
268  -  -  -  - 
269  -  -  -  - 
270  -  -  -  - 
271  -  -  -  - 
272  -  -  -  - 
274  -  -  -  - 
275  -  -  -  - 
276  -  -  -  - 
277  -  -  -  - 
278  -  +  -  - Appendix     214 
 
279  -  -  -  - 
280  -  +  -  - 
281  -  -  -  - 
282  -  +  -  - 
283  -  -  -  - 
284  -  +  -  - 
285  -  +  -  - 
286  -  -  -  - 
287  +  -  -  - 
288  +  -  -  - 
289  +  -  -  - 
290  -  +  -  - 
291  -  -  -  - 
292  -  -  -  - 
293  +  -  -  - 
294  -  -  -  - 
295  -  -  -  - 
296  -  -  -  - 
297  -  -  -  - 
298  -  -  -  - 
299  -  -  -  - 
300  +  -  -  - 
301  -  -  -  - 
302  -  -  -  - 
303  -  +  -  - 
304  -  +  -  - 
305  -  -  -  - 
306  -  +  -  - 
307  -  -  -  - 
308  -  -  -  - 
309  -  +  -  - 
310  +  -  -  - 
311  +  -  -  - 
312  +  -  -  - 
313  +  -  -  - 
314  -  +  -  - 
315  -  -  -  - 
316  +  -  -  - 
317  -  -  -  - 
318  -  +  -  - 
319  -  -  -  - 
320  -  -  -  - 
321  -  -  -  - 
322  -  -  -  - 
323  -  -  -  - 
324  -  -  -  - 
325  -  -  -  - 
326  -  -  -  - 
327  -  -  -  - 
328  -  -  -  - 
PCR amplification results for the dog samples with Babesia non-specific primers. 
+, positive. -, negative. (Data from Clare McCann). Total number of dog samples (N=190).Appendix     215 
 
 
Appendix IV 
This section of the thesis refers to the pentamidine and diminazene transport assay results 
obtained from the ABR strain selected against high level diminazene (Chapter 6, section 
6.4.1). 
Pentamidine transport in the ABR strain selected against high 
level diminazene  
The KO-B48 strain selected against pentamidine (130-fold) did not display a detectable 
HAPT1 activity (Bridges et al, 2007). HAPT1 and LAPT1 are responsible for pentamidine 
transport in the tbat1
-/- line. The ABR line selected for growth in high levels of diminazene 
was found to be cross-resistant to pentamidine (Table 6.3). To determine whether the 
observed resistance correlated with reduced HAPT1 or LAPT1 activity, pentamidine 
transport assays were performed using [
3H]-pentamidine at 60 nM for HAPT1 and 2 µM 
for LAPT1 respectively as described (section 6.3). HAPT1 activity was found to be absent 
in the ABR strain in which [
3H]-pentamidine was not measurably inhibited by less than 10 
µM unlabelled pentamidine (Graph 1, panel B). In contrast, [
3H]-pentamidine uptake in 
WT s427 was potently inhibited by unlabelled pentamidine, with typical IC50 values 
between 35 and 55 nM (Graph 1, panel A), which is in close agreement with the reported 
Km for HAPT1 of 36 nM (de Koning, 2001b). Similarly, [
3H]-pentamidine uptake in wild 
type cells was inhibited by propamidine, a selective inhibitor of HAPT1 but not of LAPT1 
(de Koning, 2001b), whereas propamidine had no effect on pentamidine uptake in the ABR 
strain, 
LAPT1 mediated pentamidine uptake was observed to be present in both the ABR strain as 
in WT s427 as shown on page 216 (Graph 2, panel A and B). The Km value for [
3H]-
pentamidine uptake in the ABR strain was 59±11 µM (n=3), identical to the published 
value for LAPT1 of 56±8 µM (de Koning, 2001b). The Vmax value of 1.2 ± 0.4 pmol/10
7 
cells)
-1s
-1 was also identical to the published value for LAPT1, showing that LAPT1 in 
contrast to P2 is not down regulated in cultured cells. 
The above results strongly suggested that the pentamidine cross-resistance in ABR strain 
adapted to high diminazene concentration was due to loss of HAPT1 transport.  
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Graph 1 HAPT1 activity in WT s427 (panel A) but not in the ABR strain (panel B). 
Uptake of 30 nM [
3H]-pentamidine over 60 seconds in the presence of propamidine (■) or 
unlabelled pentamidine (▼). Results shown are representative of three independent 
experiments at various concentrations as indicated.  
Transport measured as [(pmol/10
7 cells)
-1s
-1]. 
 
 
 
 
Graph 2 LAPT1 activity in WT s427 (panel A) and the ABR strain (panel B) 
Uptake of 1 µM [
3H]-pentamidine over 60 seconds in the presence of propamidine (■) or 
unlabelled pentamidine (▼). Results shown are representative of three independent 
experiments at various concentrations as indicated.  
Transport measured as [(pmol/10
7 cells)
-1s
-1]. 
Diminazene transport in the ABR strain selected against high 
level diminazene 
Previous studies had only shown that diminazene uptake in T. brucei is dependent on P2 
transport (Matovu et al, 2003;de Koning et al, 2004). The loss of HAPT1 in the ABR strain 
adapted to high diminazene concentration suggests that this could be a second route for 
diminazene uptake. Therefore no diminazene uptake should take place in the ABR strain if 
diminazene resistance correlates to loss of both TbAT1/P2 and HAPT1. To determine 
whether this is the case, the ABR cell line was subjected to a diminazene transport assay Appendix     217 
 
using 1 µM [
3H]-diminazene as described for pentamidine transport (section 6.3). The B48 
strain (adapted to high pentamidine concentration and lacking both P2 and HAPT1 activity 
is not more resistant to diminazene than tbat1
-/- (Bridges et al, 2007), was included in the 
assay for comparison. The results obtained revealed that diminazene transport was not 
completely abolished in the ABR and B48 cell lines at 1 µM [
3H]-diminazene (Graph 3). 
Uptake of 1 µM [
3H]-pentamidine was only 24% reduced in tbat1
-/- compared to WT s427 
and by 40% and 35% in the B48 and ABR strains respectively (n=3-4). This is explained 
by the fact that at this concentration, pentamidine is mostly transported by LAPT1 (Bray et 
al, 2003), which is present in all four strains. However, uptake of 1 µM [
3H]-diminazene 
was more dramatically affected by the loss of P2 activity (68%) and reduced to just 12% or 
20% of WT s427 uptake rates in the B48 and ABR strains, respectively. This clearly is 
consistent with the expected higher proportion of diminazene uptake through P2, even at 
this high concentration of radiolabel. It further shows that the reported loss of HAPT1 
activity in B48 (Bridges et al, 2007) and ABR (this result section ) correlates with reduced 
diminazene uptake. However, a measurable rate of [
3H]-diminazene uptake even in these 
strains shows that, like pentamidine, diminazene must have at least three routes by which it 
can enter trypanosomes, and the rate by which it is able to utilise each transporter is a 
function of its concentration. Preliminary results from the De Koning group indicate that 
the third (and least important) diminazene transporter is probably LAPT1 (results not 
shown). 
 
Graph 3 Pentamidine and diminazene transport in the different T. brucei strains 
Rates were determined from the slopes of time courses with 6-7 points spread over 10 
minutes. Slopes were determined by linear regression with r
2 values >0.9. Data shown are 
the average and standard errors of 3-4 independent experiments, each performed in 
triplicate.Appendix     218 
 
 
Alamar Blue assay Raw data 
Glasgow start cell density (2 x 10
5 cells/ml) 
  ak expt 1       
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF       
WT s427  3.67E-09  1.00  8.80E-08  1.00  1.03E-08  1.00  3.21E-09  1.00       
KO  3.94E-09  1.07  2.57E-07  2.92  7.95E-08  7.72  7.94E-09  2.47       
KO-B48  1.84E-07  50.14  5.78E-08  0.66  3.11E-08  3.03  1.33E-07  41.36       
WT s427  4.26E-09  1.00  4.69E-08  1.00  4.72E-09  1.00  2.55E-09  1.00       
KO  1.03E-08  2.42  2.57E-07  5.48  5.84E-08  12.39  9.40E-09  3.69       
KO-ABR  7.23E-08  16.97  1.79E-06  38.08  2.28E-07  48.38  2.32E-08  9.08       
                       
  ak expt 2      
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF  PAO  RF   
WT s427  6.48E-09  1.00  5.44E-07  1.00  2.20E-07  1.00  3.66E-09  1.00  1.06E-09  1.00   
KO  5.98E-09  0.92  4.67E-06  8.58  1.10E-06  4.98  6.80E-09  1.86  8.49E-10  0.80   
KO-B48  3.03E-07  46.75  1.28E-06  2.36  2.66E-07  1.21  4.23E-08  11.57  4.88E-10  0.46   
WT s427  5.05E-09  1.00  3.93E-07  1.00  1.34E-07  1.00  3.68E-09  1.00  1.29E-09  1.00   
KO  1.28E-08  2.54  3.59E-06  9.15  5.78E-07  4.32  1.37E-08  3.72  7.30E-10  0.57   
KO-ABR  1.25E-07  24.80  8.44E-06  21.51  1.34E-06  10.00  2.01E-08  5.45  8.68E-10  0.67   
                       
                       
  ak expt 3   
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF  PAO  RF   
WT s427  1.36E-08  1.00  8.66E-07  1.00  4.15E-07  1.00  6.33E-09  1.00  6.74E-10  1.00   
KO  7.03E-09  0.52  2.93E-06  3.39  6.69E-07  1.61  7.61E-09  1.20  8.23E-10  1.22   
KO-B48  5.72E-07  42.14  2.51E-06  2.90  6.92E-07  1.67  6.32E-08  9.99  8.66E-10  1.28   
WT s427  1.23E-08  1.00  1.71E-06  1.00  7.72E-07  1.00  4.53E-09  1.00  9.33E-10  1.00   
KO  7.05E-08  5.71  7.51E-06  4.40  1.84E-06  2.38  2.44E-08  5.39  1.32E-09  1.42   
KO-ABR  4.57E-07  37.04  1.29E-05  7.56  5.23E-06  6.77  2.86E-08  6.31  1.08E-09  1.16   Appendix     219 
 
Glasgow start cell density (2 x 10
5 cells/ml) 
                       
  cpw expt 1       
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF       
WT s427  7.44E-09  1.00  5.86E-07  1.00  1.35E-07  1.00  4.39E-09  1.00       
KO  8.13E-09  1.09  3.73E-06  6.37  4.13E-06  30.70  1.37E-08  3.11       
KO-B48  1.55E-06  208.85  3.41E-06  5.83  4.03E-06  29.93  6.09E-08  13.87       
WT s427  1.26E-08  1.00  3.81E-07  1.00  2.03E-07  1.00  6.69E-09  1.00       
KO  3.77E-08  3.00  3.51E-06  9.21  4.47E-06  22.00  3.47E-08  5.18       
KO-ABR  6.06E-07  48.08  8.00E-06  21.02  9.62E-06  47.37  4.49E-08  6.72       
                       
                       
  cpw expt 2   
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF  PAO  RF   
WT s427  3.84E-09  1.00  1.10E-06  1.00  1.61E-07  1.00  3.28E-09  1.00  2.57E-10  1.00   
KO  2.87E-09  0.75  1.63E-05  14.84  7.97E-07  4.94  4.92E-09  1.50  4.95E-10  1.92   
KO-B48  3.82E-07  99.32  3.42E-05  31.08  3.31E-07  2.05  2.94E-08  8.96  1.93E-10  0.75   
WT s427  4.34E-09  1.00  7.86E-07  1.00  1.70E-07  1.00  3.44E-09  1.00  4.67E-10  1.00   
KO  5.75E-09  1.32  1.64E-05  20.80  6.14E-07  3.62  1.06E-08  3.07  8.38E-10  1.80   
KO-ABR  1.09E-07  25.03  2.93E-05  37.21  1.17E-06  6.88  2.61E-08  7.57  4.12E-10  0.88   
                       
                       
  cpw expt 3   
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF  PAO  RF   
WT s427  4.54E-09  1.00  6.58E-07  1.00  2.61E-07  1.00  4.25E-09  1.00  5.71E-10  1.00   
KO  2.06E-09  0.45  2.79E-06  4.24  6.71E-07  2.58  6.85E-09  1.61  8.12E-10  1.42   
KO-B48  3.97E-07  87.41  3.48E-06  5.29  4.78E-07  1.83  4.46E-08  10.50  5.95E-10  1.04   
WT s427  4.04E-09  1.00  3.94E-07  1.00  6.29E-08  1.00  2.87E-09  1.00  2.69E-10  1.00   
ak KO  1.90E-07  46.99  7.37E-06  18.73  1.82E-06  28.93  1.50E-08  5.24  3.20E-10  1.19   
KO-ABR  4.12E-07  102.06  1.42E-05  36.03  5.44E-06  86.46  1.78E-08  6.22  9.13E-10  3.39   
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Swiss cell start density (4 x 10
4 cells/ml) 
                       
  ak expt 1   
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF  PAO  RF   
WT s427  2.24E-09  1.00  2.83E-07  1.00  2.06E-08  1.00  2.44E-09  1.00  2.36E-10  1.00   
KO  2.23E-09  0.99  2.77E-06  9.76  6.45E-07  31.28  6.05E-09  2.48  1.80E-10  0.76   
KO-B48  2.89E-07  129.04  9.86E-07  3.48  2.89E-07  14.03  3.42E-08  14.03  1.25E-10  0.53   
WT s427  1.80E-09  1.00  2.70E-07  1.00  2.92E-08  1.00  2.55E-09  1.00  1.83E-10  1.00   
KO  1.26E-08  7.02  2.00E-06  7.41  5.31E-07  18.21  1.35E-08  5.30  2.14E-10  1.17   
KO-ABR  1.09E-07  60.76  6.95E-06  25.76  1.25E-06  42.90  2.13E-08  8.33  3.02E-10  1.65   
                       
                       
  ak expt 2   
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF  PAO  RF   
WT s427  5.91E-09  1.00  1.50E-07  1.00  1.51E-08  1.00  2.45E-09  1.00  2.81E-10  1.00   
KO  4.54E-09  0.77  1.29E-07  0.86  1.32E-08  0.87  2.60E-09  1.06  2.63E-10  0.94   
KO-B48  2.30E-07  38.93  2.00E-07  1.33  1.04E-07  6.88  2.37E-08  9.66  2.53E-10  0.90   
WT s427  1.48E-09  1.00  4.97E-08  1.00  8.22E-09  1.00  1.47E-09  1.00  2.08E-10  1.00   
KO  2.51E-08  16.97  1.84E-06  36.99  3.68E-07  44.78  9.59E-09  6.54  2.95E-10  1.42   
KO-ABR  3.96E-08  26.76  3.73E-06  75.04  3.73E-07  45.34  1.24E-08  8.49  3.74E-10  1.79   
                       
                       
  ak expt 3   
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF  PAO  RF   
WT s427  2.38E-09  1.00  2.79E-07  1.00  4.26E-08  1.00  3.26E-09  1.00  2.48E-10  1.00   
KO  3.66E-09  1.54  2.99E-07  1.07  1.64E-08  0.39  2.60E-09  0.80  3.07E-10  1.24   
KO-B48  3.37E-07  141.57  1.67E-06  5.98  3.55E-07  8.35  4.18E-08  12.84  2.15E-10  0.87   
WT s427  5.65E-09  1.00  3.10E-07  1.00  3.51E-08  1.00  3.61E-09  1.00  2.25E-10  1.00   
KO  5.26E-08  9.32  3.86E-06  12.46  4.66E-07  13.27  1.52E-08  4.22  3.84E-10  1.71   
KO-ABR  7.90E-08  13.99  7.35E-06  23.74  1.06E-06  30.20  1.71E-08  4.75  2.73E-10  1.21   
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cpw expt 1 
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF  PAO  RF   
WT s427  5.58E-10  1.00  2.30E-07  1.00  1.40E-08  1.00  1.76E-09  1.00  8.54E-11  1.00   
KO  5.12E-10  0.92  1.87E-06  8.15  3.50E-07  25.03  4.84E-09  2.75  5.20E-12  0.06   
KO-B48  2.25E-07  402.62  1.19E-06  5.18  1.82E-07  12.99  2.97E-08  16.91  1.98E-10  2.32   
WT s427  9.26E-10  1.00  2.93E-07  1.00  2.42E-08  1.00  2.44E-09  1.00  1.14E-10  1.00   
KO  8.44E-09  9.11  3.58E-06  12.24  4.69E-07  19.34  1.14E-08  4.67  1.74E-10  1.52   
KO-ABR  8.56E-08  92.39  7.13E-06  24.36  1.02E-06  42.22  1.77E-08  7.27  2.16E-10  1.89   
                       
                       
  cpw expt 2   
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF  PAO  RF   
WT s427  2.75E-09  1.00  1.93E-07  1.00  3.56E-09  1.00  7.75E-10  1.00  2.21E-12  1.00   
KO  1.96E-10  0.07  1.94E-07  1.00  1.07E-08  3.00  1.09E-09  1.41  1.22E-10  55.08   
KO-B48  8.65E-08  31.42  1.56E-07  0.81  3.91E-08  10.98  1.95E-08  25.20  2.10E-10  95.10   
WT s427  1.77E-11  1.00  6.40E-08  1.00  1.42E-09  1.00  6.31E-10  1.00  5.95E-14  1.00   
KO  1.37E-08  771.88  1.61E-06  25.09  1.80E-07  126.84  6.10E-09  9.66  2.12E-11  356.64   
KO-ABR  2.53E-08  1429.70  4.08E-06  63.80  2.68E-07  189.55  8.63E-09  1.42         
                       
                       
  cpw expt 3   
   Pentamidine  RF  Diminazene  RF  DB75  RF  Cymelarsan  RF  PAO  RF   
WT s427  4.17E-10  1.00  2.72E-07  1.00  1.40E-08  1.00  1.59E-09  1.00  2.22E-10  1.00   
KO  4.52E-10  1.08  2.53E-07  0.93  1.57E-08  1.12  1.63E-09  1.02  2.23E-10  1.00   
KO-B48  3.08E-07  739.04  1.88E-06  6.89  1.93E-07  13.78  2.76E-08  17.35  1.33E-10  0.60   
WT s427  5.32E-10  1.00  2.81E-07  1.00  1.56E-08  1.00  1.81E-09  1.00  2.23E-10  1.00   
KO  3.92E-08  73.59  4.06E-06  14.43  3.39E-07  21.71  1.32E-08  7.31  2.76E-10  1.24   
KO-ABR  3.78E-08  70.98  6.63E-06  23.58  5.49E-07  35.12  1.48E-08  8.20  1.94E-10  0.87   
                       
IC50 values obtained from Alamar blue triplicate experiments performed concurrently with Dr. C Ward for comparison. 
Swiss cell start density (4 x 10
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